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Abstract
Measurement of exhaled nitric oxide concentration in
asthma: a systematic review and economic evaluation of
NIOX MINO, NIOX VERO and NObreath
Sue E Harnan,1* Paul Tappenden,1 Munira Essat,1 Tim Gomersall,1
Jon Minton,2 Ruth Wong,1 Ian Pavord,3 Mark Everard4
and Rod Lawson5
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Advanced Quantitative Methods Network (AQMEN), University of Glasgow, Glasgow, UK
3Nuffield Department of Medicine, University of Oxford, Oxford, UK
4School of Paediatrics and Child Health, University of Western Australia, Princess Margaret
Hospital, WA, Australia
5Department of Respiratory Medicine, Royal Hallamshire Hospital, Sheffield, UK
*Corresponding author s.harnan@sheffield.ac.uk
Background: High fractions of exhaled nitric oxide (FeNO) in the breath of patients with symptoms of
asthma are correlated with high levels of eosinophils and indicate that a patient is likely to respond to
inhaled corticosteroids. This may have a role in the diagnosis and management of asthma.
Objective: To assess the diagnostic accuracy, clinical effectiveness and cost-effectiveness of the hand-held
electrochemical devices NIOX MINO® (Aerocrine, Solna, Sweden), NIOX VERO® (Aerocrine) and NObreath®
(Bedfont Scientific, Maidstone, UK) for the diagnosis and management of asthma.
Data sources: Systematic searches were carried out between March 2013 and April 2013 from database
inception. Databases searched included MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews,
the Database of Abstracts of Reviews of Effects, Science Citation Index Expanded and Conference
Proceedings Citation Index – Science. Trial registers such as ClinicalTrials.gov and the metaRegister of
Controlled Trials were also searched in March 2013. All searches were updated in September 2013.
Review methods: A rapid review was conducted to assess the equivalence of hand-held and
chemiluminescent FeNO monitors. Systematic reviews of diagnostic accuracy and management efficacy
were conducted. A systematic review of economic analyses was also conducted and two de novo
health economic models were developed. All three reviews were undertaken according to robust
high-quality methodology.
Results: The rapid review (27 studies) found varying levels of agreement between monitors (Bland–Altman
95% limits of agreement up to ±10 parts per billion), with better agreement at lower FeNO values.
Correlation was good (generally r> 0.9). The diagnostic accuracy review identified 22 studies in adults
(all ages) and four in children. No studies used NObreath or NIOX VERO and seven used NIOX MINO.
Estimates of diagnostic accuracy varied widely. FeNO used in combination with another test altered
diagnostic accuracy only slightly. High levels of heterogeneity precluded meta-analysis. Limited observations
included that FeNO may be more reliable and useful as a rule-in than as a rule-out test; lower cut-off
values in children and in smokers may be appropriate; and FeNO may be less reliable in the elderly. The
management review identified five randomised controlled trials in adults, one in pregnant asthmatics and
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seven in children. Despite clinical heterogeneity, exacerbation rates were lower in all studies but not
generally statistically significantly so. Effects on inhaled corticosteroid (ICS) use were inconsistent, possibly
because of differences in management protocols, differential effectiveness in adults and children and
differences in population severity. One UK diagnostic model and one management model were identified.
Aerocrine also submitted diagnostic and management models. All had significant limitations including
short time horizons and the selective use of efficacy evidence. The de novo diagnostic model suggested
that the expected difference in quality-adjusted life-year (QALY) gains between diagnostic options is likely
to be very small. Airway hyper-responsiveness by methacholine challenge test is expected to produce the
greatest QALY gain but with an expected incremental cost-effectiveness ratio (ICER) compared with FeNO
(NObreath) in combination with bronchodilator reversibility of £1.125M per QALY gained. All remaining options
are expected to be dominated. The de novo management model indicates that the ICER of guidelines plus
FeNO monitoring using NObreath compared with guidelines alone in children is expected to be approximately
£45,200 per QALY gained. Within the adult subgroup, FeNO monitoring using NObreath compared with
guidelines alone is expected to have an ICER of approximately £2100 per QALY gained. The results are
particularly sensitive to assumptions regarding changes in ICS use over time, the number of nurse visits for
FeNO monitoring and duration of effect.
Conclusions: Limitations of the evidence base impose considerable uncertainty on all analyses. Equivalence
of devices was assumed but not assured. Evidence for diagnosis is difficult to interpret in the context of
inserting FeNO monitoring into a diagnostic pathway. Evidence for management is also inconclusive, but
largely consistent with FeNO monitoring resulting in fewer exacerbations, with a small or zero reduction in
ICS use in adults and a possible increased ICS use in children or patients with more severe asthma. It is
unclear which specific management protocol is likely to be most effective. The economic analysis indicates
that FeNO monitoring could have value in diagnostic and management settings. The diagnostic model
indicates that FeNO monitoring plus bronchodilator reversibility dominates many other diagnostic tests.
FeNO-guided management has the potential to be cost-effective, although this is largely dependent on the
duration of effect. The conclusions drawn from both models require strong technical value judgements
with respect to several aspects of the decision problem in which little or no empirical evidence exists. There
are many potential directions for further work, including investigations into which management protocol is
best and long-term follow-up in both diagnosis and management studies.
Study registration: This study is registered as PROSPERO CRD42013004149.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Airway hyper-responsiveness Synonymous with bronchial hyper-responsiveness and an indicator of
asthma. Usually assessed using a bronchial challenge test. In a bronchial challenge test an agent such as
histamine or methacholine is inhaled. If these agents trigger bronchospasm at a significantly lower
threshold than normal an individual is considered to have airway hyper-responsiveness.
Airway reversibility Airway obstruction that improves when a bronchodilator or corticosteroids
are taken.
Antihistamine A drug that inhibits the action of histamine in the body and which may be effective in
treating allergic asthma.
Area under the curve A measure of the diagnostic accuracy of a technology based on the geometric
inspection of a receiver operating characteristic plot, which plots true-positive rate against false-positive
rate. A technology with perfect diagnostic accuracy will have an area under the curve of 1, a technology
that is no better than chance will have an area under the curve of 0.5 and a technology that miscategorises
on every occasion will have an area under the curve of zero.
Atopy/atopic disorder A predisposition towards the development of some forms of allergic
hypersensitivity. Atopy is considered to be a risk factor for asthma.
Attrition bias A statistical bias caused by systematic differences in rates of attrition in the control and
intervention arms of a study. For example, the intervention may make some patients receiving it better but
may cause others to experience severe side effects and be more likely to leave the study.
Bland–Altman plot Also known as a difference plot and used to estimate the level of agreement
between two devices or assays used for measuring the same thing. Observations are paired and the mean
of the paired observations is plotted against the difference in estimates between the two devices for the
same observation.
Bronchoconstriction Constriction of the airways in the lungs as a result of the action of surrounding
smooth muscle, airway inflammation or excessive production of mucus because of allergy or irritation from
air friction, overcooling or drying of the airways. It is characterised by coughing, wheezing and shortness
of breath.
Chemiluminescence A broad range of methods in which light is emitted as a result of a chemical reaction.
Used to detect the presence and level of nitric oxide in exhaled breath.
Chronic obstructive pulmonary disease A lung disease in which airflow is persistently poor because
of lung tissue damage and dysfunction of the small airways. Some treatment for chronic obstructive
pulmonary disease is similar to that for asthma but, unlike asthma, chronic obstructive pulmonary disease
is usually acquired rather than inherited and the prognosis and health-related quality of life are poorer.
Cut-off In a binary categorisation exercise, a value within a range of values used to categorise observations
into one of two mutually exclusive groups. With respect to the fraction of exhaled nitric oxide devices
considered in this assessment, the cut-off threshold is expressed as parts per billion of nitric oxide in exhaled
breath; those with values above the threshold are considered ‘positive’ and those with values below the
threshold are considered ‘negative’.
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Detection bias Detection bias refers to systematic differences between groups in how outcomes are
determined. This usually occurs as a result of preconceptions about treatment efficacy. As such, blinding
(or masking) of outcome assessors may reduce the risk that knowledge of which intervention was received,
rather than the intervention itself, affects outcome measurement. Blinding of outcome assessors can
be especially important for assessment of subjective outcomes such as degree of postoperative pain.
The outcome assessor can be the patient when outcomes are self-assessed.
Diagnostic accuracy The effectiveness of a diagnostic test in correctly categorising patients as either
‘positive’ or ‘negative’. There are several ways that this can be expressed, for example the area under the
curve or the sum of sensitivity and specificity.
Exacerbation A worsening of symptoms that may be acute or subacute. In the case of asthma, this can
also be termed an ‘asthma attack’. Symptoms include shortness of breath, wheezing, cough and chest
tightness. Exacerbations also lead to decreases from baseline in lung function, such as forced expiratory
volume in the first second.
Extended dominance The state when a strategy under study is both less effective and more costly than a
linear combination of two other strategies with which it is mutually exclusive.
False negative An individual who has been incorrectly categorised as a member of the category
‘negative’ in a binary categorisation exercise when the only other possible classification is ‘positive’, for
example someone who has asthma but who has been categorised as not having asthma.
False positive An individual who has been incorrectly categorised as a member of the category ‘positive’
in a binary categorisation exercise when the only other possible classification is ‘negative’, for example a
patient incorrectly diagnosed with asthma.
Forced expiratory volume in the first second The volume of air expelled by a patient within the
first second.
Fraction of exhaled nitric oxide The concentration of nitric oxide in exhaled breath, also known as
fractional exhaled nitric oxide.
Index test A diagnostic test whose sensitivity and specificity are assessed by comparing its categorisations
(positive, negative) with another diagnostic test, known as a reference standard, which is assumed to have
perfect sensitivity and specificity. In this assessment the index test is the fraction of exhaled nitric oxide.
Inhaled corticosteroid responsiveness The degree to which the asthma condition improves in response
to treatment with inhaled corticosteroids.
Juniper score A quality of life measure for patients with asthma.
Negative predictive value The probability that a patient who has been categorised as ‘negative’ really
is negative.
Peak expiratory flow rate The maximum rate of expiration of breath, as measured by a peak flow
metre. Considered a measure of lung function.
Pearson correlation A measure ranging between –1 and 1 indicating the degree and direction of linear
dependence between two variables. Values close to zero indicate no/very low correlation and values
close to 1 indicate very high correlation.
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Performance bias A statistical bias caused by the control and treatment groups receiving different
standards of care or being exposed to factors other than the interventions of interest.
Positive predictive value The probability that a patient who has been categorised as ‘positive’ really
is positive.
Receiver operating characteristic plot A graph that plots the joint sensitivity and specificity of a
diagnostic test at a range of cut-off thresholds.
Reference standard A diagnostic test used to estimate the sensitivity and specificity of another diagnostic
test, known as an index test. The reference standard is assumed to have perfect sensitivity and specificity
and so, when both tests categorise something differently, the index test categorisation is assumed to be
incorrect (either a false negative or a false positive).
Reporting bias Reporting bias refers to systematic differences between reported and unreported findings.
In any given study, analyses with statistically significant differences between intervention groups are more
likely to be reported than analyses with non-significant differences. This is also known as outcome
reporting bias or selective reporting bias. Reporting bias can also occur when results are reported in such a
way that they cannot be included in a meta-analysis.
Selection bias Systematic differences in the baseline characteristics of the intervention and control
groups. Randomisation should result in study groups with similar baseline characteristics but this
can be subverted if there is a lack of allocation concealment (preventing foreknowledge of
forthcoming allocations).
Sensitivity The proportion of ‘positives’ within a population undergoing diagnostic testing who are
identified as such.
Simple dominance When a given treatment alternative is less effective and more expensive than
its comparator.
Specificity The proportion of ‘negatives’ within a population undergoing diagnostic testing who are
identified as such.
Spirometry Lung function tests based on the measurement of exhaled air under controlled conditions
using a device called a spirometer.
Standardised mean difference A summary statistic showing the difference between two groups,
calculated as the difference in mean outcomes between two groups divided by the standard deviation of
scores for all study participants. This can be used to meta-analyse data for an outcome that has been
measured using different metrics.
True negative An individual who has been correctly categorised as a member of the category ‘negative’
in a binary categorisation exercise when the only other possible classification is ‘positive’, for example
someone who has been correctly identified as not asthmatic.
True positive An individual who has been correctly categorised as a member of the category ‘positive’ in
a binary categorisation exercise when the only other possible classification is ‘negative’, for example
someone who has been correctly diagnosed with asthma.
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SCIE Science Citation Index Expanded
SCM specialist committee member
SD standard deviation
SE standard error
SF-12 Short Form questionnaire-12 items
SIGN Scottish Intercollegiate Guidelines
Network
TN true negative
TP true positive
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed academic-in-confidence.
The full report was used by the Appraisal Committee at NICE in their deliberations. The full
report with each piece of academic-in-confidence data removed and replaced by the
statement ‘academic-in-confidence information removed’ is available on the NICE website:
www.nice.org.uk. The present monograph presents as full a version of the report as is
possible while retaining readability, but some sections, sentences, tables and figures have
been removed. Readers should bear in mind that the discussion, conclusions and implications
for practice and research are based on all the data considered in the original full NICE report.
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Plain English summary
H igh levels of nitric oxide in exhaled breath are thought to be a sign that a person might have asthmaor that their asthma is poorly controlled. We aimed to assess the evidence relating to this and to
estimate whether the cost of using NIOX MINO, NIOX VERO and/or NObreath to measure exhaled nitric
oxide was worth the health benefits. We found that studies using exhaled nitric oxide to help diagnose
asthma reported different results to one another but that, overall, exhaled nitric oxide was probably more
able to indicate that a person does have asthma than to indicate that they do not. We also looked at
studies that used exhaled nitric oxide levels to tailor treatment in people with asthma. These studies all
reported fewer asthma attacks when exhaled nitric oxide was used, but this was not statistically significant
in most studies. Most also reported less medication use, although some reported an increase in medication
use. There were some differences between studies in adults and studies in children and between those
with different severities of asthma. By making some assumptions about how long the benefits would last
and how the test would be used in practice, it seems possible that using exhaled nitric oxide would be
cost-effective in certain groups in both the management and the diagnosis of asthma. There is a lot of
uncertainty over all of the conclusions drawn in the assessment, however, because not all of the evidence
needed was available and some of the evidence used was not of the highest quality.
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Scientific summary
Background
Asthma is a chronic disorder of the airways, caused primarily by inflammatory processes and
bronchoconstriction. Symptoms of asthma include recurrent episodes of wheezing, breathlessness, chest
tightness and coughing. The diagnosis of asthma is a clinical one, based on symptoms and clinical
respiratory measurements. However, there is no definitive, objective diagnostic test and as such there is
significant over- and underdiagnosis.
In 2011, an estimated 5.4 million people in the UK were receiving treatment for asthma. Deaths from
asthma are generally rare, with 1041 in England and Wales in 2011.
The management of asthma aims to control symptoms, prevent exacerbations and achieve the best lung
function, with minimal side effects. For both children and adults, asthma is monitored and managed in
primary care by routine clinical review on at least an annual basis. Patients are managed in a stepwise
manner, with escalation of medication until control is reached.
High fractional exhaled nitric oxide (FeNO) levels in a patient with symptoms suggestive of asthma may
suggest that the patient has eosinophilic asthma that could be treated with inhaled corticosteroids (ICSs).
In individuals already diagnosed with asthma, FeNO levels may indicate how well they are responding to
ICS-based medication, whether medication is being adhered to and whether medication dosage should be
increased or decreased (step up/step down).
Objectives
To assess the clinical effectiveness and cost-effectiveness of FeNO measurement for the diagnosis and
management of asthma in adults and children using the hand-held monitors NIOX MINO® (Aerocrine,
Solna, Sweden), NIOX VERO® (Aerocrine) and NObreath® (Bedfont Scientific, Maidstone, UK).
Methods
This report consists of two main parts: (1) an assessment of the clinical effectiveness of FeNO in the
diagnosis and management of asthma and (2) an assessment of the cost-effectiveness of FeNO compared
with standard care in the diagnosis and management of asthma.
Clinical evidence review
The following systematic reviews were conducted:
l Rapid review of the equivalence of FeNO devices. Aimed at establishing whether studies that used
other FeNO measurement devices could inform this appraisal.
l Systematic review of the diagnostic accuracy of FeNO measurement for asthma. All levels of evidence were
considered but, because of a lack of higher levels of evidence, diagnostic cohort studies informed this
assessment. When available, three pairs of sensitivity and specificity estimates were selected: (1) the highest
sum of sensitivity and specificity; (2) the highest sensitivity for rule-in scenarios; and (3) the highest specificity
for rule-out scenarios. In rule-in scenarios, patients testing positive are assumed to have asthma and those
testing negative go on to have further tests for asthma. In rule-out scenarios, those who test negative are
assumed not to have asthma and those who test positive go on to have further tests for asthma.
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l Systematic review of the efficacy of FeNO-guided management of asthma. Randomised controlled trial
(RCT) evidence was included and lower levels of evidence included when RCT evidence was not
available for pre-defined subgroups.
Databases searched included MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, the
Database of Abstracts of Reviews of Effects, Science Citation Index Expanded and Conference Proceedings
Citation Index – Science. Trial registers such as ClinicalTrials.gov and the metaRegister of Controlled Trials
were also searched. Initial searches were undertaken between March 2013 and April 2013 and update
searches for the diagnostic and management reviews were performed in September 2013. All reviews
considered adults and children separately. Subgroups of interest included older adults, pregnant women
and smokers. All three reviews were undertaken according to robust high-quality methodology.
Cost-effectiveness assessment
The cost-effectiveness assessment of FeNO included two components: a systematic review of existing
economic analyses and the development of two de novo health economic models:
l Systematic review and critical appraisal of existing economic evaluations. This included published
studies and evidence submitted by manufacturers.
l Development of two de novo models. Independent health economic models were developed to assess
the incremental cost-effectiveness of FeNO compared with standard care in the diagnosis and
management of asthma.
Results
Clinical effectiveness results
Rapid review of FeNO device equivalence
In total, 27 studies were included. Although there was often good correlation between FeNO measurement
devices, equivalence of readings could not necessarily be assumed in all situations. The 95% limits of
agreement were sometimes very wide (around ±10 parts per billion) and equivalence was generally poorer
between FeNO devices at higher FeNO levels. The direction of disagreement varied between studies and
comparator devices.
Correlation between measurements across all devices was high. Consequently, sensitivities and specificities
were assumed to be interchangeable, but it could not be assumed that the cut-off points used would be
the same for each device; this is an important issue.
Test failure rates were generally low although there may be some problems with using the NIOX MINO
device in younger children, with failure rates ranging from 5.5% to 27%.
Systematic review of the diagnostic accuracy of FeNO measurement
for asthma
In total, 27 studies were included in the review, 23 in adults (all ages) and four in children. Studies that
were similar to one another in terms of the position of the patients in the UK diagnostic pathway
[Scottish Intercollegiate Guidelines Network (SIGN) guidelines] and the reference standards used were
grouped together. No meta-analysis was conducted in any group as the clinical heterogeneity between
studies was very high.
Estimates of cut-off points, sensitivity and specificity were not consistent within groups and ranged widely
when used as a rule-in test and a rule-out test and when considering the highest sum of sensitivity and
specificity. The large variation in estimates within groups may obscure any true underlying differences in
the accuracy of FeNO between groups and compared with different reference standards. The evidence is
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especially difficult to interpret in the context of inserting FeNO into the UK diagnostic pathway. The
nearest equivalent to a pathway was reported in two studies in which FeNO was interpreted in conjunction
with results from another test, resulting in a change in both sensitivity and specificity, but it was not clear
whether clinical effectiveness and cost-effectiveness would also change. Some limited observations were
made: 100% specificity was achieved more often than 100% sensitivity and ranges of specificity were
generally smaller. This may indicate that FeNO has the highest potential for consistency and accuracy as a
rule-in test. It was also concluded that FeNO cut-off points should probably be lower in children than
in adults.
No cohort studies were found that provided evidence relating to pregnancy, the elderly and smokers/
children with environmental tobacco exposure. Consequently, lower levels of evidence were consulted.
l smokers: accuracy seemed similar but FeNO was generally lower in smokers and children exposed to
tobacco smoke
l the elderly: FeNO is unlikely to be a useful test in the diagnosis of asthma in the elderly
l pregnant women: pregnancy did not alter FeNO levels in asthmatics or non-asthmatics and FeNO
distinguished between asthmatic and non-asthmatic pregnant and healthy women.
Systematic review of the efficacy of FeNO-guided management of asthma
Five adult population studies were included. High levels of heterogeneity in multiple study characteristics
and outcome definitions prevented the External Assessment Group (EAG) from drawing any firm conclusions
with regard to which step-up/step-down protocol or cut-off points offered the best efficacy. All studies
reported fewer exacerbations in the FeNO arm, mostly driven by mild and moderate exacerbations, which
was statistically significant in only one study. The effects on ICS use were heterogeneous, although it
was not possible to conclude if this was because of differences in study populations or differences in
management protocols. Pooled analysis showed less ICS use in the intervention arm, but the difference was
not statistically significant. Health-related quality of life (HRQoL) was infrequently reported; two studies both
showed no effect on the global Asthma Quality of Life Questionnaire (AQLQ) score, but one found a
statistically significant difference in the symptoms score.
No study exceeded 12 months’ follow-up; it is unclear if any observed effects would be maintained over
longer time periods.
Seven studies in children were included. The severity of the patients’ symptoms varied between studies. All
studies except one reported a decrease in exacerbations in the intervention arm, but only one reported a
statistically significant reduction. The effects on ICS use were heterogeneous with two studies showing
a statistically significant increase in ICS use, two showing a non-significant increase, one showing no
difference, one being difficult to interpret and one further study not reporting this outcome. HRQoL was
reported in only one study; insufficient details were reported to draw conclusions.
A RCT of asthma management using FeNO in pregnant asthmatics was included. Statistically significant
differences in all exacerbations, OCS use and ICS use were reported, favouring the intervention.
Non-RCT evidence indicated that FeNO was unlikely to be useful in elderly asthmatics. In smokers, the
four non-RCT studies identified suggested that FeNO levels were lower in adult asthmatic smokers than in
adult asthmatic non-smokers and that FeNO can no longer detect asthma control in those smokers treated
with ICSs. The use of repeated measures and within-patient change from baseline may be worth
further investigation.
Cost-effectiveness results
There is very limited available evidence concerning the cost-effectiveness of FeNO for the diagnosis and/or
management of asthma. The systematic review identified one published UK model of FeNO testing in the
diagnostic setting and one published UK model of FeNO testing in the management setting. Both models
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were published within the same paper. Aerocrine also submitted a model of FeNO testing for diagnosis and
a model of FeNO testing for management; these models were similar to, but not the same as, the published
UK models. The existing economic diagnostic models indicate that NIOX MINO is likely to be cost saving
compared with other tests routinely used in the diagnosis of asthma, but may be more expensive than
standard diagnostic tests when used in conjunction with other tests. Neither diagnostic model captures the
health consequences associated with correct or incorrect diagnostic outcomes; hence, these models do not
provide any information regarding the economic trade-off between additional health gains resulting from
the more accurate diagnosis of asthma and health losses associated with displacing existing services. The
existing management models indicate that NIOX MINO produces more health gains at a lower cost than
guidelines alone. The EAG critique of these management models highlighted several problems including the
use of short time horizons, the selective use of efficacy evidence from different sources, the assumptions
about the equivalence between sputum count monitoring and FeNO and invalid assumptions about the
health losses associated with exacerbations. No economic evidence was submitted by the manufacturers for
either NIOX VERO or NObreath.
The EAG developed two de novo models. The first model assesses the cost-effectiveness of FeNO testing
using NIOX MINO, NIOX VERO and NObreath in addition to, or in place of, existing tests compared with
other diagnostic options commonly used in the diagnosis of asthma. The second model assesses the
cost-effectiveness of NIOX MINO, NIOX VERO and NObreath plus guidelines compared with guidelines
alone for the management of asthma.
The EAG diagnostic model suggests that, across the diagnostic options included in the economic analysis,
the expected difference in quality-adjusted life-year (QALY) gains is likely to be very small. Airway
hyper-responsiveness [assessed using the methacholine challenge test (MCT)] is expected to produce the
greatest QALY gain. The incremental cost-effectiveness ratio (ICER) of airway hyper-responsiveness (MCT)
compared with FeNO (NObreath) plus bronchodilator reversibility is expected to be £1.125M per QALY
gained. All remaining options are expected to be ruled out because of dominance. The results of the
analysis are sensitive to assumptions about the time required to resolve misdiagnoses, assumptions about
health losses associated with false-negative diagnoses, the costs of asthma management and the use of
‘rule-in’ and ‘rule-out’ diagnostic decision rules.
The EAG management model was evaluated across two subgroups: (1) children and (2) adults. Studies
from the clinical effectiveness review were selected for the model, based on similarity to UK practice and
patient populations. Sensitivity analyses were conducted using alternative studies to test the stability of the
results in other populations and against different comparators. Within both the child and adult subgroup
analyses, FeNO testing is expected to produce a small incremental QALY gain compared with guidelines
alone. In both subgroups, NIOX MINO and NIOX VERO are expected to be dominated as their marginal
per-test cost is higher than that for NObreath. Within the child subgroup, the ICER of guidelines plus FeNO
monitoring using NObreath compared with guidelines alone is expected to be approximately £45,200 per
QALY gained. Within the adult subgroup, FeNO monitoring using NObreath compared with guidelines
alone is expected to cost approximately £2100 per QALY gained. A similarly favourable result was
produced within a further analysis based on a subgroup of women who are pregnant. Importantly, these
positive results are not held when alternative trials are used to inform the analysis. The results in the child
and adult subgroups are particularly sensitive to assumptions about changes in ICS use over time, the
number of nurse visits for FeNO monitoring and the duration over which FeNO monitoring impacts on
exacerbations and ICS use.
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Conclusions
Implications for service provision
There is considerable uncertainty associated with all analyses within this assessment. This is largely because
of the limitations of the evidence base.
Studies using the devices that are the focus of this review were not available for all analyses and, in the
absence of an alternative, equivalence has been assumed but is not assured.
The clinical evidence relating to the use of FeNO for the diagnosis of asthma is highly heterogeneous and
difficult to interpret in the context of the insertion of FeNO into a diagnostic pathway.
Evidence for management is also inconclusive although consistent with FeNO resulting in fewer
exacerbations, with a small or zero reduction in ICS use in adults and a possible increase in ICS use in
children or patients with more severe asthma. It is unclear which specific management protocol is likely to
be most effective. There was no evidence relating to whether these effects would be maintained over a
longer time period.
The health economic analysis indicates that FeNO could have value in both the diagnostic setting and the
management setting. In particular, the diagnostic model indicates that FeNO plus bronchodilator reversibility
dominates many other diagnostic tests and may render airway hyper-responsiveness cost-ineffective. In the
management setting, FeNO-guided management has the potential to appear cost-effective although this is
largely dependent on the expected duration over which it continues to impact on medication decisions.
The conclusions drawn from both models require strong technical value judgements with respect to several
aspects of the decision problem in which little or no empirical evidence exists.
Suggested research priorities
Several research priorities were identified. The two key priorities, of equal importance, were:
1. What is the clinical utility of FeNO used in sequence with current guidelines for the diagnosis of asthma
and/or ICS responsiveness compared with current guidelines alone, when a reference standard of
long-term follow-up of diagnoses is used? What is the optimal placement for FeNO testing within the
diagnostic pathway?
2. What is the most effective step-up/step-down protocol for the management of asthma using FeNO? Is
it safe to step down treatment on the basis of low FeNO alone (e.g. in the presence of symptoms)?
Study registration
This study is registered as PROSPERO CRD42013004149.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Condition and aetiology
Introduction
Asthma is a chronic disorder of the airways, caused primarily by inflammatory processes and constriction of
the smooth muscle in airway walls (bronchoconstriction). It is characterised by airflow obstruction and
increased responsiveness of the airways to various stimuli. Symptoms include recurrent episodes of wheezing,
breathlessness, chest tightness and coughing. Typical asthma symptoms tend to be variable, intermittent and
worse at night. Asthma is commonly triggered by viral respiratory infections, exercise or external factors such
as smoke, a change in weather conditions and allergens, for instance pollen, mould and house dust mites.
Asthma usually develops in childhood but may start at any age. It runs in some families but many people
with asthma have no other family members affected. In adults, asthma is more common in women than in
men.1 There is no cure for asthma, although people may experience long periods of remission. Poorly
controlled asthma can have a significant impact on the quality of life of the affected individual and his or
her family. However, there may be variation in an individual’s perception of the symptoms and how he or
she adapts to the condition over time. Clinical measures such as lung function may not correlate with an
individual’s quality of life scores, but if asthma is well controlled near-maximal scores on quality of life
instruments can be achieved.
Classification of asthma
There are several ways of categorising different types of asthma, including:
l Intrinsic and extrinsic asthma. Asthma can be divided into extrinsic (external cause) and intrinsic
(when no causative agent can be found) asthma. Extrinsic asthma is triggered by allergens and hence
it is also termed ‘allergic asthma’. In extrinsic asthma the immune system reacts to substances such as
pollen and produces antibodies. Individuals with a predisposition to developing such allergies are said
to be atopic and may develop any combination of the triad of hay fever, eczema and asthma. In the
case of asthma, the allergic reaction is observed in bronchi and bronchioles, which results in the
production of excess mucus that obstructs the air passages. Extrinsic asthma is commonly seen in
children. About 90% of childhood asthma cases are caused by specific allergens. Individuals with a
family history of atopy are at a higher risk of developing extrinsic asthma. In contrast, intrinsic asthma
is a non-seasonal, non-allergic form of asthma, which usually first occurs at a later point in life than
allergic asthma. Intrinsic asthma tends to be chronic and persistent rather than episodic. It is not related
to specific allergens and may be provoked by the inhalation of chemicals such as cigarette smoke or
cleaning agents, non-steroidal anti-inflammatory drugs, chest infections, emotion, exercise, cold air,
food preservatives or various other non-specific irritants.
l Eosinophilic and non-eosinophilic asthma (neutrophilic asthma). Asthma can also be categorised as
eosinophilic or non-eosinophilic. There is some evidence that eosinophils may play an important
proinflammatory role in the pathogenesis of asthma,2,3 although there remains some uncertainty
around this and other pathogenic mechanisms associated with asthma. Eosinophils are found in the
airways of asthmatics but not healthy subjects and are believed to be related to exacerbations. It has
also been noted that suppression of eosinophil infiltration is often associated with amelioration of
symptoms2 but that the relationship is not close. Poor inflammation control is most closely related to
the risk of future exacerbations. The presence of eosinophils may be used to direct treatment as
patients without eosinophilic inflammation are thought to be less responsive to inhaled corticosteroid
(ICS) treatment.4 High levels of eosinophils are correlated with high levels of fractional exhaled nitric
oxide (FeNO) and it is thought that FeNO could be used as a biomarker of eosinophilic inflammation
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1
and therefore of ICS responsiveness.5,6 However, the presence of eosinophils is not always a marker of
severity of disease; fatal asthma may be associated with neutrophilia rather than eosinophilia.7
Targeting the type of inflammation may be a better guide to treatment than measures of disease
severity alone. For instance, glucocorticosteroids are typically very effective in eosinophilic inflammation
but less so if the inflammation is neutrophilic.
l Eosinophilic and non-eosinophilic airway disease. Eosinophilic inflammation occurs in both asthma and
chronic obstructive pulmonary disease (COPD) and in both cases the appropriate treatment is ICSs.6
There is a view held by some clinicians that, rather than a diagnosis of asthma, a diagnosis of
responsiveness to ICSs [irrespective of diagnostic label (asthma or COPD)] may be a more helpful
approach in terms of directing treatment, reducing costs and reducing exacerbations.6 However,
this form of classification has not yet been officially adopted in the British Thoracic Society (BTS)
and Scottish Intercollegiate Guidelines Network (SIGN) guidelines8 and this report will focus on the
diagnosis of asthma as described in these guidelines.
l Molecular approaches to classifying asthma phenotypes. There is an increasing trend to characterise
asthma by molecular and cellular factors to enable more targeted and personalised therapy. Such
efforts are ongoing and specific phenotypes and the implications of these are not yet fully elucidated.9
l Exercise-induced bronchoconstriction (EIB). Most patients with asthma will experience EIB but approximately
11% of the population without other forms of asthma also experience this. It is characterised by a
reduction in the forced expiratory volume in the first second (FEV1) of > 10% after exercise and can be
treated pharmacologically with short-acting beta2-agonists (SABAs) or leukotriene receptor antagonists
(LTRAs) and non-pharmacologically with a light warm-up before vigorous exercise for example. The exact
mechanisms behind EIB are not fully understood but may include neural and biochemical mediators.10
Prevalence of asthma
It is estimated that 5.4 million people in the UK are receiving treatment for asthma. Of these, 1.1 million
are children (one in 11) and 4.3 million are adults (one in 12) [see www.asthma.org.uk/asthma-facts-and-
statistics (accessed 21 May 2015)]. The UK has one of the highest prevalence rates of asthma symptoms in
children worldwide. In adults, occupational asthma, for instance because of allergens from animals, flour
or grain, may affect up to 20% of the workforce exposed to the sensitiser. An analysis of routine UK
databases undertaken by Anderson et al.11 indicates that the prevalence of asthma in all age groups has
risen substantially between 1955 and 2004 (Figure 1).
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FIGURE 1 Patients consulting general practitioners for asthma per 100,000 population, England and Wales,
1955–88.11 GPRD, General Practice Research Database; MSGP, Mortality Statistics in General Practice. Reproduced
from Thorax, 50 years of asthma: UK trends from 1955 to 2004, Anderson H, Gupta R, Strachan D, Limb E, vol. 62,
pp. 85–90, 2007, with permission from BMJ Publishing Group Ltd.
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Estimates of the prevalence of doctor-diagnosed asthma by age and sex are presented in Table 1, taken
from the Health Survey for England 2011.12
Based on data from the 2010 Health Survey for England,12 the prevalence of lifetime doctor-diagnosed
asthma was 16% among men and 17% among women and decreased with age for both sexes. At the
time of the survey, approximately 9% of men and 10% of women were classed as currently having
asthma as they had experienced symptoms of asthma or were controlling their symptoms with medication
in the previous 12 months. The proportion of respondents with asthma in the last 12 months did not vary
by age group in either sex. Of those individuals who had doctor-diagnosed asthma, 30% of men and
TABLE 1 Prevalence of doctor-diagnosed asthma by age and sex, 2010
Age group (years)
Total16–24 25–34 35–44 45–54 55–64 65–74 75+
Men (%)
Ever
Self-reported doctor-diagnosed asthma 25 20 16 12 13 13 9 16
Doctor-diagnosed asthma and in last 12 months
Symptoms of asthma 6 7 7 4 5 5 4 5
No symptoms, asthma controlled with
medications
4 3 3 3 3 5 4 3
Current asthma: with symptoms of asthma
or taking medication
10 10 10 7 8 9 8 9
No symptoms and no medication for asthma 90 90 90 93 92 91 92 91
Women (%)
Ever
Self-reported doctor-diagnosed asthma 21 20 17 16 15 16 14 17
Doctor-diagnosed asthma and in last 12 months
Symptoms of asthma 7 7 7 7 8 5 5 7
No symptoms, asthma controlled with
medications
4 3 4 3 2 7 5 4
Current asthma: with symptoms of asthma
or taking medication
10 10 11 10 10 12 10 10
No symptoms and no medication for asthma 90 90 89 90 90 88 90 90
Bases (unweighted)
Men 378 493 642 624 642 518 402 3699
Women 476 695 820 874 722 566 563 4716
Bases (weighted)
Men 644 701 754 720 608 429 318 4174
Women 610 686 760 730 630 470 441 4327
Source: Hall and Mindell.12 Copyright © 2015, Reused with the permission of the Health and Social Care Information
Centre. All rights reserved.
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39% of women had experienced an asthma attack in the previous 12 months. Of these patients, 42% of
men and 52% of women had experienced symptoms during the day in the last week, 22% of men and
29% of women reported that their symptoms had interfered with their usual activities in the last week and
19% of men and 28% of women reported difficulties with sleep in the last week.12
Any data on the prevalence of asthma are subject to the problems associated with diagnosing asthma. As
there is no definitive, objective test, there is significant over- and underdiagnosis of the condition.
Asthma mortality
In England and Wales, deaths resulting from asthma are rare. In 2011, the Office for National Statistics
(ONS) reported that there were 1041 reported deaths from asthma in England and Wales [see www.ons.
gov.uk/ons/rel/vsob1/death-reg-sum-tables/2011–provisional-/deaths-summary-tables—2011.xls (accessed
21 May 2015)]. Approximately two-thirds (67.2%) of these were in women and almost 79% of all asthma
deaths were in adults aged > 65 years (Figure 2).
As noted elsewhere,13 audit and case–control studies14–18 indicate that risk factors for death can be
separated into four categories: (1) disease severity, (2) medical care factors both before and during the
fatal episode, (3) health behaviour such as reduced concordance with prescribed medication, poor inhaler
technique and reduced contact with primary care services and (4) adverse psychosocial factors. Shepherd
et al.13 suggest that, given this categorisation, a proportion of asthma-related deaths are preventable,
especially in patients aged < 65 years.
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FIGURE 2 Registered deaths from asthma, England and Wales, 2011. Source: ONS [see www.ons.gov.uk/ons/rel/
vsob1/death-reg-sum-tables/2011–provisional-/deaths-summary-tables—2011.xls (accessed 21 May 2015)].
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Impact of the health problem
Impact of asthma on patients
The principal symptoms of asthma are wheezing attacks and episodic shortness of breath. An acute onset
of symptoms is known as an exacerbation. Coughing, which worsens at night, may also be a symptom.
Asthma exacerbations tend to vary considerably in terms of frequency and duration. Some people
experience one or two per year lasting for a few hours, whereas others have exacerbations lasting for
weeks or experience them more frequently. Exacerbations may be precipitated by a wide range of triggers,
as described in Classification of asthma. Asthma is a major cause of impaired quality of life and may
impact on a patient’s work, recreational activities, physical activities and emotions. However, although
patients’ health-related quality of life (HRQoL) may be impacted on by poor asthma control and the
incidence of exacerbations, it has been noted elsewhere that meeting clinical treatment goals may not
result in noticeable changes in a patient’s quality of life.13
In the long term, asthma may lead to permanent airflow obstruction and associated loss of quality of life,
especially when it is persistent or poorly controlled.19 Asthma also has a substantial impact on a patient’s
ability to work and study and has been estimated to result in at least 12.7 million lost working days per
year.12 Many patients will undergo regular monitoring and will be required to take medication for the rest
of their life. There have been concerns that long-term ICS use may reduce growth rates in children,
although evidence is conflicting and it appears that any reduction in growth may be transient, with
patients eventually achieving a normal adult height.20,21
Burden on the NHS
Given the high prevalence of people with asthma, asthma treatment represents a significant cost to the
NHS. The Health Survey for England 2010 estimated that direct health-care costs associated with asthma
are £1B per year.22 In addition, estimates from 2002 indicate that general practitioner (GP) prescriptions
alone are worth approximately £600M per year.22
As asthma is an incurable condition, treatment, or at the least monitoring, is usually required for the
remainder of the patient’s lifetime. However, as the diagnosis of asthma is not definitive there is the
potential for misdiagnoses to go undetected for many years or even an entire lifetime. Misdiagnosis can
occur when a patient appears to respond to treatment but in fact has experienced a natural resolution of
the symptoms of another underlying condition such as a cold, a respiratory infection or allergy. In these
cases, patients will appear well controlled and a treating physician may simply assume that the treatment is
working. The BTS/SIGN guidelines8 recommend that patients who are well controlled should ‘step down’
their therapy dose. This could result in a patient being taken off treatment altogether and their diagnosis
being reconsidered. However, clinical input to this review suggests that step down of doses does not always
occur as treatment is relatively cheap per patient and physicians are cautious not to risk exacerbations. As
such, there may be long-term unnecessary NHS expenditure associated with these misdiagnoses. Similarly,
both overtreatment and undertreatment of patients who have been correctly diagnosed with asthma may
be sources of substantial NHS expenditure. Undertreatment may increase costs to the NHS as poor control
may lead to an increased rate of severe exacerbations, which require additional primary care management
and acute hospital admissions. Overtreatment may increase costs to the NHS because a patient may be able
to receive the same level of symptom control with less medication and so the condition could have been
treated as effectively at a lower cost.
Guidelines for the diagnosis and management of asthma
Detailed guidelines on the diagnosis and management of asthma have been published and updated.8
These guidelines are referred to as the BTS/SIGN guidelines throughout the remainder of this report.
DOI: 10.3310/hta19820 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 82
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
Diagnosis of asthma
The diagnosis of asthma is a clinical one and there is no standardised definition of the condition. Central
to all definitions in adults is the presence of symptoms (wheezing, breathlessness, chest tightness and
cough) and of variable airflow obstruction measured through objective tests of lung function [such as peak
expiratory flow rate (PEFR) and FEV1 divided by forced vital capacity (FVC), known as the Tiffeneau–Pinelli
index (FEV1/FVC)] and percentage of predicted FEV1 (FEV1%; calculated as the percentage of the predicted
FEV1 for a person of the same height, sex and age without diagnosed asthma). Variability in PEFR and
FEV1, either spontaneously or in response to therapy, is a characteristic feature of asthma. The BTS/SIGN
guidelines8 indicate that the severity of asthma should be judged according to symptoms and the amount
of medication required to control symptoms.
More recently, descriptions of asthma have included airway hyper-responsiveness and airway inflammation.
It is unclear how these features relate to each other, how they are best measured and how they contribute
to the clinical manifestations of asthma.
Figures 3 and 4 present the diagnostic pathways for children and adults, respectively, as they currently stand.8
Diagnosis in children is clinically based on recognising a characteristic pattern of episodic symptoms in the
absence of an alternative explanation. Lung function tests are less useful because of variability and the
inability of very young children to perform these tests reliably. According to the BTS/SIGN guidelines,8
clinical features that increase the probability of asthma include:
l More than one of the following symptoms: wheeze, cough, difficulty breathing, chest tightness,
particularly if these symptoms:
¢ are frequent and recurrent
¢ are worse at night and in the early morning
¢ occur in response to, or are worse after, exercise or other triggers, such as exposure to pets,
cold or damp air, or with emotions or laughter
¢ occur apart from colds
l Personal history of atopic disorder
l Family history of atopic disorder and/or asthma
l Widespread wheeze heard on auscultation
l History of improvement in symptoms or lung function in response to adequate therapy.
Reproduced with permission from BTS/SIGN guidelines8
If asthma is suspected, an initial clinical assessment should be carried out to estimate the probability of
asthma. According to the BTS/SIGN guidelines,8 based on initial clinical assessment a child can be classified
according to their risk of having asthma as:
l high probability, where an asthma diagnosis is likely
l low probability, where a diagnosis other than asthma is likely
l intermediate probability, where the likely diagnosis is uncertain.
For children identified as having a low probability of asthma, a more detailed investigation and specialist
referral should be considered. For children with a high probability of asthma, a trial of treatment should be
started immediately, with review at 6–8 weeks. When the response is good, the ICS dose should be reassessed
every 6 months. Those with a poor response to treatment should undergo more detailed investigations.
There is insufficient evidence at first consultation to make a firm diagnosis of asthma in some children,
particularly those aged < 4–5 years.8 For those children who can perform spirometry and for whom airway
obstruction is evident, change in forced expiratory flow volume or peak expiratory flow monitoring should
be assessed in response to an inhaled bronchodilator and/or in response to a trial of treatment for a
specified period.
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Clinical assessment
HIGH PROBABILITY:
diagnosis of asthma
likely
Trial of asthma
treatment
Response?
Yes
Continue
treatment and
find minimum
effective dose
Assess compliance and
inhaler technique.
Consider further
investigation and/or referral
Further investigation.
Consider referral
Continue
treatment
No YesNo
Response?
+ VE – VEConsider tests of
lung functiona
and atopy
Consider
referral
Investigate/
treat other
condition
LOW PROBABILITY:
other diagnosis likely
INTERMEDIATE
PROBABILITY:
diagnosis uncertain
or poor response to
asthma treatment
FIGURE 3 Diagnosis of asthma in children according to BTS/SIGN guidelines.8 –ve, negative; +ve, positive. a, Lung
function tests include spirometry before and after bronchodilator (test of airway reversibility) and possible exercise
or methacholine challenge (tests of airway responsiveness). Most children over the age of 5 years can perform
lung function tests. Reproduced with permission from BTS/SIGN. British Guideline on the Management of Asthma:
a National Clinical Guideline. Edinburgh and London: BTS/SIGN; 2012.8
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Clinical assessment including spirometry
(or PEF if spirometry not available)
Presentation with suspected asthma
HIGH PROBABILITY:
diagnosis of asthma
likely
Response?b
Yes
Continue
treatment 
Further investigation.
Consider referral
Continue
treatment
No YesNo
Response?
Investigate/
treat other
condition
Trial of
treatmenta
LOW PROBABILITY:
other diagnosis likely
INTERMEDIATE
PROBABILITY:
diagnosis uncertain
FEV1/FVC
< 0.7
FEV1/FVC
> 0.7
Assess compliance and
inhaler technique.
Consider further
investigation and/or referral
FIGURE 4 Diagnosis of asthma in adults according to BTS/SIGN guidelines.8 PEF, peak expiratory flow. a, See section
2.5.1 of the BTS/SIGN guidelines; b, see table 6 of the BTS/SIGN guidelines. Reproduced with permission from
BTS/SIGN. British Guideline on the Management of Asthma: a National Clinical Guideline. Edinburgh and London:
BTS/SIGN; 2012.8
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In children with an intermediate probability of asthma who can perform spirometry and who have no
evidence of airway obstruction, tests for atopic status, assessment of bronchodilator reversibility and, if
possible, assessment of bronchial hyper-responsiveness using methacholine, exercise or mannitol should be
considered, although these last three would be performed in secondary care. In such cases specialist
referral should always be considered.
Other investigations to support a diagnosis of, or alternatively rule out, asthma in children include tests of
eosinophilic airway inflammation using induced sputum or exhaled nitric oxide concentrations, tests of
atopy by skin prick test or blood eosinophilia and chest radiography or other imaging techniques to
investigate other causes.
Diagnosis in adults is also based on clinical history and includes the recognition of a characteristic pattern
of symptoms and signs and the absence of an alternative explanation for them. However, in contrast to
the diagnostic pathway for children, in adults spirometry is performed at the first consultation to assess the
presence and severity of airflow obstruction.
As in the diagnosis of children, adults are also classified as having a high, low or intermediate probability
of asthma. Chest radiography and specialist referral may be considered in any patient presenting atypically
or with additional symptoms or signs.
Monitoring and management of diagnosed asthma
Asthma management aims to control symptoms (including nocturnal symptoms and exercise-induced
asthma), prevent exacerbations and achieve the best possible lung function, with minimal side effects of
treatment. For both children and adults, asthma is monitored and managed in primary care by routine
clinical review on at least an annual basis. These reviews include (but are not limited to) assessment of a
patient’s symptom score (using a validated questionnaire), exacerbations, oral corticosteroid (OCS) use, time off
school or work, growth and inhaler technique; in adults, lung function is also assessed by spirometry of peak
expiratory flow. Patients are managed in a stepwise manner, with escalation of medication until control is
reached. This approach to pharmacological management for children and adults is represented in Figures 5
and 6 respectively.8 Treatment is started at the step most appropriate to the initial severity of the asthma, with
the aim of achieving early control of symptoms and optimising respiratory function. Control is maintained by
stepping up treatment as necessary and stepping down when control is good.
Monitoring asthma in children
The BTS/SIGN guidelines8 on the management of asthma state that the monitoring of asthma in children
should include the assessment and recording of:
l symptom score, e.g. Children’s Asthma Control Test, Asthma Control Questionnaire
l exacerbations, oral corticosteroid use and time off school/nursery due to asthma since
last assessment
l inhaler technique
l adherence, which can be assessed by reviewing prescription refill frequency
l possession of and use of self management plan/personalised asthma action plan
l exposure to tobacco smoke
l growth (height and weight centile).
Reproduced with permission from BTS/SIGN guidelines8
The guideline is indistinct with respect to the use of biomarkers such as FeNO in the monitoring of asthma.
It states that ‘a better understanding of the natural variability of biomarkers independent of asthma is
required and studies are needed to establish whether subgroups of patients can be identified in which
biomarker guided management is effective’ (reproduced with permission from BTS/SIGN guidelines).8
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Monitoring asthma in adults
According to the BTS/SIGN guidelines,8 symptom-based monitoring is adequate in the majority of adults
with asthma. Those patients with poor lung function and a history of exacerbations in the previous year
may be at a greater risk of future exacerbations for a given level of symptoms. For adults, the factors that
should be assessed and recorded include:
l symptomatic asthma control: best assessed using directive questions such as the . . . Asthma
Control Questionnaire or Asthma Control Test
l lung function, assessed by spirometry or PEF [peak expiratory flow]
l exacerbations, oral corticosteroid use and time off work or school since last assessment
l inhaler technique
l adherence, which can be assessed by reviewing prescription refill frequency
l bronchodilator reliance, which can be assessed by prescription refill frequency
l possession of and use of self management plan/personal action plan.
Reproduced with permission from BTS/SIGN guidelines8
Description of technologies under assessment
The potential role of FeNO devices in the diagnosis and management
of asthma
Nitric oxide monitors measure FeNO. High FeNO levels in a patient with symptoms suggestive of asthma,
such as coughing and wheezing, may suggest that the patient has eosinophilic asthma that could be
treated with ICSs (see Classification of asthma). In individuals already diagnosed with asthma, changes in
FeNO levels may indicate how well a patient is responding to ICS-based medication, whether medication is
being adhered to and whether the dosage of medication should be increased or decreased (titrated or
step-up/step-down adjustment). Consequently, FeNO monitors may have a role in the diagnosis,
monitoring and management of patients with asthma.
However, current opinion is divided as to the utility of this measurement, in large part because of the
potential for various factors to confound FeNO levels. Amongst these are age, sex, smoking status,
exposure to environmental tobacco, pregnancy, height, measurement technique and atopic status and
medication.23,24 A further consideration is the observation that the dose–response plateaus within the
therapeutic range of ICSs,25,26 although doses up to 800 µg of beclomethasone dipropionate have been
reported to be distinguishable from placebo.27
Current service provision
A number of FeNO devices have been developed. Some of these are hand-held portable devices (such as
the devices that are the focus of this assessment) and others are stationary devices that measure FeNO
through chemiluminescent techniques. Both types of FeNO monitor have been available for use in the NHS
for a number of years. However, they are not available in all secondary care settings and their use in
primary care is extremely rare. There are a number of possible reasons why FeNO devices have not had a
more widespread diffusion into care, including the lack of clear guidance in the BTS/SIGN guidelines8 on
how they should be used, which itself is a consequence of contradictory research, and the previously
prohibitive cost and operational requirements of large chemiluminescent devices.
A number of other diagnostic interventions are commonly used in the diagnosis of asthma in England and
Wales, as described in Diagnosis of asthma. Some of these are performed in primary care, such as
spirometry, reversibility testing and trials of treatment, whereas others are performed in secondary care,
such as airway hyper-responsiveness [methacholine challenge test (MCT)] and sputum induction. As noted
earlier, monitoring and management of asthma in diagnosed patients is guided by BTS/SIGN guidelines.8
BACKGROUND
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Technologies under assessment
The three hand-held FeNO devices included in this assessment are NIOX MINO® (Aerocrine, Solna,
Sweden), NIOX VERO® (Aerocrine) and NObreath® (Bedfont Scientific, Maidstone, UK).
NIOX MINO
The NIOX MINO device determines FeNO concentration in a breath sample. The device is small, hand-held
and portable and it can be used by both adults and children. It requires a 10-second exhalation of breath
by the patient at an exhalation pressure of 10–20 cmH2O to maintain a fixed flow rate of 50± 5ml/second.
The last 3 seconds of the 10-second exhalation are analysed by a calibrated electrochemical sensor to give
a definitive result in parts per billion (ppb). Clinical cut-off values can be applied to the FeNO values to
categorise readings as low, intermediate or high, according to the reference ranges for ages < 12 years
and ≥ 12 years, as detailed in the sponsor’s submission (Aerocrine. Clinical Guide to Interpretation of FeNO
Values. Sponsor’s submission, 2013).
The NIOX MINO device is precalibrated and designed to ensure a service- and calibration-free system. It
can be used as a stand-alone device or connected to a PC for monitoring with the NIOX MINO Data
Management Program and for use with electronic medical record systems.
The device is Conformité Européenne (CE) marked and was launched in the UK in November 2004.
According to information provided by the manufacturer,28 there are currently 18 units available in primary
care settings, including general practices and nurse outreach projects, and 197 units in 127 hospitals
across the UK.29 The manufacturer claims that NIOX MINO is indicated for use as follows:
l to diagnose the specific type of airway inflammation to guide treatment
l to predict the onset of asthma symptoms or loss of asthma control as a result of eosinophilic
airway inflammation
l to monitor compliance to corticosteroid therapy and the effectiveness of treatment (frequency
of exacerbations).
NIOX VERO
During the assessment, Aerocrine began launching a new FeNO device that is intended to replace the
NIOX MINO device. The new device is called the NIOX VERO. This is a battery-powered device that features
a longer operational life and extended test volume life than the NIOX MINO device.
NObreath
The NObreath device is a diagnostic monitoring device that measures FeNO. The reading is presented in
ppb and is claimed to be directly related to the severity of inflammatory disease (e.g. asthma). NObreath
requires 12 seconds of exhalation of breath in adults and 10 seconds in children. The device weighs
approximately 400 g (including batteries). It has a battery life that lasts for up to 120 tests. The device is CE
marked. The device does not have a set lifetime as sensor cells can, and should, be replaced every 2 years.
Anticipated costs associated with the intervention
The marginal per-test costs of each of the three technologies considered within this assessment depend on
both fixed costs, such as the initial cost of the devices, and variable costs, such as the costs of consumables.
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The NIOX MINO device has a unit cost of £2100 and has an effective unit lifetime of 3 years or 3000 tests
(whichever comes first). The NIOX VERO device has a unit cost of £2310 and has an effective unit lifetime
of 5 years or 5000 tests (whichever comes first). The NObreath device costs £1995 and has an unlimited
unit lifetime. Maintenance for the NObreath device is provided free of charge by Bedfont Scientific.
Test kits for NIOX MINO are available in packs of 300 at a price of £1350, packs of 500 at a price of
£2100 or packs of 1000 at a price of £3950. Test kits for NIOX VERO are available in packs of 300 at a
price of £1500, packs of 500 at a price of £2200 or packs of 1000 at a price of £4200. Mouthpieces
for NObreath are available in packs of 50, 100, 300 or 1000 at prices of £195, £365, £995 and
£2995 respectively.
The NObreath device requires replacement of the sensor unit every 2 years at a cost of £295. Besides test
kits, there are no other replacement costs for the NIOX MINO and NIOX VERO devices.
This information is summarised in Table 2.
TABLE 2 Cost of equipment and consumables for the NIOX MINO, NIOX VERO and NObreath devices
Item NIOX MINO (£) NIOX VERO (£) NObreath (£)
Lifetime 3 years or 3000 tests 5 years or 5000 tests Unlimited
Equipment cost 2100 2310 1995
Test kits – 100 NA NA 365
Test kits – 300 1350 1500 995
Test kits – 500 2100 2200 NA
Test kits – 1000 3950 4200 2995
Sensor replacement NA NA 295
Maintenance NA NA Provided free by Bedfont Scientific
NA, not applicable.
BACKGROUND
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Chapter 2 Definition of the decision problem
Purpose of the decision to be made
The aim of the assessment was to assess the clinical effectiveness and cost-effectiveness of FeNO
measurement in people with asthma. This was separated into two distinct questions:
1. What is the clinical effectiveness and cost-effectiveness of FeNO testing in the diagnosis of asthma in
adults and children?
2. What is the clinical effectiveness and cost-effectiveness FeNO testing in the management and
monitoring of asthma in adults and children?
The cut-off values used in diagnostic technologies affect their sensitivity and specificity and result in different
proportions of patients being true positives (TPs), true negatives (TNs), false positives (FPs) and false negatives
(FNs). The consequences of being TP, TN, FP and FN are different in terms of costs and health impacts; hence,
the highest sum of sensitivity and specificity may not necessarily lead to optimal health outcomes. This is
relevant to the use of FeNO in the diagnosis of asthma and also to its use in guiding asthma management.
Definition of the scope of the assessment
The scope of this assessment was informed by two scoping workshops attended by specialist committee
members (SCMs), the External Assessment Group (EAG), the manufacturers, the National Institute for
Health and Care Excellence (NICE) and patient stakeholders. The definition of the decision problem reflects
the initial NICE scope29 and the subsequent discussions in the second workshop.
Definition of the interventions
Two monitors were identified at the scoping stage for this appraisal: NIOX MINO, which is manufactured
by Aerocrine, and NObreath, which is manufactured by Bedfont Scientific. During the latter stages of
the assessment, Aerocrine alerted the EAG to a follow-up device to NIOX MINO, the NIOX VERO device.
This device is also considered within this assessment although the evidence base is limited. All
three interventions are evaluated in the context of the diagnosis and management of asthma.
Populations and relevant subgroups
Relevant population for the assessment of FeNO in the diagnosis of asthma
The population of interest is people with clinical characteristics suggestive of asthma. Relevant subgroups are:
l any patient aged ≥ 5 years presenting to primary care with symptoms of asthma
l people with clinical characteristics suggestive of asthma who are difficult to diagnose
l patients who may experience different outcomes from those of the main population under assessment
with the use of FeNO, defined as smokers, the elderly and pregnant women.
Relevant population for the assessment of FeNO in the management of asthma
The population of interest is patients aged ≥ 5 years and diagnosed with asthma. There are two subgroups
of particular interest:
l those with good asthma control who are being considered for a dose reduction
l those with uncontrolled asthma who are experiencing exacerbations or worsening of symptoms and who
are being considered for a dose increase of ICSs or who are being checked for compliance with treatment.
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Comparators
The relevant comparators are diagnosis or management according to the current UK guidelines, as
described in Chapter 3. In the diagnostic setting, the relevant comparator consists of the current diagnostic
pathway without the use of FeNO measurements; this is different for children and adults (see Guidelines
for the diagnosis and management of asthma). In the management setting, the relevant comparator is
management according to current guidelines without the use of FeNO.
Relevant outcomes for the assessment
The assessment includes consideration of the available evidence across a wide range of clinical and
economic outcomes.
Clinical considerations
The intermediate measures for consideration include:
l diagnostic test accuracy
l test failure rate.
The clinical outcomes for consideration include:
l asthma control, which includes asthma symptoms
l exacerbation rates, which includes the frequency of exacerbations requiring unscheduled contact with
health-care professionals, visits to accident and emergency departments or hospitalisations
l clinical complications associated with acute exacerbations
l levels of ICSs
l use of OCSs
l adverse effects of treatment (including bronchodilators and steroids)
l HRQoL
l mortality.
Cost considerations
l Costs of equipment, reagents and consumables.
l Maintenance and renewal of equipment.
l Costs associated with asthma medication.
l Cost associated with acute exacerbations.
l Cost of further investigations avoided.
Place of the intervention in the diagnostic/treatment pathways
During the scoping phase of this appraisal, workshop attendees considered that the interventions should
be assessed when added to current practice. There are a number of potential places within the diagnostic/
treatment pathways where FeNO may be of clinical use and each is likely to have different consequences
for clinical effectiveness and cost-effectiveness.
Position of FeNO in the diagnostic pathway: children
During the scoping workshop it was agreed that FeNO is likely to be of most use in positions 1, 2 and 3 in
Figure 7. This figure is based on the BTS/SIGN clinical guidelines,8 with input from a clinician about how
the tests are used in practice (Dr John White, York Teaching Hospital NHS Foundation Trust, 17 July 2013,
personal communication). This equates to patients who are difficult to diagnose. Depending on whether
FeNO is used as a direct replacement for a test or as a rule-in or rule-out test at these positions in
the pathway, it may have the ability to prevent expensive secondary care visits if used in primary care.
In secondary care it may have additional value alone or in conjunction with existing secondary care tests.
FeNO could also be considered to replace the whole pathway or be inserted at other points along the
pathway. Tables 3–5 detail the actions and consequences associated with some different replacement and
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TABLE 3 Consequences of using FeNO as a direct replacement for the whole pathway or for airway
hyper-responsiveness in patients indicated for this test within the pathway: adults and children
Replacement
scenario
FeNO
measurement Action taken Consequence 1 Consequence 2
TP High FeNO
measurement
Treat as asthma Correct diagnosis of
asthma reached
None
FP Patient’s misdiagnosis goes
undetected until worsening
of symptoms or routine
review or continues lifelong
None
TN Low FeNO
measurement
Treat as not asthma Further tests for other
conditions
Correct diagnosis reached
FN Further tests negative,
re-enter asthma pathway or
remain misdiagnosed until
exacerbation or return to GP
with ongoing symptoms
TABLE 4 Consequences of using FeNO as a rule-out test before airway hyper-responsiveness: adults and children
Rule-out
scenario
FeNO
measurement Action taken Consequence 1 Consequence 2
TP High FeNO
measurement
Treat as possibly
asthma and
undertake further
confirmatory tests
Further tests confirm
asthma diagnosis
Treat as asthma
FP Further tests reject asthma
diagnosis
Further tests for other
conditions or diagnose as
non-specific symptoms
TN Low FeNO
measurement
Treat as not asthma Further tests for other
conditions
Correct diagnosis reached
FN Further tests negative,
re-enter asthma pathway or
remain misdiagnosed until
exacerbation or return to GP
with ongoing symptoms
TABLE 5 Consequences of using FeNO as a rule-in test before airway hyper-responsiveness: adults and children
Rule-in
scenario
FeNO
measurement Action taken Consequence 1 Consequence 2
TP High FeNO
measurement
Treat as asthma Correct diagnosis of
asthma reached
None
FP Patient’s misdiagnosis goes
undetected until worsening
of symptoms or routine
review or continues lifelong
None
TN Low FeNO
measurement
Further tests for
asthma
Tests for asthma negative Further tests for other
conditions or diagnose as
non-specific symptoms
FN Correct diagnosis of
asthma reached
None
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rule-in/rule-out scenarios. In rule-in scenarios, patients testing positive are assumed to have asthma and
those testing negative go on to have further tests for asthma. In rule-out scenarios, those who test
negative are assumed not to have asthma and those who test positive go on to have further tests
for asthma.
Position of FeNO in the diagnostic pathway: adults
For the diagnostic pathway in adults, FeNO is thought to be of most use in positions 1 and 2 in Figure 8.
This equates to patients who are difficult to diagnose. This figure is based on the BTS/SIGN clinical
guidelines,8 with input from a clinician about how the tests are used in practice (Dr John White, 17 July 2013,
personal communication). This led to the understanding that, in nearly all or at least most cases, patients
would undergo a trial of treatment or airway reversibility testing before being referred to secondary care,
regardless of their FEV1/FVC ratio. This is slightly different from our initial reading of the BTS/SIGN guidelines,
in which only patients with a FEV1/FVC ratio of < 0.7 would undergo these tests, with those with a FEV1/FVC
ratio of > 0.7 going on to secondary care for airway hyper-responsiveness testing. Our initial diagrammatic
representation of the adult pathway can be viewed on the NICE website (www.nice.org.uk/guidance/dg12/
documents/measurement-of-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-and-nobreath-
final-protocol2).
Depending on whether FeNO is used as a direct replacement for an existing test or as a rule-in or rule-out
test at these positions in the pathway, it may have the ability to prevent expensive secondary care visits if
used in primary care. In secondary care it may have additional value alone or in conjunction with existing
secondary care tests. FeNO could also be considered to replace the whole pathway or be inserted at
other points along the pathway.
Position of FeNO in the management pathway
The measurement of FeNO may be helpful in individuals diagnosed with asthma to facilitate titration of
corticosteroid therapy, to check for compliance with medication and ultimately to lead to better asthma
control. It is likely that management decisions would be based on a combination of the monitoring
information collected at review and FeNO measurements. In these scenarios, high levels of FeNO could
indicate that a patient’s asthma is not fully treated and may be interpreted in combination with symptoms
and medication use. A lack of control could be the result of worsening of the disease or it could be the
result of failure to comply with medication. The latter could be ascertained through additional checks on
the collection of prescriptions or the number of doses used, as measured by a dose-counter inhaler. Low
levels of FeNO could indicate that asthma is well controlled and may be interpreted in combination with
symptoms and medication use; this could guide a step down of medication and subsequent monitoring
of control.
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Positive response
(> 400-ml improvement)
F. Assess compliance and inhaler
technique. Withdraw treatment and
observe. Objective assessment of
symptoms with validated tools
1: Assess FeNO
Poor response
G. Test for airway
hyper-responsiveness and/or
airway inflammation
Treat as asthma
High: increase dose and assess response
Low: treat as poor response
2: FeNO
H. Further tests or referral,
including reconsider asthma
diagnosis
Consider performing chest radiography in any patient presenting atypically
or with additional symptoms or signs. Additional investigations such as full
lung function tests, blood eosinophil count, serum immunoglobulin and 
allergen skin prick tests may be of value in selected patients
High: trial of treatment with high dose
Low: refer for further tests
E. Trial of treatment
and/or reversibility
test
B. High risk C. Intermediate risk
A. Clinical characteristics suggestive of asthma (primary care)
Unclear or poor response
(< 400-ml improvement)
+
+
+
–
i.
ii.
iii.
iv.
v.
vi.
vii.
Symptoms pattern and triggers
Tests of atopy/family history
Auscultation
History of abnormal lung function (FEV1 or PEF, historical or serial readings)
Peripheral blood eosinophilia
FEV1/FVC < or > 0.7
PEF
Investigate other
conditions
Treat as not
asthma
D. Low risk
–
–
FIGURE 8 Potential positions for FeNO in the diagnostic pathway: adults. PEF, peak expiratory flow.
Source: BTS/SIGN guidelines8 with clinical input from Dr John White (17 July 2013, personal communication).
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Structure of the assessment report
The assessment report consists of two main parts: (1) an assessment of the clinical evidence relating to
FeNO in the diagnosis and management of asthma and (2) an assessment of the cost-effectiveness of
FeNO compared with standard care in the diagnosis and management of asthma.
Clinical evidence review
Two systematic reviews and one rapid review were conducted concurrently to identify clinical evidence
relevant to the decision problem:
l Rapid review of the equivalence of FeNO devices. It was not clear at the outset if there would be
sufficient primary research evidence relating to the three devices to inform the appraisal. As such, a
review of the equivalence of these devices to other FeNO measurement devices was anticipated and
appropriate searches were conducted. The review of equivalence was conducted in full when it became
apparent that sufficient evidence was not available from the diagnostic accuracy review and
management efficacy review. The equivalence review aimed to establish whether measurements from
different FeNO measurement devices could be considered to be equivalent to one another and
therefore whether studies that used other devices could helpfully inform this appraisal. This review was
thought to be the least critical in terms of informing key model inputs and a rapid review using
systematic methods was therefore conducted because of time and resource constraints. This represents
a change to the published assessment protocol.30 (www.nice.org.uk/guidance/dg12/documents/
measurement-of-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-and-nobreath-final-protocol2.)
l Systematic review of the diagnostic accuracy of FeNO measurements for asthma. The ideal study would
recruit patients with symptoms of asthma, have a cohort design or randomise patients to diagnosis
using FeNO or diagnosis using other methods and follow them to clinical outcomes. Such studies are
known as end-to-end studies and demonstrate the ability of the test to improve patient outcomes.
In the absence of such studies, diagnostic cohort studies represent the next best level of evidence,
with modelling of clinical outcomes based on the numbers of patients classed as TP, TN, FP and FN.
Below this are correlation studies. All levels of evidence were searched for in this review; lower levels
of evidence were consulted when the higher levels of evidence were not identified. When available,
three pairs of sensitivity and specificity values were selected: those that produced the highest sum of
sensitivity and specificity; those that had the highest sensitivity for rule-in scenarios; and those that had
the highest specificity for rule-out scenarios. In rule-in scenarios, patients testing positive are assumed
to have asthma and those testing negative go on to have further tests for asthma. In rule-out scenarios,
those who test negative are assumed not to have asthma and those who test positive go on to have
further tests for asthma.
l Systematic review of the efficacy of FeNO-guided management of asthma. Existing systematic reviews
of randomised controlled trial (RCT) evidence in adults31 and children32,33 meant that only RCT evidence
was searched for in this review, with additional interrogation of the database for data on subgroups
when RCT evidence was not found.
Cost-effectiveness assessment
The cost-effectiveness assessment of FeNO includes two components: a systematic review of existing
economic analyses and the development of two de novo health economic models:
l Systematic review of the cost-effectiveness of FeNO for the diagnosis and/or management of asthma.
A systematic review was undertaken to identify all existing economic analyses of FeNO testing for
asthma; this includes published studies as well as evidence submitted by the manufacturers of NIOX
MINO, NIOX VERO and NObreath. This included a critical appraisal of the available evidence and a
summary of methodological problems and concerns relating to these analyses.
l Development of two de novo models. Independent health economic models were developed to assess
the incremental cost-effectiveness of FeNO compared with standard care in the diagnosis and
management of asthma.
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Chapter 3 Clinical review
Methods
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
As described in Chapter 2, Clinical evidence review, two systematic reviews and one rapid review were
conducted concurrently to identify clinical evidence relevant to the decision problem:
l rapid review of the equivalence of FeNO devices
l systematic review of the diagnostic accuracy of FeNO testing for asthma
l systematic review of the efficacy of FeNO-guided management of asthma.
The protocol is registered with PROSPERO (reference number CRD42013004149) and can be accessed at
www.crd.york.ac.uk/NIHR_PROSPERO/.
Search methodology for the clinical reviews
Systematic searches were carried out between March 2013 and April 2013. Update searches were
conducted in September 2013 for the diagnostic and management reviews. For the review of device
equivalence and for both diagnostic and management reviews, the following databases were searched:
l MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (Ovid): 1948–present
l EMBASE (Ovid): 1974–present
l The Cochrane Library (Wiley Interscience):
¢ Cochrane Database of Systematic Reviews (CDSR): 1996–present
¢ Database of Abstracts of Reviews of Effects (DARE): 1995–present
¢ Cochrane Central Register of Controlled Trials (CCRCT): 1898–present
¢ Health Technology Assessment (HTA) database: 1995–present
¢ NHS Economic Evaluation Database (NHS EED): 1995–present
l Science Citation Index Expanded (SCIE) (Web of Science): 1899–present
l Conference Proceedings Citation Index – Science (CPCI-S) (Web of Science): 1990–present.
The search strategies used in MEDLINE are provided in Appendix 1.
The following trial registers and websites were searched in March 2013 for all three reviews and again in
September 2013 for the diagnostic and management reviews (search terms used are provided in
Appendix 1):
l ClinicalTrials.gov (http://clinicaltrials.gov/)
l metaRegister of Controlled Trials (www.controlled-trials.com/mrct/)
l US Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database
(www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm)
l EuroScan International Network (http://euroscan.org.uk/).
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Management review searches
Searches for the management review were developed following the identification of a 2009 Cochrane
review.31 Study design filters were not applied to the strategy in case lower levels of evidence were needed
for the subgroups defined a priori in the protocol. The strategy (Figure 9) was made up of (1) free-text
terms for NIOX MINO and NObreath (including manufacturer names), (2) subject heading and free-text
terms for asthma (e.g. respiratory hypersensitivity, bronchoconstriction) and (3) subject heading and
free-text terms for lower respiratory tract symptoms (e.g. coughing, wheezing, chest pain). Search
strings (2) and (3) were combined with subject heading and free-text terms for exhaled nitric oxide and the
results were added to the results for search string (1). Searches were limited to publications since 2009.
A summary of the search records retrieved from the searches is provided in Table 6.
Diagnostic review searches
Similar to the management review search strategy, the diagnostic search consisted of terms for NIOX
MINO and NObreath, including manufacturer names, and subject heading and free-text terms for asthma
and lower respiratory tract symptoms combined with terms for exhaled nitric oxide (see Figure 9). The
strategy was combined with three filters: (1) a systematic reviews filter, (2) a RCT filter and (3) a diagnostic
filter. No date limits were applied to the searches.
A summary of the search records retrieved from the searches is provided in Table 7.
Equivalence of devices review searches
The analytical validity study searches for NIOX MINO and NObreath were carried out using terms for NIOX
MINO and NObreath and the manufacturer names without any application of filters and limits in the
databases listed (Figure 10). The numbers of records retrieved by database are provided in Table 7
(final column).
TABLE 6 Search records retrieved by database: management review
Database Number of records
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 991
EMBASE 2269
CDSR 44
DARE 1
CCRCT 117
HTA database 8
SCIE 1387
CPCI-S 70
Total unique references 2747
CLINICAL REVIEW
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Asthma terms
2009–onwards
limit
Intervention and
manufacturer terms
Lower respiratory
tract symptom
terms
Exhaled nitric
oxide terms
Exhaled nitric
oxide terms
AND
AND AND
OR
OR OR
OR
Systematic reviews
filter
RCT filter Diagnostic filter
For example, NIOX MINO,
NObreath, aerocrine, bedfont
For example, asthma,
bronchoconstriction,
bronchial spasm
For example, FeNO,
ENO, fractional NO
Asthma diagnostic reviewAsthma management review
AND
FIGURE 9 Management and diagnostic studies of FeNO devices.
TABLE 7 Search records retrieved by database: diagnostic review
Database
Search by study design
Equivalence reviewSystematic reviews RCTs Diagnostic studies
MEDLINE and MEDLINE In-Process &
Other Non-Indexed Citations
26 958 377 97
EMBASE 114 1386 452 282
CDSR 44 – – 0
DARE 1 – – 0
CCRCT – 509 – 10
HTA database 8 – – 4
NHS EED 2 – – 1
SCIE 76 637 284 92
CPCI-S 3 17 10 8
Total unique references 227 1635 680 309
Intervention and
manufacturer terms
For example NIOX MINO,
NObreath, aerocrine, bedfont 
Equivalence review
FIGURE 10 Equivalence studies of FeNO devices.
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Additional search for NIOX VERO
Aerocrine’s new device, NIOX VERO, was brought to the attention of the EAG in July 2013. An additional
search was conducted on 13 August 2013 to check for any publications relating to this device that would have
been missed by the original search. This search consisted of simply the term ‘Niox Vero’. A summary of the
search records retrieved from the searches is provided in Table 8.
Management and diagnostic review update searches: September 2013
In response to stakeholder comments received as part of the appraisal process, an update to the
management and diagnostic reviews was undertaken in September 2013. Table 9 summarises the search
records retrieved. Searches were limited to papers published in 2013.
Reference management
All retrieved citations were downloaded into Reference Manager bibliographic software version 12
(Thomson ResearchSoft, San Francisco, CA, USA) and deduplicated to include only unique citations.
The update searches were also deduplicated but not against the original searches.
Study selection
Retrieved citations were considered for inclusion in several stages. First, titles were considered and any
studies obviously not relevant were excluded. Second, abstracts were consulted. At this stage, tags were
applied to studies in Reference Manager to identify the device used, the age group of the participants and
the study design. In instances in which it was obvious which review the study was likely to inform, this tag
was also applied. In the third stage, articles tagged as the highest levels of evidence for each review were
retrieved and the full texts were compared against the inclusion and exclusion criteria.
TABLE 8 Additional searches for NIOX VERO
Database Number of records
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 0
EMBASE 0
CDSR 0
DARE 0
CCRCT 0
HTA database 0
NHS EED 0
SCIE 0
CPCI-S 0
ClinicalTrials.gov 0
metaRegister of Controlled Trials 0
MAUDE database 0
EuroScan International Network 2
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Once the full-text selection process was complete, a decision was made whether there were gaps in the
evidence that would require lower levels of evidence to be consulted. This was the case for the diagnostic
review, in which no end-to-end studies were identified; for the management review, in which only limited
evidence was identified for NIOX MINO and no evidence was identified for NObreath; and for some of
the subgroups of interest to the review. For the diagnostic review, studies including any device were
included rather than just those using NIOX MINO, NIOX VERO or NObreath (see Review of the diagnostic
accuracy of FeNO testing for asthma) and, for the management review, studies using any FeNO device
were included (see Review of the efficacy of FeNO-guided management of asthma); the rapid review of
the equivalence of devices was conducted in full (see Review of the equivalence of devices). To retrieve
relevant titles from the database for the subgroups of interest to the review, the keyword search facility in
Reference Manager was used to search for the following keywords:
l elderly asthmatics: elderly, old, older and elderly care
l smokers: smoke, smoking, smoking.adverse effects, smoking.epidemiology, smoking cessation,
smoking cessation programme, smoking habit, smoking/ae [adverse drug reaction] and
smoking: epidemiology
l pregnant women: pregnant, pregnancy, expectant, pregnancy complication/co [complication],
pregnancy complication/si [side effect], pregnancy complications, pregnancy diabetes mellitus,
pregnancy diabetes mellitus/dt [drug therapy], pregnancy outcome, pregnancy test and
pregnant women.
These titles were then sifted by title, abstract and full text for inclusion in the review with relation to
criteria for population, intervention and comparator. Criteria on study design and specific outcomes were
relaxed and studies of the next best level of evidence that provided data evaluating the use of FeNO
measurements in appropriate subgroups were included. The hierarchy of evidence used was as described
in the NICE guidelines methods guide.34
TABLE 9 Update of the management and diagnostic reviews: search records retrieved by database
Database Number of records
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 206
EMBASE 341
CDSR 12
DARE 0
CCRCT 0
HTA database 0
SCIE 250
CPCI-S 8
Total 817
Total unique 464
Clinical trials.gov 9
metaRegister of Controlled Trials 32
MAUDE database 0
EuroScan International Network 15
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Review of equivalence of devices
Table 10 describes the inclusion and exclusion criteria for this review.
Review of the diagnostic accuracy of FeNO testing for asthma
Table 11 describes the inclusion and exclusion criteria for this review and any differences from the
published protocol (www.nice.org.uk/guidance/dg12/documents/measurement-of-exhaled-nitric-oxide-
concentration-in-asthma-niox-mino-and-nobreath-final-protocol2). At full-text sift stage, some unforeseen
questions about the scope were sent to SCM clinicians for clarification. This is documented in Appendix 2.
Review of the efficacy of FeNO-guided management of asthma
Table 12 describes the inclusion and exclusion criteria for this review and any differences from the
published protocol (www.nice.org.uk/guidance/dg12/documents/measurement-of-exhaled-nitric-oxide-
concentration-in-asthma-niox-mino-and-nobreath-final-protocol2).
Data extraction
A different standardised data extraction form was developed for each review following the guidelines given
in the Cochrane Handbook for Systematic Reviews of Interventions36 and the Centre for Reviews and
Dissemination (CRD) Guidance for Undertaking Reviews in Healthcare;37 these forms were piloted using two
studies per review. Missing fields were added as appropriate and backfilled where necessary. Appendix 3
lists the fields that were data extracted for each review. Data were extracted from the studies by one of three
reviewers and checked by a second reviewer (SH, ME, TG), except for the rapid review of the equivalence
of devices for which a sole reviewer (SH) extracted all relevant data. Any discrepancies were resolved by
discussion, with involvement of a third reviewer when necessary. When appropriate, authors were contacted
for missing or unclear data. Data from multiple publications of the same study were extracted and quality
TABLE 10 Inclusion and exclusion criteria for the review of equivalence of devices
Criterion Inclusion Exclusion
Change from
protocol
Population Studies conducted in humans only, regardless of
asthmatic status or recruitment methods
Studies performed in vitro on
gas samples unless no test
evidence was found in humans
None
Primary device NIOX MINO, NIOX VERO or NObreath operated
in accordance with ATS 2005 guidelines:35
l expiratory flow rate of 50ml/second
(0.05 l/second)
l an exhalation time of ≥ 10 seconds for adults
and ≥ 6 seconds for children
NIOX VERO
added
Comparator Other chemiluminescent devices operated in
accordance with ATS 2005 guidelines:35
l expiratory flow rate of 50ml/second
(0.05 l/second)
l an exhalation time of ≥ 10 seconds for adults
and ≥ 6 seconds for children
If no studies at this flow rate and with this
exhalation time were found, any flow rate or
exhalation time was to be included
None
Outcomes Studies of analytical validity were included if they
reported the ability of the test to measure FeNO
accurately, by any statistical method, compared
with chemiluminescent devices
Studies of inter-rater reliability
or intersubject repeatability
were excluded
None
Study design Any None
ATS, American Thoracic Society.
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TABLE 11 Inclusion and exclusion criteria for the review of diagnostic accuracy
Criterion Inclusion Exclusion Change from protocol
Population Primary population is patients
presenting with clinical
characteristics suggestive of asthma.
The main relevant subgroups within
this population are:
l those presenting with clinical
characteristics suggestive of
asthma and who are difficult
to diagnose
l women during pregnancy
l older people
l smokers
Studies were included if they
recruited a wider population but
reported a priori subgroup analyses
for the populations of relevance to
this review
l Children < 5 years old
l Studies that recruited a
wider population and did
not report a priori subgroup
analyses for the populations
of relevance to this review
l Animal models
l Unselected specific
populations (e.g. firefighters,
obese people, athletes)
None
Intervention Use of NIOX MINO or NObreath in
the diagnosis of asthma, either with
or without another test or tests.
NIOX MINO and NObreath devices
are set to record according to
American Thoracic Society 2005
criteria:35
l expiratory flow rate of
50ml/second (0.05 l/second)
l an exhalation time of
≥ 10 seconds for adults and
≥ 6 seconds for children
If data were not available for the
above interventions, studies were
included if they reported the clinical
validity of FeNO measured by any
chemiluminescent device with
appropriate measurement methods:
l expiratory flow rate of
50ml/second (0.05 l/second)
l an exhalation time of
≥ 10 seconds for adults and
≥ 6 seconds for children
l online measurement
Studies that did not report any of
these details were included and
discussed in the narrative review.
Studies using any cut-off value or
combination of cut-off values were
included
l Expiratory flow rate not
50ml/second (0.05 l/second)
l An exhalation time of
< 10 seconds in adults and
< 6 seconds in children
l Offline measurements
l Alveolar nitrogen oxide or
nasal nitrogen oxide
measurements
The protocol stated that studies
using the following cut-off
values would be included:
l FeNO < 25 ppb (< 20 ppb
in children) indicates that
eosinophilic inflammation
and responsiveness to
corticosteroids are
less likely
l FeNO > 50 ppb (> 35 ppb
in children) indicates that
eosinophilic inflammation
and, in symptomatic
patients, responsiveness to
corticosteroids are likely
l FeNO values between
25 ppb and 50 ppb
(20–35 ppb in children)
should be interpreted
cautiously and with
reference to the clinical
context
However, no studies using
these exact cut-off values were
found and so all cut-off values
were included
Because no studies using
NObreath or NIOX VERO were
found, the contingency to
include any chemiluminescent
device was affected
continued
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TABLE 11 Inclusion and exclusion criteria for the review of diagnostic accuracy (continued )
Criterion Inclusion Exclusion Change from protocol
Comparator Any combination or selection of tests
and clinical characteristics described
in the BTS/SIGN guidelines8 for the
diagnosis of asthma
Uses tests to diagnose asthma
that are not included in the
BTS/SIGN guidelines8 or if the
comparator includes the use
of FeNO measurements
Studies using tests not in
routine use in the UK but
mentioned in the BTS/SIGN
guidelines8 were included in
the review
Outcome l End-to-end studies – include
studies with relevant clinical
outcomes (see Table 12)
l Clinical validity studies – include
studies which report data that
allow the extraction of the
numbers of patients who are TP,
TN, FP and FN against the
reference standard. Studies that
report test failure rates were
also included
Does not report useable
diagnostic validity data
(i.e. extraction of the numbers of
patients who are TP, TN, FP and
FN against the reference
standard)
None
Study design l End-to-end studies (which follow
patients from diagnostic test
to clinical outcomes) – if no
evidence was found at this level,
clinical validity studies (which
compare the diagnosis of
patients by the intervention with
that by a reference standard)
were included. These should be
prospective cohort studies,
cross-sectional studies or
retrospective cohort studies. If
studies of these designs were
not located, other study
designs were considered
(e.g. case–control studies)
l Both studies deriving cut-off
values for diagnosis and studies
validating existing cut-off values
for diagnosis to be included
l Abstracts with comparable data
that do not exist in full
published studies
l Preclinical and biological
studies
l Editorials and opinion pieces
l Studies published only in
languages other than English
Studies published as abstracts
and not reporting sufficient
methodological details to allow
critical appraisal of study
quality were not excluded
Setting Primary care, secondary care,
outpatient clinic or specialist clinic
Emergency care diagnosis of
exacerbation
None
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TABLE 12 Inclusion and exclusion criteria for the review of FeNO-guided management of asthma
Criterion Inclusion Exclusion Change from protocol
Population Patients diagnosed with asthma. The two
subgroups of particular interest were:
l those with good asthma control
who are being considered for a
dose reduction
l those with uncontrolled asthma
who are experiencing
exacerbations or worsening of
symptoms and who are being
considered for a dose increase of
ICSs or who are being checked
for compliance to treatment
In addition, further subgroups within
each of these categories were included:
l women during pregnancy
l older people
l smokers
Studies were included if they recruited
whole asthma populations or patients
exclusively from any of the subgroups
l Children < 5 years old
l Patients not diagnosed
with asthma
l Animal models
l Unselected specific
populations (e.g. firefighters,
obese people, athletes)
None
Intervention Use of NIOX MINO or NObreath in the
diagnosis of asthma, either with or
without another test. NIOX MINO and
NObreath devices are set to record
according to American Thoracic
Society 2005 criteria:35
l expiratory flow rate of
50ml/second (0.05 l/second)
l an exhalation time of
≥ 10 seconds for adults and
≥ 6 seconds for children
If data were not available for the
above interventions, studies were
included if they reported the clinical
validity of FeNO measured by any
chemiluminescent device with
appropriate measurement methods:
l expiratory flow rate of
50ml/second (0.05 l/second)
l an exhalation time of
≥ 10 seconds for adults and
≥ 6 seconds for children
l online measurement
Studies that did not report any of
these details were included and
discussed in the narrative review
Studies monitoring at intervals of
> 2 weeks were included
Any protocols and cut-off values for
management decisions or compliance
monitoring were included
Device that is not validated for
measuring FeNO:
l expiratory flow rate not
50ml/second (0.05 l/second)
l an exhalation time of
< 10 seconds offline
measurements
Studies in which FeNO is
measured on a more regular
basis (i.e. not during routine
annual review) were excluded
Studies that did not report
any details about the device
or measurement methods
were included and discussed
in the narrative review
The protocol stated that ‘only
studies using FeNO
measurements in:
l routine annual monitoring
l dose titration indicated
during routine monitoring
l assessment of compliance
will be included in the
review’
However, no such studies
were located and so studies
monitoring at intervals of
> 2 weeks were included
continued
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TABLE 12 Inclusion and exclusion criteria for the review of FeNO-guided management of asthma (continued )
Criterion Inclusion Exclusion Change from protocol
Comparator l Studies comparing the
interventions to any other
management strategy that does
not utilise FeNO measurements
were included
l Studies using management
strategies that closely match all or
part of UK practice as described
in the BTS/SIGN guidelines8
were included
l When no studies that closely
match UK practice were found,
studies using other management
strategies were included
Includes the use of FeNO
measurements as part of the
management strategy
None
Outcome l Incidence of acute exacerbations,
including those requiring
unscheduled contact with
health-care professionals, visits to
accident and emergency
departments or hospitalisations
l Other measures (time-to-event
data; numbers of patients
experiencing an exacerbation)
were considered only if
insufficient data were available for
the rate of exacerbations. Any
definition of exacerbation was
acceptable
l Asthma control, which includes
asthma symptoms, either reported
individually or by use of a
standardised patient outcome
measure or symptom score
l Clinical complications associated
with acute exacerbations
l Levels of ICSs
l Use of OCSs
l Adverse effects of treatments
(including bronchodilators
and steroids)
l HRQoL
l Mortality
l Compliance
l Does not report data on
FeNO-guided step-up
step-down therapy
l Measurement of alveolar
nitrogen oxide or nasal
nitrogen oxide
None
Study
design
l RCTs
l If insufficient RCT evidence is
identified, other study designs will
be included according to the
hierarchy of evidence for efficacy
trials
l Abstracts with comparable data
that do not exist in full published
studies and with sufficient
methodological details were
included
l Preclinical and
biological studies
l Editorials and opinion pieces
l Studies published only in
languages other than
English
Studies published as abstracts
and not reporting sufficient
methodological details to
allow critical appraisal of
study quality were not
excluded
Setting Primary care, secondary care,
outpatient clinic or specialist clinic
Emergency care None
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assessed as a single study. In a change from the protocol, data were not extracted from existing systematic
reviews, but directly from the primary research journal articles and conference abstracts.
Quality assessment
As it was a rapid review, quality assessment was not conducted for the review of the equivalence
of devices.
Diagnostic cohort studies were assessed using the Quality Assessment of Diagnostic Accuracy Studies –
second revision (QUADAS-2) tool.38 The tool was adapted to the specifics of this appraisal and the scoring
scheme can be found in Appendix 4. Because of the complexity of this assessment, items within QUADAS-2
that related to applicability were omitted and this was addressed in detail as follows:
(a) Are there concerns that the included patients do not match the review question? – addressed through
the subcategorisation of studies according to patient characteristics.
(b) Are there concerns that the index test, its conduct or its interpretation differs from the review
question? – addressed through a review of the equivalence of devices and through the selection of
studies that recorded FeNO according to American Thoracic Society (ATS) guidelines.35
(c) Are there concerns that the target condition as defined by the reference standard does not match the
review question? – addressed through the subcategorisation of studies according to the reference
standard used.
Management RCT studies were assessed using domains listed in the Cochrane risk of bias tool.36
The scoring scheme can also be found in Appendix 4.
Studies of lower quality were not formally quality assessed but were considered on their individual merits.
Quality assessment was conducted by one reviewer and checked by a second. A third reviewer was
consulted in cases of disagreement.
Analysis and synthesis
A narrative synthesis was conducted for the rapid review of the equivalence of devices and no
meta-analysis was planned or attempted.
A narrative synthesis was conducted for the review of diagnostic studies. A meta-analysis was planned if
sufficient studies of acceptable clinical heterogeneity in terms of patient populations, devices, cut-off points
and reference standards were available. A meta-regression to allow the use of multiple cut-off points in
the modelling was planned, again if the necessary data were available with appropriate levels of
heterogeneity between studies. However, data were not suitable for meta-analysis or meta-regression.
A narrative synthesis was conducted for the review of management studies. A meta-analysis was planned
if enough studies of acceptable clinical heterogeneity in terms of patient populations, devices, cut-off
points, interventions, comparators and outcomes were available. Clinical heterogeneity indicated that such
an analysis was unlikely to produce meaningful results, but exploratory analyses and sensitivity analyses in
relation to elements of study design were conducted in the review of adult studies, even though clinical
heterogeneity was high. For rate outcomes, the generic inverse variance method was used in Review
Manager version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark)
to meta-analyse rate ratios. For continuous outcomes, a standardised mean difference analysis was
conducted as metrics for ICS use were different.
In all cases, fixed effects were used first and random effects were applied if the I2 statistic indicated that
heterogeneity was moderate or high. This was judged to be the case at > 40%.
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Results
A total of 4859 citations were retrieved and considered for inclusion in the review. After scrutiny of the
titles and abstract, 4454 studies were excluded and the full texts of 405 citations were obtained and
consulted. Of these, 338 were excluded (see Appendix 5), one additional study was retained for the
subgroup reviews of management in pregnant women and 58 other studies (66 citations) were included in
the review. The update search yielded 495 citations. These were not deduplicated against the original
search. Of these, 489 were excluded and six studies (six citations) were included in the review. As such, in
total, 65 studies (71 citations39–109 plus two sponsors’ submissions: Fukuhara A, Sato S, Saito J, Sato Y,
Nikaido T, Inokoshi Y, et al. Conversion equations of FeNO levels measured by two portable and a
stationary analyzers. Sponsor’s submission, 2013. Unpublished abstract submitted by Bedfont, 2013.
Hedlund A. A Randomized, Multi-center Study to Determine the Agreement between the NIOX MINO®
Nitric Oxide Monitoring System and the NIOX VERO@ Device Using the 10-Second Exhalation Mode.
Sponsor’s submission received 18 July 2013) were included in the main equivalence, diagnostic and
management reviews, including one study on the management of pregnant women with asthma.102
For the review of subgroups, a total of 162 citations were identified of which 14 studies (14 citations)
were included.110–123 A further three references124–126 (two new studies and one update of a study already
included in the main management review) were identified during the update search. Appendices 5
(update search) and 6 (subgroup searches) summarise the process of identifying and selecting relevant
literature. As such, a total of 17 studies (17 citations) were included in the subgroup reviews.
No end-to-end studies were identified within the review.
As previously described, a review of the equivalence between FeNO devices was undertaken, alongside a
review of diagnostic validity (cohort study design) and a review of management (RCT study design), with
data for subgroups of interest to the review taken from lower levels of evidence when necessary. This
report considers each review separately in the following order:
l rapid review of the equivalence of devices [analytical validity; see Equivalence of devices
(analytical validity)]
l systematic review of diagnostic studies (diagnostic validity; see Diagnostic review)
l systematic review of management studies (see Management review).
Equivalence of devices (analytical validity)
A total of 27 studies [30 citations39–68 plus two sponsors’ submissions (Fukuhara 2013 and Hedlund 2013)]
comparing the intervention devices (NIOX MINO, NIOX VERO and NObreath) with other devices were
included in the review. One additional study127 was excluded as it compared NIOX MINO with another
hand-held device (NoVario; FILT, Berlin, Germany) not in the scope of this appraisal. The studies have been
categorised for presentation and discussion according to the devices compared and population age ranges
as follows:
l NIOX MINO compared with the Niox chemiluminescent device (Aerocrine) in adults
l NIOX MINO compared with the Niox chemiluminescent device in children
l NIOX MINO compared with other stationary chemiluminescent devices in adults and/or children
l NIOX VERO compared with NIOX MINO
l NObreath compared with other stationary chemiluminescent devices in adults and/or children
l NIOX MINO compared with NObreath in adults and/or children
l area under the curve (AUC), cut-off points and correction equations
l test failure rates
l conclusions.
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Three main comparisons were considered in this review:
l Comparison of means – comparison between reported mean FeNO values as measured by each device
in the same cohort. This comparison may be confounded by natural within-patient variance between
measurements by the two devices.
l Correlation coefficients – these show whether measurements by the two devices are correlated but not
whether the actual values produced are the same (agreement). Highly correlated devices might produce
slopes on a graph (plotting FeNO measurement against a known FeNO concentration) of the same
gradient but at different heights, indicating that one device measures consistently higher or lower than
another. Correlation coefficients can be confounded by the fact that comparison over wider ranges of
values can lead to higher correlation values.128
l Bland–Altman analysis – produces a number of useful comparison statistics that assess agreement
between devices rather than just correlation. Bland–Altman plots128 plot the mean of two measurements
by two devices (x-axis) against the difference between the measurements (y-axis). If the devices agreed
perfectly across the whole range of measurements, all points would be at point zero on the y-axis across
the range of measurements. However, if agreement is not perfect, the points will fall above and below
zero. If there is a systematic bias in the results, such as one device consistently reading higher than the
other, the mean of the points will be clustered either above or below zero on the y-axis and this will be
evident both visually and by the mean difference value produced. If this deviation is consistent and can
be relied on, readings between devices can be corrected by subtracting or adding the mean difference.
However, if there is also variance in the difference between devices, points will be more scattered and
there will be a wider ‘limit of agreement’, which is calculated as ± 2 standard deviations (SDs). If this
limit of agreement is wide by clinical standards, it may be concluded that the devices are not clinically
interchangeable, even if the mean difference is relatively small.
NIOX MINO compared with the Niox chemiluminescent device in adults
Eight studies compared NIOX MINO with the Niox chemiluminescent device (Table 13), of which five
studies were carried out exclusively with adults39–43 and three studies were undertaken with a mix of adults
and other age groups.44–46 When considering the mean values recorded in each study, differences between
studies ranged from 0.3 to 9 ppb. NIOX MINO was found to give largely similar results to the Niox
chemiluminescent device in five studies39,41,43,45,46 but gave higher FeNO readings in two other studies.42,44
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One further study40 tested two NIOX MINO devices side by side and found that the mean FeNO recorded
was higher for one device than for the Niox chemiluminescent device but similar for the other device and
the Niox chemiluminescent device. Another study45 tested three devices and found excellent correlation
between them and no statistically significant difference between them. This may indicate that there is
some variation between NIOX MINO devices themselves, which may account for some of the heterogeneity
in estimates of equivalence with other devices in other studies. In summary:
l When the cohort mean FeNO value was < 30 ppb as measured by the Niox chemiluminescent device,
studies showed small differences between the cohort means for devices,39,40,46 whereas when the mean
FeNO value was > 35 ppb as measured by the Niox chemiluminescent device, larger and statistically
significant differences in cohort means were seen.42,44
l Correlation coefficients ranged from 0.73 to 0.998.
l Bland–Altman analyses were not reported in a consistent way, with some studies using proportions,
some using absolute values and some using log values. It is not clear whether log transformation
is appropriate as results varied across studies and were apparently conflicting on this point. When the
relationship between devices was multiplicative, differences between devices became greater at higher
values. Studies saw limits of agreement (when reported on the absolute scale) of around 10 ppb in
both directions.45,46 These large limits of agreement may be due to an assumption that the relationship
is additive rather than multiplicative. The difference in percent reported by Korn et al.41 is large, with
limits of agreement of –46% to 73%, and it is assumed that a log transformation was performed.
However, the log values reported by Menzies et al.39 indicate tighter limits of agreement, but the
Bland–Altman plot did not suggest a multiplicative relationship on the absolute scale. It is therefore
unclear if the upper and lower limits of agreement between devices are of clinical importance and
whether this is a multiplicative or an additive relationship. It seems likely that a range of 20 ppb could
be important even at high FeNO values.
NIOX MINO compared with the Niox chemiluminescent device in children
Three studies compared NIOX MINO with the Niox chemiluminescent device in children (Table 14). All
cohorts included children with asthma.
l One study47 reported statistically significantly higher mean FeNO values with NIOX MINO whereas two
studies48,49 reported statistically significantly lower values. One of these studies49 had low mean
values (< 10 ppb).
l All studies reported good correlation between the devices.
Bland–Altman statistics were reported in two studies48,49 and indicated that NIOX MINO gave lower
readings in both cases, by 1.1 ppb (limits of agreement –4.4 to 6.7 ppb) and 3.9 ppb (limits of agreement
–1.1 to 8.9 ppb) respectively.
NIOX MINO compared with other chemiluminescent devices in adults
and children
Twelve studies compared NIOX MINO with chemiluminescent devices other than the Niox chemiluminescent
device and were included in the review (Table 15). Six studies [reported across nine studies and one
sponsor’s submission (Fukuhara 2013)] were carried out in adults,50–57,64 three were carried out in an
unspecified age group58–60 (two of which had potentially largely overlapping cohorts and will be considered
as one study)58,59 and three were carried out in children.61–63 All studies included at least some asthmatic
patients, except that by de Laurentiis et al.57 Mean FeNO values varied across the studies (from 7 ppb in a
healthy cohort of patients52,53 to 64.3 ppb in an asthmatic cohort54). Devices studied in adults/unspecified
age groups were the EndoNO (SERES, Aix en Provence, France), N-6008 (SIR, Madrid, Spain), NA623N
(CHEST Inc., Tokyo, Japan), NOA 280i (Sievers, Boulder, CO, USA), CLD 88sp (ECO MEDICS, Dürnten,
Switzerland), NOA (Sievers, Boulder, CO, USA) and LR2000 (Logan Research Ltd, Rochester, UK),
whereas devices tested in children were the CLD 88 and CLD 77 (ECO MEDICS). Within subgroups no
chemiluminescence device was tested in more than one study apart from LR2000, which was tested in one
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comparatively large study (n= 118)58,59 and one small study (n= 16) within the subgroup mixed including
some asthmatics.60 In summary:
l correlation coefficients (r) in adults/unspecified age groups ranged from 0.876 to 0.96, indicating a
good level of correlation between devices.
However, comparison of mean FeNO levels between devices and Bland–Altman statistics within studies
recruiting adult or mixed populations show a more variable picture:
l NIOX MINO appeared to give higher readings than the comparator device according to the mean FeNO
values in two studies50–53 and lower readings in a further two studies.54–56 Devices appeared to be
comparable in only two studies.57,64 Absolute differences in mean FeNO values on the natural scale
were not always reported, but when they were they ranged from 9 ppb50,51 to 47 ppb,52,53 which could
represent a clinically meaningful difference.
l Bland–Altman statistics were reported in only four studies,50,51,55–57,64 and were not reported
consistently. Mean values were reported as relative values, log-transformed data and absolute data.
Interpretation would suggest that mean differences were small, 0–5 ppb, but that limits of agreement
were much larger, with ranges of around 10 ppb above and below the mean. The studies with the
largest mean differences in absolute FeNO values did not report Bland–Altman statistics.
In children:
l Correlation coefficients (r) in children ranged from 0.69 to 0.98, indicating variable correlation. The
study with the poorest correlation61 also had higher mean FeNO levels and it would be tempting to
suggest that the poorer correlation is the result of the greater variability at higher FeNO values.
However, the study authors state that correlation improved at higher values. One study63 noted that
the direction of disagreement was different in children aged over and under 12 years.
l The back-transformed Bland–Altman statistics63 and range of ratios reported62 indicate a wide range of
agreement and suggest that the devices are not interchangeable.
NIOX VERO compared with NIOX MINO
(Academic-in-confidence information has been removed.) The results are summarised in Table 16.
NObreath compared with chemiluminescent devices in adults and children
Four studies compared NObreath with chemiluminescent devices (Table 17).54,60,65,66 All studies were carried
out in adults or in an unspecified age group likely to be adults and all included some asthmatic patients
and reported good correlation coefficients. Only one study compared NObreath with the Niox
chemiluminescent device;65 this study reported a small statistically significant difference between the
devices [intervention arm: geometric mean 22.6 ppb (geometric standard error of the mean 1.075), control
arm: geometric mean 24.6 ppb (geometric standard error of the mean 1.073 ppb); p= 0.0002] and a good
level of agreement with Bland–Altman analysis. However, the cut-off points with the best combination of
sensitivity and specificity derived in this study for each device differed by 10 ppb (25 ppb for NObreath,
15 ppb for Niox; see Areas under the curve, cut-off points and correction equations), indicating that even
small differences in agreement may have potentially large effects on derived sensitivity and specificity.
The NObreath device was compared with three other chemiluminescent devices: NA623N, LR2500 and
LR2000. Bland–Altman analysis was reported in only one study66 and showed a mean difference of
–3.95 ppb compared with the LR2500 device in a healthy cohort with low FeNO values, with wide limits
of agreement (–10.98 to 4.08 ppb). Similarly, another study using a Logan device (LR2000) reported an
absolute mean difference in FeNO measurements of –3.81 ppb.60 Comparison with the NA623N device54
showed small differences between mean FeNO values for the cohorts, with NObreath giving lower values
in some cohorts.
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NObreath compared with NIOX MINO in adults and children
Table 18 details the two studies that compared NObreath with NIOX MINO in adults.54,66 Both studies
found that in most analyses NIOX MINO provided lower mean FeNO values than NObreath. This
contradicts the available evidence for comparisons between NIOX MINO and the Niox chemiluminescent
device and NObreath and the Niox chemiluminescent device, for which NIOX MINO>Niox>NObreath.
This would predict that NIOX MINO should provide higher readings than NObreath. However, it should be
noted that there is only one study comparing NObreath with Niox65 and the difference observed was small.
The two direct comparisons between NObreath and NIOX MINO include small numbers of patients; only
one includes asthmatic patients54 and this study does not provide a Bland–Altman analysis to assess
agreement. As such, it is unclear whether the two devices are interchangeable and, if not, in which
direction the difference may be.
One study compared NIOX MINO and NObreath in children with asthma67,68 and found that NIOX MINO
measured statistically significantly higher than NObreath with a mean difference of 7.8 ppb (95% limits of
agreement –11.5 to 27.52 ppb; p< 0.001) in Bland–Altman analysis.
Areas under the curve, cut-off points and correction equations
The mean FeNO values, correlations and Bland–Altman data for each of these trials have already been
considered in the previous narrative synthesis; this section considers the impact that differences between
devices can have on cut-off points and reports the attempts that researchers have made to provide
correction equations for measurements between devices.
Six studies reported other comparative data between devices (Table 19). One study39 demonstrated that
the AUC and cut-off points derived to diagnose asthma using the Niox chemiluminescent device or NIOX
MINO were very similar (this study used a case–control design and so data were not includable in the
diagnostic review), supporting the conclusion that the Niox chemiluminescent device and NIOX MINO are
roughly interchangeable. However, another study44 reported a correction factor that should be used to
convert NIOX MINO values to Niox values. Three50,51,54,65 of the remaining four studies demonstrate how
cut-off points derived using measurements from different devices can be very different, with 7 ppb, 9 ppb
and 10 ppb differences. One of these studies65 compared NObreath with the Niox chemiluminescent device
directly and found a 10-ppb difference between cut-off points that provide the highest AUC (15 ppb and
25 ppb respectively) and very different sensitivity and specificity values at these cut-off points. Another
study54 compared NObreath with NIOX MINO and found a 7-ppb difference in derived cut-off points. In
this case, the cut-off point for NObreath was higher at 36 ppb. Two studies52–54 also reported correction
equations between various devices, indicating that measurements from these devices are not
directly interchangeable.
Test failure rates
Nine studies39,45,46,48,49,63–65,67 were included in the review of test failure rates and are described in
Table 20. The review intended to draw evidence from studies included in the review of equivalence of
devices, the diagnostic accuracy review and the review of the efficacy of FeNO-guided management for
asthma. However, all nine of the studies that provided some relevant information with respect to test
failure rates came from the review of the equivalence of devices. Eight studies39,45,46,48,49,63,64,67 examined
NIOX MINO and two studies65,67 used NObreath. The definition of a test failure was reasonably consistent
across the body of literature. Boot et al.,64 Kalliola et al.,49 Kapande et al.,67 Khalili et al.,45 Pisi et al.65 and
Menzies et al.39 all defined test failure rates in terms of the number of patients who could not perform
acceptable measurements. However, McGill et al.48 specified a test failure as the inability to provide a
successful reading from six attempts; Chladkova et al.63 defined a test failure as three unsuccessful
attempts; and Alving et al.46 defined a test failure as three invalid readings out of six or one failed single
first attempt, depending on the device used.
DOI: 10.3310/hta19820 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 82
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
TA
B
LE
18
Eq
u
iv
al
en
ce
re
vi
ew
:
N
O
b
re
at
h
co
m
p
ar
ed
w
it
h
N
IO
X
M
IN
O
in
ad
u
lt
s
an
d
ch
ild
re
n
A
u
th
o
r,
ye
ar
Sp
o
n
so
re
d
?
Po
p
u
la
ti
o
n
M
ea
su
re
m
en
t
ac
co
rd
in
g
to
A
TS
20
05
g
u
id
el
in
es
35
?
n
a
Fe
N
O
N
IO
X
M
IN
O
(p
p
b
)
Fe
N
O
N
O
b
re
at
h
(p
p
b
)
C
o
m
p
ar
is
o
n
d
at
a
C
o
rr
el
at
io
n
co
ef
fi
ci
en
t
B
la
n
d
–
A
lt
m
an
an
al
ys
is
(9
5%
lim
it
s
o
f
ag
re
em
en
t)
In
te
rp
re
ta
ti
o
n
A
d
u
lt
s:
as
th
m
at
ic
s
o
r
m
ix
in
cl
u
d
in
g
so
m
e
as
th
m
at
ic
s
Fu
ku
ha
ra
20
11
,5
4
Fu
ku
ha
ra
20
13
(s
po
ns
or
’s
su
bm
is
si
on
)
Y
es
A
S
–
tr
ea
te
d
N
R
13
M
ea
n
(9
5%
C
I)
50
.0
(2
6.
5
to
73
.4
)
M
ea
n
(9
5%
C
I)
55
.6
(2
8.
1
to
83
.2
)
p
=
0.
13
5
N
R
N
R
N
IO
X
M
IN
O
lo
w
er
(t
re
nd
,
N
SD
)
Fu
ku
ha
ra
20
11
,5
4
Fu
ku
ha
ra
20
13
(s
po
ns
or
’s
su
bm
is
si
on
)
Y
es
A
S
–
un
tr
ea
te
d
N
R
14
M
ea
n
(9
5%
C
I)
52
.3
(2
8.
8
to
75
.7
)
M
ea
n
(9
5%
C
I)
66
.8
(3
8.
3
to
95
.4
)
p
≤
0.
00
1
N
R
N
R
N
IO
X
M
IN
O
lo
w
er
(S
S)
Fu
ku
ha
ra
20
11
,5
4
Fu
ku
ha
ra
20
13
(s
po
ns
or
’s
su
bm
is
si
on
)
Y
es
A
S,
H
E
N
R
32
N
R
N
R
p
<
0.
00
1
r=
0.
97
3,
p
<
0.
00
1
N
R
N
IO
X
M
IN
O
lo
w
er
(S
S)
A
d
u
lt
s:
h
ea
lt
h
y
p
ar
ti
ci
p
an
ts
b A
nt
us
20
10
66
Y
es
H
E
Y
es
18
G
M
(9
5%
C
I)
12
.6
(9
.3
to
17
.1
)
G
M
(9
5%
C
I)
14
.9
(1
1.
9
to
18
.8
)
p
=
0.
40
9
r=
0.
66
1,
p
=
0.
00
4
4.
36
(–
7.
38
to
16
.1
)p
pb
N
IO
X
M
IN
O
lo
w
er
(S
S
in
tw
o
an
al
ys
es
);
co
rr
el
at
io
n
re
la
tiv
el
y
po
or
G
M
(9
5%
C
I)
10
.3
(7
.8
to
13
.4
)
G
M
(9
5%
C
I)
16
.1
(1
3.
3
to
19
.6
)
p
=
0.
01
0
r=
0.
75
0,
p
<
0.
00
1
G
M
(9
5%
C
I)
10
.9
(8
.4
to
14
.2
)
G
M
(9
5%
C
I)
16
.3
(1
2.
8
to
20
.6
)
p
=
0.
04
3
r=
0.
65
4,
p
=
0.
00
3
Fu
ku
ha
ra
20
11
,5
4
Fu
ku
ha
ra
20
13
(s
po
ns
or
’s
su
bm
is
si
on
)
Y
es
H
E
N
R
5
M
ea
n
(9
5%
C
I)
23
.4
(7
.1
8
to
39
.6
)
M
ea
n
(9
5%
C
I)
25
.0
(7
.8
7
to
42
.1
)
p
=
0.
66
9
N
R
N
R
Si
m
ila
r
(N
SD
)
C
h
ild
re
n
:
as
th
m
at
ic
s
K
ap
an
de
20
11
,6
8
20
12
67
N
o
A
S
Y
es
c
10
9
N
R
N
R
N
R
Li
n’
s
C
C
(rh
o)
=
0.
65
w
ith
re
du
ce
d
m
aj
or
ax
is
sl
op
e
of
1.
32
an
d
in
te
rc
ep
t
of
5.
03
7.
8
(–
11
.5
to
27
.5
2)
pp
b;
N
IO
X
M
IN
O
hi
gh
er
N
IO
X
M
IN
O
hi
gh
er
(S
S)
A
C
T,
A
st
hm
a
C
on
tr
ol
Te
st
;
A
S,
as
th
m
at
ic
;
C
C
,
co
nc
or
da
nc
e
co
rr
el
at
io
n;
G
M
,
ge
om
et
ric
m
ea
n;
H
E,
he
al
th
y;
N
R,
no
t
re
po
rt
ed
;
N
SD
,
no
t
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
ly
di
ff
er
en
t;
SS
,
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
.
a
N
um
be
r
an
al
ys
ed
.
b
Fe
N
O
m
ea
su
re
d
at
th
re
e
tim
e
po
in
ts
.
c
A
t
le
as
t
pa
rt
ia
lly
.
CLINICAL REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
TABLE 19 Equivalence review: AUCs, sensitivity, specificity and cut-off points using different devices and correction
equations derived to convert FeNO values between devices
Author,
year Population
Comparator
device AUC
Sensitivity,
specificity and
cut-off values Correction equation
NIOX MINO vs. Niox: adults/adolescents – mix including some asthmatics
Menzies
200739
AS, HE Niox Niox: 0.654 (95% CI 0.565
to 0.744, p= 0.002); NIOX
MINO: 0.619 (95% CI
0.527 to 0.711, p= 0.018)
Pairwise comparison
difference in AUC of 0.036
(95% CI –0.002 to 0.073,
p= 0.061)
Sens 83.2%, spec
27%; Niox 13 ppb,
NIOX MINO 12.5 ppb
NR
Pizzimenti
200844
AS, HE Niox NR NR FeNO Niox= –1.656
(SE 0.61)+0.808
(SE 0.009) × FeNO
NIOX MINO
Correction factor=
approximately 0.81 to
convert NIOX MINO
values to Niox values
NIOX MINO vs. other chemiluminescent devices: adults – mix including some asthmatics
Fortuna
2006,52
Fortuna
200753
AS, HE N-6008 NR NR Correction factor= 3
For HE people: FeNO
NIOX MINO= 10+
(1.5 × FeNO N6008)
Fukuhara
2011,54
Fukuhara
2013
(sponsor’s
submission)
AS, HE NObreath,
NA623N
NR NObreath: > 36 ppb;
NIOX MINO: > 29 ppb
FeNO
NA623N= FeNO NIOX
MINO×1.278+3.065;
FeNO NA623N= FeNO
NObreath×0.953+
5.779
Ozier 2010,50
Ozier 201151
AS EndoNO NR To identify patients
who will lose control:
NIOX MINO: 40 ppb
(sens 85.7%, spec
87.8%); EndoNO:
31 ppb (sens 80.0%,
spec 91.1%)
NR
NObreath vs. Niox: adults, asthmatics
Pisi 201065 AS Niox To identify patients who
have ACT≥20 (uncontrolled
asthma): NObreath: 0.607
(95% CI 0.525 to 0.684);
Niox: 0.644 (95% CI 0.562
to 0.719)
Pairwise comparisons of
difference in AUC of 0.0369
(95% CI 0.004 to 0.0697,
p=0.028)
To identify patients
who have ACT≥ 20
(uncontrolled
asthma): NObreath:
15 ppb (sens 84%,
spec 42%); NIOX:
25 ppb (sens 53%,
spec 69%)
NR
AS, asthmatic; CI, confidence interval; HE, healthy; NR, not reported; SE, standard error; sens, sensitivity; spec, specificity.
DOI: 10.3310/hta19820 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 82
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
TABLE 20 Test failure rates
Author, year
Patient sample and no.
of participants
Relevant device(s)
used
Definition of test
failure Test failure rates
Alving 200646 Asthmatic and healthy,
all ages (n= 75)
NIOX MINO Successful test defined as
three valid readings out
of six or one single first
attempt
All: 92% (65/71)
successful; children:
84% (31/37) successful;
adults: 100% (34/34)
successful
Boot 200864 Asthmatic and healthy
adults (n= 50)
NIOX MINO Number of patients who
could not perform
acceptable measurement
0/50
Chladkov
200863
Children with asthma
(n= 82)
NIOX MINO Number of patients who
could not perform
acceptable measurement
within three attempts
2/36
Kalliola 201149 Children referred because
of asthma symptoms and
healthy age-matched
children (total n= 55)
NIOX MINO Number of patients who
could not perform
acceptable measurement
15/55 (younger than
successful measurement
group, p= 0.004)
Kapande
201267
Children (aged 4–14
years) with asthma
(n= 109)
NIOX MINO,
NObreath
Number of patients who
could not perform
acceptable measurement
NIOX MINO: 7/109;
NObreath: 0/109
Khalili 200745 Patients (all ages) with
asthma (n= 115)
NIOX MINO Number of patients who
could not perform
acceptable measurement
1/115; a few subjects
needed to perform a
test four to seven times
McGill 200648 Children attending
respiratory clinic aged
> 5 years (n= 55)
NIOX MINO Number of children
unable to provide a single
measurement in of
six attempts
11/55 (therefore at least
66 failed tests out of
330= 20% test failure
rate)
Menzies
200739
Patients known to have
mild to moderate asthma
(n= 101) and healthy
volunteers (n= 50)
NIOX MINO Number of patients who
could not perform
acceptable measurement
0
Pisi 201065 Patients aged ≥ 14 years
diagnosed with asthma
according to GINA
guidelines;129 included
only patients able to
perform at least two
acceptable measurements
with both devices
NObreath Number of patients who
could not perform
acceptable measurement
NObreath: 5/154; both
(Niox and NObreath): 1;
unapproved values: 2
GINA, Global Initiative for Asthma.
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All studies included patients with confirmed asthma or symptoms suggestive of asthma; however, the criteria
for establishing this diagnosis varied across the literature. For instance, Pisi et al.65 included those who met
the criteria for a diagnosis of asthma according to Global Initiative for Asthma (GINA) guidelines129 whereas
Menzies et al.39 stated that they included those with mild to moderate persistent asthma, McGill et al.48
included children attending a respiratory clinic and Kalliola et al.49 included children who had been referred to a
specialist clinic because of asthma-like symptoms. In terms of the age range of study samples, the studies by
Kalliola et al.,49 Kapande et al.,67 Chladkova et al.63 and McGill et al.48 were all conducted with children whereas
the study by Boot et al.64 was conducted with adults. In addition, although Menzies et al.39 did not report any
cut-off ages for inclusion, the mean age of the study sample suggests that it was conducted with adults only.
Alving et al.46 included all ages and provided separate data for children and adults whereas Khalili et al.45
included all ages and reported test failures for the whole study cohort. Pisi et al.65 included adolescents and
adults (the cut-off age for inclusion was ≥ 14 years of age).
NIOX MINO
Eight studies39,45,46,48,49,63,64,67 reported test failure rates with NIOX MINO. The studies by Kalliola et al.,49
Kapande et al.,67 Chladkova et al.63 and McGill et al.48 were conducted with children whereas the studies
by Boot et al.64 and Menzies et al.39 were conducted with adults only. Alving et al.46 and Khalili et al.45
included all age ranges; however, only Alving provided separate data for adults and children. Although the
data sets were limited in both age cohorts, the test failure rates for NIOX MINO were consistently higher in
the studies of children. In the adult-only studies of Boot et al.64 and Menzies et al.,39 no test failures were
observed in cohorts of 50 and 151 participants, respectively, and, similarly, the adult cohort in Alving
et al.46 showed a test failure rate of 0% (0/34 participants). The overall test failure rate in adults is
therefore likely to be close to 0%. However, data were unavailable on how many attempts were required
on average to obtain a successful reading.
In the children’s cohorts, however, there were test failures in each study. The rate ranged from two out of
36 (5.6%) in Chladkova et al.63 to 27% (15/55 participants) in Kalliola et al.49 Alving et al.46 reported a
failure rate of 16% (6/37 participants). McGill et al.48 classified failures as those who were unable to
provide a successful reading from six attempts. They reported 11 patients who fell into this category
(20%). In terms of overall FeNO measurement attempts, there were at least 66 failed tests out of 330, that
is, also a 20% test failure rate. It was also notable that, in the study with the highest incidence of failure,49
the age of the children who failed was significantly lower than the age of those who successfully provided
a measurement (p= 0.004). In Khalili et al.,45 a failure rate of approximately 0.9% was observed (one
failure out of 115 participants); however, as data were not presented separately for adults and children,
the age of this participant was not clear.
NObreath
Only two studies65,67 reported test failure rates with the NObreath device. In the study by Pisi et al.65 of
adolescents and adults there were five failures in a cohort of 154 patients (3.2%) and a single patient who
failed with both NObreath and the Niox chemiluminescent device. Two patients were said to have provided
‘unapproved values’; however, it was unclear whether this was with Niox chemiluminescence, NObreath or
both. The study by Kapande et al.67 of children only reported no test failures in a cohort of 109.
NIOX VERO
(Academic-in-confidence information has been removed.)
Based on the available data, FeNO test failure rates appeared to generally be low. Most studies reported
test failure rates in terms of the number of patients who were unable to provide a satisfactory reading;
however, the data also appeared to indicate that multiple readings would be needed for some patients. As
this data were not quantified, and usually not reported at all, it is likely that the review underestimates the
number of test failures. Moreover, variations in failure rates may be a result of individual differences in
operator skills and techniques. Notably, the highest rate of test failure for both NIOX MINO and
chemiluminescence was observed in the same study.49
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There may also be important variations in test failure rates depending on age, particularly when using
NIOX MINO. Three of the four NIOX MINO studies of adults reported failure rates of 0% whereas one
study reported a withdrawal rate of 13.3%; however, it was unclear whether withdrawals could be treated
as synonymous with test failures. By contrast, the failure rate in children’s studies ranged from 5.5%
to 27%. Indeed, in the study that reported the latter figure,49 the children who failed the test were
significantly younger than those who provided a successful reading. Although the study by Khalili et al.45
included all age groups and reported a much lower failure rate (approximately 0.9%), the mean age of the
study cohort (41.9 years, range 6–86 years) may indicate that few children took part. Hence, although the
data are too limited to make any definitive conclusions, it seems likely that higher test failure rates may be
encountered when using NIOX MINO with children. Finally, with respect to NObreath, the data were
particularly sparse, although a low failure rate was apparent. Pisi et al.65 reported six failures in a cohort of
154 adults and adolescents (3.9%) whereas Kapande et al.67 saw no failures in a cohort of 109 children.
Discussion
It is worth noting that there were data available within some of these studies on which device was used
first. However, because of time constraints, these data were not formally analysed. In some cases the order
was random, in others the order was fixed and in yet others this information was not provided. We
therefore cannot rule out the possibility that the order of device use may have confounded the results.
NIOX MINO
The comparability of NIOX MINO to chemiluminescent devices appears to be influenced by several factors.
There may be some variability between NIOX MINO devices themselves,40 although the extent of this is
unclear and may be small.45 There seems to be a generally consistent observation of poorer equivalence
between FeNO devices at higher FeNO levels. There also appears to be a lack of comparability between
other chemiluminescent devices themselves, as concluded by one study,41 which leads to heterogeneity in
estimates of the comparability of NIOX MINO to chemiluminescent devices. Comparability studies gave
different estimates of equivalence between NIOX MINO and other devices and it is therefore unclear if
equivalence can be assumed.
NIOX VERO
Only one study provided data on this device. (Academic-in-confidence information has been removed.)
NObreath
There are not enough data and too much apparently conflicting data on the comparability of NObreath
to other devices to draw any specific conclusions about its comparability with other devices in asthma
populations. However, based on the available evidence it would seem likely that any differences in
absolute values between NObreath and other devices are relatively small, although derived cut-offs and
maximum sensitivity and specificity may be quite different.
Test failure rates
Because of the small number of studies using NObreath and NIOX VERO, it is not possible to state
definitively whether any FeNO measurement device has advantages over any other in terms of test failure
rates. In all three studies of adults using NIOX MINO,39,46,64 the test failure rate was 0%, whereas none
of the studies using NIOX MINO in children reported a 0% test failure rate, with the lowest being 5.5%63
and the highest 27%.49 As such, there may be some problems with using NIOX MINO with children,
although further research would be needed to confirm this pattern. Conversely, with regard to NObreath,
the study in adults reported a 3.3% failure rate65 whereas the study in children reported a 0% failure
rate.67 (Academic-in-confidence information has been removed.)
In summary, the overall test failure rate for FeNO measurement in adults was generally low across all
devices and most patients appear to be able to provide FeNO readings, provided that they are permitted
sufficient measurement attempts. There may be a higher test failure rate in children using NIOX MINO.
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Conclusions
Overall, it cannot be concluded that any two devices are equivalent in all situations. Although there may
be situations when they are similar, it appears to depend on the characteristics of the studies and cannot
be generalised to all situations. Further research is required to identify what is driving the variability
between studies and devices. However, as there is mostly a high degree of correlation between
measurements across all devices, estimates of sensitivity and specificity are likely to be a reasonable
indication of the potential diagnostic accuracy of using FeNO to guide diagnosis and management, but the
derived cut-off points are not likely to be interchangeable between devices. As such, for the purpose of
this assessment sensitivities and specificities will be assumed to be interchangeable but it cannot be
assumed that the cut-off points that should be used to achieve them will be the same for each device,
and there is still some doubt whether the same diagnostic accuracy would be achievable with all devices.
The committee will need to consider this in their recommendations.
Diagnostic review
In the absence of an end-to-end study, the next best study design is a cohort study. The ideal cohort study
would have recruited patients presenting to their GP with symptoms of asthma and would have assessed
the standard UK diagnostic pathway8 as well as this pathway with the addition of FeNO against a
reference standard of long-term follow-up. No studies of this design were found. Instead, studies that
compared FeNO with or without another test against a reference standard of any test or combination of
tests in the UK guidelines (see Figures 3 and 4) were included. UK guideline tests include:
l Spirometry and lung function tests (mostly FEV1%, FEV1/FVC, PEFR).
l Airway reversibility: airway obstruction that shows reversibility when a bronchodilator is taken.
l ICS responsiveness: response to a trial of treatment with ICSs.
l Airway hyper-responsiveness to methacholine, histamine, exercise or mannitol.
l Tests for airway inflammation (FeNO or sputum eosinophil counts), although these are currently
restricted to a few specialist centres. Studies that use sputum eosinophils within the reference standard
are not considered to be similar to UK practice as this test is not widely available.
Twenty-three cohort studies [across 26 publications54,69–79,82–91,93–96 and one sponsor’s submission
(Fukuhara 2013)] that reported the sensitivity and specificity of FeNO testing (alone or in combination with
another test or tests) compared with the sensitivity and specificity of some or all of the tests within the
UK diagnostic pathway were identified and included in the review. A further three studies80,81,92 were
identified from the update search. Four of these studies70,77,87,95 included data for FeNO testing in
conjunction with another test.
Studies were not similar enough to warrant a meta-analysis, with substantial heterogeneity in populations,
cut-off values, devices used and reference standards. We decided to instead focus on key studies that most
closely resembled UK practice and resifted the included studies to separate out these studies. We did not,
however, want to exclude completely the other studies in case they might prove useful to the committee
in their decision-making, especially as some were studies that the SCMs had indicated might be of use
when consulted during the clarification of the inclusion and exclusion criteria (see Appendix 2).
This review is subdivided into a number of sections and to aid reading a summary is given here:
l Studies including adults, adults plus adolescents, all age groups and unspecified age groups.
¢ Studies meeting the inclusion criteria – this section tabulates all included studies and assesses their
relevance to the decision problem.
¢ Studies relevant to the decision problem using only FeNO as the index test – this section provides
an appraisal of study quality, a narrative synthesis and greater detail relating to these studies, along
with estimates of sensitivity and specificity.
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¢ Studies using FeNO in conjunction with another test as the index test – this section provides a
narrative synthesis and greater detail relating to these studies, along with estimates of sensitivity
and specificity.
l Studies including children or children and adolescents.
¢ Studies using only FeNO as the index test – because of the smaller number of studies relating to
children, all studies are included without selection based on their relevance to the decision
problem. This section provides a narrative synthesis and greater detail relating to these studies,
along with estimates of sensitivity and specificity.
¢ Studies using FeNO in conjunction with another test as the index test – this section provides greater
detail relating to one study, along with estimates of sensitivity and specificity.
l Studies providing data on subgroups of interest to the review:
¢ adult smokers
¢ children exposed to tobacco smoke
¢ pregnant women
¢ the elderly.
More detailed descriptions of the study characteristics for studies that were judged to be less relevant,
along with sensitivity and specificity data, are included in Appendices 7 and 8 for reference.
Adults, adults plus adolescents, all age groups and unspecified age groups
Of the 26 studies included in the review, 22 (26 citations) were conducted in adults (13 studies,
16 citations54,69–81,91), adults plus adolescents (three studies, four citations82–85), all age groups (three studies,
three citations86–88) or an unspecified age range (three studies, three citations89,90,92). Table 21 summarises
the characteristics of the studies and provides a brief description explaining their relevance to the decision
problem (note: Schneider et al.71,72 appears twice in this table as this study reported two differently defined
populations). This table should be read alongside Figure 8, which ascribes a letter to positions that already
exist in the current diagnostic pathway and a number to the positions where FeNO could be added to the
pathway, as agreed during the scoping workshop.
Studies meeting the inclusion criteria
Of the 22 studies conducted in adults that met the inclusion criteria for the review:
l Nine studies54,69–72,82–84,86,87,90 recruited patients with symptoms of asthma who were broadly equivalent
to patients entering the UK pathway at position A (see Figure 8). Of these, six69,71,72,82–84,86,87 were
considered to be of most relevance to the decision problem, although the studies had not necessarily
been conducted in the UK.
l Nine studies73–77,81,85,88,89,91 recruited patients who could be considered ‘difficult to diagnose’ and are
located at other points along the diagnostic pathway. These patients had already undergone some
of the tests in the UK pathway and had tested negative for asthma thus far. One further study71,72
reported a subset of difficult-to-diagnose patients from a larger cohort of patients at position A (see
Figure 8). Of these, seven studies73,74,76,77,81,85,88 were considered to be of most relevance to the decision
problem, although the studies had not necessarily been conducted in the UK.
l One study78 recruited patients with suspected EIB. This study was considered to be relevant to the
decision problem, although it had not been conducted in the UK.
l One study79 recruited army recruits, amongst whom a high proportion are thought to have lied about
their asthmatic status. This study was not considered to be relevant to the decision problem and it had
not been conducted in the UK.
l Two studies80,92 did not describe the populations they included and their relevance to the decision
problem is therefore unknown.
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Reasons for considering a study not relevant to the decision problem are given in Table 21. A total of
14 studies69,71–74,76–78,81–88 were considered relevant and a further two80,92 were considered to be of
unknown relevance and are considered in greater detail in the following section. Full study details and
results for the six studies54,70,75,79,89–91 considered not relevant are provided in Appendices 7 and 8.
Studies relevant to the decision problem using only FeNO as the index test
From the initial 22 studies conducted in adults, adults plus adolescents, all age groups and unspecified age
groups, 14 studies were considered to be of most or of some relevance to the decision problem. These
studies are Schneider et al.,69 Schneider et al.,71,72 Schleich et al.,77 Prieto et al.,76 El Halawani et al.,78
Hsu et al.,73 Hahn et al.,74 Pedrosa et al.,85 Heffler et al.,82 Smith et al.83 (de la Barra et al.84 reports
additional analyses to Smith et al.83) Smith et al.,86 Bobolea et al.,88 Cordeiro et al.87 and Katsoulis et al.81
Two further studies80,92 had unclear relevance to the decision problem and are also considered.
Table 22 groups the 14 studies considered to be of relevance to the decision problem according to the
position on the pathway and the reference standard and tabulates the study and patient characteristics.
Appendix 9 provides more detail about the specifics of the reference standards used and Appendix 10
provides more detail about the patient inclusion and exclusion criteria. There are several main sources of
heterogeneity amongst these studies that preclude meta-analysis of the results. These include: the age
groups recruited; the spectrum of patients in terms of their position in the pathway and other restrictions
in recruitment such as having rhinitis or chronic cough; the device used to measure FeNO; the reference
standards used; and the cut-offs reported.
For each study we have selected and presented in tables three sets of sensitivity and specificity estimates.
These are:
l The highest sum of sensitivity and specificity as reported by the authors of the study.
l The highest sensitivity – in this scenario a negative test result rules out a diagnosis of asthma (see
Tables 3–5 for details). This was selected as the cut-off that provided the highest sensitivity. When
100% sensitivity was reported for more than one cut-off, the cut-off that maintained the highest
specificity was selected. It should be noted that some studies did not report 100% sensitivity, although
this may have been achievable at lower cut-off points. When the cut-off with the highest sensitivity
was not also the cut-off with the highest positive predictive value (PPV), this latter cut-off was
also presented.
l The highest specificity – in this scenario a positive test result rules in a diagnosis of asthma (see
Tables 3–5 for details). Selected as for the highest sensitivity but for specificity. When the cut-off with
the highest specificity was not also the cut-off with the highest negative predictive value (NPV), this
latter cut-off was also presented.
It should be noted that superior sets of sensitivity and specificity values may in fact have been achieved but
selection was limited to the range of cut-off points reported within studies.
Quality assessment of studies relevant to the decision problem Sixteen studies (18 citations69,71–74,76–78,80–88,92)
exploring FeNO measurement for the diagnosis of asthma in adults were assessed for quality according to
QUADAS-2 criteria for diagnostic accuracy studies.38 Although based on the same data as the study by
Smith et al.,83 the study by de la Barra et al.84 was assessed separately as the analysis was different.
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The overall study quality was variable, with the study by Smith et al.83 scoring well on all of the domains
and thus being at least risk of bias. The studies at highest risk appeared to be those by Hsu et al.73 and
Cordeiro et al.,87 neither of which provided sufficient information on the nature of blinding for the index
and reference standard tests. There were also some issues in terms of patient flow in both studies. In the
study by Cordeiro et al.,87 patients did not all receive the same reference test (MCT was provided only if
asthma was suspected from other tests). Similarly, in the study by Hsu et al.,73 the reference standard was
allocated based on an algorithm rather than on an a priori set of tests (Figure 11). The studies by Katsoulis
et al.81 and Brannan et al.92 were poorly reported and at unknown risk of bias. The risk of bias from the
conduct of the index test scored worst overall, with only one study scoring positively for this domain.
Studies scored poorly for risk of bias from the conduct of the reference standard, with 12 having a score of
‘unclear’ for this domain.
Bobolea 201288
Pa
ti
en
t 
se
le
ct
io
n
In
d
ex
 t
es
t
R
ef
er
en
ce
 s
ta
n
d
ar
d
Fl
o
w
 a
n
d
 t
im
in
g
Brannan 201392
Chancafe-Morgan 201380
Cordeiro 201187
de la Barra 201184
ElHalawani 200378
Hahn 200774
Heffler 200682
Hsu 201373
Katsoulis 201381
Pedrosa 201085
Prieto 200976
Schleich 201277
Schneider 200971,72
Schneider 201369
Smith 200583
+ +? ?
? ?? ?
+ ? ? ?
+ –
–
–
–
–
–
–
? ?
+ +?
+ +? ?
+ +?
+ +?
+ ? ?
?? ??
+ +?
+ ++?
+ +?
+ +?
+ +
+
+?
+ +++Smith 200486
+ +++
FIGURE 11 Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.
Dark green circles with + sign, low risk of bias; light green circles with – sign, high risk of bias; medium green
circles with ?, unclear risk of bias.
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Risk of bias from patient selection As far as we could ascertain, patient selection did not appear to
be a source of bias in the body of literature. All studies avoided a case–control design and recruited
appropriately (i.e. those patients presenting with clinical signs of asthma or a subset thereof or patients at
a definable point in the UK pathway). However, it was unclear in seven cases73,74,76,77,81,87,92 whether a
consecutive sample was recruited.
Risk of bias from the conduct of the index test The conduct of the index test was a potentially
important source of bias, with only the study by Smith et al.83 being free from bias in this domain as a
whole. There were two component questions for this domain, one relating to blinding and one to whether
the study was a derivation study or a validation study. Ten studies were unclear whether the index test
was interpreted blind to the reference standard.71,73,74,77,80–82,85,88,92 The studies by de la Barra et al.84 and
Cordeiro et al.87 were not explicit with regard to the blinding of the reference standard results; however, as
the index test was performed before the reference standard, it would not have been possible for the
investigator to be aware of the reference results at the time of the index test unless interpretation was not
performed at the time of the test. This would seem unlikely as FeNO measurement carried out according
to standardised protocols is objective and interpretation is not required.
Several further studies were at potential risk of bias in that they were derivation studies that fitted cut-off
points to the data post hoc and were thus likely to overestimate accuracy.69,74,76–78,82,84,85,87
Risk of bias from the conduct of the reference standard The reference standard and its interpretation
was a further source of bias among much of the literature, with only the study by Prieto et al.,76 the two
studies by Schneider et al.69,71 and the study by Smith et al.83 being free of bias. It was not possible to
ascertain in any of the remaining literature whether the operator conducting the reference standard had
been blinded to the results of the index test.
Risk of bias from patient flow and timing of the study For the most part there was little concern
about the patient flow and study timing. However, at least two studies did not provide an identical
reference standard for all patients. In the study by Cordeiro et al.87 patients received MCT only if asthma
was suspected based on other tests, whereas in the study by Hsu et al.73 reference standard provision was
algorithm based, with some patients not receiving ICS treatment. It was not necessarily clear in all other
studies whether patients received all reference standard tests or a sequence. In other respects, the patient
flow and study timing were satisfactory. Dropout rates were low and, when dropouts occurred, these were
adequately accounted for in the study reports.
Summary The corpus of included literature was of variable quality, with the study by Smith et al.83 being
at the least risk of bias and the two Schneider studies69,71 also performing well. The conduct of the index
test was identified as a potentially serious source of bias among the literature, with few studies providing
adequate information on how blinding to the reference test results was achieved. Most studies were
derivation studies and, in fitting cut-off points to the data post hoc, are likely to overestimate the accuracy
of FeNO as a diagnostic test. In terms of the conduct of the reference standard, few studies provided
satisfactory information on how operators were blinded to the results of the index test. However, it is
important to stress that this may reflect lack of clarity in the study reports rather than in the conduct of the
reference test itself. The likelihood of unblinding biasing the results is therefore unclear.
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Studies recruiting patients at Position A Position A is the start of the UK pathway. Patients will have
undergone no other tests. The reference standard used in studies that recruit patients at this position will
determine whether the results relate to a scenario in which FeNO is replacing the whole pathway or a
scenario in which it is replacing just one test within the pathway. When replacing just one test it could be
used as a rule-in scenario; patients testing positive would go on to be treated as asthmatic and patients
testing negative would go on to have further tests for asthma. When a rule-out scenario is used, patients
testing positive would go on to have further tests and patients testing negative would go on to be treated
as not asthmatic.
Position A compared with the whole pathway Population: Four studies69,71,72,83,86 recruited patients
with symptoms of asthma who had not undergone any other tests. These studies are unlikely to have
recruited the full spectrum of patients at this point in the pathway because of common exclusions
such as those who had experienced a respiratory infection in the last month and those taking ICSs
(see Appendix 10). As in many cases a GP may provide a patient with ICSs before confirmation of asthma;
these exclusions may result in a patient spectrum that does not reflect UK practice.
Of the four studies, those by Schneider et al.69,71,72 recruited adults, that by Smith et al.83 recruited adults
and adolescents and that by Smith et al.86 recruited patients of any age. The largest study was that by
Schneider et al.69 with 393 participants and the smallest was that by Smith et al.86 with 44 participants.
Mean age and FEV1% and FeNO values were not always reported for the whole cohort, making it difficult
to compare across studies. All studies recruited more females than males, with the proportion of males
ranging from 38.5% to 45%. Schneider et al.69,71,72 and Smith et al.83 recruited a mix of smokers,
ex-smokers and non-smokers whereas Smith et al.86 did not recruit any smokers, although this was not
listed as an exclusion criteria and may be a result of the small sample size. Only Smith et al.83 reported how
many participants were atopic, with a high prevalence of 77%; the other three studies did not list atopy
as an exclusion criterion, making it likely they included a proportion of atopic patients. The study by
Schneider et al.69 excluded pregnant women.
Intervention: The two Schneider studies69,71,72 both used NIOX MINO. The study by Smith et al.83 used the
Niox chemiluminescent device and that by Smith et al.86 did not report the device used.
Reference standard: The reference standard for both studies by Schneider et al.69,71,72 was airway
reversibility or airway hyper-responsiveness (depending on spirometric test results), whereas in both studies
by Smith et al.83,86 the reference standard also incorporated ICS responsiveness. Although these reference
standards do differ, bronchodilator reversibility and ICS responsiveness appear to be used interchangeably
in the UK pathway and so both reference standards are equivalent to the whole pathway. However,
it is likely that these reference standards may differentially influence estimates of FeNO diagnostic accuracy
as FeNO would be expected to correlate better with ICS responsiveness than airway reversibility testing
with a bronchodilator.
Study design and setting: All studies were prospective, consecutive cohort studies and none of the studies
was funded by the manufacturers of a FeNO device. Both studies by Schneider et al.69,71,72 were conducted
in Germany in primary care or private practice whereas both studies by Smith et al.83,86 were conducted in
New Zealand in secondary care.
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Estimates of diagnostic accuracy: Table 23 details the estimates of sensitivity and specificity for these
studies. The results do not appear to be similar between studies. The cut-off for the highest sum of
sensitivity and specificity varied from 20 ppb to 47 ppb and this did not appear to be dependent on any
variable. The studies by Schneider et al.69,71,72 and Smith et al.83 all reported higher specificity values than
sensitivity values, whereas the study by Smith et al.86 reported the opposite. This study recruited a mixed
population of adults and children and also did not report the device used to measure FeNO. Sensitivities
varied greatly across studies, ranging from 32% to 88%. Specificities were more consistent across studies,
ranging from 75% to 93%.
Rule-out cut-off points varied from 9 ppb to 16 ppb with sensitivities between 69% and 96%, specificities
between 13% and 53%, PPVs between 29.4% and 56.5% and NPVs between 37.1% and 83.8%. Rule-in
cut-off points varied from 47 ppb to 76 ppb, with specificities between 92% and 100%, sensitivities
between 13% and 55.6%, PPV between 79.5% and 100% and NPV between 56.7% and 65.7%. The
two studies by Schneider et al.69,71,72 reported very similar rule-in (71 ppb and 76 ppb respectively) and
rule-out (9 ppb and 12 ppb respectively) cut-off points, but the cut-off providing the highest sum of
sensitivity and specificity was not similar between these two studies (25 ppb and 46 ppb respectively).
Smith et al.83 reported a similar rule-out cut-off point (15 ppb) to these studies but a quite different
rule-out cut-off point (47 ppb). Only Schneider et al.71,72 reported a 100% PPV that would reliably rule
patients in, with no studies reporting a 100% NPV.
Position A compared with airway reversibility De la Barra et al.84 performed a secondary analysis of
the data from Smith et al.83 against a reference standard of airway reversibility only. This is equivalent to
replacing airway reversibility with FeNO, or placing FeNO before airway reversibility as a rule-in test or
rule-out test, with patients going on to receive this and further tests as appropriate. The cut-off point with
the best sum of sensitivity and specificity (41.7 ppb) seemed fairly similar to that reported in Smith et al.83
(47 ppb). The rule-out cut-off point was somewhat higher at 25ppb, compared with 15 ppb in
Smith et al.,83 and the rule-in cut-off point was higher at 110 ppb (or 90 ppb if selecting the cut-off with
the highest NPV) compared with 47 ppb respectively. Sensitivity and specificity values were also different
(see Table 23).
Subset of patients at Position A compared with airway reversibility or airway
hyper-responsiveness Population: These studies recruited patients who may represent a narrower selection
of the full spectrum of patients who present with symptoms of asthma than described in the previous
studies. Heffler et al.82 recruited 48 adults and adolescents with rhinitis and symptoms of asthma whereas
Cordeiro et al.87 recruited 114 patients with a ‘high prevalence of atopy’. However, it would appear that
these two studies are in fact reasonably comparable to the studies that recruited a full spectrum of patients
at position A. The prevalence of atopy in the study by Heffler et al.82 was higher than that in the study by
Cordeiro et al.,87 at 92% compared with 71%. The study by Smith et al.83 was the only study to report
the prevalence of atopy among the studies that recruited the fuller spectrum of patients at position A and
this study reported a similar prevalence of 77%. Similar to the previous studies, Heffler et al.82 did not recruit
any smokers whereas 9.6% of the participants in the study by Cordeiro et al.87 were smokers. Mean age,
severity and FeNO values were not reported in a way that allowed comparison between studies.
Intervention: Heffler et al.82 used the Niox chemiluminescent device and Cordeiro et al.87 used NIOX Flex.
Reference standard: Both studies used a combination of airway reversibility and airway
hyper-responsiveness as the reference standard, which is equivalent to the whole UK pathway.
Study design and study setting: The study by Heffler et al.82 was a prospective consecutive cohort study
conducted in Italy in an allergy and immunity clinic. The study by Cordeiro et al.87 was a retrospective
analysis of a prospective database conducted in the Netherlands in secondary care. Neither study was
funded by the manufacturers of the FeNO devices.
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TABLE 23 Diagnostic review: diagnostic accuracy of FeNO tests in adults, adults and adolescents and all agesa
Author,
year Population Device n Reference standard
Highest sum of sensitivity and specificity
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Position A vs. whole pathway
Schneider
200971,72
Adults
Position A
NIOX MINO 160 FEV1, FEV1/FVC, airway
reversibility, airway hyper-
responsiveness (MCT)
46 32 93 77.3 59.5
Schneider
201369
Adults
Position A
NIOX MINO 393 FEV1, FEV1/FVC, airway
reversibility, hyper-responsiveness
(MCT)
25 49 75 56.0 69.5
Smith
200486
All patients NR 44 Airway reversibility, positive
response to ICSs, airway
hyper-responsiveness (MCT)
20 88 79 70 91.7
Smith
200583
Adults and
adolescents
Position A
Niox 52 Airway reversibility, positive
response to ICSs, airway
hyper-responsiveness (MCT)
47 55.6 92 88.2 65.7
Position A vs. airway reversibility
de la Barra
201184
Adults and
adolescents
Position A
Niox 52 Airway reversibility 41.7 NR NR
Subset of Position A vs. airway reversibility or airway hyper-responsiveness
Cordeiro
201187
All ages
with high
prevalence
of atopy
Position A
NIOX Flex 114 Airway reversibility, airway
hyper-responsiveness (histamine)
27 78 92 84.6 88
NIOX Flex,
airway
reversibility
Airway reversibility, airway
hyper-responsiveness (histamine)
27 87 90
Heffler
200682
Adults and
adolescents
with rhinitis
Position A
Niox 48 Airway hyper-responsiveness
(MCT) or airway reversibility
36 77.8 60 53.8 81.8
Difficult to diagnose vs. airway hyper-responsiveness
Bobolea
201288
All ages
Position H
NIOX MINO 30 Adenosine challenge test 30b 100 29.2 26 100
Katsoulis
201381
Adults
Position G
NIOX MINO 112 Hyper-responsiveness (MCT) 32 47 85 70.1c 68.1c
Atopics 51 26 55 85 NR NR
Pedrosa
201085
Adults and
adolescents
Position G
NIOX MINO 114 Airway hyper-responsiveness
(MCT)
40 74.3 72.5 54.1 86.3
Schleich
201277
Adults with
chronic
cough
Position G
Niox 174 Airway hyper-responsiveness
(MCT)
34 35 95 87.8 62.4
Niox, FEV1
≤101%
Airway hyper-responsiveness
(MCT)
34 24.4 98.9
Suspected EIB vs. exercise challenge test
El Halawani
200378
Adults
Suspected
EIB
NOA/
Sievers
280A
49 Exercise challenge 12b 100 31 19.4 100
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Rule out Rule in
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
12 85 24 49.6 64.5 76 13 100 100 56.7
16 69 53 56.5 66.2
9 96 13 41.6 83.8 71 18 97 79.5 64.6
NR NR NR NR NR NR NR NR NR NR
15 81.5 48 29.4 37.1 As highest
sum
25 83.3 57.5 37.0 92 110 25 95 60 80.9
90 41.7 92.5 62.5 84.1
NR NR NR NR NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR
25 100 46.7 52.9 100 100 27.8 100 100 69.8
NR NR NR NR NR NR NR NR NR NR
10d 81 39 49.9c 73.2c 30d 49 82 67.1c 68.2c
10d 90 10% NR NR 30d 48 85 NR NR
NR NR NR NR NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR
continued
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TABLE 23 Diagnostic review: diagnostic accuracy of FeNO tests in adults, adults and adolescents and all agesa (continued)
Author,
year Population Device n Reference standard
Highest sum of sensitivity and specificity
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Position H with chronic cough vs. ICS responsiveness
Hahn
200774
Adults with
chronic
cough
Position H
NOA 280i 64 ICS responsiveness 38 90 85 89.5 84.6
Hsu 201373 Adults with
chronic
cough
Position H
NOA 280i 81 ICS responsiveness 33.9 94.7 76.3 80 94
Prieto
200976
Adults with
chronic
cough
Position H
Niox 43 ICS responsiveness 20 53 63 52.6 62.5
Unclear position in the pathway vs. airway hyper-responsiveness
Brannan
201392
Unclear HypAir 401 Mannitol challenge 47 30.2c 96.3c 65.7c 85.5c
Chancafe-
Morgan
201380
Unclear NR 30 Airway
hyper-responsiveness (MCT)
35 75 83.3 75 83.3
NR, not reported.
a A table of all results reported by these studies is given in Appendix 11.
b Unclear if this is the best sum of sensitivity and specificity.
c Calculated by reviewer.
d Only reported cut-offs for 10–30 ppb.
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Rule out Rule in
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
NR NR NR NR NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR
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Estimates of diagnostic accuracy: Table 23 details the estimates of sensitivity and specificity for these
studies. In Heffler et al.,82 the sensitivity and specificity for the highest sum of sensitivity and specificity do
not seem noticeably different from the values in studies recruiting the fuller spectrum of patients with
symptoms of asthma (77.8% and 60% respectively), although the rule-in scenario achieved 100% for
specificity and the rule-out scenario achieved 100% for sensitivity, which was not achieved by the studies
with a full spectrum of patients at position A. This study also reported higher values for the paired
sensitivity and specificity in the rule-in and rule-out scenarios than the studies with a fuller spectrum of
patients at position A. In the study by Cordeiro et al.,87 sensitivity and specificity were 78% and 92%,
which has a similar sum to the highest pair of sensitivity and specificity values reported for studies
recruiting the full spectrum of patients, reported by Smith 200486 at 88% and 79% respectively, but with
the balance between sensitivity and specificity inverted.
Studies recruiting patients who are difficult to diagnose of relevance to the decision problem The
most appropriate reference standard in the difficult-to-diagnose population in relation to UK guidelines
varies according to where in the pathway the group is recruited from, in other words, which tests they
have already undergone and which test they would get next. As previously described, when a rule-in
scenario is used, patients testing positive would go on to be treated as asthmatic and patients testing
negative would go on to have further tests for asthma. When a rule-out scenario is used, patients testing
positive would go on to have further tests and patients testing negative would go on to be treated as
not asthmatic.
Population Four studies recruited patients who fall into the difficult-to-diagnose category and were of
relevance to the decision problem, but none recruited the same spectrum of patients at exactly the same
point in the pathway (see Appendix 10 for more details of study inclusion criteria). Schleich et al.77
recruited adults with chronic cough who had a negative test for airway reversibility and normal spirometry
(position G in the UK pathway). Pedrosa et al.85 and Katsoulis et al.81 also recruited patients at position G
but in the study by Pedrosa et al.85 this was not restricted to those with chronic cough and included
adolescents as well as adults. Bobolea et al.88 recruited a somewhat different spectrum of patients who
were of all ages and who had a negative test for airway reversibility, normal spirometry and a negative
MCT. Mean ages were between 34 and 41 years and FEV1% when reported was similar at 97% and
104%; however, FeNO values were not reported in a way that allowed comparison between studies. The
studies by Schleich et al.,77 Katsoulis et al.81 and Pedrosa et al.85 recruited smokers and atopic patients,
although the prevalence of atopy was higher in the study by Pedrosa et al.85 at 87%, compared with 48%
and 45.5% in the studies by Schleich et al.77 and Katsoulis et al.81 respectively.
Intervention The studies by Katsoulis et al.,81 Pedrosa et al.85 and Bobolea et al.88 used NIOX MINO,
whereas the study by Schleich et al.77 used the Niox chemiluminescent device.
Reference standard All four studies77,81,85,88 used airway hyper-responsiveness as the reference standard,
which was appropriate to the UK pathway for the patients selected. The studies by Katsoulis et al.,81
Schleich et al.77 and Pedrosa et al.85 used MCT whereas Bobolea et al.88 used an adenosine challenge test
as patients had already had a negative MCT test.
Estimates of diagnostic accuracy Table 23 details the estimates of sensitivity and specificity for these
studies. Katsoulis et al.,81 Schleich et al.77 and Pedrosa et al.85 reported quite similar cut-offs for the highest
sum of sensitivity and specificity at 32, 34 and 40 ppb respectively. The paired estimates of sensitivity and
specificity were similar in Katsoulis et al.81 and Schleich et al.,77 with sensitivities of 47% and 35% and
specificities of 85% and 95% respectively. Pedrosa et al.85 reported a sensitivity of 74.3% and a specificity
of 72.5%. There is no one obvious characteristic of the studies that correlates with the differences in
results. Bobolea et al.88 reported 100% sensitivity but only 29.2% specificity, indicating that FeNO
measurement in this position would be most likely to be useful as a rule-out test. No data were available
for other cut-off points.
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In comparison to studies that recruited patients at position A in the pathway, patient populations are
perhaps somewhat younger. Other patient spectrum characteristics look comparable. The range of
estimates of sensitivity and specificity also look largely comparable. A sensitivity of 100% was achieved by
Bobolea et al.,88 although it is not clear if this was for the highest sum of sensitivity and specificity or if the
cut-off was selected so that FeNO could perform as a rule-out test with high sensitivity.
Studies recruiting patients with chronic cough at position H
Population The studies by Prieto et al.,76 Hsu et al.73 and Hahn et al.74 all recruited adults with chronic
cough who were negative for some other causes of cough (see Appendix 10 for more details on the
inclusion and exclusion criteria). Prieto et al.76 recruited patients with a FEV1 of at least 80% predicted with
chronic cough and no signs of other lung disease. Hsu et al.73 recruited patients who were negative for
upper airway cough syndrome and gastro-oesophageal reflux disease (GORD) and who had no obvious
chest radiograph abnormalities. Hahn et al.74 recruited patients with normal chest radiographs. All three
patient groups appear to be equivalent to patients at position H in the UK pathway, who were classed as
being at low risk for asthma, who have undergone tests for other conditions and for whom an asthma
diagnosis is being reconsidered. All three studies recruited no current smokers and only the study by
Prieto et al.76 reported the prevalence of atopy and this was 100%. Cohorts were perhaps somewhat older
than in other studies, with all averaging in the mid- to high 40s.
Intervention The device used was the NOA 280i in Hsu et al.73 and Hahn et al.74 and the Niox
chemiluminescent device in Prieto et al.76
Reference standard The reference standard was ICS responsiveness, which would be the next test in UK
practice for some or all of these patients.
Estimates of diagnostic accuracy Table 23 details the estimates of sensitivity and specificity for these
studies. In the study by Prieto et al.,76 sensitivity and specificity were poor at 53% and 63%, respectively,
although the studies by Hsu et al.73 and Hahn et al.74 both report high sensitivities (94.7% and 90%
respectively) and fairly high specificities (76.3% and 85% respectively), indicating that FeNO could be a
useful rule-out test. It is not clear why the estimates reported by Prieto et al.76 differ from those reported
by the other two similar studies, but it may be the result of differences in patient selection. Although the
device used by Prieto et al.76 was Niox, it is not thought that this would alter estimates of diagnostic
accuracy, rather the cut-off points derived.
Other studies of some interest to the assessment Table 23 details the estimates of sensitivity and
specificity for other studies of some interest to the assessment. The study by El Halawani et al.78 recruited
adults with suspected EIB. As in the study by Arora et al.,79 which was not considered relevant to the
review because of the reference standard used, this group of patients was made up of army recruits. It is
not clear what previous tests these patients had undergone, if any. None of the patients was a smoker or
atopic. The reference standard was an exercise challenge test, which will identify only patients with EIB
rather than other forms of asthma. The device used (NOA/Sievers 280A) is of unknown equivalence to
NIOX MINO and NObreath. The study reports 100% sensitivity and 31% specificity, indicating that this test
could be used as a rule-out test.
The studies by Brannan et al.92 and Chancafe-Morgan et al.80 both used airway hyper-responsiveness (MCT
or mannitol challenge) as the reference standard but it is not clear if the patient spectrum matches UK
practice for patients being referred for such testing. The next most similar studies are those by Schleich
et al.,77 Pedrosa et al.85 and Katsoulis et al.,81 all of which use MCT challenge testing as the reference
standard, in patients with asthma symptoms. In the study by Chancafe-Morgan et al.,80 the cut-off point
was comparable to that in the other studies at 35 ppb, whereas in the study by Brannan et al.92 the cut-off
point was higher than in any of the other studies at 47 ppb (next highest 40 ppb85), which may reflect the
use of a device known to read higher than the Niox chemiluminescent device (despite a correction of
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0.6 ppb). Brannan et al.,92 Katsoulis et al.81 and Schleich et al.77 all report sensitivities and specificities in
similar ranges, with low sensitivity but high specificity, whereas Chancafe-Morgan et al.80 and Pedrosa
et al.85 report a more even split between sensitivity and specificity (sensitivities of 75% and 74.3% and
specificities of 83.3% and 72.5% respectively).
Diagnostic accuracy meta-analysis From Table 22 it can be seen that only two sets of two studies are
similar enough to each other to warrant meta-analysis:
l Schneider et al.71,72 and Schneider et al.69 – two studies conducted by the same research group with
populations recruited in 2006–7 and 2010–11 respectively
l Hsu et al.73 and Hahn et al.74 – these studies recruited in 2009–10 and 2004–5, respectively, and were
conducted in China and the USA respectively.
However, the value of such a meta-analysis is limited given that these studies are no more or less relevant to
the decision problem than any of the other studies found.
Studies using FeNO in conjunction with another test as the index test
From the initial 22 studies conducted in adults, adults plus adolescents, all age groups and unspecified age
groups, two77,87 reported diagnostic accuracy data for FeNO in conjunction with another test as the index
test. One further sudy70 did not report actual data but did state that the addition of certain tests (see next
paragraph) did not increase accuracy.
The study characteristics of the studies by Schleich et al.,77 Cordeiro et al.87 and Fortuna et al.70 are
presented in Tables 21 and 22 and the diagnostic accuracies in the studies by Schleich et al.77 and
Cordeiro et al.87 are presented in Table 23. Neither the study by Schleich et al.77 nor that by Cordeiro et al.87
reported a change in the optimum cut-off for FeNO when using it in conjunction with another test, but
sensitivities and specificities did change. The study by Fortuna et al.70 was not judged to be of high relevance
to the decision problem as it used sputum eosinophilia as part of the reference standard. This test is not
widely available in the UK and so this study has low generalisability. The study reported that the addition of
sputum eosinophilia to FeNO measurements increased specificity from 64% to 76%; sensitivity was not
reported for the two tests together. The authors also stated that the addition of lung function tests and
bronchodilator tests did not increase accuracy, but actual data were not provided.
Cordeiro et al.87 used FeNO with a cut-off of 27 ppb in conjunction with airway reversibility in a population
of patients at position A in the UK pathway. If patients were positive by either test they were considered to
have tested positive. Compared with using FeNO at a cut-off of 27 ppb alone, sensitivity increased from
78% to 87% whereas specificity decreased from 92% to 90%. However, it should be noted that the
reference standard for this study was airway reversibility or airway hyper-responsiveness to histamine. As
such, the study results are at high risk of incorporation bias as the reference standard incorporates some of
the same results as the index test. This is likely to overestimate the actual diagnostic accuracy of this
combination of tests.131
Schleich et al.77 used FeNO with a cut-off of 34 ppb in conjunction with a FEV1% predicted of ≤ 101% in a
population of patients with chronic cough and at position E (difficult to diagnose) in the diagnostic
pathway. Patients were required to have both a FeNO > 34 ppb and an FEV1% predicted ≤ 101% to be
judged positive by this combination of tests. This resulted in an increase in specificity from 95% to 98.9%,
but a decrease in sensitivity from 35% to 24.4%. In this case the reference standard was airway
hyper-responsiveness to MCT and so incorporation bias was avoided.
Conclusions In both cases the improvements in diagnostic accuracy are modest (or negative when
considering the sum of sensitivity and specificity) and necessitate the usual trade-off between sensitivity
and specificity. As both studies are derivation studies rather than validation studies (in which the cut-off
points are pre-set), it is possible that the gains seen are an overestimate of increases in diagnostic accuracy.
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However, it would seem that using a combination of tests may have additional benefit to using FeNO on
its own, and these studies equate more accurately to adding FeNO into the pathway than studies that
do not use FeNO in conjunction with other tests.
Studies including children or children and adolescents
Studies using only FeNO as the index test
Four studies that recruited children (plus adolescents and/or young adults) and compared FeNO- guided
diagnosis to non-FeNO-guided diagnosis were identified.93–96 All of the studies were based in secondary care and
each study was undertaken in a different country: Finland,93 Switzerland,94 Israel95 and Korea.96 Funding sources
were reported only in the studies by Linkosalo et al.93 and Woo et al.:96 these were the Tampere Tuberculosis
Foundation/Medical Research Fund of Tampere University Hospital and the National Research Foundation of
Korea respectively. The study by Sivan et al.95 declared that there were no conflicts of interest in the research.
Quality assessment The four studies exploring FeNO measurement for the diagnosis of asthma in
children were assessed for quality according to QUADAS-2 criteria for diagnostic accuracy studies.38 The
overall quality was variable, with no one study being free from potential bias in all domains and no single
domain being free from bias in all studies. The Woo et al. study96 appeared to be at the lowest risk of bias
whereas the studies by Ramser et al.94 and Linkosalo et al.93 displayed the highest risk of bias (Figure 12).
Risk of bias from patient selection The studies by Sivan et al.95 and Woo et al.96 both appeared to be
free of bias in terms of patient selection. Both studies enrolled consecutive samples, avoided a case–control
design and recruited appropriately (i.e. those patients presenting with clinical signs of asthma). However,
there were potential sources of bias in the studies by Linkosalo et al.93 and Ramser et al.94 in that neither
study explicitly clarified whether it had enrolled patients consecutively.
Risk of bias from the conduct of the index test There was potential bias in the conduct of the index
test throughout the corpus of literature. All four studies93–96 were derivation studies; hence, in fitting the
cut-off points to the data post hoc they are likely to provide liberal estimates of diagnostic accuracy. There
was an additional source of possible bias in the Ramser et al. study94 in that it was not clear whether the
index test was interpreted blind to the results of the reference standard.
Risk of bias from the conduct of the reference standard The studies by Sivan et al.95 and Woo et al.96
both appeared to provide a satisfactory reference standard in that both adhered to all or part of the UK
guidelines and clearly stated that the results were interpreted by a blinded investigator. Neither the study
by Linkosalo et al.93 nor that by Ramser et al.94 provided sufficient information to confirm whether the
result was interpreted blind to the index test results.
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FIGURE 12 Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.
Dark green circles with + sign, low risk of bias; light green circles with – sign, high risk of bias; medium green
circles with ?, unclear risk of bias.
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Risk of bias from patient flow and timing of the study The patient flow and test timing appeared to
be broadly satisfactory. The studies by Linkosalo et al.,93 Ramser et al.94 and Woo et al.96 each conducted
tests consecutively, provided the same reference standard to all patients and included all enrolled patients
in the final analysis. The one study that did display a potential source of bias in this domain was that by
Sivan et al.95 These investigators provided a list of criteria that may have been used to confirm a diagnosis
of asthma, but it was not clear precisely which of these tests in which combination(s) were given to
which patients.
Summary The small body of research was of variable quality, with the study by Woo et al.96 displaying the
least risk of bias and that by Ramser et al.94 being at the highest risk of bias. The most important source
of potential bias in this literature is concerned with the conduct and interpretation of the index test. All
studies fitted FeNO cut-off points to the data post hoc and are thus likely to overestimate diagnostic
accuracy. In addition, the study by Ramser et al.94 did not provide sufficient information to judge whether
the index test results had been interpreted blind to the reference standard. Study flow and timing was the
least likely domain to contain sources of bias in that only the study by Sivan et al.95 did not provide
sufficient clarity on whether all patients received the same reference standard.
All studies included in the review of diagnostic accuracy of FeNO in children
Study design and timeline of studies Study characteristics and timelines are provided in Tables 24 and
25. All four studies had a prospective cohort design and, with the exception of the study by Linkosalo
et al.93 (when the relevant information was not reported), they each enrolled consecutive patients. The
timing of diagnostic procedures among the studies also appeared broadly comparable. Linkosalo et al.93
performed FeNO measurement before an exercise challenge test, after which spirometric testing was used
at 4, 10 and 15 minutes. Final spirometry occurred at 20 minutes, after salbutamol inhalation. Ramser
et al.94 likewise performed FeNO measurement before pulmonary function assessment and spirometric
testing. In addition, patients who did not react to the exercise testing were provided with an additional
MCT at 1 hour. Sivan et al.95 also assessed FeNO first and followed up with spirometry and sputum
induction 1–2 hours later, although sputum induction did not contribute to the diagnosis of asthma, which
was based on assessment by a certified paediatric pulmonologist after at least 18 months’ follow-up and
treatment. Finally, Woo et al.96 asked all participants to fill in an ISAAC (International Study of Asthma
and Allergies in Childhood) questionnaire132 and undergo clinical assessment. FeNO measurements were
then taken, followed by spirometry and a MCT.
Population The study populations were broadly similar in terms of their position on the diagnostic
pathway and all recruited children and adolescents, although upper and lower age cut-offs varied a little,
with the most inclusive being those in the study by Sivan et al.95 at 5–18 years and Linkosalo et al.93 at
6–19 years and the least inclusive being those in the study by Ramser et al.94 at 6–16 years. There were
some further differences in the inclusion criteria. Linkosalo et al.93 included only children and adolescents
with confirmed atopy whereas Ramser et al.94 and Woo et al.96 included a mix of atopic and non-atopic
patients. Sivan et al.95 did not report the number of patients with atopy but did not specifically include on
this basis and the study is therefore likely to have included a mix of atopic and non-atopic patients. All
studies recruited patients at position A in the UK pathway; Linkosalo et al.93 recruited patients who had
been referred to an allergist with asthma-like symptoms (position A); Ramser et al.94 included children in
position A who had been referred to an outpatient clinic for diagnostic assessment of possible reactive
airway disease; Woo et al.96 included children presenting with non-specific respiratory symptoms suggestive
of asthma and who had not been receiving controller medications for at least 3 months prior to FeNO
testing (position A); and Sivan et al.95 also recruited from position A – in this case those with non-specific
respiratory symptoms suggestive of asthma for at least 3 months. This study also excluded patients with
any other conditions that may have interfered with FeNO testing or sputum eosinophil count, especially
unresolved respiratory tract infection or underlying systemic or inflammatory disease.
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Sample size ranged from 3093 to 24596 and the mean age (often reported for subgroups rather than whole
cohorts) ranged from 9.693 to 12.6 years,95 although mean age was not provided by Ramser et al.94 Unlike
adult studies in which male participants were in the minority, there was a preponderance towards male
participants in all four studies, with the lowest percentage being observed in the Sivan et al.95 study (55.3%).
Interventions Three of the four studies measured FeNO via chemiluminescence, although each used a
different device: Linkosalo et al.93 used the NOA280i; Ramser et al.94 used the CLD 77 AM; and Sivan
et al.95 used the CLD 88. Woo et al.96 was the only study to use NIOX MINO for FeNO evaluation. In terms
of FeNO cut-off points, Linkosalo et al.93 and Ramser et al.94 both used the same prespecified cut-off points of
10, 20, 30, 40 and 50 ppb. Sivan et al.95 used cut-offs of 15, 18, 19, 25 and > 20/< 15 ppb. Woo et al.96
reported a large number of cut-off values, ranging from 5 ppb to 50 ppb.
Reference standard None of the studies fully replicated the UK guidelines. Linkosalo et al.93 used an
exercise challenge test (free-running test) with spirometric tests before and after exercise and after salbutamol
inhalation. Sivan et al.95 based the diagnosis of asthma on a history of two or more exacerbations, evidence of
airway reversibility in response to ICSs or bronchodilators or airway hyper-responsiveness at any time during a
period of 18 months’ follow-up. Woo et al.96 performed a battery of tests similar to those in the UK treatment
pathway (spirometry, MCT and atopy assessment), with FeNO being measured before these other tests.
Ramser et al.94 reported results against a reference standard of MCT or exercise challenge testing.
Summary The study of greatest relevance for this assessment is that by Woo et al.,96 which recruited patients
in position A on the pathway and used the NIOX MINO device compared with a reference standard that
roughly equates to UK practice. In this study FeNO replaces the whole pathway prior to ICS use.
The three remaining studies were of varying relevance to the UK context:
l Sivan et al.95 used an ECO MEDICS CLD 88 device in patients at position A in the pathway compared
with a reference standard similar to UK practice. In this study FeNO replaces the whole pathway prior
to ICS use.
l The study by Ramser et al.,94 used an Eco Physics CLD 77 AM device for patients in position A on the
pathway with a reference standard of airway hyper-responsiveness to exercise or methacholine. As
MCT is a very good test for asthma, this study can be seen as similar to testing FeNO against the whole
UK diagnostic pathway.
l Linkosalo et al.,93 used a Sievers NOA280i chemiluminescence device for patients at position A on the
pathway with a reference standard of an exercise challenge test. In the UK this test is reserved for
those with symptoms of EIB.
No studies in children were identified that incorporated ICS responsiveness in the reference standard.
Estimates of diagnostic accuracy The sensitivity and specificity values for each of the studies are
presented in Appendix 12.
Table 26 also displays three sets of sensitivity and specificity values for each of the studies. These are:
l The highest sum of sensitivity and specificity as reported by the authors of the studies.
l The highest sensitivity – in this scenario a negative test result rules out a diagnosis. This was selected
as the cut-off that provided the highest sensitivity. When 100% sensitivity was reported for more than
one cut-off, the cut-off that maintained the highest specificity was selected. When the cut-off with the
highest sensitivity was not also the cut-off with the highest PPV, this latter cut-off was also presented.
l The highest specificity – in this scenario a positive test result rules in a diagnosis of asthma. Selected as
for the highest sensitivity but for specificity. When the cut-off with the highest specificity was not also
the cut-off with the highest NPV, this latter cut-off was also presented.
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TABLE 26 Diagnostic review: diagnostic accuracy of FeNO tests in children and adolescents
Author,
year Population Device Reference standard
No.
analysed
Highest sum of sensitivity and specificity
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Position A vs. whole pathway
Linkosalo
201293
Position A with
confirmed atopy
NOA280i
(chemiluminescence)
Airway
hyper-responsiveness
to exercise
30 20 72 83 86.7 66.7
Ramser
200894
Position A CLD 77 AM
(chemiluminescence)
Airway
hyper-responsiveness
(MCT or exercise)
169 20 49 76 74 51
Sivan
200995
Position A CLD 88
(chemiluminescence)
Exacerbation history,
airway reversibility,
airway hyper-
responsiveness
150 19 86 89 92.2 79.6
>20 or
<15
89 88 93.5 82.1
Woo
201296
Position A NIOX MINO Airway reversibility,
airway hyper-
responsiveness (MCT)
245 21 56.9 87.2 90.5 50.0
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Rule out Rule in
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
10 89 33 66.7 66.7 30 50 92 90 55
10 76 36 63 51 50 20 93 80 45
20 49 76 74 51
15 90 70 82.7 81.6 As highest sum
5 94 14.1 70.0 50 41 23.4 100.0 100 37.9
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It should be noted that superior sets of sensitivity and specificity values may have in fact been achieved but
selection was limited to the range of cut-off points reported within studies.
There was a high degree of agreement as to the cut-off point that produces the highest sum of sensitivity
and specificity, despite the heterogeneity in devices and reference standards, with values between 19 and
21 ppb (see Table 26). However, estimates of sensitivity at these cut-off points were not similar across
studies, ranging from 49% to 86%; specificity was more similar between studies, ranging from 76% to
89%. Rule-out cut-off points were not similar and varied from 5 to 20 ppb; rule-in cut-off points similarly
ranged from 30 to 50 ppb. For ruling out, the highest sensitivity was reported by Woo et al.,96 at 100%,
with a paired specificity of 14.1%, PPV of 70% and NPV of 50%. Sensitivities ranged from 76% to 94%.
For ruling in, the highest specificity was also reported by Woo et al.96 at 100%, with a paired sensitivity of
23.4%, PPV of 100% and NPV of 37.9%. Specificities varied less than sensitivities, from 89% to 100%. It
should be noted that superior rule-in and rule-out sets of sensitivity and specificity may in fact have been
achieved but selection was limited to the range of cut-off points reported within the studies.
No meta-analysis was performed on these data because of heterogeneity in FeNO measurement devices
and reference standards.
Studies using FeNO in conjunction with another test as the index test
One study recruiting children reported estimates of diagnostic accuracy for FeNO in conjunction with
another test.95 This study was described in more detail in the previous section but in summary recruited
children at position A in the pathway and used FeNO in conjunction with sputum eosinophilia against a
reference standard of evidence of airway reversibility in response to ICSs or bronchodilators or airway
hyper-responsiveness at any time during 18 months’ follow-up. Sputum eosinophilia is not a test in
widespread use in the UK and the combination of it and FeNO as a diagnostic test is of low relevance to
the UK pathway. The results showed that improvements in diagnostic accuracy were very small: sensitivity
increased from 86% to 87% and specificity remained the same at 89%.
Studies providing data on subgroups of interest to the review
Adult smokers
Results are presented in Table 27. Malinovschi et al.110 and Katsoulis et al.81 investigated the effects of
smoking on the usefulness of FeNO in diagnosing asthma. The study by Malinovschi et al.110 was not
included in the main diagnostic review as the method of recruitment was unusual.
Study design and setting Both studies were prospective cohort studies, with the study by Malinovschi
et al.110 conducted in Denmark and that by Katsoulis et al.81 conducted in Greece in an army hospital.
Population Neither study recruited an ideal spectrum of patients. Both recruited patients on the basis of
the presence of symptoms of asthma as reported in a questionnaire rather than through presentation to a
GP. In the study by Malinovschi et al.110 the questionnaire was mailed to the general population whereas in
the study by Katsoulis et al.81 the reason for patients filling in the questionnaire is not clear but may be for
the purpose of army recruitment (army general hospital).
Intervention Both studies used NIOX MINO to measure FeNO values.
Reference standard In the study by Malinovschi et al.,110 to be diagnosed with asthma patients had to
exhibit symptoms and test positive by one of MCT; airway reversibility to bronchodilator use; daily use of
steroids or SABAs; or asthma symptoms during but not outside the pollen season supported by allergic
rhinitis. As the cohort was recruited from a random sample of the population with asthma symptoms and
did not exclude existing asthmatics, the reference standard in part depends on a previous diagnosis of
asthma in that a patient already prescribed steroids or SABAs is automatically classed as asthmatic. In
practice, this reference standard may therefore include patients who have been wrongly diagnosed in
primary care. In the study by Katsoulis et al.81 the reference standard was MCT.
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Estimates of diagnostic accuracy In both studies,81,110 cohorts of smokers alone had lower cut-off values
than mixed cohorts (11 ppb compared with 32 ppb81 and 17 ppb compared with 20 ppb110) but the
difference was small in one study.110 Differences in cut-off values were not as apparent for rule-in and
rule-out scenarios between these two subgroups. Malinovschi et al.110 also reported data for never smokers
and ex-smokers. Surprisingly, ex-smokers had a higher derived cut-off (22 ppb) than all other subgroups,
but this difference did not hold true in rule-in and rule-out scenarios.
Children exposed to tobacco smoke
We were unable to identify any studies that evaluated the diagnostic accuracy of FeNO testing in children
exposed to tobacco smoke. However, evidence from the review on the use of FeNO measurements in the
management of asthmatic children exposed to tobacco smoke may provide some insight (albeit limited) on
how environmental tobacco smoke may impact on mean FeNO values and therefore FeNO cut-off points.
Mahut et al.111 and Hanson et al.112 both reported that FeNO levels were not statistically significantly
different between those exposed and those not exposed to tobacco smoke whereas de la Riva-Velasco113
reported that FeNO values were lower in ICS-treated children who were exposed to tobacco smoke.
Similarly, evidence from a diagnostic cohort study110 (see the previous section) that investigated the effects
of smoking on the usefulness of FeNO in diagnosing asthma in adults and adolescents (rather than
children) suggested that FeNO could differentiate asthmatic subjects from non-asthmatic subjects with
asthma-like symptoms equally well in both never and current smokers. However, the FeNO cut-off levels
were lower in current and ex-smokers.
The findings from the above studies suggest that it may be necessary to consider a child’s exposure status
when interpreting the results of FeNO testing for the diagnosis of asthma, as FeNO levels may be lower in
children exposed to tobacco smoke.
Pregnant women
Although no studies were identified that evaluated the diagnostic accuracy of FeNO testing in pregnant
women, a cross-sectional study by Tamasi et al.,114 conducted in Hungary, compared FeNO levels in
pregnant and non-pregnant asthmatic and healthy women. A total of 102 women were recruited from an
outpatient clinic, of whom 35 were healthy non-pregnant women, 27 were healthy pregnant women,
20 were asthmatic non-pregnant women and 20 were asthmatic pregnant women. The exclusion criteria
were as follows: current smokers or > 5 pack-years of smoking history, other chronic diseases (e.g. chronic
rhinitis, hypertension), acute infection within 3 weeks of measurement or a body mass index > 30 kg/m2.
Asthma was diagnosed using the GINA guidelines129 and all asthmatic patients had persistent disease.
All asthmatic patients were receiving ICSs. In addition, 14 patients were on long-acting beta2-agonists
(LABAs) and seven patients received additional LTRA therapy. Mean age ranged from 27 years for
non-pregnant healthy women to 31 years for non-pregnant asthmatic women. FeNO was measured using
the NIOX MINO device.
The authors found no significant difference in median FeNO levels between healthy pregnant subjects
[16 ppb, interquartile range (IQR) 9–35 ppb] and healthy non-pregnant subjects (16, IQR 8–31 ppb).
Similarly, no significant difference was observed in the level of asthma control between pregnant and
non-pregnant asthmatic subjects and there was no significant difference in the total Asthma Control Test
(ACT) scores (20.78± 2.96 vs. 19.17± 3.1 respectively; p= 0.17). In contrast, FeNO levels in pregnant
asthmatic women were significantly higher than those in pregnant healthy women (28 ppb, IQR 10–56 ppb
vs. 16 ppb, 9–35 ppb respectively; p< 0.05). Similarly, the FeNO levels in non-pregnant asthmatic women
were significantly higher than those in non-pregnant healthy women (38 ppb, IQR 9–54 ppb vs. 16 ppb,
8–31 ppb respectively; p< 0.0001). In addition, the authors reported that there was no significant
difference between the two groups of asthmatic women: the mean FeNO value (estimated from a graph in
the published paper) for pregnant asthmatic women was 29 ppb and that for non-pregnant asthmatic
women was 32 ppb.
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TABLE 27 Diagnostic review: diagnostic accuracy in adult and adolescent smokers, non-smokers and ex-smokers in
studies recruiting all ages
Author,
year Device Reference standard Population
No.
analysed
Highest sum of sensitivity and specificity
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Katsoulis
201381
NIOX
MINO
Airway hyper-
responsiveness (MCT)
All (excluded
recent
ex-smokers)
112 32 47 85 70.1 68.1
Smokers NR 11 85 50 NR NR
Malinovschi
2012110
NIOX
MINO
Symptoms plus one of
airway reversibility, airway
hyper-responsiveness (MCT),
prescribed steroids or
SABAs, symptoms in pollen
season plus allergic rhinitis
All 282 20 52.08 82.8 61 77
Smokers 112 17 56.3 82.5 56.3 82.5
Never smokers 108 15 77.8 63.5 60.3 80.0
Ex-smokers 62 22 62.2 86.1 66.7 84.1
NR, not reported.
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Rule out Rule in
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Cut-off
(ppb)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
10 81 39 49.9 73.2 30 49 82 67.1 68.2
10 84 55 NR NR 30 12 95 NR NR
10 87.5 33.3 40.4 83.8 50 15.6 96.8 71.4 69.0
7 90.6 15.0 29.9 80.0 50 9 98 60 72.9
10 78 48 37.3 84.4 35 16 96 62.5 74.0
10 91 27 47.1 81.0 50 20 95 75 62.5
10 95 16 33.3 87.5 35 37 98 87.5 77.8
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Overall, the study authors concluded that pregnancy itself does not alter FeNO levels either in healthy
patients or in asthmatic patients and that FeNO levels in pregnant asthmatic patients correlate with asthma
control levels.
The elderly
No diagnostic studies that used FeNO to diagnose asthma in the elderly were identified; however, one
study115 that examined FeNO levels and eosinophilic airway inflammation in elderly subjects with airflow
obstruction was identified. In asthma diagnosis, the main use of FeNO testing is to identify patients with
eosinophilic airway inflammation who are likely to respond to ICSs, as a surrogate for other methods
of ascertaining eosinophilic inflammation such as sputum counts. As such, this study should provide some
evidence on whether FeNO still acts as a surrogate marker for eosinophilic inflammation in the elderly. This
observational case–control study was conducted in Australia and was reported in abstract form only and
thus provides limited data. The study recruited 65 elderly patients with or without fixed airflow obstruction
and 32 healthy control subjects. The setting from which the patients were recruited is unclear and the
majority of patients (86%) with air flow obstruction were on ICS treatment.
The authors found that participants with eosinophilic airway inflammation (sputum eosinophil count > 3%)
had similar FeNO levels to those with non-eosinophilic inflammation (16.1 ppb vs.19.1 ppb respectively;
p= 0.762). Those with a diagnosis of asthma had similar FeNO levels to those with COPD. There was no
correlation between FeNO level and sputum eosinophils or any clinical markers. The authors concluded
that FeNO was not a surrogate marker for eosinophilic airway inflammation in older people and showed
no relationship with clinical outcomes.
Management review
This section is broken down into a number of subsections by population age and subgroup. Briefly,
these are:
l FeNO-guided management in adults:
¢ quality assessment
¢ study details
¢ estimates of efficacy.
l FeNO-guided management in children:
¢ quality assessment
¢ study details
¢ estimates of efficacy.
l FeNO-guided management in subgroups defined in the scope:
¢ pregnant women
¢ the elderly
¢ adult smokers
¢ children exposed to tobacco smoke.
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Adults
Four studies that recruited adults and compared FeNO-guided management with non-FeNO-guided
management were included in the review.97–100 One additional study101 was identified from the update
search. The study by Shaw et al.98 was based in the UK, that by Smith et al.97 was based in New Zealand,
that by Syk et al.99 was based in Sweden, that by Calhoun et al.100 was based in the USA and that by
Honkoop et al.101 was based in the Netherlands. The studies by Smith et al.,97 Syk et al.,99 Calhoun et al.100
and Honkoop et al.101 were at least partly supported by Aerocrine and the study by Syk et al.99 was
submitted as part of Aerocrine’s sponsor submission. An additional study by Powell et al.102 was conducted
in adult pregnant women and is discussed separately as this group was defined a priori as a distinct group.
Quality assessment
The quality of the five adult management studies was assessed according to criteria proposed in the
Cochrane Handbook for Systematic Reviews of Interventions36 and Systematic Reviews – CRD’s Guidance
for Undertaking Reviews in Healthcare.37 The studies by Powell et al.102 and Shaw et al.98 appeared to be
the highest-quality articles, with each containing only one potential source of bias (industry sponsorship
and uncertain outcome assessor blinding respectively) (Figure 13). The study at highest risk of bias
was the unpublished study by Syk et al.;99 this was because of the lack of participant/personnel blinding,
incomplete outcome data and selective reporting. In addition, Calhoun et al.100 was largely at unclear or
high risk, making this study a potential source of bias. The study by Honkoop et al.101 was published as an
abstract and some methodological data were available from the published protocol. However, it is unclear
if the execution of the study was per protocol and so quality assessment items were scored as unclear.
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FIGURE 13 Methodological quality summary: review authors’ judgements about each methodological quality item
for all included studies. Dark green circles with + sign, low risk of bias; light green circles with – sign, high risk of
bias; medium green circles with ?, unclear risk of bias.
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Risk of selection bias All of the included studies were described as randomised and two of the five
studies provided satisfactory information on both random sequence generation and allocation
concealment. In the study by Shaw et al.,98 allocation was performed by an independent individual;
Syk et al.99 drew lots from sealed envelopes. There may have been adequate randomisation procedures
in the remaining three studies97,100,101 but this could not be confirmed on the basis of the reports.
Risk of performance bias The study at highest risk from lack of blinding was that by Syk et al.,99 which
was described as an open-label study. The study by Smith et al.97 was rated as ‘unclear’ on this item
as the study was single blind (participants only). As many of the outcomes were patient reported, patient
blinding may have been the most important source of bias to avoid, although the blinding of other study
personnel who were deciding whether to step patients up or down may also have been important. The
study by Honkoop et al.101 was also scored as ‘unclear’. The remaining two studies98,100 were double-blind
and therefore at low risk of performance bias.
Risk of detection bias The poor reporting of outcome assessment blinding in the studies means that
unblinded outcome assessment may be a potentially important source of bias throughout this body of
literature. However, as outcome assessment blinding often goes unreported in journal articles, it was
unclear whether any potential bias was the result of reporting practices or methodological shortcomings in
the conduct of the studies themselves.
Risk of attrition bias The studies by Shaw et al.98 and Smith et al.97 appeared to be at low risk of attrition
bias. Dropout rates from these studies were low, adequately reported and corrected for in the statistical
analyses. In addition, Smith et al.97 performed analysis by intention to treat and extrapolated missing data.
There was a potentially high risk of bias in the Syk et al. study99 in that patients were missing and not
corrected for in multiple analyses. However, Syk et al.99 did consistently report the number of patients
included in each analysis and so the attrition rate was transparent. There were two possible sources of bias
in the Calhoun et al. study:100 it was unclear how missing data were corrected for and there were more
dropouts in the intervention arm. If these patients were dropping out because of unsatisfactory outcomes
(which was not clear from the report), this could skew the results in favour of FeNO. Finally, the study by
Honkoop et al.101 was scored as ‘unclear’ for this item.
Risk of reporting bias Two of the five studies appeared to have provided data on all of the prespecified
outcomes.97,98 However, there was some evidence of selective reporting in Calhoun et al.100 and Syk
et al.99 Calhoun et al.100 failed to report oral prednisone levels, although this had been specified as an
outcome in the study protocol, and Syk et al.99 did not report the number of severe exacerbations.
Syk et al.99 also used medians rather than means in several of the outcomes, precluding these from
meta-analysis. However, these data were supplied by the manufacturer (Aerocrine) on request. Finally,
the study by Honkoop et al.101 was scored as ‘unclear’ for this item.
Risk of other bias There were a number of further potential sources of bias in the studies. Smith et al.97
reported receipt of commercial sponsorship whereas Syk et al.,99 Calhoun et al.100 and Honkoop et al.101 reported
at least partial commercial funding. Three studies97,99,100 also conducted a run-in period before randomisation.
It is unclear whether this may have introduced bias to the results in the studies by Smith et al.97 and Syk et al.99
In the study by Calhoun et al.100 patients were excluded if their asthma did not remain controlled when
administered two puffs twice a day of beclomethasone HFA (40 µg/puff). This is likely to have influenced the
spectrum of patients recruited to this trial towards those with less severe asthma. However, this is likely to affect
external validity rather than internal validity as both arms are subject to the same run-in period. No further sources
of bias were identified in the remaining studies.
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Summary The quality of the sampled literature was variable, with the study by Shaw et al.98 being at the
lowest risk of bias. The only potential source of bias that we identified in this study pertained to the failure
to explicitly state the blinding of outcome assessors. However, it was unclear whether this was an actual
methodological flaw or merely inadequate reporting, and at least some of the outcomes were patient
reported (patients were blinded). Among the remaining literature, the most important potential source of
bias was selective reporting in the Calhoun et al.100 and Syk et al.99 studies, both of which failed to report
some prespecified outcomes. The study at highest overall risk of bias was the open-label Syk et al.99
investigation. In addition to lack of blinding, and the aforementioned selective reporting, this study may
have been subject to attrition bias. In the absence of information on why data were missing from this
study, it is difficult to ascertain how this may have biased the results and in what direction. However, there
may be debate about the impact of blinding as a source of bias in these studies. For example, patients
could use knowledge of their FeNO readings to guide their self-management, which may capture
real-world clinical benefits that would not be observable in double-blind studies.
Study details
Unlike other reviews of FeNO for asthma management, in this review our primary analysis of studies that
assess the efficacy of guiding treatment by FeNO measurement in adults considers the study in pregnant
women102 separately, as this subgroup of patients was defined a priori as a separate group. This study
is described and discussed later. This current section considers the other five studies in adults.
Study design and timeline of studies Table 28 provides details of study design and the timelines of the
studies. All five studies were RCTs. The studies by Smith et al.97 and Shaw et al.98 were both single blind
whereas that by Syk et al.99 was an open-label study. The study by Calhoun et al.100 was described as
‘multiply blinded’, although it is not entirely clear who was blinded. The study by Honkoop et al.101 did not
report blinding. No two studies followed the same timeline exactly. Smith et al.,97 Syk et al.99 and Calhoun
et al.100 had a run-in period pre randomisation in which LABAs were reduced or withdrawn and/or doses
of ICSs were standardised. Post randomisation, all studies except that by Honkoop et al.101 had an initial
period of time in which visits were more frequent. In the study by Calhoun et al.,100 visits were made every
2 weeks for the first 6 weeks post randomisation and then were 6-weekly after that. In Shaw et al.98 initial
visits were monthly for 4 months and then every 2 months up to 12 months. In the study by Smith et al.,97
treatment consisted of two phases: a optimisation phase of 3–12 months and a titration phase of a further
12 months. Patients were randomised before both phases and both phases managed patients according to
protocols that either did or did not incorporate FeNO measurements. However, data on exacerbations
were reported only for the titration phase and it was these data that were incorporated into the analysis.
In the study by Syk et al.99 participants had an initial visit 2–4 weeks after the initial titration visit, followed
by every 2 months up to 4 months and then every 4 months up to 12 months. All studies titrated doses
for at least 12 months except that by Calhoun et al.100 in which doses were titrated for 9 months only.
Calhoun et al.100 included a third intervention arm that was not relevant to this review in which the ICS
dose was controlled by matching ICS use on a puff-by-puff basis to the rescue use of albuterol in response
to the occurrence of symptoms.
Population Table 29 provides details of patient characteristics across studies. All studies were of a moderate
size, with numbers analysed ranging from 9497 to 611.101 All patients were recruited from primary care, except
in the study by Calhoun et al.,100 in which it was not clear whether patients were recruited from primary or
secondary care settings. All had either a doctor’s diagnosis of asthma or asthma diagnosed according to
guidelines. In the study by Calhoun et al.,100 the doctor’s diagnosis was confirmed with either a positive MCT or
demonstration of airway reversibility. Inclusion and exclusion criteria varied across studies but, when compatible
data are reported, study populations seem broadly similar in terms of age (mean ranged from around 34.5100
to 4597 years), FEV1% (mean ranged from 81.4% to 87.7%) and FeNO values (range of geometric means
18.88–29.0 ppb). It is difficult to determine the comparability of study populations in terms of severity at
baseline as different scales for severity and different metrics for medication use have been used. Inclusion and
exclusion criteria suggest that at least three studies97,99,100 recruited populations with mild to moderate asthma.
Smith et al.97 excluded those with four or more severe exacerbations in the previous 12 months and those ever
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TABLE 28 Adult management review: study design and timelines
Author,
year Study design Timeline of study
Calhoun
2012100
RCT – multiply blinded,
multicentre study
Visit 1 (week 0): consent and start of run-in period of 2 weeks – two puffs
b.i.d. of beclomethasone HFA (40 µg/puff). If asthma acceptably controlled at
this level, enrolled in trial. Visits 2 and 3 (weeks 2–8): pre-randomisation period –
patients given two pairs of inhalers to facilitate blinding, one with beclomethasone
(2×40µg b.i.d.) and a placebo counterpart and one with albuterol and a placebo
counterpart (taken together on demand). Visit 4 (week 8): randomisation to group
1 or group 2. Visits 5–12 (titration): 2, 4, 6, 12, 18, 24, 30 and 36 weeks post
randomisation – dose adjustments made at time of clinic visits, monitoring of
secondary outcomes
Honkoop
2013101
RCT – cluster design From protocol:
Visit 1: introduction session run by practice nurses; randomisation by GP cluster
with stratification on postcode; baseline measurement of IPQ, MARS, BMQ,
ICQ, FACCT, SF-36, AQLQ, TTO, ASUI, EQ-5D and CostQ, all at home. Visit 2
(titration): GP measures ACQ, FEV1 and FeNO and titrated dose according to
algorithm. Visit 3 (titration): 3 months – GP measures ACQ, FEV1 and FeNO;
patients measure AQLQ, EQ-5D and CostQ at home. Visit 4 (titration):
6 months – GP measures ACQ, FEV1 and FeNO; patients measure IPQ, MARS,
BMQ, ICQ, FACCT, SF-36, AQLA, TTO, ASUI, EQ-5D and CostQ, all at home.
Visit 5 (titration): 9 months – as visit 3. Visit 6 (titration): 12 months – as visit 4
Shaw
200798
RCT – single blind,
parallel group
Titration at each visit
Visit 0: randomisation – FeNO, FEV1, FVC, PC20, induced sputum analysis, skin
prick test, Juniper score. Visit 1: 2 weeks after visit 0 – FEV1, FeNO, Juniper
score. Visits 2–5: monthly visits to 4 months – FEV1, FeNO, Juniper score.
Visit 6: at 6 months – FEV1, FeNO, Juniper score, PC20, sputum analysis. Visits 7
and 8: at 8 and 10 months respectively – FEV1, FeNO, Juniper score. Visit 9:
12 months – FEV1, FeNO, Juniper score, PC20, sputum analysis
Smith
200597
RCT – single blind,
single centre, placebo
controlled
Visit 1: enrolment, start of 2-week run-in period in which LABA withdrawn,
reinstated at fixed dose if not tolerated. Visit 2 (week 2): FeNO and spirometry;
patients begin 4 weeks of 750 µg/day fluticasone or 500 µg/day if previous dose
< 200 µg/day. Visit 3 (week 6): randomisation and start of phase 1
Titration phase 1 (3–12 months after randomisation): visits every 4 weeks, FeNO
and spirometry, dose adjustment to optimal dose by downwards titration until
FeNO ≥ 15 ppb (equivalent to 35 ppb at 50-ml flow rate) or uncontrolled, then
uptitrated until controlled/≤ 15 ppb. This dose deemed the ‘optimal dose’
Titration phase 2 (12 months after completion of phase 1): visits every 2 months,
upwards adjustments when control lost/FeNO> 15 ppb, downwards adjustment
if controlled/FeNO≤ 15 ppb for two consecutive visits, but not below optimal
dose. Treatment orders assigned by blinded investigator. Compliance assessed
by inhaler weight
Syk 201399 RCT – open label,
parallel group,
multicentre
Visit 1: eligibility and consent – capillary blood for IgE confirmation, LABA
withdrawn, ICSs continued (salbutamol inhaler with dose counter). Visit 2
(titration): 2–4 weeks later – FeNO, spirometry, reversibility, Juniper mini-AQLQ,
generic quality of life, Juniper six-item ACQ, questionnaire on allergen
exposure, venous blood for IgE analysis. ICSs and LTRAs altered according to
(a) FeNO levels and six fixed treatment steps in FeNO group and (b) usual care
(patient report, SABA use, physical examination, pulmonary function tests) in
the control group, with FeNO measured but not revealed to treatment
decision-maker or patient. Visit 3 (titration): 2 months – ACQ, FeNO and
treatment altered. Visit 4 (titration): 4 months – mini-AQLQ, ACQ, FeNO
and treatment altered. Visit 5 (titration): 8 months – as visit 3. Visit 6 (titration):
12 months – identical to visit 2. Outcomes recorded at visits 2–6
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; ASUI, Asthma Symptoms Utility Index;
b.i.d., twice a day; BMQ, Beliefs about Medicines Questionnaire; CostQ, cost questionnaires; EQ-5D, European Quality of
Life-5 Dimensions; FACCT, Foundation for Accountability; ICQ, undefined in source document; IgE, immunoglobulin E;
IPQ, Illness Perception Questionnaire; MARS, Medication Adherence Report Scale; PC20, provocative concentration that
causes a positive reaction; SF-36, Short Form questionnaire-36 items; TTO, time-trade-off.
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admitted to intensive care for asthma, whereas Syk et al.99 and Calhoun et al.100 stated that all patients were
mild to moderate asthmatics. Smith et al.97 and Syk et al.99 also required patients to have been receiving ICS
treatment for > 6 months and Calhoun et al.100 recruited only patients who were well controlled when
prescribed two puffs twice a day of beclomethasone HFA (40 µg/puff) and who were ≥ 75% compliant with
medication during the 2-week run-in period. Shaw et al.98 on the other hand may have recruited patients
with a wider spectrum of severity. Patients were required only to have had one prescription for asthma
medication in the previous 12 months, making it possible that patients with comparatively less severe or less
well-documented asthma were included, but excluded only those with severe exacerbations in the previous
4 weeks, making it possible that severe asthmatics were included. Honkoop et al.101 included patients with
a broad spectrum of severity and excluded only very mild asthmatics. Unlike other studies, that by Honkoop
et al.101 had an upper age limit of 50 years.
The study by Smith et al.97 included smokers (current or ex) with a history of < 10 pack-years whereas the
studies by Shaw et al.,98 Syk et al.99 and Calhoun et al.100 all excluded current smokers but included
ex-smokers with a past smoking history of < 10 pack-years. Smith et al.,97 Shaw et al.98 and Calhoun et al.100
all included a mix of atopic and non-atopic patients whereas Syk et al.99 included only atopic patients.
Honkoop et al.101 included atopic patients and smokers. It is unclear whether studies in atopic patients will
over- or underestimate efficacy or have no impact at all, although clinical input to the assessment suggested
that it would be expected to increase estimates of efficacy as atopy is correlated with ICS responsiveness.
Overall, patient populations recruited by Honkoop et al.,101 Smith et al.97 and Shaw et al.98 are likely to be
the most representative of the general asthma population in the UK as these studies included atopic and
non-atopic patients. Honkoop et al.101 included smokers and a broad spectrum of patients from mild to
severe, Smith et al.97 included some smokers and Shaw et al.98 included a potentially broader spectrum
of patients than Smith et al.97 Calhoun et al.100 also recruited a mix of atopic and non-atopic asthmatics,
but the run-in requirements for treatment tolerance and compliance may mean that generalisation to a
wider population is difficult. However, were the application of FeNO management to be limited in the
UK to certain populations (e.g. only atopic patients, only stable patients, only mild to moderate patients),
data from Calhoun et al.100 or Syk et al.99 may be more appropriate.
Interventions Table 30 provides details of the interventions used in each study. Syk et al.99 and
Honkoop et al.101 used NIOX MINO. It is not possible to determine whether the other studies used the
same devices as this information is not clearly reported.97,98,100 Smith et al.97 used an unusual flow rate but
justified their conversion to 35 ppb equivalent at 50ml/second. None of the studies used the same protocol or
cut-off points for the management of asthma with FeNO. Syk et al.99 and Calhoun et al.100 used FeNO only to
guide management, Smith et al.97 used FeNO only, with a safety measure based on symptoms, bronchodilator
use and spirometry, and Shaw et al.98 used FeNO in addition to the Juniper score, which gauges control
through symptoms. The study by Honkoop et al.101 was similar to that by Shaw et al.98 in that it used FeNO in
conjunction with symptoms, spirometry and medication use [all captured in the Asthma Control Questionnaire
(ACQ)]. Doses and medications used also varied from study to study, with Smith et al.97 and Calhoun et al.100
titrating only ICSs, Shaw et al.98 titrating ICSs, LTRAs and bronchodilators and Syk et al.99 titrating ICSs and
LTRAs. Honkoop et al.101 controlled multiple treatment doses rather than just ICSs. There were some
differences between the doses and combinations of treatments indicated and the study allowed for a
step-down in treatment on the basis of low FeNO in the presence of moderate symptoms (when FeNO
was low for > 3 months) but not in the presence of a high ACQ score. This is in contrast to Shaw et al.98
and Smith et al.97 which did not allow step-down if moderate symptoms were present,98 or did not allow
the dose to fall below the optimum derived in the first titration phase,97 thus placing a limit on how far
ICS could be decreased. The number of cut-off points also varied. Smith et al.97 used only one cut-off of
35 ppb (equivalent). Honkoop et al.,101 Shaw et al.98 and Calhoun et al.100 each used two cut-offs but at
different cut-points, one for titrating down (< 25 ppb, < 16 ppb and < 22 ppb respectively) and one for
titrating up (50 ppb, > 26 ppb and > 35 ppb respectively), with an intermediate area in between where
symptoms also guided treatment98,101 or the dose remained the same.100 Syk et al.99 used three cut-offs,
with different values for men and women (< 19 ppb, ≥ 24 ppb and ≥ 30 ppb for men; < 21 ppb, ≥ 25 ppb
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and ≥ 32 ppb for women). Given the uncertain comparability in FeNO measurements between devices, it
is difficult to assess how similar these cut-off points may in fact be.
Control Table 31 provides details of the control interventions used in each study. As with the interventions,
none of the studies used the same criteria, protocols or treatment doses for the management of asthma in
the control arm of the studies. Generally speaking, the control arms considered symptoms, self-reported
medication use and sometimes lung function to guide titration. In terms of similarity to UK practice,
Shaw et al.98 state that BTS/SIGN guidelines8 were followed, using the Juniper scale to score symptoms.
It is not clear how similar to UK practice other studies may be.
Estimates of efficacy
Exacerbations Exacerbations were reported in all studies but definitions varied (Table 32) and results were
not entirely consistent across studies.
Major or severe exacerbations This outcome was defined differently across studies. Smith et al.97
reported two such outcomes: ‘major exacerbations’ defined according to global daily asthma scores and
exacerbations leading to a course of oral prednisone. A similar outcome, ‘worsening requiring a course of
oral prednisone’, was also reported in Syk et al.99 Shaw et al.98 did not report rates of oral prednisone use
alone but did report a composite outcome of ‘exacerbations resulting in the use of oral prednisone or
antibiotics’. Calhoun et al.100 reported an outcome called ‘exacerbations’, which included exacerbations
leading to oral prednisone use, increased ICS use or additional medication for asthma. This last definition
may incorporate exacerbations that other studies would have classified as moderate or minor, although the
study does define an additional outcome called ‘treatment failure’, which is likely to incorporate minor,
moderate and major exacerbations. As such, the outcome ‘exacerbations’ in the study by Calhoun et al.100
will be considered in this analysis. Honkoop et al.101 reported courses of oral prednisone, as in Smith et al.97
and Syk et al.99
Honkoop et al.101 and Shaw et al.98 reported lower rates per person-year of major/severe exacerbations in
the intervention arm and Smith et al.97 reported lower rates per person (data per person-year not reported)
but the difference did not reach statistical significance compared with the control arm in any of the studies
(these data were available only as odds ratios for Honkoop et al.101). Syk et al.99 reported higher rates per
person-year of oral prednisone use in the intervention arm, but the level of significance was not reported.
Calhoun et al.100 showed very similar rates per person-year of exacerbations in both arms of the trial, with
no statistically significant difference between them. The best improvement in major/severe exacerbations
per person-year was seen in the study by Shaw et al.,98 at –21% (95% CI –57% to 43%; p= 0.43)
(reviewer-calculated rate ratio 0.79, 95% CI 0.66 to 0.94), and the worst improvement was seen in the
study by Syk et al.,99 which reported a higher rate per person-year, although not statistically significantly so,
in the intervention arm (0.113) than in the control arm (0.0875) (p-value not reported) (reviewer-calculated
rate ratio 1.29, 95% CI 0.83 to 2.03).
Despite the high level of heterogeneity in study characteristics, an exploratory meta-analysis of the rates
of major/severe exacerbations was performed. As data per person-year were not reported in or calculable
for Smith et al.,97 this study was excluded from the meta-analysis. The standard error (SE) was not reported
in the study by Honkoop et al.101 and analyses were performed without these data and with various
imputed SEs. The pooled estimate of the rate ratio without the data from Honkoop et al.,101 using random
effects methods (Figure 14a), was 0.94 (95% CI 0.66 to 1.34), with a p-value of 0.73. This indicated no
difference between the two intervention groups in major or severe exacerbations. The I2 statistic was 52%,
however, indicating moderate heterogeneity between studies.
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TABLE 31 Adult management review: description of the control group management strategies
Author, year Decisions based on Step-up/step-down protocol Doses
Calhoun
2012100
NHLBI guidelines134
(US version of the
SIGN guidelines)
Use severity classification chart, assessing both
domains of impairment and risk, to determine initial
treatment. Use asthma control chart, assessing both
domains of impairment and risk, to determine if
therapy should be maintained or adjusted (step up if
necessary, step down if possible). Use multiple
measures of impairment and risk: different measures
assess different manifestations of asthma; they may
not correlate with each other; and they may respond
differently to therapy. Obtain lung function measures
by spirometry at least every 1–2 years, more
frequently for not well-controlled asthma. Asthma is
highly variable over time and periodic monitoring
is essential. In general, consider scheduling patients
at 2- to 6-week intervals while gaining control; at
1–6 month intervals, depending on step of care
required or duration of control, to monitor if sufficient
control is maintained; at 3-month intervals if a step
down in therapy is anticipated. Assess asthma control,
medication technique, written asthma action plan,
patient adherence and concerns at every visit
As for intervention
Honkoop 2013101
Strict
strategy
ACQ scores135 When ACQ ≤ 0.75: if < 3 months,
no change; if > 3 months, step down
When ACQ > 0.75 and < 1.50: step up (choice of
treatments)
When ACQ ≥ 1.50: step up (choice of treatments)
As for intervention
Sufficient
strategy
When ACQ ≤ 0.75: step down
When ACQ > 0.75 and < 1.50: no change
When ACQ ≥ 1.50: step up (choice of treatments)
As for intervention
Shaw 200798 BTS/SIGN guidelines8
using the Juniper
scale to score
symptoms
Scored by Juniper scale. Treatment doubled if
score > 1.57, treatment halved if score < 1.57 for
2 consecutive months
Step 1: SABA as required;
step 2: add inhaled steroid
200–800 µg/day BDP
equivalent; step 3: add
inhaled LABA; step 4:
increase ICS up to
2000 µg/day and addition
of fourth drug, e.g. LTRA,
theophylline, LABA;
step 5: oral prednisolone,
high-dose ICS, refer to
specialist care
Smith 200597 GINA guidelines;136
symptoms,
bronchodilator use,
spirometry
GINA uncontrolled asthma criteria:125 (1) symptoms
present on > 2 days/week with 24-hour asthma
score ≥ 2/5; (2) More than one night-time
waking/week; (3) bronchodilator use on more than
four occasions/week or on > 2 days per week;
(4) variation in PEFR > 20 (amplitude % of mean
over previous 7 days); (5) FEV1 < 90% of baseline
As for intervention but
without the personalised
management plan
Syk 201399 Symptoms,
lung function,
beta-agonist use
Usual care (patient symptom report, SABA use,
physical examination, pulmonary function tests)
Assume same doses as for
intervention
BDP, beclomethasone dipropionate; NHLBI, National Heart, Lung, and Blood Institute.
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TABLE 32 Adult management review: exacerbation and OCS use rates in adult patients with or without
FeNO-guided management
Author, year,
time of outcome Definition of outcomes n
Intervention
per person-year
Control per
person-year
Between-group
comparison
Calhoun 2012100 Exacerbation: unscheduled
medical contact for increased
asthma symptoms that results
in the use of OCSs, increased
ICSs or additional medication
for asthma
229 0.21 (97.5% CI
0.1 to 0.32)
0.23 (97.5% CI
0.1 to 0.37)
‘Did not differ’
Treatment failure defined as
exacerbation or loss of controla
0.27 (97.5% CI
0.14 to 0.39)
0.43 (97.5% CI
0.23 to 0.64)
‘Were not
different’
Honkoop 2013101
12 months
Course of oral prednisone 611 0.20 per person-
year
Strict: 0.29 per
person-year;
sufficient: 0.29
per person-year
Odds ratio: vs.
strict: 0.52
(95% CI 0.20 to
1.30); vs.
sufficient: 0.73
(95% CI 0.28
to 1.85)
Shaw 200798
12 months
Course of oral steroids or
antibiotics
118 0.33 (SD 0.69) 0.42 (SD 0.79) –21% (95% CI
–57% to 43%;
p= 0.43)
Smith 200597
3–12 months
optimisation
(exacerbation rates
not reported for
this period) plus
12 months titration
Minor: global daily asthma
scoreb of 2 on ≥2 consecutive
days
94 Minor:c 0.36 Minor:c 0.75 Minor: p= 0.24
Major: global daily asthma scoreb
of 3 on ≥2 consecutive days
(or in one day, in the context of
a minor exacerbation). Major
exacerbation or medical
emergency: global daily asthma
scoreb of 4 in one day
Major:c 0.13 Major:c 0.14 Major: p= 0.91
Any minor or major
exacerbation
0.49 (95% CI
0.20 to 0.78)
0.90 (95% CI
0.31 to 1.49)
–45.6% (95% CI
–78.6 to 54.5;
p= 0.27)
Course of oral prednisone 22 events in
46 patients
(0.48 events
per patient)
29 events in
48 patients
(0.60 events
per patient)
p= 0.60
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TABLE 32 Adult management review: exacerbation and OCS use rates in adult patients with or without
FeNO-guided management (continued )
Author, year,
time of outcome Definition of outcomes n
Intervention
per person-year
Control per
person-year
Between-group
comparison
Syk 201399
End points
analysed from
visit 2 to visit 6
(2–4 weeks to
12 months)
Moderate exacerbationd – need
to step up controller treatment
for at least 2 days with or
without clinic visit. Prophylactic
use before pollen season
excluded
165 0.1 0.325 NR
Severe exacerbationd – worsening
requiring a course of OCSs
0.113 0.0875 Not significant
Moderate or severe
exacerbation
0.22 0.41 Total: p= 0.024
CI, confidence interval; NR, not reported.
a At-home measurements: any of the following three criteria, when not associated with the increased asthma symptoms,
satisfies treatment failure criteria: (i) pre-bronchodilator morning PEFR of < 65% of the baseline on two consecutive
mornings, scheduled measurements; (ii) post-bronchodilator PEFR of < 80% of baseline despite 60 minutes of rescue
beta-agonist treatment; (iii) post-bronchodilator PEFR may be taken at any time of day. An increase in albuterol use of
more than eight puffs per 24 hours over baseline use for a period of 48 hours or more than 16 puffs per 24 hours for
more than 48 hours. In-clinic measurements: (i) pre-bronchodilator FEV1 values from two consecutive sets of spirometric
determinations measured 24–72 hours apart that are < 80% of the baseline pre-bronchodilator value (baseline value for
adherence period: FEV1 value at visit 3; baseline for randomisation period: FEV1 value at visit 4); all participants found
to have a FEV1 of < 80% of baseline at any centre visit but who are not considered to meet treatment failure or
exacerbation criteria must be seen again within 72 hours to have FEV1 measured or (ii) physician judgement for patient
safety or (iii) patient dissatisfaction with asthma control achieved by study regimen or (iv) requirement for open-label
ICS or another (non-systemic corticosteroid) new asthma medication (e.g. montelukast) without the addition of
systemic corticosteroids.
b Asthma scores: 0 (stable): morning PEFR > 75% of best PEFR in 14-day run-in period without deterioration in any
symptom scores; 1 (mildly unstable): one or more of the following: (i) bronchodilator use on two or more occasions in
24 hours more than the rounded mean number of occasions during the run-in period, (ii) increase in symptom score
of ≥ 1 point compared with the rounded mean during the run-in period, (iii) onset of or increase in nocturnal waking:
one or more times in the previous 7 nights more than the rounded mean number of times during the run-in period or
morning PEFR of 61–75% without deterioration in any of the above categories; 2 (minor deterioration): morning PEFR of
61–75% of the best PEFR during the run-in period and one or more criteria for an asthma score of 1 or morning
PEFR of 41–60% without deterioration in any criteria for an asthma score of 1; 3 (major deterioration): morning PEFR of
41–60% of the best PEFR during the run-in period and one or more criteria for an asthma score of 1; 4 (major
exacerbation or medical emergency): morning PEFR of ≤ 40% of the best PEFR during the run-in period regardless of
symptoms or attendance at a clinician’s office or emergency department because of severe asthma.
c Estimated from graph.
d ATS/ERS Task Force Criteria 2009.137
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A SE of 0.1, 0.2, 0.3 or 0.4 was imputed for Honkoop et al.,101 based on the range of errors observed in
other studies. Depending on the error imputed, rate ratios ranged from 0.82 (95% CI 0.64 to 1.05;
p= 0.11) to 0.89 (95% CI 0.67 to 1.17; p= 0.40), which is not statistically significant. Figure 14b presents
the analysis imputing an error of 0.2.
In a prespecified sensitivity analysis, only studies that reported data relating to exacerbations resulting in
the use of OCSs were included. Only Syk et al.99 and Honkoop et al.101 reported this outcome although
Honkoop et al.101 did not report SEs, leaving only the study by Syk et al.99 This study reported a rate ratio
of 1.29 (95% CI 0.83 to 2.03), indicating no significant difference between the intervention groups
(p= 0.26) (Figure 15).
In further sensitivity analyses, SEs of 0.1, 0.2, 0.3 and 0.4 were imputed for Honkoop et al.101 based on the
range of errors observed in other studies. Depending on the error imputed, rate ratios ranged from 0.91
(95% CI 0.47 to 1.77; p= 0.79) to 1.00 (95% CI 0.53 to 1.90; p= 1.00), indicating no significant
differences between the intervention groups. Heterogeneity statistics were high, ranging from 80% to
53% and reflecting the opposite direction of effect reported in these two studies.
Sensitivity analyses including imputed data for Smith et al.97 were not conducted and it is unclear how the
exclusion of these data affects the meta-analyses.
All exacerbations or treatment failures When considering other, wider definitions of exacerbation, as
described in Table 32, three studies report composite outcomes that can be considered to be broadly
similar and which represent what may be termed ‘treatment failure’. In the studies by Smith et al.97 and
Syk et al.99 this was ‘any major or minor exacerbation’, whereas in the study by Calhoun et al.100 it was
exacerbation or any loss of control by a variety of measures (see footnotes to Table 32 for details). In the
studies by Smith et al.97 and Calhoun et al.,100 FeNO-guided groups showed numerically but not statistically
significantly lower rates of treatment failure. In the study by Syk et al.99 the improvement was statistically
significant, with a rate of 0.22 in the intervention arm compared with 0.41 in the control arm (p= 0.024)
(reviewer-calculated rate ratio 0.52, 95% CI 0.44 to 0.61).
Despite the high level of heterogeneity in study characteristics, an exploratory meta-analysis of these rates
using random effects methods (the I2 statistic was 0%) was conducted (Figure 16). The pooled relative risk
(RR) was 0.53 (95% CI 0.46 to 0.61), which represents a statistically significant effect in favour of using
FeNO-guided management in asthmatics for this outcome (p< 0.00001).
Moderate and/or minor exacerbations Smith et al.97 and Syk et al.99 both reported the rates of less severe
exacerbations separately from the rates of all exacerbations and from the rates of major/severe exacerbations
(see Table 32). In both cases the point estimate reduction in minor/moderate exacerbations was far greater
than the reduction in severe/major exacerbations. Smith et al.97 reported 0.36 minor exacerbations per
person-year in the intervention arm and 0.75 per person-year in the control arm, with a p-value of 0.24.
Syk et al.99 reported 0.1 moderate exacerbations per person-year in the intervention arm and 0.325 in the
control arm. The p-value was not reported. When considering the results reported by Calhoun et al.100 for
exacerbations alone and the composite outcome treatment failure, it can be seen that the larger difference in
rates of treatment failure in favour of the intervention arm is not driven by the exacerbation rates, which are
very similar at 0.21 (97.5% CI 0.1 to 0.32) and 0.23 (97.5% CI 0.1 to 0.37), and it must therefore be due to a
decrease in less severe exacerbations/loss of control in the intervention arm. The impact on quality of life and
the costs of such exacerbations are much lower than for major/severe exacerbations.
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Inhaled corticosteroid use All studies except that by Honkoop et al.101 provided some data on ICS use
and these are presented in Table 33. Smith et al.97 and Shaw et al.98 reported ICS use as a mean per day at
the end of the study, with mean differences of –270 µg/day (95% CI –430 µg/day to –112 µg/day;
p= 0.003) and –338 µg/day (95% CI –640 µg/day to –37 µg/day; p= 0.028), respectively, in favour of
FeNO-guided management. Syk et al.99 reported median values that were not statistically significantly
different. Means were supplied on request but without significance tests and showed a small increase in
ICS use in the intervention arm [586 µg (SE 454 µg) vs. 540 µg (SE 317 µg) in the control arm]. Calhoun
et al.100 reported mean use per month, although it is unclear if this was an average over the whole course
of the study or the mean for the final month of the study. The means were very similar at 1617 µg/month
in the intervention group and 1610 µg/month in the control group. It should also be noted that this study
managed and followed patients for only 9 months whereas the other studies did so for 12 months.
When looking at mean use over time (graphical data not reproduced here) in Smith et al.97 and Syk et al.,99
ICS use fell initially in the FeNO arm (both when compared with baseline and in comparison to the control
arm) and then rose at the final measurement to a level above that in the control arm in Syk et al.99 but
staying below that in the control arm in Smith et al.97 Conversely, in the Shaw et al.98 study, ICS use
initially rose and then fell at the final two measurement points to below the baseline level and below the
control arm level. Only Shaw et al.98 reported the AUC for ICS use and this showed an 11% greater use of
ICSs in the FeNO group. Based on the ‘mean use over time’ figures, this is unlikely to be true for the study
by Syk et al.,99 in which a visual interpretation of the AUC would suggest very similar levels of total ICS
use in both arms, with little change over time. Appropriate data were not available for the study by
Calhoun et al.100 or that by Smith et al.97 These differences may be the result of the different titration
protocols and cut-off values used in the studies and it is difficult to draw a generalised conclusion as to the
direction of effect and the trends over time for ICS use. However, it would seem most likely that ICS use
TABLE 33 Adult management review: ICS use
Author,
year
ICS
measurement Intervention Control
Between-group difference
expressed as intervention
minus controla
Calhoun
2012100
ICS use
(unclear if
mean over
whole study or
final value)b
Mean 1617 µg/month Mean 1610 µg/month NR
Shaw
200798
Final value ICS
useb
557 µg 895 µg Mean difference –338µg/day
(95% CI –640µg to –37µg;
p=0.028)
Total used in
study (AUC)
11% greater use in FeNO
group (95% CI –15% to
37%)
Smith
200597
Final value ICS
usec
Baseline: mean 411 µg/day
(95% CI 344 µg to 478 µg);
end of phase 2: mean
370 µg/day (95% CI 263 µg
to 477 µg)
Baseline: mean 491 µg/day
(95% CI 403 µg to 579 µg);
end of phase 2: mean
641 µg/day (95% CI 526 µg
to 756 µg)
Mean difference –270µg/day
(95% CI –112µg to –430µg;
p=0.003)
Syk
201399
ICS used Median 0 (IQR –400 to
400) µg; baseline: mean 604
(SE 370) µg; final value: 586
(SE 454) µg
Median 0 (IQR –200 to
200) µg; baseline: mean 626
(SE 391) µg; final value: 540
(SE 317) µg
0.945
CI, confidence interval; NR, not reported.
a Negative values indicate that the FeNO group had lower ICS use.
b Beclomethasone dipropionate or equivalent.
c Fluticasone or equivalent.
d The equivalent dose for budesonide when a different drug (e.g. fluticasone) has been used.
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will either remain the same or fall in FeNO-managed groups when taken as an average over the course of
the first year. The first year of titration is likely to be when the greatest gains are made, as patients reach a
stable dose. It is unclear how ICS use will change in the following years as no study reported results
beyond 1 year of follow-up, as the severity of the disease may progress, stay stable or remiss over time.
Despite the high level of heterogeneity in study characteristics, an exploratory meta-analysis of ICS use
incorporating data from all four studies was conducted (Figure 17). As studies reported values for different
ICSs (fluticasone, beclomethasone and budesonide), a standardised mean difference analysis was
performed. A random-effects model was used as both clinical and statistical heterogeneity were high, but
the I2 statistic remained high at 75%. SDs for Calhoun et al.100 were imputed based on consideration of
the other three studies. Sensitivity analyses in which the imputed SDs were altered by an order of
magnitude in either direction, and in which a value of 10,000 was used for the intervention arm and 5000
for the control arm (to mirror the SDs of Syk et al.99), did not have a big effect, with the pooled-analysis
CIs crossing the line of no effect in every case and the pooled mean value ranging from –0.25 to –0.23
standardised mean difference. The results of the meta-analysis agree with the conclusions drawn from the
narrative consideration of the data; it would seem most likely that ICS use will either remain the same or
fall in FeNO-managed groups, probably depending on factors such as step-up/step-down protocols, cut-off
values selected, treatments incorporated in the treatment protocol and comparator interventions.
Health-related quality of life Syk et al.99 Calhoun et al.100 and Honkoop et al.101 reported quality of life
data. This was measured by the mini Asthma Quality of Life Questionnaire (mAQLQ) in Syk et al.99 and
the Asthma Quality of Life Questionnaire (AQLQ) in Calhoun et al.100 and Honkoop et al.101 In all studies
the overall score, and in Syk et al.99 three of four domains, did not show a statistically significant change
over time. The symptoms domain did, however, show a relatively small but statistically significant
between-group difference in change from baseline of 0.10 (Table 34) in Syk et al.99 An exploratory meta-analysis
of the overall scores (Figure 18) showed no effect, with a standardised mean difference of 0.00 (95% CI –0.20
to 0.20). In this case, data from the study by Honkoop et al.101 were not included as there was not enough
information provided to calculate a mean AQLQ score across the two control groups.
Asthma control and other medication use Four studies reported data for asthma control.97–100 Smith
et al.97, Calhoun et al.100 and Shaw et al.98 reported no change in asthma control, whereas Syk et al.99
reported a statistically significant difference in change in ACQ score from visit 2 to visit 6 between the two
trial arms (Table 35). This matches the change seen in the AQLQ symptoms domain previously mentioned.
Smith et al.,97 Calhoun et al.100 and Syk et al.99 reported use of other medications; Smith et al.97 and
Calhoun et al.100 reported no significant difference between groups for bronchodilator use, although in the
study by Calhoun et al.100 there was a trend towards less use in the intervention arm, and Syk et al.99
reported non-significant trends towards greater numbers using LTRAs and higher mean use of LTRAs and
SABAs (significance not reported) in the FeNO-controlled arm.
Adverse events, mortality, compliance and test failure rates No data were reported in the four
studies for adverse events or mortality, although Calhoun et al.100 reported one unrelated adverse event
(hip surgery) in the control arm. Compliance was reported by Smith et al.97 and Calhoun et al.100 and was
85% and 89% in the intervention and control arms, respectively, in Smith et al.97 and ≥ 95% (median) in
both groups in Calhoun et al.100 No test failure rates for NIOX MINO or NObreath were reported.
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TABLE 34 Adult management review: HRQoL
Author,
year Intervention Control Between-group difference
Calhoun
2012100
AQLQ change from baseline 0.02
(97.5% CI –0.14 to 0.18),
p= 0.75
AQLQ change from baseline 0.02
(97.5% CI –0.14 to 0.17),
p= 0.80
AQLQ between-group difference
0.00 (97.5% CI –0.22 to 0.23),
p= 0.96
Syk 201399 Appears to be some data missing
(n= 78–86)
Total change over time in mAQLQ
(n= 80/87), median (IQR): 0.23
(0.07 to 0.73); final mean (SE)
value 6.07 (0.90)
Visit 2 and visit 6 data, median
(IQR): mAQLQ symptoms – visit 2:
5.60 (4.80 to 6.20), visit 6: 6.00
(5.60 to 6.60); activity limitation –
visit 2: 6.50 (5.75 to 6.75), visit 6:
6.75 (6.00 to 7.00); emotional
function – visit 2: 6.00 (4.67 to
6.67), visit 6: 6.33 (5.67 to 7.00);
environmental stimuli – visit 2:
6.00 (5.00 to 6.67), visit 6: 6.33
(5.67 to 6.67)
GQLI change (n= 85/88): 0.06
(–0.22 to 0.28)
Appears to be some data missing
(n= 77–85)
Total change over time in mAQLQ
(n= 77/78), median (IQR): 0.07
(–0.20 to 0.80); final mean (SE)
value 5.98 (0.83)
Visit 2 and visit 6 data, median
(IQR): mAQLQ symptoms – visit 2:
5.70 (4.80 to 6.40), visit 6: 6.00
(5.20 to 6.40); activity limitation –
visit 2: 6.25 (5.50 to 7.00), visit 6:
6.50 (5.75 to 7.00); emotional
function: visit 2: 6.00 (4.67 to
6.67), visit 6: 6.00 (5.33 to 6.67);
environmental stimuli: visit 2: 5.67
(5.00 to 6.67), visit 6: 6.33 (5.33
to 6.67)
GQLI change (n= 78/78): 0 (–0.39
to 0.39)
Analyses of median (IQR) change
between visit 2 and visit 6:
mAQLA overall: p= 0.197;
mAQLQ symptoms: p= 0.041;
activity limitation: p= 0.544;
emotional function: p= 0.596;
environmental stimuli: p= 0.193;
GQLI: p= 0.666
CI, confidence interval; GQLI, Gothenburg Quality of Life Instrument.
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TABLE 35 Adult management review: other outcomes
Author,
year Outcome Intervention Control
Between-group
difference
Asthma control
Calhoun
2012100
Night-time symptoms, difference
from beginning to end of
treatment period using
model-based estimates (97.5% CI)
0.01 (–0.00 to 0.02),
p= 0.07
0.01 (–0.00 to 0.02),
p= 0.11
0.00 (–0.02 to 0.02),
p= 0.86
Daytime symptoms, difference
from beginning to end of
treatment period using
model-based estimates (97.5% CI)
–0.00 (–0.02 to 0.02),
p= 0.86
0.01 (–0.00 to 0.03),
p= 0.06
–0.01 (–0.04 to 0.01),
p= 0.17
ACQ score, difference from
beginning to end of treatment
period using model-based
estimates (97.5% CI)
–0.01 (–0.15 to 0.12),
p= 0.81
0.03 (–0.10 to 0.16),
p= 0.64
–0.04 (–0.23 to 0.15),
p= 0.62
ASUI score, difference from
beginning to end of treatment
period using model-based
estimates (97.5% CI)
0.01 (–0.02 to 0.04)
p= 0.40
0.01 (–0.02 to 0.03)
p= 0.64
0.00 (–0.04 to 0.04)
p= 0.79
Shaw
200798
Asthma control Data NR. No difference between groups in Juniper score throughout the
study; however, in both groups the score decreased from baseline.
Significance NR
Smith
200597
Symptom score (daily score
previous 7 days): final scores,
mean (95% CI)
0.4 (0.1 to 0.7) 0.6 (0.4 to 0.9) p= 0.23
Nocturnal waking (nights/week,
previous 7 days): final scores,
mean (95% CI)
0.2 (0.0 to 0.6) 0.2 (0.0 to 0.4) p= 0.89
Asthma score (% of days),
mean (95% CI)
Score 0: 85.2 (78.4 to
92.0); score 1: 14.0
(7.4 to 20.6); score
≥ 2: 0.8 (0.3 to 1.3)
Score 0: 78.5 (70.4 to
86.6); score 1: 19.9
(12.3 to 27.5); score
≥ 2: 1.7 (0.3 to 3.1)
Between-group final
scores (not change
from baseline)
p= 0.19
Syk 201399 ACQ score change between visit
2 and 6, median (IQR)
–0.17 (–0.67 to 0.17)
(n= 81/88)
0 (–0.33 to 0.50)
(n= 74/78)
p= 0.045
Other medication use
Calhoun
2012100
Albuterol rescue use (puffs/day),
difference from beginning to end
of treatment period using
model-based estimates (97.5% CI)
–0.04 (–0.10 to 0.02),
p= 0.15
0.02 (–0.03 to 0.08),
p= 0.30
–0.06 (–0.14 to 0.02),
p= 0.08
Shaw
200798
Medication use NR NR NR
Smith
200597
Bronchodilator use (occasions/day,
previous 7 days), mean (95% CI)
0.4 (0.1 to 0.7) 0.4 (0.1 to 0.6) p= 0.98
Safety buffer criteria used 16/436 assessments NA NA
Syk 201399 LTRA use, n/N (%) 33/92 (35.9) 19/85 (22.4) p= 0.069
Mean months on LTRA 2.87 (4.42) 1.81 (3.89) p= 0.094
SABA use between visit 5 and
visit 6 (8–12 months), median
(IQR)
1.56 (0.06 to 5.18) 0.94 (0.03 to 2.81) NR
ASUI, Asthma Symptoms Utility Index; CI, confidence interval; NA, not applicable; NR, not reported.
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Children
Five studies103–107 that recruited children (plus adolescents and/or young adults) and compared FeNO- guided
management to non-FeNO-guided management were identified from the initial search and a further two
studies108,109 were identified during the update search. The study by Fritsch et al.103 was based in Vienna,
Austria; that by Szefler et al.104 was based in the USA; that by Verini et al.105 was based in Italy; that by
Pijnenburg et al.106 was based in Rotterdam, the Netherlands; that by Petsky et al.107 was based in Australia;
that by Peirsman et al.109 was conducted in Belgium; and that by Pike et al.108 was the first UK-based study
identified on this topic in children. Fritsch et al.103 received technical and analytical support from Aerocrine;
one of the authors in the study by Szefler et al.104 received speaker fees from Aerocrine; the study by
Pijnenburg et al.106 was supported by the Kroger Foundation/Sophia Children’s Hospital Foundation,
although Aerocrine had provided a grant to the department; the study by Petsky et al.107 was funded by
the Royal Children’s Hospital Foundation, Asthma Foundation of Queensland; the study by Pike et al.108 was
funded by Sparks charity; the study by Peirsman et al.109 was funded by Merck & Co., with equipment
provided by Aerocrine; and Verini et al.105 did not report their source of funding.
Quality assessment
Study quality varied, with no one study scoring well on every item and no item scoring well in every study
(Figure 19). Of the studies included in the review, the study with the highest overall quality appeared to be
that by Szefler et al.,104 in which the only potential source of bias identified was study funding by a company
with a commercial interest in FeNO measurement. The study with the lowest quality appeared to be that by
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FIGURE 19 Methodological quality summary: review authors’ judgements about each methodological quality item
for all included studies. Dark green circles with + sign, low risk of bias; light green circles with – sign, high risk of
bias; medium green circles with ?, unclear risk of bias.
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Petsky et al.,107 which was not scored as ‘low risk’ on any of the quality assessment items. As it was a
conference abstract, Petsky et al.107 was at especially high risk of selective reporting, whereas Verini et al.105
was at risk of bias as the statistical comparison data were presented poorly (as discussed in the following
sections). Potential sources of bias for the evidence base as a whole are discussed in the following sections.
Risk of selection bias All of the included studies were described as randomised. However, only the study
by Szefler et al.104 provided sufficient information on sequence generation and allocation concealment.
Pike et al.108 did demonstrate random sequence generation but the method of allocation concealment was
unclear. In all other studies the method of sequence generation and allocation concealment was not reported.
Risk of performance bias In terms of blinding, Szefler et al.,104 Pijnenburg et al.106 and Pike et al.108
appeared to have performed adequate blinding for both participants and study personnel. Fritsch et al.103
blinded participants but did not report whether this was the case for study personnel and so this study was
rated as ‘unclear’ on this item. Peirsman et al.109 blinded participants but not personnel. Neither Petsky
et al.107 nor Verini et al.105 provided sufficient information to make a judgement on participant and personnel
blinding and so these studies were rated as ‘unclear’. As many of the step-up/step-down protocols and criteria
for exacerbations were based on participant symptom reporting and physician judgement, any potential lack
of blinding in the studies could significantly affect the direction and size of the outcomes.
Risk of detection bias Szefler et al.,104 Peirsman et al.109 and Pike et al.108 clearly stated that outcome
assessment blinding had been performed. The poor reporting of outcome assessment blinding in the other
studies means that unblinded outcome assessment may be a potentially important source of bias
throughout this body of literature.
Risk of attrition bias In terms of outcome data completeness, Pijnenburg et al.,106 Szefler et al.104 and
Peirsman et al.109 appeared to be at low risk of bias. There may have been some bias in terms of outcome
data completeness in the remaining four studies. Fritsch et al.103 did not report the reasons for participant
withdrawal or correction for missing FeNO values and there may have been missing outcome data in the
study by Petsky et al.,107 but this is unknown as only a conference abstract of this study was identified.
In the study by Verini et al.105 it was reported that 64 patients were recruited; however, it was unclear
whether this was the total number after dropout or whether no participants dropped out. Consequently,
the study was rated as ‘unclear’ on outcome data completeness. Pike et al.108 reported 23% of dropouts in
the intervention arm but only 7% in the control arm and was scored as being at high risk of attrition bias.
Risk of reporting bias Selective reporting risk may also have been present in some of the data. The study by
Petsky et al.107 was reported in a conference abstract and so this was rated as ‘high risk’ for this item. In the
study by Fritsch et al.,103 medication usage was reported as median (IQR) values rather than mean values and
so these values could not be used in the planned meta-analysis; however, although planned, a meta-analysis
was not possible because of study heterogeneity and so this bias did not affect the synthesis of data. The
study by Verini et al.105 was rated as having a low risk of bias for selective reporting; respiratory function and
immunoallergological parameters were inadequately reported (i.e. no numerical data were provided; it was
stated only that there were no significant between-group differences on these outcomes), but these outcomes
were not of relevance to this review. Szefler et al.,104 Pijnenburg et al.106 Pike et al.108 and Peirsman et al.109 appear
to have reported all of the outcomes that they set out to measure and so these studies were rated as ‘low risk’.
Risk of other bias There were a number of further potential sources of bias in each of the studies.
Fritsch et al.103 and Szefler et al.104 were both in receipt of sponsorship from the pharmaceutical industry and
there was evidence of some such sponsorship in the studies by Peirsman et al.109 and Pijnenburg et al.106
The statistical comparison data reported in Verini et al.105 was of poor quality in that most comparisons
were presented as within-group longitudinal trends. Pike et al.,108 Pijnenburg et al.,106 Szefler et al.104 and
Fritsch et al.103 all conducted run-in periods before randomisation, which have an unknown risk of bias
attached to them. Finally, it was unclear whether there may have been additional sources of bias in the
study by Petsky et al.,107 as this research was presented as a conference abstract only.
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Summary The quality of the sampled literature was variable, with selective reporting being the most common
potential source of bias. The studies by Fritsch et al.,103 Petsky et al.107 and Verini et al.105 were rated as ‘unclear’
on the majority of quality items. Such ratings were given for those aspects of study design that were not clearly
presented within the articles themselves, meaning that it was unclear whether there is likely to be bias in the
conduct of the studies themselves or whether the lack of clarity was a result of inadequate reporting. Other
common potential sources of bias were random sequence generation, allocation concealment and outcome
assessor blinding. Pharmaceutical industry sponsorship was declared as the source of funding by Fritsch et al.103
and Szefler et al.104 and at least partially funded the activities of one author in the studies by Pijnenburg et al.106
and Peirsman et al.109 The studies at lowest risk of overall bias appeared to be those by Szefler et al.104 and
Pike et al.108 (low risk on six and five of seven items respectively) and the studies by Szefler et al.,104 Pike et al.108
and Pijnenburg et al.106 were the only studies in which it was possible to confirm blinding of both participants
and study personnel. Possible lack of participant blinding may be a particularly important source of bias given
that the study outcomes were largely based on subjective measurements (i.e. self-reporting of symptoms);
blinding of study personnel may also be an important source of bias as they decide whether a patient’s
medication step should be changed and there is some degree of interpretation in this decision. Finally, there
was the possibility of selective reporting in Petsky et al.,107 which may predispose the results to favour the
intervention over the control.
Study details
Study design and timeline of studies All seven studies were RCTs, with varying degrees of blinding
(see previous section). Study timelines are presented in Table 36. Study duration ranged from 6 months103 to
12 months.105,107–109 Pijnenburg et al.,106 Szefler et al.,104 Fritsch et al.103 and Pike et al.108 reported run-in
periods of 2, 3, 4 and 4–16 weeks respectively. In Pijnenburg et al.106 and Fritsch et al.,103 details of the
run-in period were not provided. In Szefler et al.104 patients were provided with a treatment programme
based on previous treatment, adherence and control and in Pike et al.108 patients were stabilised when
necessary. Verini et al.105 and Petsky et al.107 reported no run-in. In addition, the frequency of visits varied
from study to study. Fritsch et al.103 and Szefler et al.104 reported visits every 6–8 weeks, Pike et al.108 every
2 months, Pijnenburg et al.106 and Peirsman et al.109 every 3 months and Verini et al.105 every 6 months.
Petsky et al.107 did not report the frequency of visits and provided outcomes for 12 months only.
Population The study and population characteristics are provided in Table 37. Eligibility criteria varied from
study to study. With the exception of Verini et al.,105 all studies included children with confirmed or persistent
asthma. It is difficult to determine whether severity was comparable in the studies as scores have not
been reported in a way that allowed comparison. Fritsch et al.103 did not report severity; Szefler et al.104
reported ACT scores; Verini et al.105 and Peirsman et al.109 classified participants on the basis of GINA scores;
Pijnenburg et al.106 reported mean daily symptom scores; and Pike reported exacerbations and OCS use in the
previous year. Some insight into severity can be gained from considering the inclusion criteria and setting of
each study. Three studies appeared to recruit patients who were uncontrolled.104,105,107 Verini et al.105 and
Petsky et al.107 recruited patients attending a specialist clinic, perhaps suggesting difficult to control patients,
although in Verini et al.105 patients had not yet started ICS therapy; an alternative explanation would be that all
patients are sent to a specialist clinic before starting ICS therapy in this region and the patients were therefore
not necessarily uncontrolled. Szefler et al.104 recruited only patients with evidence of persistent or uncontrolled
disease. Studies recruiting patients who are difficult to control are likely to capture the efficacy of FeNO for
increasing control but not for decreasing ICS use in patients who are well controlled. Pike et al.108 aimed to
recruit patients with moderate to severe asthma and specified that children must be receiving therapy
equivalent to stage 4 in the BTS/SIGN guidelines,8 as well as a requirement to demonstrate responsiveness to a
bronchodilator (i.e. an increase in FEV1 of 15%). Fritsch et al.103 recruited mild to moderate persistent asthma
patients at an outpatients clinic. Pijnenburg et al.106 recruited atopic asthma patients who were attending a
children’s hospital, although it is not clear if this was a scheduled appointment, an emergency admission or
just the location of the study follow-up and it is therefore unclear what level of severity of asthma these
patients may have. As they had all had a stable dose of ICS for the previous 3 months, it may be reasonable to
assume that these patients were reasonably well controlled. Peirsman et al.109 recruited the broadest spectrum
of patients, including mild to severe persistent asthmatics.
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TABLE 36 Children management review: study timelines
Author, year Timeline of study Final assessment
Fritsch 2006103 Visit 1: 4-week run-in. Visit 2: randomisation. Visit 3: visits at 6, 12, 18
and 24 weeks; symptoms, SABA use, anti-inflammatory treatment,
FeNO and spirometry recorded. Bronchial challenge test (4.5%
hypertonic saline) was carried out between the first and second visit
24 weeks
Peirsman 2013109 Visit 1: baseline. Visits 2–5: visit every 3 months; assessed symptom-free
days (assessed daily), exacerbations, unscheduled asthma-related visits,
hospital or emergency admissions, non-attendance at school and need
for caregiver to take time off; FeNO recorded in all participants
12 months
Petsky 2010107 Spirometry, FeNO, QoL and asthma/cough diary every visit 12 months
Pijnenburg 2005106 Visit 0: 2-week run-in. Visit 1: randomisation, FeNO, FEV1, PD20, diary
card. Visits 2–4: visit every 3 months; FeNO and symptoms (diary card
previous 2 weeks) recorded at each visit. Visit 5: FeNO, FEV1, PD20,
diary card
9 months
Pike 2013108 Unclear when baseline measurements performed. Visit 0: start of run-in
period (4–16 weeks). Visit 1: randomisation. Visits 2–7: visit every
2 months for assessment – FeNO, exacerbations, symptoms and reliever
use over previous 2 months recorded, treatment adherence assessed
12 months
Szefler 2008104 Visit 1: assessed asthma symptoms, pulmonary function, skin test,
sensitivity, adherence and level of asthma control (NHLBI guidelines134).
Run-in period of 3 weeks on a regimen based on standard treatment –
physicians selected a treatment programme (one of six) based on
previous treatment, adherence and asthma control. Included 10-minute
session about adherence. Adherence measured during run-in period
with Diskus inhaler and questionnaire. Centralised block randomisation
and visit every 6–8 weeks for 46 weeks. Each visit: FeNO, days of
symptoms, use of rescue drugs, pulmonary function, use of health care,
adherence to treatment, missed days of school from asthma. Data were
entered into computer and treatment option computed based on
random allocation. In total, 546 were then randomly assigned to
46 weeks of either standard treatment or standard treatment modified
on the basis of measurements of FeNO
46 weeks
Verini 2010105 Visit 1: baseline. Visit 2: 6 months. Visit 3: 12 months. ASS, asthma
exacerbation frequency, asthma therapy score and immunoallergological
and functional data recorded at each visit
12 months
ASS, Asthma Severity Score; NHLBI, National Heart, Lung, and Blood Institute; PD20, dose of methacholine causing a 20%
fall in FEV1 from baseline; QoL, quality of life.
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Interestingly, atopy is a known confounder to FeNO measurements as atopic subjects have raised FeNO
levels regardless of asthma status. Asthmatic atopic patients are thought to have the highest levels overall
and so FeNO is theoretically able to distinguish between controlled and uncontrolled atopic asthmatics as
well as between controlled and uncontrolled non-atopic asthmatics.138 However, atopic asthma patients
tend to have ICS-responsive asthma more often than non-atopic patients and so studies recruiting atopic
patients will have limited generalisability. It is unclear whether studies in atopic patients will over- or
underestimate efficacy or have no impact at all, although clinical input to the assessment suggested that
it would be expected to increase estimates of efficacy as atopy is correlated with ICS responsiveness.
Atopic patients were recruited by Peirsman et al.,109 Fritsch et al.,103 Verini et al.105 and Pijnenburg et al.106
Pike et al.108 recruited only patients who demonstrated responsiveness to bronchodilators, but not all
were atopic.
Petsky et al.107 was the only study to include young children only, with all other studies including
adolescents and/or young adults as well as young children, or adolescents only in the case of
Szefler et al.104 The studies also varied in terms of size (range 52103–546104) and baseline FeNO was
inconsistently reported.
Interventions Table 38 describes the interventions used in each study. NIOX MINO was used in the two
most recent studies;108,109 the NIOX device was used in three of the studies;103,104,106 Verini et al.105 used the
ECO MEDICS CLD 88 device; and it was unclear what device was used by Petsky et al.107
None of the studies used the same protocol or cut-off points for the management of asthma with FeNO.
The protocol of Fritsch et al.103 was based on FeNO readings only. Other studies used a combination of
FeNO levels and symptoms, with various cut-off points and numbers of cut-off points: Szefler et al.104
specified three levels of cut-off, Pike et al.108 specified two cut-off points, Petsky et al.107 did not report
cut-offs and all other studies used just one cut-off point. These cut-off points ranged from 12 ppb to
40 ppb. Treatments indicated at each step were also highly heterogeneous across studies, with Pike et al.,108
Peirsman et al.,109 Fritsch et al.103 and Szefler et al.104 indicating doses for ICSs, LTRAs and LABAs and
Pijnenburg et al.106 indicating doses only for ICSs. Verini et al.105 and Petsky et al.107 did not report doses.
The treatment in the study by Pike et al.108 was most similar to that in the BTS/SIGN guidelines,8 with some
minor modifications. Importantly, in the studies by Szefler et al.,104 Pike et al.108 and Peirsman et al.,109 step
down could not occur on the basis of low FeNO levels if patients were still experiencing symptoms. This
may have limited any potential reduction in ICS use for patients who were non-ICS responsive.
Control Table 39 provides details of the control group interventions. As with the interventions, none of
the studies used the same criteria, protocols or treatment doses for the management of asthma in the
control arm of the study, but, when reported, they all used the same treatment steps in both arms of the
study. Management was typically guided by symptom severity and/or FEV1. Verini et al.105 and Peirsman
et al.109 used GINA guidelines136 as a control and Pike et al.108 used BTS/SIGN guidelines8 with some
minor modifications.
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TABLE 38 Child management review: description of the intervention management strategies
Author,
year
Decisions based on flow
rate, device and cut-off
points Step-up/step-down protocol Doses
Fritsch
2006103
Based on FeNO readings
only
Flow rate; device:
50ml/second with the
single-breath online
method; NIOX device
Cut-off: FeNO > 20 ppb
In patients with stable asthma, an
increased FeNO level was considered a
sign of insufficient anti-inflammatory
treatment (either because of insufficient
dosing or because of low adherence to
prescribed therapy); hence, aimed to
improve adherence to therapy in patients
on anti-inflammatory treatment with
raised FeNO. These patients were provided
with 2-week diary cards to record daily
symptoms, beta-agonist use and controller
medication requirements and telephone
calls were made regularly to check
adherence to therapy. Asymptomatic
patients on therapy with beta-agonists on
demand only, with normal lung function
but increased FeNO levels, were prescribed
low-dose steroids. Step up was performed
irrespective of FeNO level if FEV1%
predicted was <80% and/or there were
severe symptoms over the last 4 weeks
and/or beta-agonist use involved six or
more puffs over the last 14 days. If FeNO
was raised in these patients they received
2-week diary cards as well. Step down was
performed if FEV1% predicted was ≥80%
and there were no or mild symptoms over
the last 4 weeks and beta-agonist use
involved fewer than six puffs over the last
14 days and FeNO was ≤20ppb
Low-dose ICS: 2 × 100 µg
fluticasone or 2 × 200 µg
budesonide
Low-dose ICS+ LTRAs:
2 × 100 µg fluticasone or
2 × 200 µg budesonide+ 5mg
montelukast once daily p.o.
Low-dose ICS+ LABAs:
2 ×100µg fluticasone+2×50µg
salmeterol or 2 ×200µg
budesonide+2×12µg
formoterol
High-dose ICS+ LTRAs:
2 × 250µg fluticasone or
2× 400µgbudesonide +5mg
montelukast once daily p.o.
High-dose ICS+ LABAs:
2×250µg fluticasone+2×50µg
salmeterol or 2×400µg
budesonide+2×12µg formoterol
Peirsman
2013109
Based on FeNO readings
and symptoms
Flow rate; device:
50ml/second; NIOX MINO
Cut-off: 20 ppb
Asthma classed as ‘controlled’ (≤ 20 ppb
and symptoms controlled); ‘partly
controlled’ (≤ 20 ppb and partly
controlled symptoms); or uncontrolled
(FeNO > 20 ppb regardless of symptoms).
Medication changes were guided by
participants’ baseline therapies
Controlled: if on ICS only: step
down ICS 100µg/day, if already
<100µg stop and add LTRA;
if on LTRA only, no change; if on
ICS+ LTRA, step down ICS
100µg/day, if already
<100µg, stop ICS; if on
ICS+ LABA, stop LABA
Partly controlled: if on ICS only,
consider adding LTRA; if on LTRA
only, consider adding ICS
100µg/day (max. 200µg/day);
if on ICS+ LTRA, consider ICS step
up by 100µg/day (max.
400µg/day, then add LABA); if on
ICS+ LABA, consider adding LTRA
Uncontrolled: if on ICS only, add
LTRA; if on LTRA only, add ICS
100µg/day (max. 200µg/day); if
on ICS+ LTRA, step up ICS by
100µg/day (max. 400µg, then
add LABA); if on ICS+ LABA,
replace LABA with LTRA
Petsky
2010107
Based on FeNO and atopy
Flow rate; device: NR
Cut-offs: NR
NR (treatment adjusted according to
exhaled nitric oxide result, monthly for
4 months, then every second month for
8 months)
NR
continued
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TABLE 38 Child management review: description of the intervention management strategies (continued )
Author,
year
Decisions based on flow
rate, device and cut-off
points Step-up/step-down protocol Doses
Pijnenburg
2005106
Based on FeNO and
symptoms
Flow rate; device: presume
50ml/second; NIOX
analyser
Cut-offs: > 30 ppb;
≤ 30 ppb+ symptoms > 14
≤ 30 ppb+ symptoms ≤ 14
FeNO > 30 ppb= ICS increased; FeNO
≤ 30 ppb and symptoms > 14= ICS stays
the same; FeNO ≤ 30 ppb and symptoms
≤ 14= ICS decreased
ICS doses:
100 µg: increase to 200 µg,
decrease to 0 µg
200 µg: increase to 400 µg,
decrease to 100 µg
400 µg: increase to 800 µg,
decrease to 200 µg
500 µg: increase to 1000 µg,
decrease to 250 µg
800 µg: increase to 1200 µg,
decrease to 400 µg
1000 µg: increase to 1500 µg,
decrease to 500 µg
1200 µg: increase to 1600 µg,
decrease to 800 µg
1600 µg: increase to 2000 µg,
decrease to 1200 µg
2000 µg: no further increase,
decrease to 1000 µg
Pike
2013108
Based on FeNO readings
and symptoms
Flow rate; device: flow rate
NR; NIOX MINO
Cut-offs: ≤ 15 ppb;
> 15 ppb and ≤ 25 ppb;
≥ 25 or FeNO doubled
from baseline
FeNO ≥ 25 ppb or more than twice
baseline:
l poorly controlled: increase ICS or
add LTRA if already at SIGN/BTS
guidelines8 step 4; if after increasing
by two SIGN/BTS steps FENO remains
high do not increase therapy further
l asthma controlled or well controlled:
increase ICS or add LTRA if already at
SIGN/BTS guidelines8 step 4
FeNO > 15 ppb and ≤ 25 ppb
l poorly controlled: increase LABA
therapy; if dose maximal, increase
ICS or add LTRA if already at
SIGN/BTS guidelines8 step 4
l asthma controlled or well controlled:
continue current treatment
FeNO ≤ 15 ppb
l poorly controlled: increase LABA; if
dose maximal, increase ICS or
add LTRA if already at SIGN/BTS
guidelines8 step 4
l asthma controlled or well controlled:
if asthma controlled for 3 months,
reduce ICS; if dose ≤ 400 µg,
reduce LABA
Step 1: no ICS
Step 2: beclomethasone 50µg
b.i.d. via spacer or budesonide
50µg b.i.d. via spacer or
turbohaler or fluticasone 50µg
once a day via spacer (or accuhaler)
Step 3: beclomethasone 100µg
b.i.d. via spacer or budesamide
100µg b.i.d. via spacer or
turbohaler or fluticasone 100µg
once a day via spacer (or accuhaler)
Step 4: beclomethasone 200µg
b.i.d. via spacer or budesamide
200µg b.i.d. via spacer or
turbohaler or fluticasone 100µg
once a day via spacer (or accuhaler)
Step 5: trial of LABA. If ineffective,
consider trial of LTRA
Step 6: fluticasone 125µg b.i.d. via
spacer
Step 7: fluticasone 250µg b.i.d. via
spacer
Step 8: consider short course of
prednisolone or other therapeutic
options
CLINICAL REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
TABLE 38 Child management review: description of the intervention management strategies (continued )
Author,
year
Decisions based on flow
rate, device and cut-off
points Step-up/step-down protocol Doses
Szefler
2008104
Based on days/nights of
symptoms (patient recall
over past 2 weeks), FEV1 as
percentage of personal
best, FeNO
Flow rate; device:
50ml/second; NIOX device
Cut-offs: 0–20, 20.1–30,
30.1–40, > 40 ppb
Step up/down based on predefined levels
of control:
Level 1 – days of symptoms in past
2 weeks 0–3; nights of symptoms in past
2 weeks 0–1; % of personal best FEV1
≥ 80%; FeNO 0–20 ppb. Medication
would not change at this level or if at
level 1 for two consecutive visits it may
be stepped down
Level 2 – days of symptoms in past
2 weeks 4–9; nights of symptoms in past
2 weeks 2; % of personal best FEV1
≥ 80%; FeNO 20.1–30 ppb. Increase
medication by one step
Level 3 – days of symptoms in past
2 weeks 10–13; nights of symptoms in
past 2 weeks 3–4; % of personal best
FEV1 70–79%; FeNO 30.1–40 ppb.
Increase medication by two steps
Level 4 – days of symptoms in past
2 weeks 14; nights of symptoms in past
2 weeks 5–14; % of personal best FEV1
< 70%; FeNO > 40 ppb. Increase
medication by three steps or two
steps+ prednisone
Step 0 – no controller medication;
rescue treatment with salbutamol
as needed
Step 1 – fluticasone by dry
powder inhaler 100µg/day
Step 2 – fluticasone by dry
powder inhaler 100µg b.i.d.
Step 3 – fluticasone by dry
powder inhaler 100µg/day and
salmeterol 50µg b.i.d.
Step 4 – fluticasone by dry
powder inhaler 250µg/day and
salmeterol 50µg b.i.d.
Step 5 – fluticasone by dry
powder inhaler 500µg/day and
salmeterol 50µg b.i.d.
Step 6 – fluticasone by dry
powder inhaler 500µg/day and
salmeterol 50µg b.i.d. plus either
low-dose theophylline or
montelukast every day
Verini
2010105
Based on GINA
guidelines136 plus FeNO
values
Flow rate; device: flow rate
NR; CLD 88
Cut-off: 12 ppb
Values > 12 ppb lead to increased
medication. Values < 12 ppb lead to a
reduction in or maintenance of amount
of drugs. Changes in drugs not reported.
Unclear whether FeNO used at visit 2
only to guide therapy
NR
b.i.d., twice per day; p.o., by mouth.
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Estimates of efficacy
Exacerbations All seven studies provided some data on asthma exacerbations, although it was unclear in
some cases what the precise definition of an exacerbation was (Table 40).
Hospitalisations Three studies104,108,109 reported the number of patients (but not the rate per person-year)
requiring hospitalisations. All three studies reported no difference between groups (see Table 40).
Exacerbations resulting in oral corticosteroid use Data on exacerbations resulting in OCS use were
reported in three studies.103,104,106 Szefler et al.104 reported rates per year and Pijnenburg et al.106 reported
the number of courses per group. In both cases rates were lower in the intervention arm. In the study by
Szefler et al.104 the rate per year was 0.66 (SE 0.085) in the FeNO group and 0.84 (SE 0.085) in the control
group. It is not clear if this analysis calculated rates per person-year to account for missing data points.
The mean difference was not statistically significant (0.17, 95% CI −0.08 to 0.41; p= 0.14). In the study
by Pijnenburg et al.106 the reviewer-calculated mean number of exacerbations per person was 0.21
(eight courses in 39 patients) in the FeNO group and 0.39 (18 courses in 46 patients) in the control group.
TABLE 39 Child management review: description of the control group management strategies
Author,
year Decisions based on Step-up/step-down protocol Doses
Fritsch
2006103
Asthma control (symptoms, SABA use,
lung function), as recommended in
current (German) asthma guidelines139
A step down in therapy was performed if
FEV1% predicted was ≥ 80% and there were no
or mild symptoms over the last 4 weeks and
beta-agonist use involved fewer than six puffs
over the last 14 days. A step up was performed
in every other case
As intervention
Peirsman
2013109
Symptoms, need for rescue treatment
in past 2 weeks, spirometry (FEV1)
based on GINA guidelines136
GINA guidelines136 (specific step-up/step-down
protocol not described) to determine if
controlled, partly controlled or uncontrolled
As intervention
Petsky
2010107
Symptoms/FEV1 Unclear NR
Pijnenburg
2005106
Symptoms Symptom score > 14= ICS increase; symptom
score ≤ 14 for first time= ICS stays the same;
symptom score ≤ 14 for second time= ICS
decrease
Symptom score calculated as mean of daily
scores for dyspnoea, wheezing and cough,
during daytime and night-time, with each
scored from 0 to 3, giving a max. score of 18,
as well as use of beta2-agonists and percentage
of symptom-free days. Calculated over previous
2 weeks for monitoring and over previous
4 weeks for end-point evaluation
As intervention
Pike
2013108
Symptom control Therapy was stepped up if symptoms were
poorly controlled and decreased if well
controlled for ≥ 3 months, according to
BTS/SIGN guidelines8
As intervention
Szefler
2008104
National Asthma Education and
Prevention Program (symptoms,
treatment use, lung function)140
Control group received standard treatment
based on the guidelines of the National Asthma
Education and Prevention Program140 (i.e. as
intervention but without FeNO measurements)
As intervention
Verini
2010105
GINA guidelines136 (symptoms, SABA
use, lung function)
GINA guidelines136 (specific step-up/step-down
protocol not described)
NR
b.i.d., twice per day; NR, not reported.
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TABLE 40 Child management review: exacerbation and OCS use rates in children and adolescents with or without
FeNO-guided management
Author,
year Definition of outcomes Intervention Control
Between-group
comparison
Hospital admission
Peirsman
2013109
One or more hospital admission 1/43 (2.3%) 1/43 (2.3%) Chi-square test: p= 1.00
Pike 2013108 Requiring ≥ 8 hours of admission 5 patients (11.4%) 3 patients (6.5%) p= 0.420
Szefler
2008104
One or more hospital admissions 3.3% (SD 1.78%) 4.1% (SD 1.98%) Mean difference –0.8
(95% CI –4.0 to 2.3),
p= 0.61
Unscheduled use of health care
Peirsman
2013109
One or more unscheduled uses
of health care
6/44 (13.6%) 15/43 (34.9%) Chi-square test: p= 0.02
Szefler
2008104
One or more unscheduled uses
of health care
21.3% (SD 4.09%) 22.7% (SD 4.19%) Mean difference –1.4
(95% CI –9.3 to 6.7),
p= 0.74
OCS use
Fritsch
2006103
OCS use (no. of patients/group) n= 2 n= 2 p=NS
Pijnenburg
2005106
Prednisone courses Eight events in
1 year=8/39=0.21
per patient
18 events in
1 year=18/46=0.39
per patient
p= 0.60a
Szefler
2008104
Prednisone courses Mean 0.66
(SE 0.085)
Mean 0.84
(SE 0.085)
Mean difference 0.17
(95% CI –0.08 to 0.41),
p= 0.14
Any/wide definition of exacerbation
Fritsch
2006103
Exacerbation defined as oral
steroid courses because of
asthma symptoms over the last
4 weeks and/or unscheduled visit
because of asthma symptoms
over the last 4 weeks and/or
increase in asthma symptoms
from a symptom score of 0 or 1
to a score of 2 and/or decline in
FEV1> 10% compared with last
visit (no. of patients/group)
17/88 observations
(18.2%) [sic]b
22/99 observations
(21.2%) [sic]b
p=NS
Peirsman
2013109
Exacerbation as per GINA
guidelines:136 an episode of
progressive increased shortness
of breath, coughing, wheezing
or chest tightness or a
combination of these symptoms
18 per yearb 35 per yearb Mann–Whitney test:
p= 0.02
Petsky
2010107
Asthma exacerbations (severity
not described)
6/31 (19.4%) 15/32 (46.9%) p= 0.021a
Pike 2013108 Patients experiencing an
exacerbation
37 patients
(84.1%)c
38 patients
(82.6%)c
p= 0.850
Szefler
2008104
Exacerbation defined as a
composite outcome consisting
of admissions to hospital,
unscheduled visits and
prednisone use
37.0% (SD 4.83%) 43.6% (SD 4.96%) Mean difference –6.5%
(95% CI –14.4 to 1.4),
p= 0.11
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The difference in the number of people experiencing an exacerbation in the study by Pijnenburg et al.106
was non-significant. Fritsch et al.103 reported no significant difference in the number of people requiring
OCSs between groups.
Any/wide definition of exacerbation Fritsch et al.,103 Szefler et al.,104 Verini et al.,105 Petsky et al.,107
Pike et al.108 and Peirsman et al.109 all reported this outcome using a broad definition of exacerbation
(sometimes called treatment failure), but used different definitions to one another. Pijnenburg et al.106 did
not report this outcome. Lack of data allowing calculation of rates per person-year precluded meta analysis.
Five studies reported numerically fewer exacerbations or treatment failures in the intervention arm, but these
differences were statistically significant in only two studies. Fritsch et al.103 used a composite outcome that
appeared to include moderate to severe exacerbations. There were 17 exacerbations out of 88 observations in
the intervention group (reported as 18.2% in Fritsch et al.103) compared with 22 exacerbations out of
99 observations in the control group (reported as 21.2% in Fritsch et al.103). These data were not convertible to
rates as some data points were missing in the study. The difference was not significant at the p< 0.05 level.
Szefler et al.104 also used a composite outcome, which appeared also to relate to moderate to severe
exacerbations. This study reported the percentage of patients in each group with more than one exacerbation;
these were 37.0% in the intervention group and 43.6% in the control group (risk ratio −6.5, 95% CI −14.4 to
1.4; p= 0.11). Verini et al.105 reported events leading to the use of SABAs, which appeared to be likely to
incorporate minor to major exacerbations. Rates per person-year were 0.83 (SD 0.98) and 1.85 (SD 1.34) in
the intervention arm and control arm respectively. No between-group comparisons were presented for this
outcome. Pike et al.108 reported the number of patients who had ≥ 48 hours of increased asthma symptoms or
therapy and showed no difference between the groups, with 37 (84.1%) patients in the intervention arm and
38 (82.6%) in the control arm experiencing an exacerbation (p= 0.850).
The two studies that reported a significant between-group difference were those by Petsky et al.107 and
Peirsman et al.109 In the study by Petsky et al.,107 exacerbations were not clearly defined but occurred in six
out of 31 participants in the intervention group (19.4%) and 15 out of 32 participants in the control group
(46.9%; p= 0.021). Peirsman et al.109 reported statistically significantly fewer exacerbations of any severity
(as defined using GINA guidelines136) in the intervention arm (18 events) than in the control arm (35 events;
p= 0.02), although rates were not calculable because of missing information about the number of participants
included in the analysis.
TABLE 40 Child management review: exacerbation and OCS use rates in children and adolescents with or without
FeNO-guided management (continued )
Author,
year Definition of outcomes Intervention Control
Between-group
comparison
Verini
2010105
ATS 2005 definition:35 number
of episodes of coughing,
dyspnoea and wheezing
requiring SABAs
0.83 (SD 0.98) per
person-year
1.85 (SD 1.34) per
person-year
Between-group
comparison NR
Other outcomes
Peirsman
2013109
Number of children with one or
more exacerbation
11/46 (23.9%) 22/46 (47.8%) Chi-square test: p= 0.02
Peirsman
2013109
One or more emergency room
admission
2/45 (4.4%) 4/46 (8.7%) Chi-square test: p= 0.41
Szefler
2008104
One or more prednisone course 32.1% (SD 4.67%) 42.0% (SD 4.94%) Mean difference
–10.3% (95% CI –18.5
to –2.2), p= 0.01
NS, not significant.
a p-value for number of patients having one or more events, not number of events.
b Unable to calculate rate per person-year as unclear how many patients were included in the analysis.
c Unable to calculate rate per person-year because of lack of data on absolute number of exacerbations per group.
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Inhaled corticosteroid use Table 41 provides details of ICS use in each study. Fritsch et al.103 and
Szefler et al.104 reported statistically significantly higher ICS use in the intervention group, Pijnenburg et al.106
reported very similar levels and the values in the remaining study105 (in terms of absolute numbers using
ICSs) were difficult to interpret. Fritsch et al.103 reported median (IQR) end-point values for ICS use in the
intervention and control groups as 316 (200 to 500) µg and 241 (26 to 607) µg respectively (β= 0.20,
p< 0.01). Pijnenburg et al.106 reported the mean (standard error of the mean) cumulative ICS dose from visit
1 to visit 5 as 4407 (367) µg in the intervention group and 4332 (383) µg in the control group (p= 0.73).
Szefler et al.104 reported the between-group difference in use of fluticasone, which was 119 µg/day greater
in the FeNO group by the final visit (95% CI 49 µg to 189 µg; p= 0.001). Finally, Verini et al.105 reported the
absolute number of participants using ICSs from each group at each time point (intervention group: T1 20,
T2 19, T3 19; control group: T1 15, T2 22, T3 19). However, the baseline values for the groups in this study
were not comparable and the absolute numbers of participants using ICSs, without concomitant data on
dosages used, provide little understanding of between-group ICS use.
TABLE 41 Child management review: ICS use
Author,
year
ICS type and measurement
definition Intervention Control
Between-group
difference
Fritsch
2006103
Fluticasone and budesonide
permitted. Data reported as
median ICS dose (µg/day);
unclear which ICS type the
doses refer to
Baseline median (IQR)
dose: 230 (100 to
400) µg; end point
median (IQR) dose:
316 (200 to 500) µg
Baseline median (IQR)
dose: 140 (0 to
400) µg; end point
median (IQR) dose:
241 (26 to 607) µg
Repeated measures
analysis: β= 10.20,
p< 0.01
Peirsman
2013109
Budesonide or equivalent:
Median (IQR) cumulative ICS
dose (calculated by summing
daily ICS dose from visit 1 to
visit 5)
Cumulative dose:
1280 (800 to
1800) µg
Cumulative dose:
1200 (675 to
1600) µg
p=NS
Median (IQR) change in daily
ICS dose from baseline
+100 (0 to + 400) µg 0 (–200 to + 80) µg p= 0.016
Petsky
2010107
NR NR NR NR
Pijnenburg
2005106
Budesonide (2mg max. daily
dose permitted). Cumulative
steroid dose (sum of mean
daily steroid doses from
visit 1 to visit 5)
Cumulative end
point: 4407 (367) µg
Cumulative end
point: 4332 (383) µg
p= 0.73
Pike
2013108
Beclomethasone, fluticasone
and budesonide permitted.
Data reported as median (IQR)
ICS dose (µg/day) in terms of
baseline, end point, change
and total dose. Unclear which
ICS type the doses refer to
Baseline dose: 750
(400 to 1000)µg/day;
end point dose: 800
(400 to 1000)µg/day;
dose change:
0 (–200 to 300) µg/day
Baseline dose: 800
(400 to 1000) µg/day;
end point dose: 500
(400 to 1000) µg/day;
dose change: 0 (–300
to 0) µg/day
Mann–Whitney
rank-sum tests: baseline
dose: p=0.629; end
point dose: p=0.543;
dose change: p=0.297
Szefler
2008104
Fluticasone NR NR Difference 119 µg/day
(95% CI 49 to 189 µg;
p= 0.001) (higher in
intervention group)
Verini
2010105
Unclear what ICS used.
Measured in terms of absolute
number of patients using per
group at each time point
T1: 20, T2: 19, T3: 19 T1: 15, T2: 22, T3: 19 NR
CI, confidence interval; NR, not reported; T, time.
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When studies recruiting patients who are or who are likely to be difficult to control103,104 were compared with
the study that recruited patients who had been on a stable dose of ICS for 3 months,106 it was seen that the
two studies recruiting the difficult to control groups saw an increase in ICS usage whereas the study that
recruited stable patients saw similar levels of ICS use across both arms. This would be expected as the difficult
to control group of patients is unlikely to need a dose reduction whereas patients who are stable may be
eligible for such a reduction. In addition to this, the Szefler et al.104 protocol did not allow step-down of ICSs
on the basis of low FeNO levels if symptoms were still present, making step-down less likely to occur.
The two studies identified from the search update reported results that agree with previous findings. The
study by Pike et al.,108 which recruited more severe patients, saw a higher final median (IQR) ICS usage
[800 (400 to 1000) µg vs. 500 (400 to 1000) µg] and higher upper and lower ends of the CIs [0 (–200 to
300) vs. 0 (–300 to 0) µg] for the median change from baseline in the intervention group, indicating that
there was an increase in ICS use. However, the differences were not statistically significant. The study by
Peirsman et al.,109 which recruited a wider spectrum of patients but which also included severe asthmatics,
also saw numerically higher doses in the intervention arm but, again, not statistically significantly so.
Health-related quality of life Table 42 provides HRQoL data. Only Petsky et al.107 provided data on
HRQoL and it was unclear which quality of life tool was used. In the intervention group, the baseline mean
was 84.38 (95% CI 77.27 to 91.48), which rose to 86 (95% CI 74.84 to 97.1) at 12 months. Conversely,
in the control group, the baseline mean of 86 (95% CI 81.49 to 90.51) dropped to 83.75 at 12 months
TABLE 42 Child management review: other outcomes
Author,
year Outcome
Intervention,
mean (SD) Control, mean (SD) Comparison
Asthma control
Fritsch
2006103
Increase in symptoms to a score of
2 (severe), n/N (%)
10/88 (11.4) 11/99 (11.1) NS at p< 0.05
Unscheduled visits, n/N (%) 5/88 (5.7) 5/99 (5.1) NS at p< 0.05
FEV1 decline > 10%, n/N (%) 7/88 (8.0) 13/99 (13.1) NS at p< 0.05
Pijnenburg
2005106
Change in mean symptom severity
scores between visit 1 and visit 5
0.1 0.6 Mean daily scores
change p= 0.40
Szefler
2008104
Maximum days with symptoms 1.93 (2.60) 1.89 (2.69) Mean difference 0.04
(95% CI −0.22 to 0.29),
p=0.78
Days of wheeze 1.71 (2.52) 1.69 (2.64) Mean difference 0.03
(95% CI −0.21 to 0.26),
p=0.83
Days of interference with activities 0.87 (1.79) 0.95 (1.98) Mean difference −0.08
(95% CI −0.26 to 0.10),
p=0.38
Nights of sleep disruption 0.52 (1.30) 0.50 (1.25) Mean difference 0.03
(95% CI −0.11 to 0.16),
p=0.71
Days of school missed 0.19 (0.79) 0.23 (0.84) Mean difference −0.04
(95% CI −0.12 to 0.05),
p=0.38
ACT score in the last month 21.89 (2.83) 21.83 (2.88) Mean difference 0.06
(95% CI −0.28 to 0.40),
p=0.72
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TABLE 42 Child management review: other outcomes (continued )
Author,
year Outcome
Intervention,
mean (SD) Control, mean (SD) Comparison
Verini
2010105
Symptom score (mean for ordinal
data: intermittent asthma= 1;
mild/moderate persistent
asthma= 2; severe persistent
asthma= 3)
T1: 1.09 (0.81);
T2: 0.56 (0.75);
T3: 0.75 (0.95)
T1: 1.09 (0.77);
T2: 0.93 (0.61);
T3: 0.92 (0.82)
NR
HRQoL
Petsky
2010107
HRQoL (metric not specified),
mean (95% CI)
Baseline: 84.38
(77.27 to 91.48);
12 months: 86
(74.84 to 97.1)
Baseline: 86 (81.49 to
90.51); 12 months:
83.75 (78.6 to 88.9)
NR
Other medication use
Fritsch
2006103
Median (IQR) beta-agonist puffs/day 1 (0 to 7) 0 (0 to 2) NR
Montelukast (LTRA) (unclear if
median or mean)
1.26mg/day 0mg/day p< 0.01
Peirsman
2013109
Median (IQR) percentage of
symptom-free days
83.7 (27.1 to
91.9)
79.6 (51.7 to 94) Mann–Whitney test:
p= 0.58
Children who missed school,
n/N, (%)
10/46 (21.7) 12/46 (26.1) Chi-square test:
p= 0.63
Children whose caregivers had to
take time off, n/N, (%)
6/45 (13.3) 8/46 (17.4) Chi-square test:
p= 0.59
Nights of sleep disruption 0.52 (1.30) 0.50 (1.25) 0.03 (95% CI −0.11 to
0.16), p= 0.71
Days of school missed 0.19 (0.79) 0.23 (0.84) −0.04 (95% CI −0.12 to
0.05), p=0.38
ACT score in the last month 21.89 (2.83) 21.83 (2.88) 0.06 (95% CI −0.28 to
0.40), p= 0.72
Petsky
2010107
– – – –
Pijnenburg
2005106
Beta-agonist use NR NR p= 0.28
Pike
2013108
Change in FeNO (ppb), mean
(95% CI)
+3.1 (–5.5 to 11.6) + 3.3 (–8.5 to 15.1) NS at p< 0.05
Szefler
2008104
Salmeterol (mean difference from
baseline), µg/day
–6.5 –12 NR
Verini
2010105
Mean of ordinal data, in which
antihistamines, ketotifen and
chromones= 1; specific
immunotherapy, LABAs and
LTRAs= 2; ICS= 3
T1: 1.5 (0.7);
T2: 1.43 (0.7);
T3: 1.53 (0.6)
T1: 1.03 (0.9);
T2: 1.62 (0.6);
T3: 1.4 (0.7)
NR
Number of patients using LTRAs T1: 8; T2: 8;
T3: 11
T1: 3; T2: 8; T3: 7 NR
Number of patients using no
anti-inflammatory drugs
T1: 4; T2: 5;
T3: 2
T1: 14; T2: 2; T3: 6 NR
CI, confidence interval; NS, not statistically significant; T, time.
DOI: 10.3310/hta19820 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 82
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
(95% CI 78.6 to 88.9). If quality of life was measured with the European Quality of Life-5 Dimensions
(EQ-5D), which seems likely, then higher values would indicate better quality of life and thus FeNO would
be favoured. The end-point difference was statistically significant (p= 0.042), although it was unclear
whether this comparison was for the change or for absolute end values.
Asthma control and other medication use Table 42 provides details of outcomes relating to asthma
control and medication use. Four studies provided some data on asthma control, none of which
demonstrated any significant effects favouring either the intervention or the control, although in the study
by Verini et al.105 significance was not reported. Furthermore, there was lack of uniformity in how asthma
control was measured. Fritsch et al.103 recorded the absolute number of participants per group whose
symptom severity score increased to 2 (i.e. severe symptoms). Ten participants in the intervention group
(11.4%), and 11 in the control group (11.1%) fulfilled this criterion (difference not significant). These
researchers also reported the absolute number of participants per group who experienced a decline in FEV1
of > 10%: seven in the intervention group (8%) and 13 in the control group (13.1%; p= not significant).
Szefler et al.104 presented between-group differences for a number of symptomatic indicators of control,
with higher numbers favouring the intervention. The measure comprised days of wheeze (risk ratio 0.04,
95% CI −0.22 to 0.29; p= 0.78), days of interference with activities (risk ratio 0.03, 95% CI −0.21 to
0.26; p= 0.83), nights of sleep disruption (risk ratio −0.08, 95% CI −0.26 to 0.10; p= 0.38), days of
school missed (risk ratio 0.03, 95% CI −0.11 to 0.16; p= 0.71) and ACT score in the last month (risk ratio
−0.04, 955 CI −0.12 to 0.05; p= 0.38). Pijnenburg et al.106 calculated symptom scores based on diary card
data for dyspnoea, wheezing and cough. Day and night were scored separately and each symptom was
scored between 0 and 3, giving a maximum possible total score of 18. The change in mean daily scores
between baseline and visit 5 was 0.1 in the intervention group and 0.6 in the control group (between-
group difference p= 0.4). Finally, Verini et al.105 measured symptom control using the GINA scale,136 which
classified participants as having remission asthma (GINA score 0), intermittent asthma (GINA score 1) or
persistent asthma (GINA score 2 or 3). The means (SDs) for these categorical data were presented for both
groups at all three time points: at visit 1 the values were 1.09 (0.81) in the intervention group compared
with 1.09 (0.77) in the control group; at visit 2 they were 0.56 (0.75) and 0.93 (0.61) respectively; and at
visit 3 they were 0.75 (0.96) and 0.92 (0.82) respectively. No intergroup comparisons were conducted,
although means in the intervention arm are numerically lower than those in the control arm.
With respect to additional medication use, three studies provided data using different metrics and mostly
without formal comparison statistics. Szefler et al.104 reported the mean difference from baseline in
salmeterol usage; This was –6.5 µg/day in the intervention group and –12 µg/day in the control group
(p-value not reported). Verini et al.105 created a categorical measure of medication use in which
antihistamines (e.g. ketotifen) and chromones= 1; specific immunotherapy, LABAs and LTRAs= 2; and
ICSs= 3. The means (SDs) of these data were presented for both groups. In the intervention group the
values were 1.5 (0.7) (visit 1), 1.43 (0.7) (visit 2) and 1.53 (0.6) (visit 3). For comparison, the values for the
control group at the same time points were 1.03 (0.9), 1.62 (0.6) and 1.4 (0.7) respectively. Verini et al.105
also provided absolute numbers using LTRA. For the intervention group these were 8, 8 and 11 at visits 1,
2 and 3 respectively and for the control group these were three, eight and seven respectively. Fritsch
et al.103 reported the median (IQR) number of beta-agonist puffs/day. In the intervention group this was
one (0 to 7) whereas in the control group the number was zero (0 to 2). Overall, two studies reported
numerically higher additional medication use in the intervention arm104,105
Studies found during the search update108,109 agreed with previous observations as neither reported a
statistically significant difference in metrics of asthma control.
Adverse events, mortality, compliance and test failure rates Data on adverse events, mortality and
compliance were reported only in Szefler et al.104 No statistically significant differences between the groups
were reported for any adverse events or for mortality. For the intervention and control groups, respectively,
adverse events were reported for eyes, ears, nose and throat (8.3% vs. 8.1%; p= 0.87), gastrointestinal
disorders (13.4% vs. 14.1%; p= 0.78), haematology disorders (27.2% vs. 28.9%; p= 0.44), infections
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(55.8% vs. 52.2%; p= 0.46), musculoskeletal symptoms (15.9% vs. 18.5%; p= 0.44), nervous system
disorders (34.4% vs. 33.7%; p= 0.20), respiratory signs and symptoms (33.7% vs. 34.1; p= 0.92) and skin
symptoms (15.6% vs. 17.8%; p= 0.18). Medication compliance was shown to be 86% in the intervention
group and 92% in the control group. No mortality was observed in either group.
Subgroups relevant to the review as defined in the scoping workshop
Pregnant women
Only one RCT of FeNO-guided management of asthmatic pregnant women was found.102
Study details The study by Powell et al.102 was a double-blind, multicentre RCT conducted in Australia
and funded from a number of industry and non-industry sources (including lecture fees from Aerocrine). In
total, 203 participants were analysed out of 242 recruited. In the run-in period, patients not already using
ICSs were started on budesonide at a dose of 200 µg twice a day. After randomisation, patients
underwent monthly reviews and titration of the ICS dose. Patients were telephoned 2 weeks after each
visit to assess symptoms and encourage adherence (Table 43). The study included no current smokers but
did include 156/206 (75.7%) atopic patients (Table 44).
Quality assessment The study by Powell et al.102 appeared to be at low risk of bias overall (see Figure 13).
Randomisation and allocation concealment were performed well, meaning that the study was at low risk
of selection bias. The study was double blind and made efforts to blind outcome assessors and is therefore
at low risk of performance and detection bias. The study also seemed to be at low risk of attrition bias,
with similar small numbers dropping out from each arm for reasons not related to treatment. Reporting
bias did not seem to affect the study as far as could be ascertained from the journal publication.
Commercial sponsorship puts the study at some risk of bias.
Intervention An ECO MEDICS device was used to measure FeNO. Patients were categorised according to
their FeNO values, with cut-offs being < 16 ppb, 16–29 ppb and > 29 ppb. Step-up and step-down criteria
are described in Table 45; decisions were based on a combination of FeNO and asthma control levels, with
asthma control levels directing the dose of LABA (formoterol) and FeNO levels controlling the dose of
ICS (budesonide).
Comparator Patients were managed according to asthma control as assessed by the ACQ (Table 46).
Medication doses were somewhat different from those in the intervention arm, with different doses of
budesonide and formoterol indicated.
TABLE 43 Pregnant women: study design and timelines
Author,
year Study details Timeline of study
Powell
2011102
Setting: antenatal outpatients,
Australia
Funding: mixed; lecture fees
from Aerocrine
Study design: double-blind,
parallel-group, multicentre
RCT
Visit 1: FeNO, spirometry, ACQ, atopy (specific IgE to aeroallergen); optimised
self-management skills including inhaler technique, knowledge, action plan
and adherence; 2-week run-in period after visit 1 – continued use of ICS
budesonide turbuhaler or uncontrolled patients not using ICSs started on
budesonide 200 µg b.i.d. Visit 2: randomisation; asthma symptoms, FeNO,
spirometry, ACQ, quality of life questionnaires. Then, monthly review with
research assistant: recorded clinical symptoms, ACQ, present treatment,
FeNO, FEV1. FeNO, ACQ and treatment data sent to algorithm keeper who
applied algorithm and sent treatment recommendation to research assistant
who informed patient. If patient uncontrolled and at maximum dose, seen by
investigator. Telephone assessments 2 weeks after visit to assess symptoms
and encourage adherence
b.i.d. twice per day; IgE, immunoglobulin E.
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Outcomes Table 47 provides details of all outcomes of relevance to the review.
Exacerbations The composite outcome of all exacerbations (in this case defined as an unscheduled visit
to a doctor, presentation to the emergency room or admission to hospital or when an OCS was used) was
reduced in the intervention arm, with a rate ratio of 0.496 (95% CI 0.325 to 0.755) (p= 0.001). It should
be noted that, unlike the other studies in adults, the composite outcome in this study did not include
moderate or minor exacerbations, but more closely matched the definitions of severe exacerbations given
in other adult studies. Data for each element of the composite outcome were reported individually and
from this it can be seen that this difference is mostly driven by the rate of OCS use and the rate of visits to
the doctor. Mean OCS use was 0.08 (95% CI 0.03 to 0.133) in the intervention arm and 0.19 (95% CI
0.08 to 0.31) in the control arm and, unlike other studies in adults, this did reach statistical significance,
with a p-value of 0.042. Similarly, the rate of visits to the doctor was 0.26 (95% CI 0.16 to 0.36) in the
intervention arm and 0.56 (95% CI 0.40 to 0.72) in the control arm, with a p-value of 0.002. The other
TABLE 45 Pregnant women: details of intervention group management strategies
Author,
year
Decisions based on flow
rate, device and cut-off
points Step-up/step-down protocol Doses
Powell
2011102
Based on FeNO and ACQ
Flow rate; device:
according to ATS
guidelines 2005;35
ECOMEDICS (Duernten,
Switzerland)
Cut-offs: < 16 ppb,
16–29 ppb, > 29 ppb
FeNO concentration used to adjust dose of ICS
and ACQ used to adjust dose of LABA:
l FeNO > 29 ppb – ICS increase one step,
LABA no change
l FeNO 16–29 ppb and ACQ ≤ 1.5 – ICS
no change, LABA no change
l FeNO 16–29 ppb and ACQ > 1.5 – ICS
no change, LABA increase one step
l FeNO < 16 ppb and ACQ ≤ 1.5 – ICS
decrease one step, LABA no change
l FeNO < 16 ppb and ACQ > 1.5 – ICS
decrease one step, LABA increase one step
If a patient had undergone two ICS dose
increments and FeNO remained > 29 ppb, ICS
was not increased further. If still symptomatic
(ACQ > 1.5) formoterol 6 µg b.i.d. was added.
For patients taking formoterol, the ICS dose
could never be zero but would be reduced
to 100 µg b.i.d. Patients who remained
uncontrolled at maximum doses referred to
respiratory physician
ICS – steps 1–5: budesonide
0, 100, 200, 400, 800 µg
b.i.d. respectively
LABA – step 1: salbutamol
as required; steps 2–5:
formoterol 6, 12, 24, 24 µg
b.i.d. respectively
b.i.d., twice per day.
TABLE 46 Pregnant women: detail of the control group management strategies
Author,
year
Decisions
based on Step-up/step-down protocol Doses
Powell
2011102
ACQ
guided
Well-controlled asthma (ACQ< 0.75) – reduce
treatment one step; partially controlled asthma
(ACQ 0.75–1.50) – no treatment change;
uncontrolled asthma (ACQ> 1.5) – increase
one step. Those at maximum dose referred to
respiratory physician
Step 1: salbutamol as required;
step 2: budesonide 200 µg b.i.d.+ salbutamol
as required; step 3: budesonide 400 µg
b.i.d.+ salbutamol as required;
step 4: budesonide 400 µg+ formoterol
12 µg b.i.d.; step 5: budesonide 800 µg
b.i.d.+ formoterol 24 µg b.i.d.
b.i.d., twice per day.
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TABLE 47 Pregnant women: all outcomes
Time of outcome Definition of outcomes Intervention Control
Between-group
comparison
Exacerbations
Monthly until birth
(max. approx.
30 weeks)
Exacerbations: an
unscheduled visit to a
doctor, presentation to
the ER or admission to
hospital or when OCSs
used. Events separated by
≥ 7 days were counted as
a second event
0.288 per pregnancy
[mean (SD) study time
17.8 (5.5) weeks]
0.615 per pregnancy
[mean (SD) study time
18.8 (3.8) weeks]
Incidence rate ratio
0.496 (95% CI 0.325
to 0.755), p= 0.001
OCS use, mean (95% CI) 0.08 (0.03 to 0.133) 0.19 (0.08 to 0.31) p-value OCS use:
0.042
Hospitalisations, mean
(95% CI)
0 (0 to 0) 0.03 (–0.004 to 0.06) p= 1.0
ER/labour ward visits,
mean (95% CI)
0.04 (0.001 to 0.07) 0.02 (–0.01 to 0.04) p= 0.399
Unplanned or
unscheduled doctors’
visits, mean (95% CI)
0.26 (0.16 to 0.36) 0.56 (0.40 to 0.72) p= 0.002
ICS use
Difference in means
(from baseline to last visit)
(read off graph) (µg/day)
–210 50 p= 0.043
BDP-equivalent ICS dose
(µg/day), median (IQR)
200 (0 to 400) 0 (0 to 800) p= 0.079
ICS users, n/N (%) 76/111 (68.5) 46/109 (42.2) p< 0.0001
Other outcomes
HRQoL, median (IQR)
SF-12 physical
component summary
(low 0, high 100)
47.7 (40.8 to 52.0) 46.9 (38.2 to 51.8) p= 0.89
SF-12 mental
component summary
(low 0, high 100)
56.9 (50.2 to 59.3) 54.2 (46.1 to 57.6) p= 0.037
AQLQ-M: total score
(good 0, poor 10)
0.75 (0.38 to 1.25) 0.81 (0.38 to 1.63) p= 0.54
Asthma control (ACQ),
mean (SD)
0.56 (0.67) 0.72 (0.80) p= 0.046
Beta2-agonist use in past
week, median (IQR)
0 (0 to 3) 1 (0 to 5) p= 0.024
LABA users, n/N (%) 45/111 (40.5) 19/109 (17.4) p< 0.0001
Adverse events, mortality,
compliance and test
failure rates
NR NR NR
AQLQ-M, Asthma Quality of Life Questionnaire – Marks; BDP, beclomethasone dipropionate; CI, confidence interval;
ER, emergency room; NR, not reported; SF-12, Short Form questionnaire-12 items.
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components of the exacerbation outcome (hospitalisations and emergency room/labour ward visits) did not
differ between groups.
Inhaled corticosteroid use The change in mean values from baseline to the final visit for ICS use was a
decrease of 210 µg/day in the intervention arm and an increase of 50 µg/day in the control arm. This
difference was statistically significant at p= 0.043. Interestingly, more women in the intervention arm were
taking ICSs (68.5% vs. 42.2%) and the median (IQR) ICS dose as beclomethasone dipropionate equivalent
(µg/day) was higher in the intervention arm [200 (IQR 0 to 400)] than in the control arm [0 µg/day
(IQR 0 to 800)], but not statistically significantly so (p= 0.079).
Health-related quality of life The median scores and p-value indicate a small but statistically significant
difference in the Short Form questionnaire-12 items (SF-12) mental component summary score in favour of
the intervention arm, with a median (IQR) score of 56.9 (50.2 to 59.3) compared with 54.2 (46.1 to 57.6)
in the control arm (p= 0.037); however, there were no statistically significant differences in the SF-12
physical component summary score or the Asthma Quality of Life Questionnaire – Marks (AQLQ-M)
total score.
Asthma control and other medication use The ACQ score at the end of the study indicated good
control in both groups, with the mean (SD) indicating statistically significantly better control in the
intervention group [0.56 (0.67)] than in the control group [0.72 (0.80); p= 0.046]. Beta2-agonist use in the
past week was higher in the intervention arm (p= 0.024) and there were statistically significantly more
LABA users in the intervention arm (p< 0.0001).
Adverse events, mortality, compliance and test failure rates None of these outcomes was reported in
the study.
An additional study by Mattes et al.,124 a follow-up to the Powell et al.102 study, was identified in the
update search. This study was identified as a conference abstract although subsequent to the update
search the full text was published. The study took the form of a prospective longitudinal birth cohort with
the aim of determining the effect of better maternal asthma management on the number of episodes of
wheezy illness in the first year of life. The abstract reports that children born to mothers who had been in
the FeNO group were significantly less likely to suffer from recurrent bronchiolitis in the first year of life
(OR 0.08, 95% CI 0.01 to 0.62; p= 0.016) than children born to mothers in the clinical treatment group.
These results indicate that there may be wider benefits to asthma management with FeNO than have been
captured in our economic model.
Conclusion In pregnant women, the outcomes of exacerbation rate as well as OCS use on its own and
doctors’ visits were all statistically significantly better in the intervention arm. ICS use and beta2-agonist
use were also lower, although LABAs were used by more patients in the intervention arm than in the
control arm. Asthma control was marginally better in the intervention arm and the mental component
summary score of the SF-12 was also better, although the physical component summary score of the SF-12
and the total score for the AQLQ-M were not statistically significantly different between groups. In
summary, the use of FeNO to guide asthma management in pregnant women appears to be as effective
as if not more effective than the use of FeNO in other adults and appears to reduce exacerbations and
ICS use. This may be because of increased efficacy in pregnant women or because of differences in
step-up/step-down protocols. Notably, this protocol allowed for the step down of ICS use on the basis of
FeNO levels alone, regardless of whether symptoms were still present or not. A follow-up study suggests
that there may be more benefits for the children born to women who had asthma management with
FeNO than have been captured in the economic model.
FeNO to assess compliance to treatment
One further study was identified for the management review.141 This open-label RCT recruited patients
aged 6–16 years with mild to moderate persistent asthma (n= 54) and excluded patients who had received
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oral or inhaled steroid treatment during the last 2 months, who had acute upper airway infection, who
had a history of bad compliance (< 65% of prescribed medication) or who had any other serious illness.
The trial consisted of a 4-week run-in period, a 4-week washout phase and a final randomised treatment
phase in which only one group was treated with inhaled budesonide and FeNO was used to attempt to
distinguish these groups, that is, the study explored FeNO as a tool to assess patient compliance. The study
showed that FeNO was able to distinguish those who had been treated with ICSs more successfully than
conventional lung function parameters. However, as the study did not examine the efficacy of FeNO
for guiding management per se, the data could not be compared with that from other studies in the
management review. It should also be noted that this potential benefit of using FeNO in the management
of asthma will have been captured in the other RCT trials if the management protocol included
investigations of compliance before stepping treatment up or down.
The elderly
In the absence of RCTs, other study designs were included to gather evidence for the use of FeNO in
the management of asthma in the elderly. Five observational studies (three cohort,116–118 one nested
case–control119 and one cross-sectional120 study), published between 2010 and 2012, were identified that
evaluated the measurement of FeNO in elderly asthmatics. A further study125 was identified during the
search update and a journal article of the abstract by Columbo et al.117 was also identified.126 A summary
of the design, patient characteristics and outcomes of the included studies is provided in Table 48. The
studies by Columbo et al.,117 Ross and Baptist120 and Smith et al.119 were based in the USA, that by Inoue
et al.116 was based in Japan, that by Roh118 was based in Korea and that by Bozek et al.125 was based in
Poland. Three studies reported where the patients were recruited from: Inoue et al.116 recruited patients
from an outpatient clinic whereas Smith et al.119 and Bozek et al.125 recruited from primary care. All
patients in the intervention group had a diagnosis of asthma; however, how asthma was defined was not
reported in any of the studies apart from that by Smith et al.,119 which used the GINA guidelines.129 The
mean disease duration of asthma was reported in three studies116,117,120 and ranged from 14.4 years116 to
35 years.117 The mean age in the intervention group ranged from 68119 to 73120 years, apart from in the
study by Bozek et al.,125 which recruited only patients aged > 80 years and which had a mean age of 84.1
(± 3.9) years. All studies included both sexes, with a slightly higher proportion of female participants, apart
from the study by Roh,118 which had a higher proportion of male participants. Three studies had a
comparative control group.116,119,125 Bozek et al.125 and Inoue et al.116 compared FeNO values between
elderly asthmatics and non-elderly asthmatics but with different age cut-offs and Smith et al.119 compared
asthmatics with non-asthmatics. The device for measuring FeNO was reported in four studies,117,119,120,125,126
with all four using NIOX MINO.
The results of the included studies are summarised in Table 48. Four of the six studies generally indicated a
trend showing that FeNO measurements may not be clinically valuable in elderly asthmatics. Smith et al.119
found no statistically significant difference in FeNO levels in elderly asthmatic subjects (20.8± 17.3 ppb)
compared with elderly non-asthmatics (18.3± 9.8 ppb) (p= 0.5). Furthermore, no statistically significant
difference was observed in FeNO levels between ICS-treated (21.4± 20.4 ppb) and -untreated asthmatics
(19.8± 14.3 ppb) (p= 0.8). Columbo et al.117 followed up stable elderly asthmatic patients for 1 year and
evaluated FeNO measurements at baseline and every 3 months for 1 year. No significant correlation was
found between FeNO levels and spirometric values, ICS usage or asthma control. Two further studies118,120
showed no correlation between FeNO levels and asthma control. Furthermore, one study,116 which
evaluated the pathophysiological characteristics of asthma in elderly patients, found that there was no
difference in FeNO levels, the percentage of induced sputum eosinophils and neutrophils or methacholine
airway sensitivity or reactivity between elderly asthmatics and non-elderly asthmatics.
Bozek et al.125 observed differences in FeNO levels between elderly and non-elderly asthmatics and
concluded that FeNO can be useful in the assessment of bronchial asthma in the elderly. However, this
study did not report data relating to correlations between measures of asthma presence/absence/severity/
control and FeNO levels and concluded only that FeNO may be higher in older asthmatic patients than in
non-elderly asthmatics.
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Overall, these results should be interpreted with caution as data were derived from studies with
lower-quality designs that have greater potential to produce biased results. In addition, three of these
studies were reported in abstract form only and hence provide limited data. However, the majority of
studies appear to indicate that FeNO is not useful in the elderly.
Adult smokers
Four studies5,121–123 were conducted in adult smokers. A summary of the design and patient characteristics
of the four included studies is provided in Table 49. Two studies5,121 were conducted in Belgium, one123
in Serbia and one122 in New Zealand. With the exception of the study by Hromis et al.,123 which did not
provide details of the funding source, all studies received funding from one or more commercial sponsor.
Kostikas et al.122 received an unrestricted research grant from Aerocrine; Michils et al.121 received technical
funding from AstraZeneca; and Schleich et al.5 received an unrestricted grant from GlaxoSmithKline,
AstraZeneca and Novartis.
Patients were recruited from a variety of settings including secondary care,5 tertiary care121 and outpatient
clinics.122 Eligibility criteria varied from study to study but all studies included smokers with confirmed or
persistent asthma. The sample sizes of the included studies ranged from 83123 to 470,121 with the mean
age of participants ranging from 38121 to 50122 years. Baseline FeNO levels were inconsistently reported:
Schleich et al.5 and Kostikas et al.122 reported median values, Hromis et al.123 reported mean values and
Michils et al.121 reported geometric means and ranges. All studies included patients who were being treated
with ICSs except one study5 in which treatment was unclear. In all studies except that by Hromis et al.,123
asthma control was evaluated according to the GINA guidelines129 and/or the ACT and Juniper’s ACQ;135
in the Hromis et al.123 study it was unclear how asthma control was evaluated. The NIOX MINO device was
used by Kostikas et al.,122 Schleich et al.5 used the Niox device, Michils et al.121 used the LR2000 device and it
was unclear which device was used by Hromis et al.123 None of the studies used the same protocol or cut-off
points for the management of asthma with FeNO.
The results are summarised in Table 49. In the study by Schleich et al.5 the median FeNO level (17 ppb) in
smokers was significantly lower than that in non-smokers (35 ppb) (p= 0.003). In addition, the FeNO threshold
for identifying a sputum eosinophil count of ≥ 3%was significantly lower in smokers (28 ppb, sensitivity 76%
and specificity 62%) than in non-smokers (46 ppb, sensitivity 58% and specificity 82%) (p= 0.066).
Michils et al.121 reported that baseline FeNO levels were reduced in smoking asthmatics (18.1 ppb vs. 33.7 ppb
in non-smoking asthmatics). Furthermore, when patients were treated with high to medium doses of ICSs,
FeNO no longer had the ability to reflect an improvement in asthma control for smoking patients, whereas for
non-smoking patients its ability was only slightly reduced. However, the authors suggested that FeNO can
reflect asthma control in smoking patients provided that changes in FeNO values detected by repeated
measurements are considered. A decrease in FeNO of < 20% precludes asthma control improvement in
non-smoking (NPV 78%) and smoking (NPV 72%) patients. An increase in FeNO of < 30% is unlikely to be
associated with a deterioration in asthma control in both groups (NPV 86% and 84% for non-smoking and
smoking patients respectively).
In the study by Kostikas et al.,122 non-smokers who were either treated or not treated with ICSs reported
higher FeNO values in uncontrolled asthma than in partly or well-controlled asthma. In contrast, smokers
not treated with ICSs showed significant differences in FeNO values between uncontrolled and well-controlled
asthma but no difference from partly controlled asthma. Smokers treated with ICSs showed no statistically
significant differences (p> 0.05) in FeNO values between the controlled, partly controlled or uncontrolled
asthma groups. The diagnostic performance of FeNO for the identification of not well-controlled (partly
or uncontrolled) asthma was better in the non-smoker groups (FeNO cut-off > 22 ppb, sensitivity 87%,
specificity 81%; FeNO cut-off > 27 ppb, sensitivity 64%, specificity 94%) than in the smoker groups (FeNO
cut-off > 19 ppb, sensitivity 56%, specificity 75%; FeNO cut-off > 23 ppb, sensitivity 45%, specificity 87%).
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Hromis et al.123 showed that FeNO levels are low in asthmatic smokers (17 ppb) compared with levels in
asthmatic non-smokers (57 ppb); however, when treated with a LABA a reduction in FeNO values was
observed in both non-smokers and smokers (32% vs. 22% respectively). A similar pattern was observed
when both groups were treated with an antileukotriene (reduction of 22% in non-smokers and 12% in
smokers). The authors concluded that the sequential changes in FeNO could be a useful marker of asthma
control, regardless of smoking status. FeNO level also depends on the applied treatment.
In addition, a study by Lehtimaki et al.142 reported that smoking can cause a small and transient but
statistically significant increase in FeNO at 1 and 5 minutes after smoking, highlighting the importance that
smokers abstain from smoking before FeNO measurements are undertaken.
Overall, the findings suggest that FeNO levels in adults tend to be lower in asthmatic smokers than in
asthmatic non-smokers and there is some evidence to suggest that, when this group of patients is treated
with ICSs, FeNO can no longer detect asthma control. However, the use of repeated measures and
within-patient change from baseline cut-offs may be worthy of further investigation in higher-quality
studies, with two studies121,123 providing promising data on this approach. However, as no high-quality RCT
studies have been conducted in this group, the evidence on the effectiveness of using FeNO to guide the
management of asthma in smokers is currently inconclusive.
Children exposed to tobacco smoke
A summary of the study design and patient characteristics of the three studies recruiting children exposed
to tobacco smoke111–113 is provided in Table 50. Two of the studies were conducted in the USA112,113 and
one in France.111 None of the studies appeared to receive funding from commercial sponsors and all were
observational studies. In the study by de la Riva-Velasco et al.,113 which was a cohort study, the authors
determined the relationship between FeNO levels and exposure to low levels of environmental tobacco
smoke in children with asthma on ICS treatment. The study by Hanson et al.112 was a retrospective chart
review study that looked at the relationship between FeNO and multiple clinical variables in children aged
4–7 years. The study by Mahut et al.111 was a cross-sectional study that evaluated whether exhaled FeNO
was independently associated with underlying pathophysiological characteristics of asthma (e.g. airway
tone and airway inflammation) and with clinical phenotypes of asthma. In two studies111,113 patients were
recruited from outpatient clinics and in one study112 patients were recruited from an asthma allergy clinic.
Eligibility criteria varied from study to study but all studies included children who had been exposed to
tobacco smoke and who had a diagnosis of asthma. The sample sizes of the included studies ranged from
33113 to 169,111 with the mean age of participants ranging from 10113 to 10.5111 years. However, Hanson
et al.112 did not report the mean age but recruited children between the ages of 4 and 7 years. Baseline
FeNO values were inconsistently reported (Mahut et al.111 and de la Riva-Velasco et al.113 reported median
values and Hanson et al.112 reported mean levels) and the studies also varied in terms of medication usage.
De la Riva-Velasco et al.113 included children who were being treated with ICSs113 whereas Mahut et al.111
included patients who were being treated with ICSs, LABAs or beta-agonists on demand. Hanson et al.112
failed to provide details on medication usage. A range of devices was used to measure FeNO levels.
Hanson et al.112 used the NIOX MINO device; Mahut et al.111 used the Niox device; and de la Riva-Velasco
et al.113 used the NIOX Flex device. None of the studies used the same protocol or cut-off points for the
management of asthma with FeNO.
The results of the included studies were varied (see Table 50). Mahut et al.111 reported that there was no
statistically significant relationship between FeNO level and smoke exposure and concluded that FeNO is
potentially helpful in asthma management. On the other hand, de la Riva-Velasco et al.113 found that
children on low to medium doses of ICSs with recent low-level environmental tobacco smoke exposure
have lower median (IQR) FeNO levels [9.6 (5.1–15.8)] than subjects not exposed to environmental tobacco
smoke [23.9 (15.2–34.5); p= 0.008]. The authors concluded that environmental tobacco smoke exposure
or third-hand smoke (that which lingers after a cigarette is extinguished) may be an important variable to
consider when interpreting FeNO levels in school-aged children with asthma.
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Overall, the findings suggest that the potential efficacy of using FeNO to inform the management of
asthma in children exposed to environmental tobacco smoke may be similar to that in children who have
not been exposed, but that it may be necessary to consider a child’s exposure status when interpreting
results as FeNO may be lower in these children. Whether this should involve the setting of lower cut-off
points or whether a more qualitative interpretation should be made on a case-by-case basis or by
comparing within-patient changes from baseline is unclear.
Discussion of the clinical evidence
Summary of key results
Equivalence of devices
The review of the equivalence of devices revealed that the level of agreement between devices is
highly variable.
NIOX MINO compared with the Niox chemiluminescent device
There was most evidence available for a comparison between the Niox chemiluminescent device and
NIOX MINO in adults. Devices gave similar mean FeNO values in five of eight studies, but higher values for
NIOX MINO in three studies. Bland–Altman analysis (reported in four of eight studies) suggested that the
limits of agreement were around 10 ppb in both directions when analysed on the absolute scale, with mean
differences of between 0.5 and 1.5 ppb. Analysis on the log scale produced better limits of agreement
in the study by Menzies et al.39 but very wide limits in the study by Korn et al.41 In a head-to-head
comparison between two NIOX MINO devices,40 there was also evidence that not all NIOX MINO devices
produce equivalent readings to one another, although another study comparing three devices found them
to be equivalent to one another.45 There was also evidence that agreement between NIOX MINO and Niox
is worse at higher FeNO values, with all studies in which cohorts had mean values of < 30 ppb reporting
better agreement and most Bland–Altman plots showing a multiplicative relationship. Agreement looked
acceptable in children, with all limits of agreement falling between –4.4 and 8.9 ppb.
NIOX MINO compared with other chemiluminescent devices
Correlation co-efficients were generally good, with a correlation between 0.76 and 0.96. However, cohort
means were far more variable, with some devices reading higher and some lower than NIOX MINO. The
highest difference between cohort mean FeNO values was 47 ppb. Although individual devices may show
good agreement with NIOX MINO, it is not possible to draw any solid conclusions as most devices were
tested in only one or two studies and, as was seen in the comparison between NIOX MINO and Niox,
results between studies appear to vary considerably.
NObreath compared with the Niox chemiluminescent device and other
chemiluminescent devices
In the one study that compared NObreath with the Niox chemiluminescent device, a good level of
agreement was seen in Bland–Altman analysis, but cut-off values derived by this study for the diagnosis of
asthma differed by 10 ppb according to which device was used.65 Other devices generally appeared to read
higher than NObreath, but not by a consistent amount.
NObreath compared with NIOX MINO
Both studies reporting this comparison54,66 found that in most analyses NIOX MINO provided lower mean
FeNO values than NObreath. This contradicts the available evidence for comparisons between NIOX MINO
and Niox and between NObreath and Niox, in which NIOX MINO>Niox>NObreath.
NIOX VERO compared with NIOX MINO
Only one study provided data on this device. (Academic-in-confidence information has been removed.)
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Test failure rates
The overall test failure rate for FeNO measurement in adults was generally low across all devices and most
patients appear to be able to provide FeNO readings, provided that they are permitted sufficient
measurement attempts. There may be a higher test failure rate in children using NIOX MINO.
Conclusion
Overall, it cannot be concluded that any two devices are equivalent in all situations. Although there may
be situations in which they are similar, it appears to depend on the characteristics of the studies and
cannot be generalised to all situations. Further research is required to identify what is driving the variability
between studies and devices. However, as there is mostly a high degree of correlation between measurements
across all devices, estimates of sensitivity and specificity are likely to be an accurate indication of the potential
diagnostic accuracy of using FeNO to guide diagnosis, but the derived cut-off points are not likely to be
interchangeable between devices.
Diagnostic accuracy of FeNO for the diagnosis of asthma
No end-to-end studies were identified and no cohort study provided a comparison between FeNO within
a sequence of tests and a suitable reference standard of the same sequence of tests without FeNO. The review
included 27 studies that estimated the diagnostic accuracy of either FeNO alone or FeNO in conjunction with
another test compared with that of a variety of reference standards and in a variety of populations.
Adults presenting with symptoms of asthma (four studies)
It is difficult to draw any conclusion about the optimal cut-off for sensitivity and specificity because of the
heterogeneity in the results, study designs and devices used.
l The cut-off for the highest sum of sensitivity and specificity ranged from 20 ppb to 47 ppb amongst the
studies and even results produced by the same authors in studies with high levels of homogeneity
varied widely (25 ppb and 46 ppb in Schneider et al.69 and Schneider et al.71,72 respectively). Sensitivities
ranged from 32% to 88% and specificities from 75% to 93%.
A range of cut-offs was not reported in all studies and it was not clear if the highest sensitivity or
specificity value was available. From those that were reported:
l when selecting the cut-off with the highest sensitivity, this ranged from 9 ppb to 15 ppb, with
sensitivities ranging from 85% to 96% and specificities ranging from 13% to 48%
l when selecting the cut-off with the highest specificity, this ranged from 47 ppb to 76 ppb, with
sensitivities ranging from 55.6% to 13% and specificities ranging from 88.2% to 100%.
The consistently smaller range and higher values of specificities than sensitivities reported suggest that
FeNO may be a more reliable and useful parameter to base diagnostic decisions on as a rule-in test than as
a rule-out test. However, this balance will depend on the clinical and cost consequences of being TP, TN,
FP and FN in each scenario.
Subset of patients at position A compared with airway reversibility or airway
hyper-responsiveness (two studies)
These studies did not produce estimates of diagnostic accuracy that were noticeably different from those
in the studies that recruited a potentially broader spectrum of patients:
l The cut-off for the highest sum of sensitivity and specificity ranged from 27 to 36 ppb. Sensitivities
from 77.8% to 87% and specificities from 60% to 92%.
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A range of cut-offs was reported in only one study.82 These reached 100% sensitivity and specificity at the
lowest and highest cut-offs, respectively, in this cohort compared with this reference standard.
l when selecting the cut-off with the highest sensitivity, this was 25 ppb, with a sensitivity of 100% and
a specificity of 46.7%
l when selecting the cut-off with the highest specificity, this was 100 ppb, with a sensitivity of 27.8%
and a specificity of 100%.
Difficult-to-diagnose patients (four studies)
These studies all used some form of airway hyper-responsiveness as the reference standard. Surprisingly,
estimates of sensitivity and specificity seemed largely comparable to those in the studies recruiting patients
presenting to primary care with symptoms of asthma, with a reference standard of airway reversibility,
ICS responsiveness and airway hyper-responsiveness.
Bobolea et al.88 recruited a set of patients who were negative by MCT and compared FeNO with an
adenosine challenge test:
l This study produced 100% sensitivity (29.2% specificity) at a cut-off of 30 ppb, meaning that FeNO is
likely to operate well as a rule-out test.
The other studies used MCT challenge in patients who were negative for asthma in previous tests:
l Cut-offs for the highest sum of sensitivity and specificity ranged from 32 to 40 ppb compared with
MCT, which is a slightly narrower range than those in the broader cohorts. Sensitivities ranged from
35.0% to 74.3% and specificities from 72.5% to 95%, which are similar ranges to those in the
broader cohorts. This perhaps reflects the fact that airway reversibility is a highly accurate test for
asthma and that the combined tests behave in a similar manner. If this is the case, it would also
suggest that FeNO has similar diagnostic properties in difficult-to-diagnose patients as in the broader
spectrum of patients.
A range of cut-offs was not reported in these studies.
Patients with chronic cough and difficult to diagnose (three studies)
These studies recruited patients with chronic cough who had tested negative for other causes. All three
studies used a reference standard of ICS responsiveness. Cut-offs for the highest sum of sensitivity and
specificity were also in the same range and sensitivity and specificity were somewhat better in two studies:
94.7% sensitivity and 76.3% specificity in Hsu et al.73 and 90% sensitivity and 85% specificity in Hahn
et al.74 This is in accordance with the expectation that FeNO is a better marker of ICS responsiveness than
of asthma itself. At this position in the pathway, FeNO may be a useful test to perform before ICS
responsiveness to indicate which patients are likely to respond to a trial of treatment. Patients with a low
FeNO level could go on for further asthma investigations (e.g. MCT) or be assumed to be non-asthmatic
depending on whether a rule-in or a rule-out scenario is used.
Studies using FeNO in conjunction with another test as the index test (three studies)
These studies reported the diagnostic accuracy of FeNO in conjunction with another test. This evidence
comes closest to testing FeNO in a diagnostic pathway but is still of very limited relevance to the decision
problem. The improvements in diagnostic accuracy were modest (or negative when considering the sum of
sensitivity and specificity) and necessitate the usual trade-off between sensitivity and specificity. As the
two studies that reported accuracy data are derivation studies rather than validation studies, it is possible
that the gains seen are an overestimate of increases in diagnostic accuracy. However, it would seem
that using a combination of tests may have additional benefits to using FeNO on its own.
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Children with symptoms of asthma (four studies)
In comparison to the adult cohorts, with a similar spectrum of patients and reference standards, the
cut-offs derived are generally lower in studies in children but with similar ranges of estimates of sensitivity
and specificity.
l There was a high degree of agreement as to the cut-off that produces the highest sum of sensitivity
and specificity, despite the heterogeneity in devices and reference standards, with values between
19 ppb and 21 ppb, which are consistently lower than those in adults. Estimates of sensitivity at these
cut-off points were also wide-ranging, at 49–86%, which is similar to estimates in adult studies
(32–88%). Again, as in adults (range 75–93%), specificity was more similar between studies, ranging
from 76% to 89%.
l When selecting the cut-off with the highest sensitivity, the results were similar to those in adult
cohorts. Cut-offs ranged from 5 to 20 ppb (vs. 9–15 ppb in adults), sensitivity from 89% to 94%
(vs. 85–96% in adults) and specificity from 14.1% to 70% (vs. 13–48% in adults).
l When selecting the cut-off with the highest specificity, results were also similar to, but perhaps a little
lower than, those in adult cohorts, ranging from 30 to 50 ppb (vs. 47–76 ppb in adults). Sensitivity
ranged from 20% to 50% (vs. 13–55.6% in adults) and specificity ranged from 92% to 100%
(vs. 88.2–100% in adults).
Adult smokers
Two studies were identified. Both recruited an unusual spectrum of patients who reported symptoms of
asthma in response to a questionnaire, rather than a population presenting with symptoms.
Cut-off values were generally lower in smokers than in cohorts consisting of never, ex- and current
smokers and it may be useful to consider a patient’s smoking status when interpreting results. It is difficult
to determine how the fairly minor differences in cut-off points and diagnostic properties of FeNO across
groups would affect cost-effectiveness and clinical utility in practice. However, it would appear that FeNO
is able to distinguish between asthmatic and non-asthmatic smokers with similar accuracy as between
non-smokers and ex-smokers, but different cut-off points may be required.
Children exposed to tobacco smoke
Evidence was limited with regard to children exposed to tobacco smoke and drew on studies reported in
the section on the management of children exposed to tobacco smoke and from the above studies reported
for adults. The overall conclusion was the same as for adult smokers: it may be necessary to consider a
child’s exposure status when interpreting the results of FeNO testing for the diagnosis of asthma, as FeNO
levels may be lower in children exposed to tobacco smoke.
Pregnant women
No diagnostic accuracy studies in pregnant women were identified. A cross-sectional study compared mean
FeNO values in pregnant asthmatic women, non-pregnant asthmatic women, healthy pregnant women
and healthy non-pregnant women. The study concluded that pregnancy does not alter FeNO levels in
asthmatic or non-asthmatic women and that FeNO can distinguish between asthmatic and non-asthmatic
pregnant and healthy women. However, it is unclear whether diagnostic accuracy would be equivalent to that
reported in other studies with non-pregnant participants or a mix of pregnant and non-pregnant participants.
The elderly
No diagnostic accuracy studies in the elderly were identified. A case–control study115 investigated FeNO levels
in elderly patients with eosinophilic airflow obstruction (sputum cell count > 3%) compared with elderly
healthy controls. No significant difference was found in the mean FeNO values, suggesting that FeNO is not
a good marker of eosinophilic airway inflammation in elderly patients. This indicates that FeNO is unlikely
to act as a useful test for the diagnosis of asthma in the elderly.
CLINICAL REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
148
FeNO-guided management in asthma
Adults (five studies)
There was a high degree of heterogeneity across studies in all aspects of study design, including levels of
blinding, inclusion criteria, visit frequency, cut-off points selected, devices used, step-up/step-down protocols and
medications controlled by the protocols. Only one study reported using UK guidelines in the comparator arm.98
Exacerbations All studies reported a fall in exacerbation rate, although it appeared that this was mostly
driven by mild and moderate exacerbations and was not always statistically significant.
Severe exacerbations:
l An exploratory random-effects meta-analysis including all definitions of severe exacerbations (excluding
the studies by Smith et al.97 and Honkoop et al.101) produced a pooled estimate of 0.94 (95% CI 0.66
to 1.34; p= 0.73). Reviewer-calculated rate ratios for major/severe exacerbations ranged from 0.79
(95% CI 0.66 to 0.94) to 1.29 (95% CI 0.83 to 2.03).
l The addition of data from Honkoop et al.101 with imputed SEs did not change the non-statistical
significance of the estimate, with rate ratios ranging from 0.82 (95% CI 0.64 to 0.1.05; p= 0.11) to
0.89 (95% CI 0.67 to 1.17; p= 0.40).
l The impact of the exclusion of the study by Smith et al.97 from the analysis is unknown.
In a prespecified sensitivity analysis removing studies with wider definitions of severe exacerbations, only
that by Syk et al.99 remained in the analysis, with a rate ratio in favour of the control group at 1.29
(95% CI 0.83 to 2.03), although the difference was not statistically significant (p= 0.26). The inclusion of
the study by Honkoop et al.101 using imputed SE values resulted in a range of rate ratios from 0.91 (95% CI
0.47 to 1.77; p= 0.79) to 1.00 (95% CI 0.53 to 1.90; p= 1.00), indicating no significant difference
between the intervention groups. Heterogeneity statistics were high, ranging from 80% to 53% and
reflecting the opposite direction of effect reported in these two studies. Differences in study characteristics,
step-up/step-down protocols and patients may account for differences in the direction of effect.
All definitions of exacerbations:
l Three studies reported a composite outcome including all types of exacerbation.97,99,100 Two reported
fewer exacerbations in the FeNO arm, but the difference did not reach statistical significance.97,100
Syk et al.,99 however, did report a statistically significant difference in favour of the FeNO arm, with 0.22
exacerbations per person-year in the intervention arm and 0.41 in the control arm (p= 0.024).
l An exploratory pooled analysis showed a statistically significant effect with a rate ratio of 0.53 (95% CI
0.46 to 0.61; p< 0.00001, I2= 0%).
Inhaled corticosteroid use All studies reported some data on ICS use. Smith et al.97 and Shaw et al.98
reported mean ICS use at the end of the study, with mean differences of –270 µg/day (95% CI –112 to
–430 µg/day; p= 0.003) and –338 µg/day (95% CI –640 to –37 µg/day; p= 0.028), respectively, in favour
of FeNO-guided management. Syk et al.99 showed a small increase in ICS use in the intervention arm
compared with the control arm [586 µg (SE 454) vs. 540 µg (SE 317)]. Calhoun et al.100 reported the mean
value per month, although it is unclear if this was an average over the whole course of the study or the
mean for the final month of the study. The means were very similar, at 1617 µg/month in the intervention
arm and 1610 µg/month in the control arm.
l An exploratory meta-analysis using standardised mean difference (as outcomes were not reported in a
standardised way) showed an overall effect of –0.24 SDs in favour of the intervention, although this
narrowly missed significance (95% CI –0.56 to 0.07; p= 0.13).
l This may indicate that some step-up/step-down protocols were better at decreasing ICS use than others
or it may be related to the characteristics of the study populations.
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Inhaled corticosteroid use and exacerbations are likely to be inversely related, regardless of the use of FeNO.
Whether the effects of FeNO-based management on these two related factors represents a cost-effective
exchange is assessed through cost-effectiveness modelling in Chapter 4.
Health-related quality of life Three studies used versions of the AQLQ to measure quality of life.
All showed no effect on the global score, but one study investigated domains and found a statistically
significant difference in the symptoms score.
Asthma control and other medication use
l Asthma control either did not change97,98,100 or increased.99
l Smith et al.97 and Calhoun et al.100 reported no significant differences between groups in
bronchodilator use and Syk et al.99 reported greater numbers using and mean use of LTRAs (statistically
non-significant) and SABAs (significance not reported) in the FeNO-controlled arm.
Adverse events and mortality No asthma-related adverse events or deaths were reported.
Conclusions for FeNO-guided management in adults Because of the high levels of heterogeneity
with regard to multiple study characteristics and outcome definitions, it was not possible to draw any firm
conclusions as to which step-up/step-down protocol or cut-off points offer the best efficacy. However,
considering the evidence base as a whole, it would seem possible that FeNO-guided management of most
descriptions may, during the first year of management, result in better management overall (fewer
exacerbations), with the potential for no increase or a small reduction in ICS use.
Children (seven studies)
There was a high degree of heterogeneity across studies with regard to all aspects of study design,
including levels of blinding, inclusion criteria, visit frequency, cut-off points selected, devices used, step-up/
step-down protocols and medications controlled by the protocols. Only Pike et al.108 reported using UK
guidelines in the comparator arm.
l Two studies recruited patients who appeared to be poorly controlled.104,107 Pike et al.108 recruited
moderate to severe patients, some of whom will have been uncontrolled.
l Peirsman et al.109 recruited mild to severe asthmatics.
l One study recruited patients who were mild to moderate persistent asthmatics.103
l One study recruited patients who had had a stable dose of ICS for the previous 3 months, suggesting
that they were reasonably well controlled.106
l It was not possible to tell whether patients in the study by Verini et al.105 were controlled or uncontrolled.
Hospitalisations Three studies104,108,109 reported the number of patients (but not the rate per person-year)
requiring hospitalisations. All three studies reported no difference between groups..
Severe exacerbations Three studies reported data on exacerbations resulting in OCS use.103,104,106 Two
reported fewer OCS courses in the FeNO arm, but the difference between groups was not statistically
significant in the study by Szefler et al.,104 whereas significance was unreported in the study by Pijnenburg
et al.106 Fritsch et al.103 reported similar numbers of OCS courses in both arms.
All definitions of exacerbations Fritsch et al.,103 Szefler et al.,104 Verini et al.,105 Petsky et al.,107 Pike et al.108
and Peirsman et al.109 all reported exacerbations that were not defined as either major or minor and which
had different definitions from one another. Five studies reported numerically fewer exacerbations or treatment
failures in the intervention arm, but these differences were statistically significant in only two studies.107,109
All studies showed at least a trend in favour of fewer exacerbations in the intervention arm. In the study by
Petsky et al.,107 exacerbations were not clearly defined but occurred in six out of 31 participants in the
intervention group (19.4%) and 15 out of 32 in the control group (46.9%; p= 0.021). Peirsman et al.109
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reported statistically significantly fewer exacerbations of any severity (as defined using GINA guidelines136) in the
intervention arm (18 events) than in the control arm (35 events; p= 0.02). Pijnenburg et al.106 did not report
this outcome.
Inhaled corticosteroid use With the exception of the study by Petsky et al.,107 all of the studies provided
some estimate of ICS use. Fritsch et al.103 and Szefler et al.104 reported statistically significantly higher ICS
use in the intervention group; Pike et al.108 and Peirsman et al.109 reported higher levels of ICS use in the
intervention group but not statistically significantly so; Pijnenburg et al.106 reported very similar levels in the
different groups; and the values in the remaining study (in terms of absolute numbers using ICSs) were
difficult to interpret. The differences in the effects on ICS usage between studies may be the result of the
specifics of the step-up/step-down protocols and/or the characteristics of the patients selected. In the case
of the study by Pijnenburg et al.,106 in which patients may have been generally better controlled at the
outset, step down of ICS use may have been more likely than in the study by Szefler et al.,105 in which
patients were poorly controlled and ICS dose was perhaps more likely to be stepped up. Having said this,
poorly controlled patients may be poorly controlled because they are non-responsive to corticosteroids, and
use of FeNO testing may actually result in a decrease in ICS use if low FeNO levels always indicate a
decrease in treatment. However, Szefler et al.,104 Pijnenburg et al.,106 Pike et al.108 and Peirsman et al.109
did not allow step down of ICS dose on the basis of low FeNO levels alone, meaning that uncontrolled
ICS-unresponsive asthmatics for whom high doses of ICS were not appropriate could not have their doses
lowered and mean ICS use may remain artificially high. It could be expected that this effect would be most
pronounced in studies that recruited patients with severe asthma. As such, it may be that the increase
in ICS usage in the study by Szefler et al.104 is a function of the population selected as well as the
management protocol.
Inhaled corticosteroid use and exacerbations are likely to be inversely related, regardless of the use of
FeNO testing. Whether the effects of FeNO-based management on these two related factors represent a
cost-effective exchange is assessed through cost-effectiveness modelling in Chapter 4.
Health-related quality of life This outcome was reported in only one study in abstract form107 and using
an unknown tool. No conclusions can be confidently drawn from these data.
Asthma control and other medication use Four studies provided some data on asthma control, none of
which demonstrated any statistically significant effects favouring either the intervention or the control.
With respect to additional medication use, three studies provided data and there did not appear to be a
clear direction of effect within the data.
Adverse events, mortality, compliance and test failure rates Szefler et al.104 reported no difference in
adverse events between groups and no mortality was observed. The adverse events listed were disorders of
the eyes, ears, nose and throat; gastrointestinal disorders; haematology disorders; infections; musculoskeletal
symptoms; and skin symptoms.
Conclusions for FeNO-guided management in children Because of the high levels of heterogeneity
with regard to multiple study characteristics and outcome definitions, it was not possible to draw any firm
conclusion as to which step-up/step-down protocol or cut-off points offer the best efficacy. Results were
generally not statistically significant, but this may be because of the small sample sizes in some cases;
meta-analysis was precluded by the ability to calculate rate ratios. Because all but one study reported
numerically smaller numbers or rates of exacerbations in the intervention arm, it would seem possible that
FeNO-guided management of most descriptions could, during the first year of management, result in
better management overall, despite the lack of statistically significant results in individual studies.
Further larger studies are needed to clarify any treatment effect. It is unclear whether ICS use is likely to
increase or decrease and this may depend on the details of the step-up/step-down protocols or the
characteristics of the patients recruited to the trials in terms of control and severity.
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Generalisability of the results to UK practice
Diagnostic review
Adults
Only studies with some relevance to UK practice were considered, of which not all used NIOX MINO or
NObreath. The studies with the highest relevance to UK practice can be broken down into four types:
l Studies of all patients presenting with symptoms of asthma and using a reference standard that
includes the most common tests in the UK pathway. The most relevant studies in this category are
those by Schneider et al.69 and Schneider et al.,71,72 who used the NIOX MINO device, and those by
Smith et al.83 and Smith et al.,86 who used the Niox chemiluminescent device and an unknown
device respectively.
l Studies recruiting patients who are difficult to diagnose and using a reference test appropriate to
UK practice:
¢ Schleich et al.,77 who used the Niox chemiluminescent device, and Pedrosa et al.85 and Katsoulis
et al.,81 who used the NIOX MINO device.
¢ Bobolea et al.,88 who also used the NIOX MINO device and who selected a population of patients
who were negative by MCT. The reference standard was the adenosine challenge test.
l Studies recruiting patients with chronic cough who have already undergone other tests. This includes
the studies by Hsu et al.,73 Hahn et al.74 and Prieto et al.76 These are useful studies in terms of
demonstrating that FeNO can predict ICS responsiveness in these patients, rather than a diagnosis of
asthma. None of these studies used the NIOX MINO device.
l Studies using FeNO in conjunction with another test compared with an appropriate reference standard:
¢ Schleich et al.77 recruited a difficult-to-diagnose group, combined FeNO with FEV1%< 101% and
used a reference standard of MCT. It could be argued, however, that in the UK only patients
negative by FEV1% would receive a MCT, in which case this combination may not be a useful one.
¢ Cordeiro et al.87 recruited patients presenting with symptoms of asthma and combined FeNO with
airway reversibility to administration of a bronchodilator. This would be equivalent to FeNO being used
to prevent a MCT, but some of the included patients would not have received a MCT under the UK
pathway anyway. As such, it is again unclear how useful this combination of tests would be in
UK practice.
Children
Only studies with some relevance to UK practice were considered. These studies, of all patients presenting
with symptoms of asthma and using a reference standard that includes the most common tests in the UK
pathway, can be broken down into the following groups:
l Woo et al.,96 who recruited patients in position A on the pathway and used the NIOX MINO device
compared with a reference standard that roughly equates to UK practice.
l Linkosalo et al.,93 who used a Sievers NOA280i chemiluminescence device for patients in position A on
the pathway with a reference standard of an exercise challenge test. Not all presenting patients would
receive this test in UK practice. FeNO testing would be positioned before the exercise challenge test
and could triage patients away from this.
l Sivan et al.,95 who used an ECO MEDICS device in patients at position A in the pathway compared with
a reference standard similar to UK practice. In this study, FeNO replaces the whole pathway prior to
ICS use.
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Management review
Adults
Generalisability to UK practice is clear-cut in the study of adults by Shaw et al.,98 which used UK guidelines
as the comparator and was based in the UK. Patients were recruited from primary care and included mild
to severe asthmatics (unless a severe exacerbation had been experienced in the previous 4 months) and
atopic patients as well as non-atopic patients. Smokers were excluded and so the results may not be
generalisable to this group. However, this study offers the best generalisability to UK practice in terms of
setting, population and comparator.
However, if management protocols that are different from that used in Shaw et al.98 were to be considered for
recommendation, other studies may offer some useful data. Input from a clinician (Professor Ian Pavord,
Nuffield Department of Medicine, University of Oxford, August 2013, personal communication) suggests that
the management protocol described by Powell et al.,102 in which symptoms control the LABA dose and FeNO
levels control the ICS dose, is generally thought to be the best design. This study was conducted in pregnant
women only and its generalisability to the whole asthma population is not assured. The protocol described
by Shaw et al.98 appears to be similar to this in that the FeNO level controls the ICS and LTRA doses whereas
symptoms scored according to the Juniper scale control the SABA, LABA and theophylline doses. Importantly,
this allows for low FeNO levels to result in a reduction in ICS dose regardless of symptoms. In practice, the
extent of ICS dose reduction may be limited by current Commission on Human Medicine advice, which states
that LABAs should not be prescribed without ICSs.143
Children
Generalisability in studies recruiting children was less clear-cut. Only the study by Pike et al.108 was set in
the UK and used UK guidelines, but this study also recruited only moderate to severe asthmatics and may
therefore not be generalisable to the whole population. This study was identified during the update search
and it was not possible to incorporate it into the model because of time constraints. From the studies
identified in the original search, and on the basis of reported quality, that by Szefler et al.104 was at lowest
risk of bias and, for patients who are uncontrolled, this may be the best study to base generalisations on.
However, clinical input to the project (Professor Ian Pavord, August 2013, personal communication)
indicated that this study has been criticised for not allowing a step down of ICS dose on the basis of low
FeNO levels if symptoms are still present. In addition, the patient population in this study was patients who
were uncontrolled, which may introduce bias in that patients will be less likely to be indicated for a step
down of ICS dose.
For patients who are mild to moderate asthmatics, the study by Fritsch et al.103 may be the best study to
select for modelling as the study by Pijnenburg et al.106 uses only symptoms to guide asthma management
in the control arm, whereas that by Fritsch et al.103 uses symptoms, SABA use and lung function tests,
which is probably more comparable with UK practice. However, Fritsch et al.103 used only FeNO to guide
management and it would seem more likely that clinicians would use other measures such as symptom
control and lung function to guide treatment. This would allow the stepping down of treatment based on
FeNO values, but may also be less sensitive than using a combination of factors. Unfortunately, there is not
a study in children that addresses this particular problem by combining FeNO testing with other indicators
in a protocol that allows step down in the presence of low FeNO levels regardless of symptomatic control.
Fritsch et al.103 did not report data in a way that allowed calculation of rates of exacerbation per
person-year and this study is of limited use for this reason. The study by Pijnenburg et al.106 provided
the necessary data and this study was selected for modelling.
The study by Peirsman et al.109 was identified in the update search. A broad spectrum of patients was
recruited but the study did not allow for step down of ICS use on the basis of FeNO levels alone and the
treatment protocol was different from UK practice. This study was not used in the modelling because of
time constraints.
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Chapter 4 The cost-effectiveness of FeNO testing
for the diagnosis and management of asthma
Introduction
This chapter presents an assessment of the cost-effectiveness of FeNO testing for the diagnosis and
management of asthma. The chapter consists of two main sections: (1) a review of existing evidence
relating to the cost-effectiveness of FeNO testing in the diagnosis and management of asthma and (2) an
exposition of the methods and results of two de novo health economic models developed by the EAG to
evaluate the cost-effectiveness of FeNO testing for the diagnosis and management of asthma.
The chapter is set out as follows. The following section describes the aims and objectives of the economic
analysis. Review of existing evidence relating to the cost-effectiveness of FeNO testing for the diagnosis
and management of asthma presents the methods and results of a critical review of existing economic
evidence on FeNO testing for asthma; this includes published studies as well as other economic evidence
submitted by the manufacturers of the FeNO devices considered in this assessment. This section also
includes a summary of methodological problems and concerns associated with undertaking economic
analyses of interventions for the diagnosis and management of asthma. Development of two de novo
models to estimate the cost-effectiveness of FeNO testing for the diagnosis and management of asthma
presents the methods of the de novo economic analyses undertaken by the EAG and De novo model
results summarises the main findings of the analyses. The final discussion section highlights the key
uncertainties surrounding the evidence base used to inform the de novo analysis.
Aims and objectives of the health economic assessment of
FeNO testing
The purpose of this chapter is to assess the expected cost-effectiveness of NIOX MINO, NIOX VERO
and NObreath compared with current standard care for the diagnosis and management of asthma.
Importantly, there is uncertainty not only with respect to whether FeNO testing might represent a cost-effective
use of health-care resources but also with respect to how FeNO testing should be used in the most
cost-effective manner within existing asthma pathways. Thus, the economic analysis attempts to address
the following questions:
1. What is the cost-effectiveness of FeNO testing using NIOX MINO, NIOX VERO and NObreath compared
with current standard tests for the diagnosis of asthma in England and Wales?
i. Should FeNO testing be used alongside existing standard tests for the diagnosis of asthma?
ii. Should FeNO testing be used in place of existing standard tests for the diagnosis of asthma?
2. What is the cost-effectiveness of FeNO testing using NIOX MINO, NIOX VERO and NObreath compared
with standard guidelines for the management of asthma in England and Wales?
3. What are the key uncertainties relating to the cost-effectiveness of FeNO testing and how might these
be resolved or reduced?
The next section presents the methods and results of a review of the existing evidence relating to the
cost-effectiveness of FeNO testing.
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Review of existing evidence relating to the cost-effectiveness
of FeNO testing for the diagnosis and management of asthma
Purpose of the review
We undertook a systematic review of existing economic analyses of FeNO testing in the diagnosis of
asthma and for the management of patients with diagnosed asthma. This also included a focused review
of economic studies of other interventions for the diagnosis and/or management of asthma. The purpose
of the review of existing health economic analyses was threefold:
1. to identify existing economic analyses of FeNO testing using NIOX MINO, NIOX VERO or NObreath for
the diagnosis and/or management of asthma
2. to identify existing models that may be used to inform the structure of the de novo economic models
developed by the EAG
3. to identify potentially relevant evidence sources to inform parameter values within the de novo
economic models developed by the EAG.
Review methods
Methods used to identify existing economic studies
We undertook systematic searches across a range of electronic databases to identify published studies of
FeNO testing for the diagnosis and/or management of asthma. We also searched for other economic
studies of interventions for the diagnosis or management of asthma. All searches were undertaken by an
information specialist (RW) during the period 30 May 2013 to 7 June 2013.
Four separate strands of searching were undertaken, which are detailed in the following sections.
Economic search 1: NIOX MINO/NObreath in either the diagnosis or the
management of asthma (30 May 2013)
This search used free-text terms relating to NIOX MINO and NObreath (including manufacturer names),
with the terms combined with a sensitive economic search filter.
Economic search 2: models of asthma and FeNO (30 May 2013)
This search used the search strategies developed for the management studies in the clinical effectiveness
review (see Chapter 3, Clinical reviews search methodology) and combined these with a sensitive economic
search filter. Studies that were found in the first search would also be retrieved in this search.
Economic search 3: asthma management models (3 June 2013)
This focused search used free-text terms for asthma combined with cost terms in the title and the
economic model subject heading. A sensitive economic filter was not applied in this search.
Economic search 4: asthma diagnostic models (7 June 2013)
This focused search used free-text terms for asthma (as used in economic search 3) combined with a
sensitive economic evaluations search filter and a diagnostic search filter.
These four searches are shown diagrammatically in Figure 20.
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All of the above searches were performed within the following databases:
l MEDLINE and MEDLINE-In-Process & Other Non-Indexed Citations (Ovid): 1948–present
l EMBASE (Ovid): 1974–present
l The Cochrane Library (Wiley Interscience):
¢ CDSR: 1996–present
¢ HTA database: 1995–present
¢ NHS EED: 1995–present
l SCIE (Web of Science): 1899–present
l CPCI-S (Web of Science): 1990–present.
The economic MEDLINE search strategy is detailed in Appendix 13.
As noted in Chapter 3 (see Additional search for NIOX VERO), an additional separate search was also
undertaken in August 2013 to identify evidence relating to NIOX VERO.
Inclusion and exclusion criteria for the review
Given the anticipated dearth of published economic analyses relating to FeNO, we adopted broad inclusion
criteria for the review (Box 1).
Data sifting
The titles and abstracts of all records identified by the search were reviewed by one member of the
research team (JM). The full texts of studies considered eligible for inclusion were then retrieved for a more
detailed examination.
Critical appraisal methods
The identified studies of FeNO were critically appraised using the Drummond et al.144 checklist for economic
evaluations and the NICE reference case for diagnostic studies.145 The identified studies were also informally
assessed against current guidelines for the development and reporting of health economic models.146
Asthma terms Asthma terms
Intervention and
manufacturer terms
Lower respiratory
tract symptom
terms  
Exhaled nitric
oxide terms
AND
AND AND AND
AND
Exhaled nitric
oxide terms
AND
Economic filter
OR OR
For example, NIOX MINO,
NObreath, aerocrine, bedfont
For example, asthma,
bronchoconstriction,
bronchial spasm
For example, FeNO, ENO,
fractional NO
Asthma model review
Model terms in title Economic filter
Diagnostic filter
Asthma combined
with economic filter
and diagnostic filter
4. 
3. 
2.
1.
FIGURE 20 Diagrammatic representation of the search approach.
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Studies of other interventions for the diagnosis and/or management of asthma were not subjected to a
formal critical appraisal but were instead used to inform the design and development of the de novo health
economic analyses (detailed in Development of two de novo models to estimate the cost-effectiveness of
FeNO testing for the diagnosis and management of asthma).
Results of the review of FeNO testing for asthma diagnosis
and/or management
Number and type of studies included in the review
The results of the four economic searches are presented in Table 51. A total of 1898 potentially relevant
citations were identified from the four searches. The full texts of 27 studies were retrieved for further
examination. The full text of one of these studies could not be retrieved and was excluded. Of the
remainder, only two studies147,148 were identified that related to FeNO testing for the diagnosis and/or
management of asthma. The focused searches did not identify any further cost–utility models of other
interventions for the diagnosis of asthma. Sifting of the focused management model searches identified a
further 13 studies149–161 that were used more generally to inform the model structure, although none of
these related to FeNO testing. In addition, one additional management study13 that was detailed in the
appendices of a UK HTA report was identified.
As part of the appraisal process, Aerocrine submitted evidence relating to the cost-effectiveness of NIOX
MINO for the diagnosis and management of asthma (Aerocrine. Submission to NICE – Assessing the
Impact of FeNO in the Management and Diagnosis of Asthma. Slideset and Microsoft Excel model, 2013).
This submission included a Microsoft Excel 2010 spreadsheet model (Microsoft Corporation, Redmond,
WA, USA) and a brief slideset. This submission is included as part of the economic review presented in this
chapter. Aerocrine did not submit any economic evidence relating to the cost-effectiveness of the NIOX
VERO device and Bedfont Scientific did not submit any evidence relating to either the effectiveness or the
cost-effectiveness of the NObreath device.
BOX 1 Inclusion and exclusion criteria for the review of economic analyses of asthma diagnosis and management
Inclusion criteria
l Economic analyses of costs and consequences of interventions for the diagnosis and/or management of
asthma in children and/or adults.
l Studies reporting on the cost-effectiveness of NIOX MINO, NIOX VERO or NObreath for the diagnosis
and/or management of asthma.
Exclusion criteria
l Letters, commentaries and editorials.
l Economic studies that do not relate to diagnostic or management interventions.
l Studies that do not relate to asthma.
l Studies that do not involve (i) a model-based analysis, (ii) economic evaluations alongside trials or other
forms of empirical clinical study or (iii) estimates of the costs and consequences of FeNO testing for the
diagnosis of asthma.
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Existing economic analyses of FeNO testing for the diagnosis of asthma
Methods and results of the included diagnostic studies
The searches included only one UK model-based published economic analysis relating to the diagnosis
of asthma;147 this study assessed the cost-effectiveness of FeNO testing (specifically NIOX MINO) compared
with standard diagnostic tests. This model has been published across two papers147,148 and also forms the
basis of the Aerocrine submission to NICE for this appraisal. The general model structure and many of
the evidence inputs are the same across these three analyses.
An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom:
diagnostic model147
Description of the economic model and analysis Price et al.147 presents the methods and results of
two economic analyses: (1) a model to assess the cost savings associated with using NIOX MINO for the
diagnosis of asthma and (2) a model to assess the cost-effectiveness of NIOX MINO for the management
of asthma. The model of asthma management is reviewed in detail in Existing economic analyses of FeNO
testing for the management of asthma.
The conceptual form of the Price et al.147 diagnostic model is presented in Figure 21. Within the model, the
costs and outcomes of competing diagnostic strategies are modelled using a simple deterministic decision
tree based on the true underlying probability of asthma and the operating characteristics of a variety of
tests used for the diagnosis of asthma in the NHS. The population under evaluation within the model is
reported to relate to ‘non-smoking adult patients with mild to severe asthma as seen in both primary and
secondary care’ (p. 433).147 The intervention is defined in the base-case analysis as FeNO testing using
NIOX MINO alone, although a secondary analysis is also reported for a joint diagnostic modality consisting
of NIOX MINO plus spirometry using FEV1 testing. The comparator within the base-case analysis is a
blended comparison of standard diagnostic tests: (1) lung function testing, (2) reversibility test, (3) bronchial
provocation and (4) sputum eosinophil count. The selection of tests included in the analysis was based on the
BTS/SIGN asthma guidelines,8 although the source for the proportionate weighting of each of these is unclear
within the Price et al.147 paper. It should also be noted that current BTS/SIGN guidelines8 state that sputum
induction is not in common usage and it currently remains a research tool. In contrast to the published
Price et al.147 model, the Aerocrine submission model does not adopt a blended comparison approach but
instead evaluates each individual diagnostic test as a decision option in its own right.
TABLE 51 Summary of the results of the economic searches
Database
Search
1. NIOX
MINO/NObreath
2. Asthma and
FeNO models
3. Asthma
management
models
4. Asthma
diagnostic
models
MEDLINE and MEDLINE-In-Process & Other
Non-Indexed Citations
2 29 311 338
EMBASE 7 144 420 590
CDSR 0 48 0 69
HTA database 4 8 4 0
DARE 0 2 3 14
NHS EED 1 2 119 12
SCIE 5 85 295 457
CPI-S 0 3 15 37
Total unique citations 14 269 567 1048
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FIGURE 21 Model structure employed within the Price et al.147 diagnostic model. Reproduced with permission from
Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United
Kingdom. Allergy 2009;64:431–8.147 John Wiley & Sons. © 2009 The Authors. Journal compilation © 2009
Blackwell Munksgaard.
The model structure employs a single decision node whereby the model cohort is assumed to receive a
single imperfect diagnostic intervention; those patients who receive an incorrect diagnosis are later assumed
to achieve a correct diagnosis of either true asthma or not asthma. The published model estimates the costs
associated with NIOX MINO compared with those of the blended comparison of standard diagnostic tests.
The analysis takes the form of a comparative cost analysis and health outcomes are not explicitly considered
in the published analysis (note that the number of misdiagnoses are not reported within the Price et al.147
paper but could be easily calculated from the table of model input parameters). Diagnostic outcomes in
terms of TPs, FPs, TNs and TPs are estimated explicitly within the Aerocrine model. Within the Price et al.147
paper, costs are valued at 2005 prices. The model time horizon is undefined but relates to the time from
presentation to correct diagnosis. No discounting is applied to costs.
The Price et al.147 diagnostic model makes the following structural assumptions:
l NIOX MINO will replace existing diagnostic tests rather than be used alongside them
l time is not explicitly considered within the model with respect to the resolution of incorrect diagnoses
(FPs or FNs)
l negative health consequences [quality-adjusted life-year (QALY) losses] associated with incorrect
diagnoses are not quantified within the model
l all incorrect diagnoses are assumed to be corrected at the next outpatient visit.
The parameter values and evidence sources from which these are drawn are reported in Table 52.
The headline results of the economic analysis are presented as a simple cost difference between NIOX
MINO and the blended comparison of standard tests for asthma diagnosis. Uncertainty surrounding model
input parameters was explored using simple one-way sensitivity analyses. These analyses include varying
model parameters describing test sensitivity, true underlying asthma prevalence in the modelled
population, the costs of NIOX MINO and other diagnostic tests, the number of additional visits required to
resolve an initially incorrect diagnosis, a comparison of NIOX MINO with reversibility testing plus peak
expiratory flow (PEF) charting and a comparison of NIOX MINO plus FEV1 and standard tests.
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TABLE 52 All parameter values and evidence sources used in the Price et al.147 diagnostic model
Parameter Value Source
Test operating characteristics
Sensitivity FeNO testing (flow rate 50ml/second; > 20 ppb) 0.88 Smith et al.86
Specificity FeNO testing (flow rate 50ml/second; > 20 ppb) 0.79
Sensitivity FeNO testing (flow rate 50ml/second; > 33 ppb)+ FEV1< 80% predicted 0.94
aSmith and Taylor162
Specificity FeNO testing (flow rate 50ml/second; > 33 ppb)+ FEV1 predicted< 80% 0.93
Sensitivity PEF A%M> 21.6% 0.43 Hunter et al.163
Specificity PEF A%M> 21.6% 0.75
Sensitivity reversibility test: FEV1> 2.9% improvement after salbutamol 0.49
Specificity reversibility test: FEV1> 2.9% improvement after salbutamol 0.70
Sensitivity bronchial provocation: methacholine PC20< 8mg/ml 0.91
Specificity bronchial provocation: methacholine PC20< 8mg/ml 0.90
Sensitivity sputum eosinophil count > 1% 0.72
Specificity sputum eosinophil count > 1% 0.80
Disease characteristics
Asthma prevalence 0.36 Smith et al.86
Comparator usage (blended comparison weightings)
Proportion using PEF charting 0.485 BTS/SIGN164
Proportion using reversibility testing 0.485
Proportion using bronchial provocation 0.025
Proportion using sputum eosinophil count 0.005
Cost parameters (£)
Cost NIOX MINO 22.90 Aerocrine
Cost peak flow charting (two visits) 89.27 NHS Reference Costs165
Cost reversibility test 29.27
Cost bronchial provocation 48.50
Cost sputum eosinophil count 48.50
Cost outpatient GP visit 30.00 Curtis and Netten166
Cost outpatient lung practitioner 44.00
methacholine PC20< 8mg/ml, provocative concentration of methacholine causing > 20% fall in FEV1; PEF, peak expiratory
flow; PEF A%M > 21.6%, maximum within-day peak expiratory flow amplitude mean percentage (calculated from PEF
measured twice daily over 14 days as the best of three blows).
a Note that this is a non-systematic review/opinion paper. Although Smith and Taylor162 do state these sensitivity and
specificity values and refer to two other empirical studies, neither includes the quoted estimates. The empirical source of
the reported values for FeNO plus FEV1 is unclear.
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Diagnostic model results presented by Price et al.147 The diagnostic model results reported by
Price et al.147 are summarised in Table 53. In the base-case analysis, the authors report that the cost of an
asthma diagnosis made using NIOX MINO was £29 per patient, or £43 less than when using standard
diagnostic tests (£72 per patient).
The results indicate that, within the base-case analysis, NIOX MINO is expected to produce cost savings
(£43) compared with the blended comparison of standard diagnostic tests for asthma. These results do not
account for potential health benefits associated with the improved accuracy of diagnosis. The sensitivity
analysis indicates that NIOX MINO is expected to produce cost savings in all scenarios except (1) when the
cost of NIOX MINO is increased by 200% and (2) within the comparison of NIOX MINO plus FEV1 testing
compared with the blended comparison of current standard diagnostic tests.
The authors note that ‘is it is likely that, in practice, FeNO measurement will be used in conjunction with
other tests rather than as their replacement. We examined this scenario and found that the combination of
FeNO measurement plus lung function testing increased costs for diagnosing asthma by £42’ (p. 435).147
Given the authors’ interpretation of the likely placement of NIOX MINO, it is unclear why the base-case
analysis within the paper does not reflect this scenario and, given the proposed placement of FeNO within
the existing pathway and the absence of quantified health outcomes within the Price et al.147 diagnostic
model, it is unclear whether the potential additional benefits associated with diagnosis using FeNO testing
outweigh the opportunity costs associated with generating them.
TABLE 53 Summary of cost-minimisation results presented by Price et al.147
Scenario
NIOX MINO
(£)
Standard tests
(£)
Incremental cost
(£)
Base case 29 72 –43
Variation in test sensitivity –50% (all tests simultaneously) 35 76 –40
Variation in test sensitivity +10% (all tests simultaneously) 29 72 –43
Variation in test sensitivity –50% (bronchial provocation and
sputum only)
39 81 –42
Variation in test sensitivity +10% (bronchial provocation and
sputum only)
28 71 –43
Asthma prevalence set to 10% 30 70 –40
Asthma prevalence set to 50% 29 74 –45
Asthma prevalence set to 90% 28 78 –50
NIOX MINO cost –50% 18 72 –54
NIOX MINO cost +200% 75 72 3
Cost of standard diagnostic tests +50% 29 72 –43
Cost of standard diagnostic tests +100% 29 102 –72
Cost of standard diagnostic tests +150% 29 131 –102
Cost of standard diagnostic tests +200% 29 161 –131
Two visits for false diagnosis 36 86 –50
Four visits for false diagnosis 49 113 –63
NIOX MINO vs. reversibility+ PEF charting 29 131 –102
NIOX MINO+ FEV1 testing vs. standard tests 115 72 42
Source: reproduced with permission from Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway
inflammation monitor in the United Kingdom. Allergy 2009;64:431–8.147 John Wiley & Sons. © 2009 The Authors. Journal
compilation © 2009 Blackwell Munksgaard.
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The next section briefly outlines the economic analysis of NIOX MINO for asthma diagnosis as presented
within the Aerocrine submission to NICE.
(ii) Additional analysis presented within the submitted Aerocrine diagnostic model
As noted earlier, Aerocrine also submitted a spreadsheet model to NICE as part of the appraisal process.
The model was accompanied by a brief Microsoft PowerPoint slideset although this does not include a
description of the intended base-case analysis results and little detail is provided supporting the structure,
assumptions or choices regarding evidence used to inform the model parameters. The submitted Aerocrine
model adopts a very similar structure and similar assumptions to those of the diagnostic model reported by
Price et al.147 It should be noted that, in the absence of a detailed written description of the Aerocrine
submission model, it is difficult to provide a full critique of its methods and results. This task was further
hindered as the worksheet tabs and many sets of calculations were structurally hidden within the Microsoft
Excel worksheet, making formula auditing problematic.
The following differences should be noted between the Price et al. diagnostic model147 and the Aerocrine
diagnostic model:
1. Differences in the specification of diagnostic options. The Aerocrine model assesses a different set of
options compared with Price et al.:147
i. spirometry alone
ii. spirometry and (if negative) MCT
iii. spirometry and (if negative) FeNO testing
iv. spirometry and FeNO testing
v. FeNO testing alone
vi. spirometry and (if negative) sputum induction.
It should be noted that some of these options include sequences of diagnostic tests. These are
implemented within the model by assuming that the probabilities of obtaining a positive or negative
result from sequences of tests are uncorrelated with one another; in other words, the use of prior tests
in a sequence will remove some candidates from the population, will alter the prevalence of true
disease in the remaining population and may impact on the diagnostic accuracy of subsequent tests in
that sequence. The validity of assuming no correlation between tests is questionable and no evidence
is presented to support this. Within the Aerocrine submission model, all standard tests are evaluated
as individual comparators in their own right rather than being combined and weighted within a
blended comparison.
2. Different assumptions relating to the cost impact of misdiagnosis and resolution. The submitted model
includes the costs of treating patients who are FP using ICSs over a 1-year time horizon; these
treatment costs were not included in the Price et al.147 diagnostic model. Conversely, the Aerocrine
model does not include the assumptions made by Price et al.147 regarding the costs of additional visits
to resolve misdiagnosis.
3. Different parameter values and evidence sources. The Aerocrine diagnostic model includes some
different parameter values from those in the Price et al.147 diagnostic model. The parameter values and
sources employed within the Aerocrine diagnostic model are detailed in Table 54.
DOI: 10.3310/hta19820 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 82
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
163
It should be noted that the marginal per-test cost for NIOX MINO within the Aerocrine model is assumed
to be £10.00; this is substantially lower than that assumed within the Price et al.147 paper (£22.90).
The manufacturer states that the model should mean this £10 cost can be amended depending on the
aspects that local payers find relevant. The charge of £22.90 was noted by Price et al.147 as is typical and
includes all secondary care costs, but this cost also needs to be amended depending on the needs of to
local payers. Most NHS costs are set; thus, the £22.90 charge may not be possible (Mr David Plotts,
Director for Northern Europe & UK Managing Director, Aerocrine, 9 July 2013, personal communication).
TABLE 54 Key parameter values and evidence sources used in the Aerocrine diagnostic model
Parameter Value Source
Test operating characteristics
Sensitivity spirometry alone 0.29 Schneider et al.71
Specificity PEF A%M> 21.6% 0.90
Sensitivity FeNO testing+ spirometry 0.94 aSmith and Taylor162
Specificity FeNO testing+ spirometry 0.93
Sensitivity FeNO testing alone 0.88 Smith et al.86
Specificity FeNO testing alone 0.79
Sensitivity MCT 0.91 Hunter et al.163
Specificity MCT 0.90
Sensitivity sputum induction 0.72
Specificity sputum induction 0.80
Disease characteristics
Asthma prevalence 0.36 Smith et al.86
Cost parameters (£)
Cost of spirometry 1 Source unclear
Cost of spirometry plus FeNO testing 11 Assumption
Cost of FeNO testing 10 Assumption
Cost of spirometry plus MCT 63 2005 NHS Reference Costs (reported in Price et al.147)
uplifted to 2012 values
Cost of spirometry and sputum induction 63 2005 NHS Reference Costs (reported in Price et al.147)
uplifted to 2012 values
Annual NHS cost for long-acting ICS (prescribing
using standard guidelines)
138 BNF 51167 (reported in Price et al.147) uplifted to 2012 values
BNF, British National Formulary; PEF A%M > 21.6%, maximum within-day peak expiratory flow amplitude mean
percentage (calculated from PEF measured twice daily over 14 days as the best of three blows).
a Note that this is a non-systematic review/opinion paper. Although Smith and Taylor162 do state these sensitivity and
specificity values and refer to two other empirical studies, neither includes the quoted estimates. The empirical source of
the reported values for FeNO testing plus FEV1 is unclear.
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Summary of the results of the Aerocrine diagnostic model
Table 55 provides the results presented within the Aerocrine diagnostic model. The results relate to a
population of 840 patients; this population size is not justified within the model.
The Aerocrine diagnostic model suggests that the combination of spirometry plus FeNO testing is expected
to result in the greatest number of correct diagnoses and the fewest number of incorrect diagnoses. This is
because of the assumed sensitivity and specificity of this combination (sourced from the expert review
paper by Smith and Taylor162), both of which are higher than the values for all other tests included in
the analysis.
Critical appraisal of the Price et al.147/Aerocrine diagnostic models The use of the Price et al.147/
Aerocrine diagnostic models to inform judgements about the cost-effectiveness of NIOX MINO compared
with standard diagnostic tests for asthma is subject to a number of problems, which are detailed in the
following sections.
Deviations from the National Institute for Health and Care Excellence reference case Table 56
shows the extent to which the Price et al.147 diagnostic model and the Aerocrine diagnostic model adhere
to the NICE reference case for economic evaluations of diagnostic interventions.145 Although the Price et al.147
diagnostic model was not originally developed to inform this NICE appraisal, the model submitted by
Aerocrine follows the same general approach and therefore should be interpreted in light of NICE’s
reference case.
TABLE 55 Results estimated within the Aerocrine diagnostic model
Diagnostic
option
No. of
correct
diagnoses
(TPs and TNs)
No. of
incorrect
diagnoses
(FPs an FNs) Difference
Cost of
incorrect
diagnoses
(diagnosis
cost only) (£)
No. of FP
diagnoses
Cost of FP
diagnoses (£)
Cost of FP
steroid use (£)
Spirometry alone 572 268 303 268 54 54 7419
Spirometry and
(if spirometry
negative) MCT
719 121 597 4319 102 3102 14,096
Spirometry and
(if spirometry
negative) FeNO
testing
659 181 478 1455 155 1171 21,441
Spirometry and
FeNO testing
combined
784 56 728 614 38 414 5193
FeNO testing
alone
691 149 542 1492 113 1129 15,580
Spirometry and
(if spirometry
negative) sputum
induction
629 211 419 9938 151 6150 20,773
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TABLE 56 Adherence of the Price et al.147/Aerocrine diagnostic models to the NICE reference case
Element of HTA Reference case EAG comments
Defining the decision
problem
The scope developed by the
NICE
The Price et al.147 diagnostic model was not developed
specifically to inform the NICE diagnostic appraisal of FeNO,
yet this same general model approach was employed within
the Aerocrine submission. The intervention and comparators
are generally in line with the NICE scope. However, the
economic outcome does not include health consequences
quantified in terms of health gains/losses. The population in
both models is restricted to non-smoking adults with mild to
severe asthma as seen in both primary and secondary care
Comparator Therapies routinely used in the
NHS, including technologies
regarded as current best practice
Comparators include tests commonly used in the NHS for
the diagnosis of asthma: bronchial provocation, lung
function testing, reversibility testing and sputum eosinophil
count. Sputum induction is not widely used in England and
Wales. Importantly, the base-case analysis is presented as a
blended comparison rather than as an incremental analysis
between individual options. This is generally inappropriate
as it may mask the most effective and/or the most
cost-effective diagnostic option. Within the Aerocrine
model, options are evaluated as individual diagnostic
interventions. These include spirometry alone, spirometry
and (if negative) MCT, spirometry and (if negative) FeNO,
spirometry and FeNO, FeNO alone and spirometry and
(if negative) sputum induction
Perspective on costs NHS and Personal Social Services A payer perspective was adopted by Price et al.;147
however, this is restricted to short-term costs only –
treatment costs for diagnosed asthma are not included.
The Aerocrine diagnostic model includes costs of
diagnostic tests and treatment costs for FPs. The time
horizon for costing is not explicit. Personal Social Services
costs are not considered in either model
Perspective on outcomes All health effects on individuals Health gains and losses associated with correct/incorrect
diagnoses are not reported by Price et al.147 The Aerocrine
model reports numbers of TPs, FPs, TNs and FNs expected
within a cohort of 840 patients
Type of economic
evaluation
Cost–utility analysis The Price et al.147 diagnostic analysis represents a cost
comparison; although diagnostic outcomes are calculable,
these are not reported. The Aerocrine model quantifies
numbers of correct/incorrect diagnoses but does not value
these in terms of health gains or losses
Synthesis of evidence on
outcomes
Based on systematic review Price et al.147 report that estimates of test sensitivity and
specificity are based on three published papers identified by
a systematic review of the literature.86,162,163 The Aerocrine
submission does not present any detail regarding methods
used to identify or select evidence used to inform its
parameters. The full range of empirical evidence relating to
the diagnostic accuracy of FeNO used in combination with
other tests is not captured in either model
Measure of health
effects
QALYs Neither the Price et al.147 diagnostic model nor the
Aerocrine diagnostic model measure or value health
outcomes associated with correct/incorrect diagnoses
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Absence of quantified health consequences resulting from diagnostic decisions A key limitation
of both the Price et al.147 diagnostic model and the Aerocrine diagnostic model is that neither model attempts
to value the health gains/losses resulting from correct/incorrect diagnoses of asthma. Although it may be
reasonably inferred that a more sensitive and specific test will result in more correct diagnoses, and hence
greater health gains from the use of that test, these factors are not captured within either model. Consequently,
it is difficult to infer whether the health gains associated with a more sensitive and/or specific test outweigh
the potential opportunity costs associated with displacing existing treatments and services.
Use of a blended comparison approach (Price et al.147 diagnostic model only) The base-case analysis
presented within the Price et al.147 paper adopts a blended comparison approach. The results are not
presented as an incremental comparison of the costs and consequences of NIOX MINO compared with
individual comparator tests. This is misleading – although the base-case analysis suggests that NIOX MINO
alone is more sensitive than the weighted mix of standard tests used to diagnose asthma, its sensitivity
and specificity are both lower than those for bronchial provocation. It would be more appropriate to
incrementally compare NIOX MINO against each individual diagnostic test; this is the approach adopted
within the Aerocrine model submitted to NICE.
Anticipated use of NIOX MINO Both the Price et al.147 diagnostic model and the Aerocrine diagnostic
model reflect a situation in which NIOX MINO would replace existing standard tests for the diagnosis of
asthma. The situation in which NIOX MINO is added to existing tests within the pathway, compared with
those existing tests, as is suggested to be the more likely use of FeNO testing within the NHS by Price et al.,147
is not adequately considered within the analysis. In addition, both models lack clarity with respect to the
diagnostic setting in which the choice of diagnostic strategy is made (i.e. primary or secondary care).
Non-specific placement of NIOX MINO within the broader diagnostic pathway for asthma The
Price et al.147 analysis crudely compares NIOX MINO with individual diagnostic tests. In reality, some
patients may achieve a positive or negative diagnosis only following a sequence of tests. This is
undoubtedly an issue relating to the available evidence base at the time of model development; however,
this limitation should be borne in mind when interpreting the results reported within the Price et al.147
paper. In contrast, the submitted Aerocrine model includes some test sequences; however, these do not
reflect potential correlations between each test in the pathway (sensitivity and specificity are assumed to
be random and uncorrelated between tests).
TABLE 56 Adherence of the Price et al.147/Aerocrine diagnostic models to the NICE reference case (continued )
Element of HTA Reference case EAG comments
Source of data for
measurement of HRQoL
Reported directly by patients
and/or carers
HRQoL is not captured in either model
Source of preference
data for valuation of
changes in HRQoL
Representative sample of the
public
HRQoL is not captured in either model
Discount rate An annual rate of 3.5% on both
costs and health effects
In both models, costs and outcomes are not discounted
Equity weighting An additional QALY has the
same weight regardless of the
other characteristics of the
individuals receiving the health
benefit
HRQoL is not captured in either model
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Crude assumptions regarding the resolution of incorrect diagnoses The Price et al.147 model assumes
that incorrect diagnoses are resolved at the next visit. Conversely, the Aerocrine model does not include
the costs of additional visits required to resolve incorrect diagnoses, but instead attempts to capture the
costs associated with ICS use in patients who are FP. Both of these factors reflect relevant costs to the NHS
and should be included in any economic analysis of FeNO testing. In addition, the time horizon over which
incorrect diagnoses prevail is unclear and no discounting is applied to cost estimates.
Questionable validity of FeNO testing plus FEV1 operating characteristics It is noteworthy that the
estimates of test sensitivity and specificity for spirometry plus FeNO testing, the most favourable option
within both diagnostic models included in this review, appear to have been derived from an expert review
paper162 rather than from an empirical study. The expert review paper does make reference to the
sensitivity and specificity estimates of 0.93 and 0.94 as used in the models and does provide an apparent
(yet ambiguous) reference to two other empirical studies.86,168 However, neither the Dupont et al.168 study
nor the Smith et al.86 study referenced by Smith and Taylor162 report these estimates (or indeed any
estimate of the joint sensitivity and specificity of FeNO testing plus FEV1). The credibility of these estimates
cannot be verified by the EAG and hence the credibility of the Price et al.147/Aerocrine model findings
should be considered highly questionable.
Lack of clarity regarding methods to identify and select evidence Within the Aerocrine model, the
sources of the costs of spirometry are unclear and the costs of NIOX MINO appear to be based solely on
assumption (see earlier personal communication). The costs of NIOX MINO are substantially different
between the two models (£22.90 vs. £10). It is unclear whether either estimate would reflect the true
costs borne by the NHS. In addition, the methods used to identify and select evidence regarding test
operating characteristics are particularly unclear within the Aerocrine model.
Limited consideration of uncertainty Both versions of the diagnostic model are evaluated
deterministically using point estimates of parameters. Probabilistic sensitivity analysis (PSA) is not reported
by Price et al.147 and is not included in the submitted Aerocrine model.
It is reasonable to suggest that the existing evidence base relating to the cost-effectiveness of FeNO testing
for the diagnosis of asthma is methodologically limited and should be interpreted with caution.
Existing economic analyses of FeNO testing for the management of asthma
Methods and results of included management studies
The Price et al.147 study also included the methods and results of a separate model of the cost-effectiveness
of FeNO testing using NIOX MINO for the management of asthma. The same model structure was also
used in the German economic evaluation of FeNO testing for asthma reported by Berg and Lindgren.148 In
addition, the submission by Aerocrine also included an asthma management model based on the analysis
published by Price et al.147 No other published papers that evaluated FeNO testing for the management
of asthma were identified.
An economic evaluation of NIOX MINO airway inflammation monitor in the
United Kingdom:147 management model
Description of the economic model and analysis The management model as described by Price et al.147
uses a decision tree approach to evaluate the cost-effectiveness of NIOX MINO compared with standard
guidelines for the management of asthma. The model adopts a UK health-care payer perspective and
costs and outcomes are evaluated over a 1-year time horizon. The results are presented in terms of the
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incremental cost per QALY gained. Patients within the model were assumed to be non-smokers with
mild to severe diagnosed asthma. Patients were assumed to be at step 3 and above as per GINA129 and
BTS/SIGN164 guidelines, that is, receiving ICSs and LABAs for asthma management. Patients were assumed
to visit their GP four times per year to determine the appropriate ICS dosage; it is unclear whether this
applies to both groups or the FeNO management group only.
The two management strategies compared within the model were:
l intervention: ICS dosage titration using NIOX MINO
l comparator: ICS dosage titration based on standard guidelines.
The model uses different sources to inform parameters relating to the baseline risks and relative risks of
exacerbation and ICS use.2,97,169 Only one of these three studies involved asthma management according
to BTS/SIGN guidelines.2
The structure of the model is shown in Figure 22. The model assumes that patients are either well
controlled or experience an exacerbation. Exacerbations are assumed to be either severe or mild to
moderate. A proportion of the severe exacerbations are assumed to require hospitalisation whereas the
remainder are assumed to be manageable on an outpatient basis. A mild to moderate exacerbation was
defined as an exacerbation requiring a SABA in addition to usual medication; a severe exacerbation
was defined as an exacerbation requiring corticosteroids (and, in some patients, hospitalisation). The
successful control of exacerbations is assumed to be related to an improvement in HRQoL and a reduction
in ICS use.
The parameter values and evidence sources listed in the Price et al.147 management model are shown in
Table 57.
In addition to the base-case analysis, the authors undertook 18 one-way sensitivity analyses. These include
examining the impact of the baseline risk of exacerbations, health utilities, number of routine visits
required per year, ICS dose reductions and costs of NIOX MINO on the cost-effectiveness of NIOX MINO
compared with standard guidelines.
Standard guidelines
Well controlled
Severe
Mild-moderate
#
prob_exac
severe_exac
#
#
Hospitalisation
Non hospital
prob_hosp
Exacerbation
Choose
NIOX MINO
1
FIGURE 22 Model structure employed within the Price et al.147 management model. Reproduced with permission
from Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the
United Kingdom. Allergy 2009;64:431–8.147 John Wiley & Sons. © 2009 The Authors. Journal compilation © 2009
Blackwell Munksgaard.
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TABLE 57 Parameter values and evidence sources used in the Price et al.147 management model
Parameters Value Source
Baseline event probabilities
Exacerbation risk during 1 year 0.71 Jayaram et al.169
Proportion of exacerbations that are severe 0.23 Jayaram et al.169
Hospitalisation for severe exacerbations 0.23 Green et al.2
Proportion of severe exacerbations requiring an outpatient visit 0.75 Andersson et al.170
Mean number of severe exacerbations per year (overall population) 2 Jayaram et al.;169
Tattersfield et al.171
Mean number of severe exacerbations per year (moderate to severe asthma) 4 Green et al.2
Impact of FeNO management
Reduction in ICS dose 0.42 Smith et al.97
Relative risk reduction of exacerbation 0.29 Jayaram et al.169
Relative risk reduction of hospitalisation for severe exacerbation 0.83 Green et al.2
Utility values
Well-controlled asthma 0.93 Szende et al.172
Mild/moderate exacerbation 0.65 Szende et al.172
Severe exacerbation 0.52 Szende et al.172
Resource cost parameters (£)
Outpatient visit to GP 30.00 Curtis and Netten166
Outpatient visit to lung specialist 44.00 Curtis and Netten166
Hospitalisation for asthma 2231.45 BNF 51167
Maintenance therapy (1 year) with LABA 359.84 BNF 51167
Maintenance therapy (1 year) with ICS 109.00 BNF 51167
Rescue therapy (1 week) with SABA 7.38 BNF 51167
Rescue therapy (1 week) with oral prednisone 5.13 BNF 51167
BNF, British National Formulary.
Source: reproduced with permission from Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway
inflammation monitor in the United Kingdom. Allergy 2009;64:431–8.147 John Wiley & Sons. © 2009 The Authors.
Journal compilation © 2009 Blackwell Munksgaard.
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Management model results presented by Price et al.147 The model results reported by Price et al.147
are presented in Table 58. For patients with moderate to severe asthma, FeNO monitoring was estimated to
result in 0.004 additional QALYs compared with standard guidelines. FeNO monitoring was also estimated
to result in cost savings of £554 per patient in this group. For patients with mild to moderate asthma,
FeNO monitoring was estimated to result in 0.06 additional QALYs compared with standard guidelines.
FeNO monitoring was also estimated to result in cost savings of £341 per patient in this group. Given its
lower cost and increased QALY gain, FeNO monitoring was expected to dominate standard guidelines in
both patient groups. It should be noted that the distinction between mild to moderate and moderate to
severe in terms of input parameters is not entirely clear from the Price et al.147 paper.
The results of the simple sensitivity analyses indicate that, for all but one scenario (NIOX MINO in addition
to rather than instead of standard lung function tests), NIOX MINO is expected to dominate standard
guidelines. Within the last scenario, NIOX MINO in addition to standard lung function tests is expected to
cost £279 per QALY gained compared with standard guidelines.
Additional analysis presented within the submitted Aerocrine management model The schematic
of the Aerocrine management model is presented in Figure 23.
Table 59 presents the parameter values and evidence sources used in the Aerocrine management model;
the column on the right hand side indicates whether the source and parameter value are the same as
those in the published Price et al.147 management model.
The management model submitted by Aerocrine is similar to the published Price et al.147 management
model in terms of its structure and both models share many common parameter values. However, the
two models do not make identical assumptions and hence do not provide identical estimates of incremental
costs and effects of FeNO monitoring compared with standard guidelines.
Summary of the results of the Aerocrine management model Although the Aerocrine management
model does not present the incremental cost-effectiveness ratio (ICER) for FeNO monitoring compared with
standard guidelines in the main results worksheet, elsewhere the model indicates that FeNO monitoring is
expected to produce an additional 0.045 QALYs and reduces costs by £103.11 compared with standard care.
Critical appraisal of the Price et al.147/Aerocrine management model The use of the Price et al.147/
Aerocrine management models to inform judgements about the cost-effectiveness of NIOX MINO is
subject to a number of methodological problems, as detailed in the following sections.
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TABLE 58 Sensitivity analysis results reported by Price et al.147
Scenario
Cost (£) QALYs
ICER
NIOX
MINO
Standard
guidelines Difference
NIOX
MINO
Standard
guidelines Difference
Moderate to severe
asthma
628 1181 –554 0.730 0.726 0.004 Dominating
1-year baseline risk of
exacerbation of 0.35
(base case 0.71)
589 915 –326 0.857 0.83 0.027 Dominating
Utility for moderate
control of asthma of
0.76 (base case 0.65)
666 1007 –341 0.835 0.800 0.035 Dominating
Different number of monitoring visits per year for mild to severe asthma (base case four visits)
Two visits per year 620 828 –208 0.785 0.726 0.059 Dominating
Six visits per year 712 1185 –473 0.785 0.726 0.059 Dominating
Different number of monitoring visits per year for moderate to severe asthma (base case, four visits)
Two visits per year 582 1003 –421 0.730 0.726 0.004 Dominating
Six visits per year 673 1360 –687 0.730 0.726 0.004 Dominating
Different NIOX MINO cost for mild to severe asthma
–50% 620 1007 –387 0.785 0.726 0.059 Dominating
+50% 712 1007 –295 0.785 0.726 0.059 Dominating
Different NIOX MINO cost for moderate to severe asthma
–50% 582 1181 –599 0.730 0.726 0.004 Dominating
+50% 673 1181 –508 0.730 0.726 0.004 Dominating
Different level of ICS dose reduction for mild to severe asthma (base case 42%)
10% 683 1007 –324 0.785 0.726 0.059 Dominating
80% 645 1007 –362 0.785 0.726 0.059 Dominating
Different level of ICS dose reduction for moderate to severe asthma (base case 42%)
10% 639 1181 –543 0.730 0.726 0.004 Dominating
80% 616 1181 –565 0.730 0.726 0.004 Dominating
Different relative risk reduction for exacerbation for mild to severe asthma (base case 29%)
10% 707 1007 –300 0.747 0.726 0.021 Dominating
50% 621 1007 –386 0.828 0.726 0.102 Dominating
Different relative risk reduction for hospitalisation for moderate to severe exacerbation (base case 0.83)
10% 869 1181 –312 0.727 0.726 0.001 Dominating
100% 571 1181 –610 0.731 0.726 0.005 Dominating
NIOX MINO in addition
to rather than instead
of standard lung
function tests (added
costs)
1023 1007 17 0.785 0.726 0.059 £279 per
QALY gained
ICER, incremental cost-effectiveness ratio.
Source: reproduced with permission from Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway
inflammation monitor in the United Kingdom. Allergy 2009;64:431–8.147 John Wiley & Sons. © 2009 The Authors. Journal
compilation © 2009 Blackwell Munksgaard.
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TABLE 59 Parameter values used in the Aerocrine management model
Variable
ID Variable description Value Source/justification
Same as
Price et al.147
model
P2 Likelihood of exacerbation using FeNO
monitoring for management
0.369 Jayaram et al.169 No
P4 Likelihood of exacerbation using standard care
guidelines for asthma management
0.520 Akinbami et al.173 No
P6 Likelihood that exacerbations will be moderate to
severe
0.230 Green et al.2 Yes
P8 Likelihood that mild to moderate asthma
exacerbations will be treated at an emergency
room or urgent care centre
0.500 Expert opiniona Unclear
P10 Likelihood that FeNO patient experiencing
moderate to severe asthma exacerbations will be
treated at an emergency room centre
0.750 Andersson et al.170 Yes
P13 Likelihood that standard care patient
experiencing a moderate to severe exacerbation
will require hospitalisation
0.230 Green et al.2 Unclear
F1 Reduction in ICS dose as a result of FeNO use 0.42 Smith et al.97 Yes
F2 Reduction in risk of hospitalisation for severe
exacerbations as a result of FeNO use
0.83 Green et al.2 Yes
F3 Reduction in risk of exacerbations as a result of
FeNO use
0.29 Jayaram et al.169 Yes
C1 Cost of FeNO monitoring £10.00 Assumption Unclear
C2 Cost of spirometry £1.00 Source unclear Unclear
C3 Annual cost of asthma medications for patients
managed with FeNO
£536.04 BNF 51167
(uplifted to 2012 prices)
Unclear
C4 Annual cost of asthma medications for patients
managed using standard guidelines
£594.00 BNF 51167
(uplifted to 2012 prices)
Unclear
C5 Cost per office visit to GP £38.00 Curtis and Netten166
(uplifted to 2012 prices)
Unclear
C6 Cost per office visit (referral) to lung specialist £144.00 Curtis and Netten166
(uplifted to 2012 prices)
Unclear
C7 Cost of A&E visit for asthma exacerbation £81.00 NHS Reference Costs174 Unclear
C8A Cost of rescue medications for moderate to
severe exacerbations
£15.00 BNF 51167
(uplifted to 2012 prices)
Unclear
C8B Cost of rescue medications for mild to moderate
exacerbations
£9.00 BNF 51167
(uplifted to 2012 prices)
Unclear
C9 Average hospital cost for asthma admission
because of exacerbation
£867.00 Weighted average of
Healthcare Resource Group
code DZ15A-F within NHS
Reference Costs174
Unclear
C10 Annual number of check-ups for asthma
management
2 Expert opinionb Yes
C13 Average annual number of exacerbations 2 Jayaram et al.169 Yes
U1 Utility value of asthma patients with good control 0.93 Szende et al.172 Yes
U2 Utility value of asthma patients with mildly
reduced control
0.76 Szende et al.172 Yes
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Deviations from the National Institute for Health and Care Excellence reference case Table 60
shows the extent to which the Price et al.147/Aerocrine management models adhere to the NICE reference
case for economic evaluations of diagnostic interventions.145
Relative risk reduction for exacerbations Price et al.147 argue that the relative risk reduction associated
with using FeNO monitoring may be overly conservative as the data used were drawn from a patient
population including patients with mild asthma whereas the relative risk reductions may be greater in
patients with more severe asthma. The validity of this statement is unclear and evidence to support this
assertion is not presented in the paper.
Impact of FeNO measurement on inhaled corticosteroid dosage Price et al.147 also argue that some of
the parameters, such as the effect of FeNO measurement on ICS usage, were based on patients in primary
care, whereas other parameters, such as impact on exacerbations, were based on patients in secondary care.
Time horizon The model adopts a very short time horizon (1 year). The impact of mortality and
discounting over a longer horizon may alter the cost-effectiveness estimates presented.
Failure to undertake probabilistic sensitivity analysis The authors did not undertake PSA. Instead, the
results are presented based on the point estimates of parameters and uncertainty analysis is restricted to
one-way sensitivity analyses. It should be noted that the economic evaluation of NIOX MINO from the
German perspective did include a full probabilistic analysis.148 The reason for the exclusion of PSA
in the UK models is unclear.
Questionable methods for the selection of evidence used to inform the model parameters The
methods used to identify and select evidence to inform the model parameters were not fully described in
either the Price et al.147 model or the Aerocrine model. It is unclear whether other evidence sources exist
which indicate that different parameter values may be more appropriate. In particular, the model draws
estimates of the relative reduction in exacerbations from FeNO monitoring from a study that used sputum
induction monitoring rather than FeNO monitoring, hence assuming equivalence, despite the fact that
exacerbation risk information was reported in the FeNO trial used to estimate reductions in ICS usage.97
Inappropriate sourcing of resource and cost estimates Several unit cost parameters within the
Aerocrine model are based on those presented in the Price et al.147 model, uplifted to 2012 values. For
parameters such as drug costs and Healthcare Resource Groups, this is inappropriate as the British National
Formulary and NHS Reference Costs are updated regularly to reflect current prices. Consequently, several
of the cost estimates included in the submitted model may not reflect the prices paid by the NHS.
TABLE 59 Parameter values used in the Aerocrine management model (continued )
Variable
ID Variable description Value Source/justification
Same as
Price et al.147
model
U3 Utility value of asthma patients with moderately
reduced control
0.65 Szende et al.172 Yes
U4 Utility value of asthma patients with poor control 0.52 Szende et al.172 Yes
A&E, accident and emergency; BNF, British National Formulary.
a The text in the model states that the model authors were unable to find statistics specific to visits for mild/moderate
exacerbations; an assumption was made that half will seek care in the emergency department setting and the other half
will visit their doctor’s surgery (GP or pulmonary specialist).
b An assumption was made that well-controlled asthma will result in two office visits per year.
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TABLE 60 Adherence of the Price et al.147/Aerocrine management models to the NICE reference case
Element of HTA Reference case EAG comments
Defining the decision
problem
The scope developed by NICE The patient population is defined in both models as
non-smoking adults diagnosed with mild to severe asthma.
This population excludes children and smokers. The intervention
and comparator are in line with the NICE scope
Comparator Therapies routinely used in
the NHS including
technologies regarded as
current best practice
The comparator is standard care without FeNO monitoring.
This is appropriate although it should be noted that the
studies used to inform the model parameters did not all use
BTS/SIGN guidelines164 to guide treatment
Perspective on costs NHS and Personal Social
Services
The published Price et al.147 management model purports to
have adopted a payer perspective. It appears that the
submitted Aerocrine model adopts the same perspective
although this is not explicitly stated in the model workbook
Perspective on outcomes All health effects on
individuals
Health outcomes reflect those accrued by NHS patients.
Health gains are assumed to be influenced only by the level
of control achieved, which is in turn assumed to be directly
related to the incidence of exacerbations
Type of economic
evaluation
Cost–utility analysis The models take the form of a decision tree-based cost–utility
analysis. This adopts a short time horizon (1 year). Longer-
term costs and outcomes associated with FeNO monitoring
are not considered within the Aerocrine management model
or the published Price et al.147 management model
Synthesis of evidence on
outcomes
Based on systematic review Parameter values appear to have been selected in a
non-systematic fashion. Estimates of relative reductions in
exacerbations are drawn from different sources from
estimates of reductions in medication use (the former relates
to monitoring using sputum induction rather than FeNO
testing but is assumed to be equivalent)
Measure of health
effects
QALYs The HRQoL impacts of different levels of control were
estimated based on estimates from the literature
Source of data for
measurement of HRQoL
Reported directly by patients
and/or carers
Health utilities were based on adequacy of asthma control
rather than exacerbations per se, based on a study reported
by Szende et al.172 Within this study, 228 consecutive adult
outpatients and inpatients at four Hungarian sites completed
a variety of HRQoL instruments including the EQ-5D. Utilities
related to control were then qualitatively mapped to the
incidence of different severities of exacerbation
Source of preference
data for valuation of
changes in HRQoL
Representative sample of the
public
Preference-based health utilities appear to have been
generated using the UK EQ-5D tariff175
Discount rate An annual rate of 3.5% on
both costs and health effects
Because of the short time horizon, costs and outcomes are
not discounted
Equity weighting An additional QALY has the
same weight regardless of
the other characteristics of the
individuals receiving the health
benefit
No additional equity weighting was applied
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Inflated baseline exacerbation rate without monitoring The Price et al.147 management model and
the Aerocrine management model assume a mean rate of two exacerbations per patient per year. It
appears that this estimate was based on the results of a Phase II prospective trial of 117 adults reported by
Jayaram et al.169 This study reported that there was a total of 126 exacerbations in 63 patients, hence an
average number of approximately two exacerbations per patient. However, the trial duration was > 1 year
and the mean number of exacerbations per patient per year was reported by the study authors to be
0.75 in one arm of the trial and 1.02 in the other arm of the trial.169 The Price et al. paper147 also mentions
a second study171 used to inform this baseline exacerbation rate. In this latter study, the authors observed
425 severe exacerbations in 852 randomised patients over a 12-month period (approximate rate= 0.499
exacerbations per year). Both studies clearly indicate that the baseline exacerbation rate used in the
Price et al.147/Aerocrine models is substantially overestimated; hence, the expected benefits of FeNO testing
are likely to be artificially inflated.
Assumption that exacerbation determines health-related quality of life for the entire time
horizon The Price et al.147/Aerocrine management models make an assumption that the incidence of
exacerbations is directly related to the level of asthma control and apply health utilities according to the
incidence of exacerbations. The models apply these health utilities over the modelled time horizon (1 year)
rather than to the duration over which the exacerbation occurs (hours to weeks). This is likely to
substantially overestimate the health benefits associated with reducing exacerbations through improved
dose titration.
Use of expert opinion The Aerocrine management model includes the use of expert opinion to inform a
small number of parameters for which the authors could not identify relevant evidence. Although expert
opinion is a valid source of evidence in such circumstances, no details are provided with respect to the
sources of these judgements or the methods used to elicit them. In the absence of a written submission
that presents these details, the credibility of such judgements remains unclear.
The existing models of FeNO monitoring for asthma indicate that NIOX MINO is expected to dominate
standard guidelines. However, given the methodological concerns identified within the critical appraisal,
these findings should be interpreted tentatively.
Other studies relating to the cost-effectiveness of asthma
management strategies
Given the limited number of studies of FeNO testing for the management of asthma, we also reviewed
other studies of interventions for asthma management to inform the key disease-specific factors that
should, or could, be included in a cost-effectiveness model of FeNO testing for the management
of asthma.
Thirteen studies149–154,157–161,176,177 (not related to FeNO testing) were included in the focused review of
economic analyses of asthma management interventions; these studies are briefly summarised in Table 61.
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TABLE 61 Summary of other identified economic analyses of asthma management interventions
Author, year Summary description
Studies reporting QALYs
Briggs 2006150 Cost–utility analysis undertaken alongside a clinical trial. The intervention was asthma treatment with
salmeterol/fluticasone propionate in combination; the comparator was fluticasone propionate. Utility
values for the model states were mapped from AQLQ scores. Within the GOAL study, patient
treatment could be titrated upwards up to three times but not downwards. The amount of titration
required was used to define three patient groups by asthma severity (stratum 1, stratum 2, stratum 3).
The model states were ‘totally controlled’, ‘well controlled’, ‘not well controlled but without an
exacerbation’ and ‘exacerbation’. The cycle length was 1 week. A multinomial regression approach
using individual patient-level data from the trial was used to estimate the transition probabilities of
moving between states over the course of each week
Doull 2007151 Simple economic model comparing the cost-effectiveness of salmeterol xinafoate/fluticasone
propionate combination inhalers with non-combination inhalers for adults and children with chronic
asthma treated according to BTS/SIGN guidelines.178 Clinical effectiveness was estimated from
meta-analyses comparing the percentage of symptom-free days for each treatment (%SFD). The
definition of SFD was assumed to be consistent with that provided in the GOAL study. The %SFD was
assumed to be time invariant; hence, differences in clinical effectiveness between treatment options
were assumed to be entirely due to this parameter. A 1-year time horizon was used. QALY gains were
estimated from AQLQ data recorded in the GOAL study using a mapping algorithm to the EQ-5D
Paggiaro 2011153 A poster that discusses a patient-level Markov model. The decision problem concerns the
cost-effectiveness of stepping down treatment according to GINA guidelines.129 Very limited detail
on the methods was available
Peters 2002149 UK technology assessment report evaluating submissions from several manufacturers of inhaler devices.
Most (six out of eight) of the manufacturers submitted cost-minimisation analyses only. The assessment
group did not develop a de novo model; instead, a QALY-based threshold analysis was performed
Wilson 2010152 Economic evaluation comparing the addition of either a LTRA or a LABA for patients who were
already receiving ICSs as part of asthma management and for whom a decision to add on additional
treatment to improve their condition had been made. The analysis was based on a pragmatic trial
involving 53 primary care practices. Patients judged to need add-on therapy were randomly assigned
to receive either a LTRA or a LABA. The trial duration was 2 years. The patient age range included
children and adults. The differences in EQ-5D and ACQ scores between the LTRA group and the
LABA group were reported, together with differences in resource use
Studies not based on QALYs
Andersson 2000177 Poster abstract which argues that using 800 µg rather than 200 µg/day of budesonide is cost saving
in patients with moderate asthma in the UK. Estimates were based on a survey of 20 physicians from
the UK, Sweden and Spain
Barnes 1999155 Poster abstract that summarises a meta-analysis comparing fluticasone propionate and budesonide
for the treatment of asthma. The study appears mainly to be a cost–consequence analysis as it refers
to differences in clinical parameters, such as morning PEF rate, successfully treated weeks and
symptom-free days. The poster concludes that fluticasone propionate is both more clinically effective
and cheaper than budesonide
Booth 1995154 Cost comparison based on a RCT comparing fluticasone propionate (200 µg) via a diskhaler with
budesonide (200 µg) via a reservoir dry powder device. The study provides estimates for the cost per
successfully controlled week
Buxton 2004159 Economic evaluation based on a 3-year international prospective RCT, the Steroid Treatment as Regular
Therapy (START) trial. The trial compared budesonide against placebo combined with usual asthma
therapy. The trial included patients from the UK although all costs were converted to US dollars for
comparability. ICERs were calculated for the UK as well as for other countries, with the measure of health
benefit being symptom-free days. Estimates for UK costs were based on only 39 patients
Everden 2002157 Economic evaluation in children aged 6–17 years inclusive alongside a prospective multicentre open-label
parallel-group study conducted in primary care in the UK and the Republic of Ireland (the FACT study).
Most (>95%) patients were at BTS step 1 or step 2 with a small proportion at step 3. The trial duration
was 12 weeks. End points were change in SABA use (primary end point), PEF, number of poorly
controlled days and quality of life evaluated using the Paediatric Asthma Quality of Life Questionnaire
(PACLQ). When the clinical outcome was symptom-free days with no SABA use, use of eformoterol was
estimated to rule out salmeterol by simple dominance, saving approximately 25 p per patient per day
whilst resulting in approximately 10 additional symptom-free days over the 12-week period
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Health outcomes and form of economic evaluation
Of the 13 studies included in the focused management review, five reported QALYs gained as the measure
of health benefit.149–153 One of these studies153 was published only in the form of a conference poster and
provided very limited detail regarding the model structure. The study reported by Peters et al.149 included
only threshold analyses, indicating the necessary QALY impact to justify an incremental increase in cost.
Of the eight studies that did not report QALYs, four were cost-effectiveness analyses. These studies
reported health benefits in terms of:
l symptom-free days with no SABA use157
l successfully controlled weeks158
l symptom-free days159
l achieving asthma control within 1 year.161
Model structures
Several of the included economic evaluations were decision analyses conducted alongside clinical trials
and did not explicitly involve the use of evidence synthesis or extrapolation. Three studies used Markov
structures.150,153,158 The Briggs et al.150 and Price and Briggs158 studies both used similar methodologies.
Each was based primarily on data from a single, although different, study. The Price and Briggs158 model
categorised health states into five discrete categories: ‘successfully controlled’, ‘suboptimal control’,
‘primary care-managed exacerbation’, ‘hospital-managed exacerbation’ and ‘treatment failure’. Treatment
failure was an absorbing state; patients could transition between any of the other states during a given
Markov cycle. The cycle length was 1 week and so the assumption was made that an individual could not
have more than one exacerbation within 1 week. The time horizon of the model was 12 weeks (equal to
the duration of the RCT) and the analysis did not extrapolate anticipated lifetime effects of treatment. The
model used the number of exacerbation-free weeks as the measure of health benefit; this disease-specific
TABLE 61 Summary of other identified economic analyses of asthma management interventions (continued )
Author, year Summary description
Kemp 2010161 Economic evaluation based on a retrospective analysis of patients recorded in the UK General
Practice Research Database (GPRD) from 1997 to 2007. Patients were included in the analysis if they
had been registered at the same practice, had a diagnosis of persistent asthma and had been
receiving treatment with ICSs. Two patient populations were identified: an initiation population who
had started ICSs and a step-up population who had been prescribed an increased ICS dose. Both
populations had to have been followed up for at least 12 months on their current regimen. The
clinical effectiveness and cost-effectiveness of three inhaler technologies were compared for these
patient populations. The clinical outcome was ‘achieving asthma control within 1 year’. Asthma
control was defined as a composite measure involving no hospital attendance for asthma, no OCS
use and no consultation or hospital admission or attendance related to asthma
Price 2002158 Markov model based on a 12-week RCT of patients diagnosed with asthma aged 12–70 years (FEV1
40–85% predicted). The main clinical outcome was the number of ‘successfully controlled weeks’.
The intervention arm received fluticasone propionate whereas the comparator arm received
salmeterol/fluticasone propionate combination. Health states included in the model were ‘successful
control’, ‘hospital-managed exacerbation’, ‘primary care-managed exacerbation’, ‘suboptimal control’
and ‘treatment failure’
Price 2007160 Cost-minimisation analysis based on a 6-month, double-blind RCT. Resource use data were collected
prospectively; these included medication costs and non-medication costs such as hospitalisations. The
trial was international, with patients recruited from 16 countries. Costs were converted to 2004 UK
costs. Patients were recruited if they were aged > 12 years at the time of recruitment and had been
diagnosed with asthma at least 6 months previously and had been using ICSs continuously for at
least 3 months. Compared with using ICSs alone, using budesonide/formoterol maintenance and
reliever therapy was estimated to save the NHS around £90 per patient over the 6-month trial period
GOAL, Gaining Optimal Asthma control.
DOI: 10.3310/hta19820 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 82
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179
outcome measure is difficult to interpret from a policy context. The Briggs et al.150 model was similar in
that it was a model based on individual patient-level data from a single trial. This model adopted four
discrete health states: ‘totally controlled’, ‘well controlled’, ‘not well controlled’ and ‘exacerbation’. These
health states differ from those in the Price and Briggs model158 in that there were three non-exacerbation
health states and only one exacerbation health state. This different categorisation implicitly reflects a
different set of assumptions about the key factors that influence the clinical effectiveness and
cost-effectiveness of different treatment options.
In addition to the studies identified by the search strategy described above, the Health Technology
Assessment journal was searched from inception onwards for asthma management models. This search
identified an additional asthma management model13 that was similar in structure to the Price and
Briggs158 model. The report assessed the comparative effectiveness of different ICS treatments with or
without LABAs for patients aged ≥ 12 years who had been diagnosed with chronic asthma. Unlike the
Price and Briggs158 model, this model was a cost–utility analysis and therefore measured health benefits
in terms of QALYs gained. The intention of this model was to represent clinical practice, as described in
the BTS/SIGN guidelines,164 by including different separate health states to represent dosage levels
corresponding to different BTS/SIGN treatment steps. For two steps, corresponding to step 2 and step 3
of the BTS/SIGN guidelines, the conceptual model is shown in Figure 24. The cycle length was 1 week
and the time horizon was 5 years. The key disease-specific factors included in the model relate to whether
the patient experiences an exacerbation within a model cycle and, if so, the severity of the exacerbation.
By allowing transitions between different levels of treatment, however, changes in treatment in response
to clinical events were also incorporated.
GP/self-
managed
exacerbation
{GXi}
Controlled
asthma
{CAi}
Controlled
asthma
{CAii}
Hospital
exacerbation
{HXi}
Step down
{SDi}
Step down
{SDii}
Step up
{SUi}
GP/self-
managed
exacerbation
{GXii}
Hospital
exacerbation
{HXii}
Step up
{SUii}
TREATMENT WITH HIGH-DOSE ICS ONLY TREATMENT WITH ICS/LABA
COMBINATION INHALER
Step 3Step 2
FIGURE 24 Conceptual model adopted by Shepherd et al.13
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Discussion of the available economic evidence on the diagnosis and
management of asthma using FeNO and other interventions
The review highlights a dearth of published studies reporting on the cost-effectiveness of FeNO testing for
the diagnosis and/or management of asthma. Only one published UK cost-effectiveness model of asthma
diagnosis was identified and included in the review;147 this model estimates the incremental costs of FeNO
testing compared with existing standard tests for asthma. No other cost-effectiveness models of FeNO or
other diagnostic tests were identified by the searches. Similarly, the review of economic analyses of asthma
management interventions identified only one UK-published study of FeNO monitoring.147 Modified
versions of these FeNO management and diagnostic models were submitted to NICE by Aerocrine. No
evidence was submitted by Aerocrine with respect to the expected cost-effectiveness of NIOX VERO.
Bedfont Scientific did not submit any economic evidence relating to the cost-effectiveness of NObreath.
The wider review of economic analyses of asthma management interventions identified a number of
other economic analyses, although few were undertaken within a formal modelling framework involving
evidence synthesis and/or extrapolation. These models have the following features in common: (1) the use
of a Markov modelling approach with generally short cycle lengths, typically 1 week in duration; (2) short
time horizons; and (3) separate states for asthma exacerbations. Only two of the model-based studies
reported QALYs as the measure of health outcome.
The available economic evidence for FeNO testing suggests that, in the diagnostic setting, monitoring using
NIOX MINO may reduce the costs of diagnosis (depending on how it is used) compared with standard tests,
whereas in the management setting monitoring using NIOX MINO may dominate standard guidelines.
However, this evidence is subject to a number of methodological problems, questionable assumptions and
weak evidence. The results of these existing analyses should be interpreted with caution.
Development of two de novo models to estimate the
cost-effectiveness of FeNO testing for the diagnosis and
management of asthma
Rationale for developing de novo models
This section describes the de novo economic models developed by the EAG to estimate the cost-effectiveness
of FeNO testing (specifically using NIOX MINO, NIOX VERO or NObreath) compared with standard care for
the diagnosis and management of asthma. The EAG analysis involves the development of two models:
(1) a de novo model to assess the expected cost-effectiveness of FeNO testing in addition to or in place of
standard tests for the diagnosis of asthma and (2) a de novo model to assess the expected cost-effectiveness
of FeNO plus standard guidelines compared with standard guidelines for the management of patients with
diagnosed asthma. Although these models are distinct, they form part of the same overall asthma service
pathway, hence they share a number of parameter values and assumptions.
The EAG models were developed to attempt to resolve the problems identified with respect to the existing
economic analyses of NIOX MINO (see Review of existing evidence relating to the cost-effectiveness of
FeNO testing for the diagnosis and management of asthma) and to address gaps in the evidence relating
to the cost-effectiveness of NObreath and NIOX VERO. It should be noted that, because of the limitations
in the evidence base (see Chapter 3), the structures of the models are necessarily simple.
The decision to develop two models rather than a single model was made because the NICE scope reflects
two distinct decision problems. Although the FeNO devices are the same in both the diagnostic setting and
the management setting, the relevant populations and the way in which FeNO may influence decisions
about appropriate clinical options for patients differ between settings; these potential effects are
summarised in Table 62.
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At the outset, the EAG had intended to model a scenario in which FeNO testing is used both as a
diagnostic option and as a management option. However, this analysis was not possible because of
the necessary differences in the structures of the EAG diagnostic and management models.
Complexity and uncertainty surrounding the economic analysis of FeNO
testing for the diagnosis and management of asthma
Given the limitations of the available evidence base (see Chapter 3), evaluating the expected cost-
effectiveness of FeNO testing alone or in conjunction with other tests for the diagnosis of asthma is
difficult. The BTS/SIGN guidelines8 for asthma diagnosis and management state that the absence of a gold
standard definition of asthma means that it is impossible to make evidence-based recommendations on
how to make a diagnosis of asthma. Further, differences in patient selection, methodological aspects of
study design and the generalisability of studies to UK practice make the unbiased interpretation of the
available diagnostic evidence extremely problematic. The current diagnostic pathway consists of a number
of tests that may be used alone or in sequence; there is not a standard set of ways in which information
from each of these tests should be evaluated and weighted when used together. The evidence base
examined within this assessment, however, mostly relates to studies that estimate the operating
characteristics of individual diagnostic tests used at particular points within this broader diagnostic
pathway. In addition, the reference standards used within studies to estimate the sensitivities and
specificities of other diagnostic tests are not always consistent or optimal, studies relate to different
population groups and comparative (head-to-head) studies are few in number. As a consequence, there is
considerable uncertainty surrounding the true diagnostic accuracy of FeNO testing and every other test
used within the diagnostic pathway.
The uncertainty in the clinical evidence base is further compounded by the lack of available economic
analyses. The review presented earlier (see Review of existing evidence relating to the cost-effectiveness of
FeNO testing for the diagnosis and management of asthma) identified only one published economic model
of options for asthma diagnosis147 (note that the same general model was used in the German economic
evaluation reported by Berg and Lindgren148). Within this study, the authors highlight a key limitation in the
scope of their analysis, that is, the analysis considers FeNO testing as a replacement for existing diagnostic
tests; this limitation is masked somewhat by the inappropriate use of a blended comparison of multiple
diagnostic tests, the absence of quantified health losses associated with misdiagnosis and the absence of a
full incremental analysis. If all diagnostic tests can be substituted for one another for all patients with
symptoms of asthma, as is implied by the design of the economic comparisons presented in the Price et al.147
paper, then the most clinically effective option will be the diagnostic test with the greatest sensitivity and
specificity (depending on the balance of health losses avoided by obtaining TP and TN diagnoses). Subject
to the per-test costs and the costs and consequences of downstream tests used to correct misdiagnoses,
this may or may not also represent the most cost-effective option. Downstream costs, sequences of
diagnostic pathways and consequences of incorrect diagnoses are not fully addressed by the Price et al.147
diagnostic model. The existing economic evidence base does not provide any information on the additional
value of FeNO testing in conjunction with current standard tests for asthma diagnosis.
TABLE 62 Clinical intent of FeNO testing in the diagnostic and management settings
Decision problem Clinical population Expected impact of FeNO testing
Diagnosis Symptomatic patients
with suspected asthma
FeNO testing, alone or in conjunction with other standard tests, may alter
the proportion of correct and incorrect diagnoses amongst patients with
suspected asthma. Changing the proportion of people with suspected
asthma who are correctly/incorrectly diagnosed may then affect the
expected downstream costs and health gains/losses
Management Patients treated for
diagnosed asthma
FeNO testing may influence the level of medication use and the rates of
exacerbations experienced by patients diagnosed with asthma. This will
influence the mean costs and health gains accrued by these patients
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As noted by Price et al.,147 in reality, FeNO testing is likely to play a role as an adjunct to existing tests
currently used within the diagnostic pathway. Although Price et al.147 attempt to consider the combination
of FeNO testing plus FEV1, this is against the blended comparison of standard diagnostic tests and thus it
still represents a replacement option. Current pathways for asthma diagnosis in adults and children are
complex;8 within the Price et al.147 diagnostic model, this complexity is avoided by the neat assumption
that all misdiagnoses are resolved at some later point in time with one subsequent test (i.e. following
misdiagnosis, the subsequent test is assumed to have perfect sensitivity and specificity, thereby correcting
all previously incorrect diagnostic decisions). This is a substantial simplification. In reality, there may be a
number of potential places in the existing pathway at which FeNO testing may provide additional
diagnostic information to improve the diagnostic accuracy of current standard tests (see Figures 7 and 8),
and misdiagnoses may prevail for months, years or, in some patients, indefinitely. These misdiagnoses may
incur unnecessary treatment costs and health losses. The Price et al.147/Aerocrine diagnostic models do not
fully address these issues but instead ask the question, ‘What is the least expensive test for the diagnosis
of asthma?’
An alternative and more sophisticated approach to evaluating the cost-effectiveness of FeNO in the
diagnostic setting would involve assessing the diagnostic accuracy and cost-effectiveness of FeNO in
addition to existing tests within the pathway. Such an analysis would address the question, ‘Where in the
existing sequences of tests, if anywhere, should FeNO be added to provide the most cost-effective
diagnostic pathway for patients with symptoms of asthma?’ This would require either (1) a similar model
structure to that employed by Price et al.,147 populated using studies that assess the accuracy of the whole
diagnostic pathway for children and adults with and without FeNO testing, or (2) the development of a
model that estimates the diagnostic outcomes of sequences of tests at each point in the pathway, which
simulates the impact of changes in the true underlying prevalence of asthma conditional on the results of
each test undertaken and which fully takes into account the impact of potential correlations between tests
that may result in non-random test outcomes in particular patients (e.g. if test A is negative would test B
also be negative in patient C?). For the former approach to be reliable, one would require studies that
have assessed FeNO plus other tests against a reference standard as well as the standard tests (without
FeNO) against the same reference standard, either by direct comparisons within the same study or by
indirect comparisons across multiple studies with similar populations and study protocols. Price et al.147
note that such data simply do not exist. The review presented in Chapter 3 did, however, identify several
studies in which FeNO was used in conjunction with other tests within part of the diagnostic pathway.
This evidence is, however, somewhat patchy. Interestingly, the Aerocrine diagnostic model does attempt to
reflect sequential options – the latter modelling approach described above – despite the problems with the
available evidence previously highlighted by Price et al.147 The Aerocrine model thus assumes that
sequential test outcomes are random and uncorrelated between tests. This represents a strong assumption
that could lead to biased estimates of the cost-effectiveness of FeNO, the magnitude and direction of
which are unclear.
These are important limitations relating to the evidence base that constrain what can be achieved through the
development of any economic model of asthma diagnosis. It would be unfair to heavily criticise any model
when the main limitations of that model are principally sourced from the weaknesses in the evidence used to
inform it. Such weaknesses do, however, limit the confidence that can and should be placed in the results of
the Price et al.147/Aerocrine diagnostic models. In light of these issues, the de novo EAG diagnostic model
attempts to resolve those weaknesses in the Price et al.147 diagnostic model that can be resolved. Problems
relating to the heterogeneity in the evidence base cannot be resolved by the EAG; hence, the results of the
de novo model should also be interpreted tentatively. Insofar as the available evidence allows, the EAG
de novo diagnostic model attempts to simultaneously address the following two questions:
1. As a replacement test – is FeNO expected to be more cost-effective than other existing tests used for
the diagnosis of asthma?
2. As an adjunctive test – is the use of FeNO in conjunction with existing tests expected to be more
cost-effective than using existing tests alone?
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The economic analysis of asthma management is subject to fewer complexities because of the availability of
more robust direct evidence sourced from RCTs. However, there remains a number of methodological and
evidence issues. The most notable of these relate to differences in the frequency of FeNO monitoring between
the trials, uncertainty regarding the longer-term benefits of FeNO monitoring over standard care, differences
between studies in terms of the step-up/step-down treatment protocols used and associated issues relating to
the generalisability of non-UK treatment guidelines and symptom management strategies to UK clinical
practice. The economic analysis of FeNO monitoring addresses the following question:
1. What is the cost-effectiveness of FeNO monitoring compared with standard guidelines in the
management of asthma?
The External Assessment Group asthma diagnostic model
Logic underpinning the diagnostic model structure
The EAG diagnostic model hinges on the expected costs and health losses associated with the misdiagnosis
of asthma. If a patient has been misdiagnosed, their treatment will not be clinically optimal until their
misdiagnosis has been corrected. Misdiagnosis has different implications for those patients who are FP and
for those patients who are FN. For patients who are FP, suboptimal treatment means receiving treatment
with asthma medication that will provide no health benefits to them (because they do not have the
underlying disease). This means there is an additional cost to the NHS without additional health benefits for
the patients. Furthermore, a proportion of patients with a FP diagnosis of asthma may have other more
serious pathology that goes undetected (e.g. cancer or tuberculosis) because of an incorrect diagnosis of
asthma. Conversely, for patients who are FN, suboptimal treatment means not receiving treatment with
asthma medication when in reality they would have benefited from the treatment. Until this misdiagnosis is
corrected, patients may suffer from poor asthma control and hence lower HRQoL because of asthma
symptoms without adequate treatment. Poor asthma control can impact on a patient’s HRQoL during
times without exacerbation and can also increase the duration of exacerbations. Clinically significant
exacerbations are costly to the NHS and in the case of exacerbations requiring hospitalisation these costs
may be substantial; hence, a patient with undiagnosed asthma may on balance be more costly to the NHS
than a patient who is correctly treated for asthma. These patients may also go on to receive expensive and
unnecessary tests such as imaging and referrals to specialists until their misdiagnosis is corrected.
An incorrect FN diagnosis may be corrected later following an asthma exacerbation, as a result of
continued asthma-related symptoms that trigger subsequent appointments and investigations or even
because of reconsideration of asthma after tests for other conditions produce negative findings. Similarly,
an incorrect FP diagnosis may be corrected later as a result of the continued non-occurrence of
exacerbations, a generally high level of HRQoL at very low treatment dosages, thus indicating that
medications currently being taken by the patient may be unnecessary, or continued deterioration as a
result of other more serious underlying pathology. Although it should be expected that the aggregate
health consequences resulting from correct decisions should be better than those resulting from incorrect
decisions, the implications for HRQoL and the costs of FP and FN diagnostic outcomes are not identical.
Because of this, a diagnostic strategy that maximises the AUC on a receiver operating curve may not
necessarily yield the most cost-effective strategy. The EAG diagnostic model is therefore intended to reflect
the implications of test sensitivity and specificity for subsequent costs and health consequences for the full
range of diagnostic options within the available evidence base.
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Model structure and assumptions
Figure 25 presents the structure of the EAG diagnostic model. The model is implemented as a simple
decision tree. The population under consideration may or may not have true underlying asthma (denoted θ
in Figure 25). The model then uses estimates of sensitivity and specificity associated with each diagnostic
test, or combination of tests, to estimate the expected probability that a patient will be diagnosed as
having asthma or as not having asthma. Therefore, the model estimates the probability that a patient with
asthma will be correctly or incorrectly diagnosed as TP or FN, respectively, and the probability that a
patient without asthma will be correctly or incorrectly diagnosed as TN or FP respectively. The model
makes the simplifying assumption that incorrect diagnoses (FNs and FPs) are resolved by subsequent tests
after some period of time (see Evidence used to inform the External Assessment Group diagnostic and
management model parameters). Unnecessary treatment costs and health losses resulting from misdiagnosis
are explicitly captured in the model.
FeNO +/–
STANDARD TESTS
Asthma (θ)
Positive
(p│θ)
TP
Asthma QALYs
Cost diagnosis
Asthma management costs
Asthma QALYs – false-negative QALY loss
Cost diagnosis
Costs additional tests + FN
exacerbations whilst undiagnosed
Healthy QALYs – false-positive QALY loss
Cost diagnosis
Costs additional tests
Costs asthma management
Healthy QALYs
Cost diagnosis
Asthma QALYs
Cost diagnosis
Asthma management costs
Asthma QALYs – false-negative QALY loss
Cost diagnosis
Costs additional tests
Healthy QALYs – false-positive QALY loss
Cost diagnosis
Costs additional tests
Costs asthma management
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TN
Negative
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Not
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STANDARD TESTS
FIGURE 25 Conceptual form of the EAG diagnostic model structure.
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The diagnostic model estimates costs and health outcomes for each diagnostic option across four groups:
1. Patients who are TP (test sensitivity × prevalence) are assumed to require the initial diagnostic test(s)
with no subsequent tests and are assumed to have their asthma controlled using ICSs plus LABAs.
2. Patients who are TN [test specificity × (1 – prevalence)] are assumed to incur the cost of the initial test(s)
with no subsequent tests and are assumed to have a normal (general population) health status for the
remainder of the model time horizon.
3. Patients who are FP [(1 – test sensitivity) × (1 – prevalence)] are assumed to incur the cost of the initial test(s)
plus the costs of subsequent tests to correct their initial misdiagnosis. These patients are assumed to incur
a reduction in health status and the costs of ICSs and LABAs until their misdiagnosis is corrected.
4. Patients who are FN [(1 – test sensitivity) × prevalence] are assumed to incur the cost of the initial test(s)
plus the costs of subsequent tests to correct their initial misdiagnosis. These patients are assumed to
lose health because of poor control until their asthma is correctly diagnosed. These patients are
assumed to incur asthma management costs after their asthma is diagnosed for the remainder of the
model time horizon. These patients also accrue costs associated with an increased rate of exacerbations
until their misdiagnosis is corrected.
The diagnostic model makes the following key structural assumptions:
l All misdiagnoses are eventually corrected within the patient’s lifetime. This assumption will bias against
those options with greater diagnostic accuracy. The time to correct a FP diagnosis may be different
from the time to correct a FN diagnosis.
l The model time horizon for the analysis is set at 5 years. This exceeds the maximum time to correct a
misdiagnosis in the base-case analysis (see Evidence used to inform the External Assessment Group
diagnostic and management model parameters). In effect, this reflects a lifetime horizon because of
the assumption that all misdiagnoses are corrected. Health benefits gained and costs accrued after the
resolution of incorrect diagnoses will be the same between all competing diagnostic decision options.
l FNs at initial diagnosis experience the same level of HRQoL after their misdiagnosis is corrected as
patients who are initially correctly diagnosed as TPs.
l FPs incur health losses until their misdiagnosis is corrected.
l The health consequences of other serious conditions that may be mistaken for the symptoms of
asthma (e.g. lung cancer, tuberculosis, COPD) are not reflected in the model.
l Patients who are FN may experience an increased rate of exacerbations (compared with TPs) whilst
their asthma remains uncontrolled.
l Improved diagnostic accuracy has no impact on mortality.
l All FeNO tests (NIOX MINO, NIOX VERO and NObreath) are assumed to have equivalent diagnostic accuracy.
l FeNO, spirometry and reversibility testing can be undertaken in primary care. Airway hyper-responsiveness
testing (MCT) and sputum induction are undertaken in secondary care.
l Tests undertaken in primary care will involve two GP consultations and a nurse visit. Tests undertaken
in secondary care will involve two attendances and a laboratory visit as well as a primary care visit
for referral.
l One additional primary care visit, one laboratory visit and two additional secondary care visits are
required to achieve resolution of an incorrect diagnosis.
l Because of a lack of evidence relating to the diagnostic accuracy of each test at each point in the
pathway by patient age group, the model structure is ‘blunt’ in that differences between the diagnostic
pathways for children and adults are not reflected.
Some of these assumptions are fairly strong and lack evidence to substantiate them. They are, however,
relevant elements of the decision problem and thus require quantification. The impact of these
assumptions is tested extensively in the sensitivity analysis (see De novo model results).
Table 63 summarises the calculations underpinning the expected costs and QALY gains associated with
each terminal node within the model.
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Scope of the External Assessment Group diagnostic model analysis
The model is intended to reflect a population of patients with symptoms of asthma as seen in primary and
secondary care in England and Wales. Table 64 details the test options included in the EAG diagnostic
model analysis and the setting in which these tests are assumed to be undertaken.
All options are compared within a full incremental analysis. In line with the NICE reference case for
diagnostic interventions,145 all costs and health outcomes are discounted at a rate of 3.5%. All costs
are valued at 2012/13 prices. No subgroup analyses were conducted because of evidence limitations
(a narrative review of subgroup analyses within the FeNO studies is presented in Chapter 3). The base-case
analyses are drawn from the results of the probabilistic model and hence reflect the expectation of the
mean. Further sensitivity analyses were undertaken deterministically using point estimates of parameters.
PSA was used to generate information on the likelihood that each test is expected to produce the greatest
net benefit over a range of willingness-to-pay thresholds.
TABLE 63 Summary of calculations of expected costs and health outcomes for each test outcome
Diagnostic
test outcome Expected cost Expected QALY gain
TP Diagnostic test costs+ (time horizon × cost asthma
management)
Time horizon × utility_asthma
FP Diagnostic test costs+ additional tests+ (time to
correct FP diagnosis × costs of asthma management)
[(Timehorizon – time to correct FP diagnosis) ×
utility_healthy]+ [time to correct FP
diagnosis × (utility_ healthy–disutility_asthma)]
TN Diagnostic test costs Time horizon × utility_healthy
FN Diagnostic test costs+ additional tests+ (time to
correct FN diagnosis × cost of increased severe
exacerbations)+ [(time horizon – time to correct FN
diagnosis) × (costs of asthma management)]
[(Time horizon – time to correct FN
diagnosis) × (utility_asthma)]+ (time to correct FN
diagnosis × disutility poor control)
TABLE 64 Options included in the EAG diagnostic model
Test(s) Setting
FeNO > 25 ppb (using NIOX MINO, NIOX VERO or NObreath) Primary care
FeNO 34 ppb (using NIOX MINO, NIOX VERO or NObreath)+ FEV1 Primary care
FeNO 19 ppb (using NIOX MINO, NIOX VERO or NObreath)+ sputum induction Secondary care
FeNO > 27 ppb (using NIOX MINO, NIOX VERO or NObreath)+ bronchodilator reversibility Primary care
FEV1/FVC Primary care
PEF monitoring Primary care
Bronchodilator reversibility Primary care
Airway hyper-responsiveness (MCT) Secondary care
Sputum induction Secondary care
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It should be noted that originally the model included an additional combination of diagnostic options –
FeNO plus FEV1 plus bronchodilator reversibility – based on the study reported by Fortuna et al.70 However,
as Fortuna et al.70 reported that diagnostic accuracy was not improved compared with FeNO alone,
incorporating this option into the model would result in a situation whereby it has the same modelled
effectiveness and same modelled cost as FeNO testing alone. In reality, the use of spirometry, reversibility
testing and FeNO testing would result in a small additional cost associated with consumables and/or minor
drug costs compared with FeNO testing alone. Consequently, given the assumption of equivalence with
FeNO testing alone and the expectation that test costs would be marginally higher than for FeNO testing
alone, FeNO plus FEV1 plus bronchodilator reversibility would always be dominated. Hence, this option was
excluded from the final economic analysis.
The External Assessment Group asthma management model
Logic underpinning the management model structure
The EAG asthma management model is principally concerned with the potential benefits associated
with using FeNO monitoring to enable better disease control in patients who have been diagnosed with
asthma. Patients with diagnosed asthma may receive ICSs, LABAs and other pharmacological treatments to
maintain control of symptoms, minimise the impact of the disease on HRQoL and reduce the risk of serious
complications of asthma.8 Treatment in the UK follows a stepped approach, with escalation of medication
until control is reached. The incidence of exacerbations generally indicates poor asthma control; these
exacerbations also impact on patient’s HRQoL and may be expensive to manage. Monitoring of FeNO
levels may provide information to allow for the better control of asthma, thereby resulting in a reduction in
unnecessary medication use in patients who do not require such treatment, the maintenance of
medication levels when appropriate and an increase in medication use in patients with poor disease
control to avoid the health losses and costs associated with exacerbations.
Model structure
Figure 26 presents the structure of the de novo EAG management model. The model adopts a simple
Markov framework with two states: (1) alive with diagnosed asthma and (2) dead. The model assumes
that differences in HRQoL between treatment groups in the alive state are driven by the incidence of
exacerbations whereas cost differences are influenced by the exacerbation rate and the mean level of
medication use in each treatment group. Each exacerbation is associated with a reduction in HRQoL and a
cost of management. Exacerbations that require hospitalisation are assumed to have a greater impact on
HRQoL losses and are assumed to be more expensive to treat than other less severe exacerbations. Within
each treatment group, the rate of exacerbations is modelled together with an estimate of required
medication over time.
Dead
Diagnosed asthma
Rate of severe exacerbations (requiring
hospitalisation or managed in primary care)
HRQoL
Baseline HRQoL minus exacerbation disutility
defined according to requirement for
hospitalisation
Cost
Drug management (± monitoring and
change in ICS use)
Primary care management costs
Hospitalisations for very severe exacerbations
FIGURE 26 Conceptual form of the EAG asthma management model.
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The management model makes the following key structural assumptions:
l Short-term impacts on exacerbations and medication use observed in the empirical studies associated
with FeNO monitoring are assumed to be maintained in the longer term (indefinitely in the base case).
Given the clinical evidence used to inform the analysis, this is a strong assumption that will favour FeNO.
l Impacts of FeNO monitoring on costs and health outcomes occur only during the period in which FeNO
monitoring is used (this applies only to the sensitivity analysis).
l Exacerbations are associated with a short-term reduction in HRQoL.
l The use of FeNO monitoring leads to impacts on exacerbations.
l A proportion of severe exacerbations may require hospitalisation whereas the remainder may be
managed in a primary care setting. Other less severe exacerbations may be managed at home.
l Improved asthma management has no impact on mortality.
l All FeNO devices (NIOX MINO, NIOX VERO and NObreath) are assumed to have an equivalent impact
on dose titration decisions in the management setting.
Scope of the External Assessment Group management model analysis
The management model analysis compares the incremental costs of four options: FeNO monitoring using
(1) NIOX MINO, (2) NIOX VERO and (3) NObreath against (4) standard guidelines in (a) children and
(b) adults. It should be noted that each FeNO option also includes the use of guidelines, as determined
by the clinical evidence used to inform the exacerbation rate and ICS use parameters. The starting age for
the child subgroup is assumed to be 5 years whereas the starting age for the adult subgroup is assumed to
be 18 years. The adult subgroup analysis also includes a separate subgroup analysis of FeNO monitoring in
women who are pregnant. No further subgroup analyses were undertaken. The model adopts a lifetime
horizon, all costs and health outcomes are discounted at 3.5% and all costs are valued at 2012/13 prices.
The base-case analyses are drawn from the results of the probabilistic model and hence reflect the
expectation of the mean. Further sensitivity analyses were undertaken deterministically using point
estimates of parameters. PSA was used to generate information on the likelihood that each option is
expected to produce the greatest net benefit over a range of willingness-to-pay thresholds.
Evidence used to inform the External Assessment Group diagnostic and
management model parameters
Table 65 presents the parameter values, distributions and evidence sources used to inform the two models.
These are described in more detail below.
TABLE 65 Parameters, distributions and evidence sources used in the de novo EAG models
Parameter Distributiona Mean Param1 Param2 Source
Diagnostic model parameters
Diagnostic accuracy
FeNO – sensitivity Beta 0.32 24.00 51.00 Schneider et al.71,72
FeNO – specificity Beta 0.93 79.00 6.00
FeNO+ FEV1 – sensitivity Beta 0.24 20.00 62.00 Schleich et al.
77
FeNO+ FEV1 – specificity Beta 0.99 91.00 1.00
FeNO+ sputum induction – sensitivity Beta 0.87 98.31 14.69 Sivan et al.95
FeNO+ sputum induction – specificity Beta 0.86 24.03 4.07
FeNO+ bronchodilator reversibility –
sensitivity
Beta 0.87 36.54 5.46 Cordeiro et al.87
FeNO+ bronchodilator reversibility –
specificity
Beta 0.90 64.80 7.20
continued
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TABLE 65 Parameters, distributions and evidence sources used in the de novo EAG models (continued )
Parameter Distributiona Mean Param1 Param2 Source
FEV1/FVC – sensitivity Beta 0.61 41.54 26.56 Hunter et al.
163
FEV1/FVC – specificity Beta 0.60 11.37 7.58
PEF – sensitivity Beta 0.43 29.15 38.64
PEF – specificity Beta 0.75 14.21 4.74
Bronchodilator reversibility – sensitivity Beta 0.49 33.29 34.65
Bronchodilator reversibility – specificity Beta 0.70 13.28 5.69
Airway hyper-responsiveness (MCT) –
sensitivity
Beta 0.91 61.01 6.03
Airway hyper-responsiveness (MCT) –
specificity
Beta 0.90 22.43 2.49
Sputum induction – sensitivity Beta 0.72 48.91 19.02
Sputum induction – specificity Beta 0.80 15.26 3.81
Disease and population parameters
Prevalence of true asthma Beta 0.47 412.00 469.00 Schleich et al.,77
Sivan et al.,95
Fortuna et al.,70
Cordeiro et al.,87
Schneider et al.71,72
Probability patient is male (children) NA 0.55 – – Sivan et al.95
Probability patient is male (adults) NA 0.40 – – Schneider et al.69
Patient age (years) at diagnosis (children) NA 5 – – Assumption to reflect
decision problem
Patient age (years) at diagnosis (adults) NA 18 – –
Resource cost parameters
NIOX MINO – marginal per-test cost NA £7.07 – – Based on information
provided by Bedfont
Scientific and
Aerocrine
NIOX VERO – marginal per-test cost NA £6.36 – –
NObreath – marginal per-test cost NA £4.82 – –
Primary care GP visit Normal £43.00 £43.00 £4.30b Curtis179
Primary care practice nurse visit Normal £13.69 £13.69 £1.39b
Secondary care respiratory medicine
outpatient visit
Normal £204.29 £204.29 £30.64 NHS Reference Costs174
Secondary care laboratory visit Normal £203.29 £203.29 £30.49 NHS Reference Costs174
Number of additional primary care tests – FP NA 1.00 – – Structural assumptions
based on expert
opinionNumber of additional secondary care
tests – FP
NA 2.00 – –
Number of additional laboratory visits – FP NA 1.00 – –
Number of additional primary care tests – FN NA 1.00 – –
Number of additional secondary care
tests – FN
NA 2.00 – –
Number of additional laboratory visits – FN NA 1.00 – –
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TABLE 65 Parameters, distributions and evidence sources used in the de novo EAG models (continued )
Parameter Distributiona Mean Param1 Param2 Source
Annual rate of additional exacerbations in
uncontrolled FNs
Normal 1.02 1.02 0.10b Assumption based on
Jayaram et al.169
Annual asthma drug management costs
(children)
Normal £201.00 £10.00 – Main et al.180
Annual asthma drug management costs
(adults)
Normal £231.00 £10.00 Shepherd et al.13
QALY gain/loss parameters
Time (years) until correct diagnosis – FP Normal 1.50 1.50 0.26 Expert opinion
Disutility FP Assumed to be equal to asthma disutility (see below)
Time (years) until correct diagnosis – FN Normal 0.67 0.67 0.17 Expert opinion
Disutility poor asthma control Beta 0.04 1.39 33.35 McTaggart-Cowan
et al.181
Disutility asthma Beta 0.05 49.92 1027.40 Sullivan et al.182
HRQoL non-asthma population Multivariate
normal
0.96 – – Ara and Brazier183
Management model parameters
Exacerbation rate parameters
Duration (years) of FeNO monitoring benefit NA Lifetime – – Assumption
FeNO annual exacerbation rate (children) Log-normal 0.36 0.36 0.00 Szefler et al.104
FeNO annual exacerbation rate (adults) Log-normal 0.33 0.33 0.09 Shaw et al.98
Guidelines annual exacerbation rate
(children)
Log-normal 0.47 0.47 0.00 Szefler et al.104
Guidelines annual exacerbation rate (adults) Log-normal 0.42 0.42 0.10 Shaw et al.98
HRQoL parameters
Disutility severe hospitalised exacerbationc Beta 0.56 1.21 3.84 Lloyd et al.184
Disutility severe non-hospitalised
exacerbation
Beta 0.32 12.06 25.62
Duration (years) severe hospitalised
exacerbation
Gamma 0.08 15.62 0.00 Expert opinion
Duration (years) severe non-hospitalised
exacerbation
Gamma 0.01 12.23 0.00
Resource cost parameters
Additional FeNO monitoring visits year 1 NA 4 – – Assumption based on
BTS/SIGN8
recommendationsAdditional FeNO monitoring visits
subsequent years
NA 4 – –
RDI ICS use year 1 FeNO (children) Normal 0.98 0.98 0.05b Szefler et al.104
RDI ICS use years 2+ FeNO (children) Normal 0.97 0.97 0.05b
RDI ICS use year 1 guidelines (children) Normal 0.87 0.87 0.05b
RDI ICS use years 2+ guidelines (children) Normal 0.78 0.78 0.05b
RDI ICS use year 1 FeNO (adults) Normal 1.20 1.20 0.05b Shaw et al.98
RDI ICS use years 2+ FeNO (adults) Normal 0.77 0.77 0.05b
RDI ICS use year 1 guidelines (adults) Normal 1.06 1.06 0.05b
continued
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Diagnostic test accuracy
Estimates of test accuracy for diagnostic tests were drawn from a number of separate studies70–72,77,87,95,163
based on the results of the systematic review (see Chapter 3). Tables 66 and 67 summarise the sources
from which these estimates were derived and the actual values selected. As far as the evidence allows, the
economic analysis included studies that presented estimates of the sensitivity and specificity of individual
tests as well as combinations of FeNO plus other standard tests.
The study reported by Schneider et al.71,72 was used to inform estimates of the sensitivity and specificity of
FeNO alone; this study was selected because of its broad population and high study quality and because
the reference standard broadly reflects the BTS/SIGN guidelines.8 This study used the NIOX MINO device.
TABLE 65 Parameters, distributions and evidence sources used in the de novo EAG models (continued )
Parameter Distributiona Mean Param1 Param2 Source
RDI ICS use years 2+ guidelines (adults) Normal 1.27 1.27 0.05b
Cost severe non-hospitalised exacerbation Normal £44.73 £44.73 – Curtis,179 BNF185
Cost severe hospitalised exacerbation Normal £1267 £1267 £253.34 NHS Reference
Costs174
NA, not applicable; RDI, relative dose intensity.
a Normal distribution: param1=mean, param2= SE; log-normal distribution: param1=mean, param2= SE; beta
distribution: param1= alpha, param2= beta; gamma distribution: param1= alpha, param2= beta; multivariate normal
distribution: variance–covariance matrix not shown.
b SE determined subjectively.
c Mean reflects additive disutility for severe non-hospitalised+ severe hospitalised.
TABLE 66 Summary of studies used to inform test accuracy parameters
Author,
year Study design Population Setting Reference standard Age range
Cordeiro
201187
Retrospective
(analysis of
prospective
database)
114 patients
referred to a general
outpatient allergy
clinic
Secondary care
(the Netherlands)
History of typical respiratory
symptoms and FEV1%
improvement of > 12% and
> 200ml or a provocative
concentration of histamine
causing a > 20% decrease in
FEV1% (PC20) of ≤ 8mg/ml,
according to GINA
guidelines112
Included
those aged
7–83 years
Hunter
2002163
Cross-sectional
case–control
study
69 asthma patients,
20 pseudoasthma
patients and 21
healthy subjects
Secondary care –
single centre (UK)
Subjects with asthma had
consistent clinical features,
were symptomatic at the
time of the investigations,
had FEV1 predicted values of
> 65% and had one or more
of the following conditions:
a provocative concentration
of a substance
(methacholine) causing a
> 20% fall in FEV1 (PC20) of
< 8mg/ml; a > 15% increase
in FEV1 10 minutes after
receiving 200 µg of inhaled
salbutamol; or a > 20%
maximum within-day
variability of PEF when
measured twice daily for
> 14 days
Mean age
44 years,
range
15–70 years
in asthma group
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TABLE 66 Summary of studies used to inform test accuracy parameters (continued )
Author,
year Study design Population Setting Reference standard Age range
Schleich
201277
Prospective
cohort study
174 steroid-naive
patients with
respiratory
symptoms
Secondary care
(Belgium)
Asthma was diagnosed
based on airway hyper-
responsiveness
demonstrated by inhaled
concentration of
methacholine provoking a
20% fall in FEV1 (PC20) of
< 16mg/ml
Range
20–59 years
Sivan
200995
Prospective,
consecutive
patients
150 consecutive
children referred for
evaluation of
possible asthma
Secondary care
(Israel)
Patient’s history of two or
more clinical exacerbations of
wheezing documented by a
physician, dyspnoea or cough
relieved by bronchodilators,
documented variability in FEV1
of ≥15% in response to
bronchodilators at any time
during the follow-up period
(reversibility) or documented
variability in FEV1 of ≥15%
over time with or without
controller medications (ICS or
montelukast). The results of
provocation tests were
included when available.
Children in whom asthma
did not manifest within
18 months of follow-up were
considered as not having
asthma
Range
5–18 years
a
Smith
200486
Prospective
cohort study
47 consecutive
patients referred by
their GP to a
pulmonary function
laboratory for
investigation of
possible asthma
Secondary care
(New Zealand)
Diagnosis of asthma made
on the basis of the
following: relevant symptom
history (present in all
patients) using the ATS
criteria113 and a positive
test for bronchial
hyper-responsiveness and/or
a positive response to a
bronchodilator
Range
8–75 years
Schneider
200971,72
Prospective,
consecutive
cohort study
393 adults with
symptoms
suggestive of
asthma
Private practice
run by five
pneumologists
(Germany)
FEV1/FVC < 0.7% or
FEV1%< 80% plus positive
bronchodilator
response= asthma. FEV1/FVC
> 0.7% or FEV1% > 80%
plus positive MCT= asthma
Unclear
(adults)
a This study is used in the sensitivity analysis only.
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The study reported sensitivity and specificity across a range of cut-offs. The cut-off of > 46 ppb had the
highest sum of sensitivity and specificity (32% and 93% respectively); hence, this estimate was used in
the model. Additional diagnostic interventions involving FeNO plus other standard tests were included
according to their availability;70,77,87,95 the FeNO cut-off values used from these studies were driven by the
availability of reported estimates and were not based on choices made by the EAG. As noted earlier,
the combination of FeNO+ FEV1 bronchodilator reversibility was excluded from the final model because,
based on data from Fortuna et al.70 and the model costing assumptions, it will always be dominated by FeNO
alone. Estimates of the operating characteristics of other standard tests for asthma diagnosis were drawn
from Hunter et al.163 This is consistent with the manufacturer’s economic analysis, although it should be
noted that this study may introduce bias through the use of a case–control design. Sensitivity analyses were
undertaken to examine whether the use of alternative estimates86 of the sensitivity and specificity of existing
tests alters the cost-effectiveness of FeNO testing (see De novo model results).
Across all diagnostic options, test operating characteristics were derived directly from data reported in the
study publications. Uncertainty surrounding sensitivity and specificity estimates was modelled using
independent beta distributions based on patient numbers reported in the studies.
Because of the limitations in the evidence base, the model necessarily makes a number of unadjusted
(naive) indirect comparisons between the included studies. As a consequence, the results of the health
economic analysis may be subject to bias and confounding because of differences between studies
in terms of study design, recruited populations and reference standards. This same limitation is evident in
the Price et al.147/Aerocrine diagnostic models and is unavoidable given the available evidence base. As the
included studies did not provide sufficient information that would allow us to meaningfully discriminate
between the sensitivity and specificity of all tests across population subgroups, we assumed that test
operating characteristics were common to all patient populations. This assumption may not hold in reality.
Disease and population parameters
The true pre-test probability of asthma in undiagnosed patients was estimated as a weighted mean of the
number of cases of asthma and non-asthma diagnosed in the studies used to inform the diagnostic test
accuracy parameters.69,70,77,86,87,95 We did not include the Hunter et al.163 study in this calculation as it did
not recruit consecutive patients because of its study design. Across these studies, 412 of 881 patients were
diagnosed with asthma (probability= 0.47).
We estimated the probability that a patient is male using two studies.69,95 This value is used only to
estimate baseline HRQoL without asthma and thus does not impact on the model results.
TABLE 67 Summary of test operating characteristics used in the EAG models
Author, year Test(s) FeNO cut-off (ppb) Sensitivity (%) Specificity (%)
Cordeiro 201187 FeNO+ bronchodilator reversibility > 27 87 90
Hunter 2002163 FEV1/FVC NA 61 60
PEF NA 43 75
Bronchial reversibility NA 49 70
Airway hyper-responsiveness (MCT) NA 91 90
Sputum induction NA 72 80
Schleich 201277 FeNO+ FEV1 > 34 24 99
Schneider 200971,72 FeNO > 46 32 93
Sivan 200995 FeNO+ sputum induction > 19 87 89
NA, not applicable.
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Non-asthma utility
Preference-based HRQoL values for patients without asthma were estimated using a general population
EQ-5D regression model reported by Ara and Brazier183 (modelled EQ-5D= 0.9508566+ 0.0212126 ×
male – 0.0002587 × age – 0.0000332 × age2). Uncertainty surrounding this regression equation was
modelled using a multivariate normal distribution. As this parameter is common to all diagnostic
comparator groups, it has no effect on the estimates of incremental health gain for the diagnostic tests
included in the economic analysis.
Disutility associated with asthma
The disutility associated with asthma was taken from the catalogue of EQ-5D values reported by
Sullivan et al.182 Within this study, community-based UK preferences were applied to EQ-5D descriptive
questionnaire responses in the US-based Medical Expenditure Panel Survey (MEPS). Sullivan et al.182 used
regression models to estimate the marginal disutility associated with a variety of diseases and conditions,
assuming an additive model. Based on these models, the disutility for asthma was estimated to be –0.0463.
Uncertainty surrounding this parameter was modelled using a beta distribution using bootstrapped
confidence intervals provided in the supplementary appendices to the paper [available from
http://mdm.sagepub.com/content/31/6/800/suppl/DC1 (accessed 1 August 2013)].
This disutility is applied indefinitely to all patients with asthma and to patients without asthma who test FP
until their misdiagnosis is corrected. It should be noted that this disutility is unlikely to fully reflect health
losses associated with the delayed diagnosis of more serious pathology such as cancer or tuberculosis.
Disutility associated with poor asthma control
The impact of poor asthma control on HRQoL was informed by a recent systematic review of studies that
reported the use of the EQ-5D in patients with asthma.186 Within this review, two studies were identified
that reported the impact of loss of control on patients’ health status.172,181 Within the study reported by
Szende et al.,172 228 consecutive adult outpatients and inpatients at four sites in Hungary completed the
EQ-5D, the Short Form questionnaire-36 items (SF-36), the St George’s Respiratory Questionnaire and a
direct time trade-off question. The patients’ level of asthma control was determined by physicians. EQ-5D
estimates are reported for four health states: ‘good control’, ‘mildly reduced control, ‘moderately reduced
control’ and ‘poor control’. EQ-5D estimates ranged from 0.93 for ‘good control’ to 0.52 for ‘poor
control’. Within the study reported by McTaggart-Cowan et al.,181 157 asthma patients completed the
Health Utilities Index Mark 3 (HUI-3), the EQ-5D and the Short Form questionnaire-6 Dimensions (SF-6D).
The degree of asthma control was self-reported by patients. The authors reported EQ-5D values for four
health states: ‘very well controlled’, ‘well controlled’, ‘adequately controlled’ and ‘not controlled’. EQ-5D
estimates ranged from 0.90 for ‘very well controlled’ to 0.80 for ‘not controlled’. The impact of loss of
control is markedly different between these two studies. As Szende et al.172 recruited inpatients and
outpatients, it is very likely that a number of study subjects were identified because they were experiencing
an exacerbation at the time at which they completed the questionnaire; this may overestimate their
valuations of HRQoL. For this reason we derived disutilities from the study by McTaggart-Cowan et al.181
We assumed that the health loss associated with poor control because of a FN diagnosis relates to the
difference between the ‘well controlled’ state and the ‘not controlled’ state (mean disutility –0.04).
Uncertainty surrounding this parameter was modelled using a beta distribution based on the mean
difference between the two health states; this method ensures that the notionally better health state
always has a monotonically better valuation than that for the notionally worse health state.
This disutility is applied to all patients with asthma who test FN until their misdiagnosis is corrected.
Time to resolution of incorrect diagnoses
There is a dearth of empirical evidence relating to the time required to resolve incorrect diagnoses (FPs and
FNs); indeed, such studies would be difficult, if not impossible, to undertake prospectively. However, the
time to resolve incorrect diagnoses is of direct relevance to the decision problem and must be quantified to
evaluate the cost-effectiveness of alternative diagnostic options for asthma. Given the lack of empirical
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evidence relating to these parameters, we attempted to elicit these quantities from clinical experts. We
asked six clinical experts (see Acknowledgements) the following questions:
1. For someone who has been incorrectly diagnosed as ‘not asthmatic’, how long on average do you think
it will take for this incorrect diagnosis to be corrected? What is your 95% confidence interval around
this average?
2. For someone who has been incorrectly diagnosed as ‘asthmatic’, how long on average do you think it
will take for this incorrect diagnosis to be corrected? What is your 95% confidence interval around
this average?
A total of four experts provided responses. One expert suggested, with considerable uncertainty, that the
time to resolve a FN diagnosis may be in the region of 4–12 months whereas the time to resolve a FP
diagnosis may be in the region of 12 months or longer. This expert indicated substantial uncertainty
around these estimates.
The second expert stated that, for FNs, the time to correct a misdiagnosis will:
mainly depend on chronicity and persistence of asthma: (a) In those with chronic persistent asthma
(BTS step 2 or higher); [the] mean will only be a few weeks with relatively tight c.i., as the patient will
presumably not be given treatment, will become symptomatic and demands further investigations/
treatment where the true diagnosis will be revealed by other methods i.e. lung function etc. (b) In
those with mild intermittent/infection induced exacerbation, it may take much longer (mean [may be]
months or even year or two with [a] wide CI) as they may not get regular symptoms so the diagnosis
(no asthma) may seem correct until they are exposed to the trigger and become symptomatic or get
an exacerbation.
With respect to FPs, the second expert stated that:
this is even more difficult to estimate but here the means and c.i. may be in years. With an incorrect
diagnosis of asthma, patients are put on treatment and they may become asymptomatic (for other
reasons e.g. placebo effect) and it is presumed that they are better because of treatment and hence
continued on it. There is a reluctance to reduce treatment if patient[s] are doing well. This was one of
the argument of using eNO (to monitor, not to diagnose), that by titrating asthma treatment with eNO
you can manage airway inflammation better with lower doses of inhaled steroids.
The third expert stated that these questions were ‘impossible questions to answer’ but indicated that
‘misdiagnosis may never be corrected [for] both false-positive and false-negative’. In addition, the third
expert stated that ‘patients may make the decision themselves and just stop going back to the doctor’ and
that ‘asthmatic symptoms may come and go’. This expert also stated that a patient who has had asthmatic
symptoms and who becomes asymptomatic might be considered an asymptomatic asthmatic or may be
said to have had an incorrect diagnosis of asthma by someone who sees them when well. The expert also
stated that these problems are the result of the absence of a reliable diagnostic test for asthma.
The fourth expert simply stated that these quantities are ‘unknowable’ but did suggest that the values
quantified by the first expert were not unreasonable.
The fifth and sixth experts were not able to provide quantitative estimates.
Based on these responses, we assumed that the time to resolve a FN diagnosis has a mean of 8 months
with a 95% CI of 4–12 months. We also assumed that the time to resolve a FP diagnosis has a mean of
18 months with a 95% CI of 12–24 months. Uncertainty surrounding these estimates was modelled using
normal distributions. These estimates should be considered to be highly uncertain and are tested
extensively in the sensitivity analysis.
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Resource costs
Test costs
Calculating the likely marginal per-test cost for NIOX MINO, NIOX VERO and NObreath is somewhat
complicated as the devices each have different lifetimes and test kits for each device are available at lower
marginal costs if higher volumes of kits are purchased. The lifetimes of the NIOX MINO and NIOX VERO
devices are determined either by time or by the number of tests undertaken (whichever limit is
reached first).
The NIOX MINO device (Aerocrine) has a unit cost of £2100 and an effective unit lifetime of 3 years or
3000 tests (whichever comes first). The NIOX VERO device (Aerocrine) has a unit cost of £2310 and an
effective unit lifetime of 5 years or 5000 tests (whichever comes first). The NObreath device (Bedfont
Scientific) costs £1995 and, according to the manufacturer, has an unlimited unit lifetime.
Maintenance for NObreath is provided free of charge. No maintenance is required for NIOX MINO or
NIOX VERO.
Test kits for NIOX MINO are available in packs of 300 at a price of £1350, in packs of 500 at a price of £2100
or in packs of 1000 at a price of £3950. Test kits for NIOX VERO are available in packs of 300 at a price of
£1500, in packs of 500 at a price of £2200 or in packs of 1000 at a price of £4200. Mouthpieces for NObreath
are available in packs of 50, 100, 300 or 1000 at prices of £195, £365, £995 and £2995 respectively.
The NObreath device requires replacement of the sensor unit every 2 years at a cost of £295. Besides test
kits, NIOX MINO and NIOX VERO do not require any further consumables or incur any replacement costs.
Based on information provided by Bedfont Scientific and Aerocrine, Table 68 presents the estimated
annuatised marginal per-test costs assuming a usage of 300 tests per device per year (this estimate is
based on estimates of mean usage provided by Aerocrine). All calculations are based on the lifetime of the
specific device and the lowest cost estimates for the required number of test kits at the assumed level of
throughput and lifetime of the device. We assumed that, although the NObreath device has an unlimited
life, advances in technology would lead to replacement of the device within 10 years. Annuatisation was
undertaken assuming a rate of 3.5%.
TABLE 68 Marginal per-test costs for FeNO devices
Item NIOX MINO (£) NIOX VERO (£) NObreath (£)
Lifetime (years) 3 5 10
Total tests assumed per year 300 300 300
Equipment 2100.00 2310.00 1995.00
Test kits: 1000 mouthpieces 3950.00 4200.00 2995.00
Test kits: 500 mouthpieces 2100.00 2200.00 NA
Test kits: 300 mouthpieces 1350.00 1500.00 995.00
Test kits: 100 mouthpieces NA NA 365.00
Sensor replacements NA NA 295.00
Total cost over device lifetime 6150.00 8910.00 12,455.00
Annuatisation factor for specific device lifetime 2.90 4.67 8.61
Annuatised marginal per-test cost 7.07 6.36 4.82
NA, not available.
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It should be noted that these marginal per-test costs do not include any costs associated with the
education and training that may be required to teach NHS staff how to instruct patients to use the devices
correctly to minimise test failure rates (see Chapter 7).
We assumed that spirometry, reversibility testing and FeNO testing can be carried out in primary care
and would require two GP visits and one nurse visit. We assumed that sputum induction and airway
hyper-responsiveness testing (MCT) would be undertaken in secondary care and would require
two secondary care visits and one laboratory visit as well as an initial GP visit for referral (Dr John White,
17 July 2013, personal communication).
The unit cost of a GP visit was taken from Curtis et al.;179 the economic analyses use an estimate of £43, which
reflects the cost of an appointment lasting 11.7 minutes including direct staff costs and qualifications. Based
on the same source179 the cost of a GP practice nurse visit was assumed to be £13.69, assuming a visit
duration of 15.5 minutes. The secondary care attendance cost was based on the Healthcare Resource Group
code for respiratory medicine attendances (cost £204.29).174 The cost of a laboratory visit was based on the
Healthcare Resource Group code for simple bronchodilator studies (cost £203.29). We assumed that SEs
around these estimates were normally distributed, with a SE equal to 15% of the mean.
As HRGs are calculated using full economic costing, we assumed that all visit costs include the costs
associated with capital, training, staff costs and procedure costs associated with all existing diagnostic tests
for asthma. For the strategies that include FeNO testing, the marginal per-test cost of FeNO measurement
was added to these visit costs (see Table 68).
Costs associated with resolving misdiagnoses
We assumed that incorrect diagnoses would be resolved at a later point in time. We crudely assumed that
one additional primary care attendance, two additional secondary care attendances and one laboratory
visit would be required to correctly diagnose FP and FN results. This is an assumption and should be
interpreted with some caution.
Costs associated with loss of control for false negatives
The model assumes that patients with asthma who initially test negative experience an increased rate of
exacerbations compared with that in TP patients who are correctly diagnosed and who receive treatment.
It is likely that ethical implications associated with the design of an empirical research study to collect this
information would be prohibitive. We assumed that FN patients would experience one exacerbation each
year in which they remain undiagnosed; this was loosely based on the higher absolute exacerbation
estimate for diagnosed patients reported by Jayaram et al.169 The model assumes that a proportion of
these exacerbations will require hospitalisation (see below).
Costs of asthma management
We assumed that, on average, patients would be at step 3 in the
BTS/SIGN asthma guidelines.8 Current technology appraisal guidance from NICE187,188 on the use of ICSs
for children and adults recommends that the least expensive option is used and does not differentiate between
drugs in terms of effectiveness. We derived estimates of the annual cost of combined inhalers from two
previous HTA reports.13,180 Main et al.180 estimated the least expensive annual cost for combined inhalers to be
£201 for children (Symbicort turbohaler). Shepherd et al.13 estimated the least expensive annual cost of
combined inhalers to be £231 for adults (Symbicort turbohaler). Scrutiny of the current version of the BNF185
indicates that the annual cost of these inhalers has not changed since the original HTA reports were published.
Additional management model parameters
General population mortality
The probability of dying from all causes was taken directly from current interim life tables189 and was
applied according to the ratio of males to females with asthma.
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Duration of benefit of FeNO monitoring
In the base-case analysis we assumed that the impact of FeNO monitoring on dose titration and
exacerbations would be retained indefinitely over the patient’s lifetime. Although this is plausible, there is
no long-term RCT evidence to support or refute this assumption. We examine the impact of this
assumption within the sensitivity analysis.
Annual exacerbation rates with FeNO monitoring and standard care
Annual exacerbation rates with and without FeNO testing were derived for children from the RCT reported
by Szefler et al.104 and for adults from the RCT reported by Shaw et al.98 Changes in ICS use with/without
FeNO monitoring for the child and adult subgroups were also drawn from these trials.
The RCT reported by Shaw et al.98 was selected for use in the adult subgroup as it was the only UK-based
study included in the systematic review for adults (see Chapter 3), because it reflects BTS/SIGN guidelines8 and
because it reported data on severe exacerbation rates and changes in ICS use (the relevant parameters for the
model). The population within this RCT relates to adult non-smokers and never smokers who were deemed to
be compliant with medication and who had not experienced a severe exacerbation within 4 weeks of study
entry. This allowed for the inclusion of a broader range of severity compared with the other studies. Patients
were aged between 20 and 81 years and were treated and followed up for 12 months.
Of the studies included in the systematic review for children (see Chapter 3), the study reported by
Szefler et al.104 appears to most closely reflect current UK practice; hence, this study was selected to inform
the exacerbation rates and ICS use parameters for the child subgroup. Within this study, patients were either
on long-term control treatment with symptoms of persistent asthma or evidence of uncontrolled disease or
not on long-term control treatment with symptoms of persistent asthma and evidence of uncontrolled
disease. Patients were treated and followed up for 46 weeks. This trial was undertaken in the US.
Szefler et al.104 reported that 32.1% (SD 4.67%) of 276 patients in the FeNO group and 42.0% (SD 4.94%)
of 270 patients in the control group received one or more courses of prednisone over the 46-week study
period; this was taken as a proxy for severe exacerbations. The authors also reported that 3.3% (SD 1.78%)
of patients in the FeNO group and 4.1% (SD 1.98%) of patients in the control group were hospitalised
at least once. We used these data to estimate the annual rate of exacerbations for each arm (0.36 for the
FeNO arm and 0.47 for the standard care arm). It should be noted that the data available in the paper relate
to the number of patients experiencing exacerbation events rather than the number of exacerbation events.
We calculated the probability that an exacerbation required hospitalisation by pooling the exacerbation and
hospitalisation data for the two study arms (probability= 0.04).
Shaw et al.98 reported 18 exacerbations in 12 patients from the FeNO group (n= 58) and 26 exacerbations
in 19 patients from the control group (n= 60) over 42 weeks. This corresponds to an annual exacerbation
rate per patient of 0.33 (SD 0.69) for the FeNO group and 0.42 (SD 0.79) for the control group. Shaw et al.98
did not report the proportion of severe exacerbations requiring hospitalisation and so this probability was
assumed to be the same as that observed in the Szefler et al. study.
Exacerbation rates were assumed to follow a log-normal distribution. The probability that an exacerbation
requires hospitalisation was modelled using a beta distribution.
Impact of exacerbations on health-related quality of life
The impact of exacerbations on HRQoL was based on a valuation study reported by Lloyd et al.;184 this
study was identified from the systematic review reported by Davis.186 Lloyd et al.184 reported the impact of
exacerbations on HRQoL in patients with moderate to severe asthma (BTS/SIGN levels 4 and 5) in the UK.
Within this study, 112 patients completed a variety of health status questionnaires including the EQ-5D.
Disutilities associated with severe non-hospitalised and severe hospitalised exacerbations (compared with
‘no exacerbation’) were calculated based on the differences between the valuations for the three states.
Uncertainty surrounding these parameters was modelled using beta distributions based on the difference
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between each state and the next worst state; this method ensures that the notionally better health state
always has a monotonically better valuation than that for the notionally worse health state. The disutility of
a severe exacerbation resulting in hospitalisation (compared with no exacerbation) was estimated to be
–0.56 whereas the impact of other exacerbations that do not result in hospitalisation (compared with no
exacerbation) was estimated to be –0.32. Disutilities are assumed to be additive and are therefore not
influenced by the baseline level of HRQoL.
Severe exacerbations not resulting in hospitalisation were assumed to last for 4 days whereas major
exacerbations resulting in hospitalisation were assumed to last for 4 weeks. These quantities were based
on subjective estimates provided by experts. These durations were assumed to follow gamma distributions
with SEs fitted to capture the range of estimates elicited (2–6 weeks for exacerbations requiring
hospitalisation and 3–7 days for other severe exacerbations).
Resource costs: additional costs of FeNO monitoring
We assumed that FeNO monitoring would be undertaken during routine GP visits and would require one
additional nurse visit once every 3 months.8 The marginal cost of FeNO monitoring was applied as the
per-test cost plus the cost of a primary care nurse appointment.
Changes in medication (inhaled corticosteroid) use over time
We derived estimates of change in ICS use with and without FeNO monitoring in children from the RCT
reported by Szefler et al.104 and in adults from the RCT reported by Shaw et al.98 We assumed that, during
the period for which ICS use was observed in each study (12 months in the study by Shaw et al.98 and
46 weeks in the study by Szefler et al.104), ICS use would reflect the observed mean, with the relative dose
intensity (RDI) calculated as the mean over the observed period divided by the baseline ICS dosage for each
study arm. Beyond this point, we assumed that ICS use would remain constant at the level of the last
observation for each study arm for the remainder of the duration over which FeNO monitoring impacts on
exacerbations and titration decisions (Table 69).
Costs of managing exacerbations
We assumed that a proportion of exacerbations would require hospitalisation whereas the remainder could
be managed in primary care. We assumed that severe exacerbations that do not require hospitalisation
would require one GP attendance (cost £43.00) plus oral steroids for 5 days (cost £1.73), based on an
earlier HTA report.180 We derived the cost of asthma hospitalisation from current NHS Reference Costs174
(cost £1266.72).
TABLE 69 Estimated ICS dose (relative to baseline)
Parameter FeNO monitoring Guidelines
Children104
Mean RDI first 39 weeks 0.98 0.87
Mean RDI subsequent 0.97 0.78
Adults97
Mean RDI first 12 months 1.20 1.06
Mean RDI subsequent 0.77 1.27
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Model evaluation
The model was evaluated probabilistically using standard Monte Carlo sampling techniques over 5000
random samples. Central estimates of cost-effectiveness are presented based on the expectation of the
mean. Headline results are presented as ICERs, cost-effectiveness planes and cost-effectiveness
acceptability curves (CEACs). In addition, a large number of deterministic sensitivity analyses (DSAs) were
undertaken; these analyses are detailed in the following sections. All incremental analyses were carried out
using an automated tabular algorithm developed by one of the study authors (PT).
Deterministic sensitivity analyses undertaken using the diagnostic model
Scenario D1: point estimates of parameters
The model was evaluated using point estimates of parameters rather than the expectation of the mean.
Scenarios D2 and D3: alternative discount rates
The model was evaluated with discount rates of 0% for costs and QALYs (scenario D2) and 6% for costs
and QALYs (scenario D3).
Scenario D4: all tests undertaken in secondary care
The model was run assuming that all tests are undertaken in a secondary care setting.
Scenarios D5 and D6: alternative asthma control disutilities for false negatives
The model was run assuming different disutilities for patients who are FN. In scenario D5, the most
extreme disutility from the study by McTaggart-Cowan et al.181 was assumed (‘very well controlled’ to
‘not controlled’ state disutility= –0.10). In scenario D6, the most extreme disutility from the study by
Szende et al.172 was assumed (‘good control’ to ‘poor control’ state disutility= –0.41).
Scenarios D7 and D8: alternative disutilities for false positives
The model was run assuming different disutilities for patients who are FP. In scenario D7, the base-case
disutility applied to FPs was doubled whereas in scenario D8 this disutility was halved.
Scenarios D9 and D10: FeNO test costs
The model was evaluated assuming that the marginal per-test costs for all FeNO devices (NIOX MINO, NIOX
VERO and NObreath) are double (scenario D9) or half (scenario D10) those assumed in the base-case analysis.
Scenarios D11–D13: alternative assumptions concerning the lifetime of the
NObreath device
Within the base-case analysis, the NObreath device is assumed to have a fixed lifetime of 10 years (for
costing purposes). In scenario D11 the analysis is repeated assuming a maximum lifetime for the NObreath
device of 3 years (equal to the maximum lifetime of the NIOX MINO device). In scenario D12 the analysis
is repeated assuming a maximum lifetime for the NObreath device of 5 years (equal to the maximum
lifetime of the NIOX VERO device). In scenario D13 the analysis is repeated assuming a maximum lifetime
for the NObreath device of 20 years (double that assumed in the base case). These alternative assumptions
result in marginal per-test costs for the NObreath device of £14.32, £8.88 and £2.32 for scenarios D11,
D12 and D13 respectively.
Scenarios D14 and D15: test visit costs
The model was evaluated assuming that all primary and secondary care visit costs are double (scenario D14)
or half (scenario D15) those assumed in the base-case analysis. This includes the costs of initial visits and
subsequent visits to resolve misdiagnosis.
Scenarios D16 and D17: false-negative exacerbation rate
The model was evaluated assuming that the base-case incremental exacerbation rate for FNs is double
(scenario D16) or half (scenario D17) that assumed within the base-case analysis.
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Scenarios D18 and D19: asthma treatment costs
The model was evaluated assuming that asthma treatment costs are double (scenario D18) or half
(scenario D19) those assumed in the base-case analysis.
Scenarios D20–D25: time to resolve misdiagnosis
The model was evaluated assuming a range of different times to resolve initial misdiagnoses (both FNs
and FPs) (2×, 3×, 4×, 5×, 10× and 0.5× the base-case time to correct diagnosis parameters in scenarios
D20–D25 respectively). In these analyses the time horizon was set to be equal to the maximum time to
resolve FP and FN results (note that this does not affect the incremental model results).
Scenarios D26 and D27: alternative sources for the diagnostic accuracy of FeNO
monitoring alone
The base-case analysis used estimates of the diagnostic accuracy of FeNO monitoring from Schneider et al.71,72
In scenario D26, the model was evaluated using alternative estimates from Schleich et al.;77 at a cut-off of
34 ppb, the sensitivity and specificity of FeNO monitoring were 0.35 and 0.95 respectively. In DSA scenario
D27, the model was evaluated using alternative estimates from Pedrosa et al.;85 at a cut-off of 40 ppb,
the sensitivity and specificity of FeNO monitoring were 0.74 and 0.73 respectively. Both of these studies
include a difficult-to-diagnose population, although it should be noted that this is not the case for the
other comparators in this scenario analysis.
Scenario D28: alternative source for the diagnostic accuracy of non-FeNO
monitoring comparators
The base-case analysis draws estimates of sensitivity and specificity for individual comparators from the study
reported by Hunter et al.163 In scenario D28, the model was evaluated using estimates of diagnostic accuracy
for FEV1/FVC, PEF and sputum induction from the comparative diagnostic study reported by Smith et al.86
Scenarios D29–D31: ‘rule-out’ diagnostic decision approach
In scenarios D29–D31, the model was evaluated assuming a ‘rule-out’ diagnostic approach for all
diagnostic tests. In these scenarios any patient who tests negative is ‘ruled out’ and treated as being not
asthmatic (as per the base-case structure), whereas any patient testing positive is assumed to immediately
undergo further tests to confirm the diagnosis. As a consequence, no patient loses health from initially
testing FP. The ‘rule-out’ approach was evaluated over three scenarios: scenario D29 – base-case test
characteristics for FeNO monitoring options; scenario 30 – best sensitivity for FeNO monitoring options;
and scenario 31 – best specificity for FeNO monitoring options.
Scenarios D32–D34: ‘rule-in’ diagnostic decision approach
In scenarios D32–D34, the model was evaluated assuming a ‘rule-in’ diagnostic approach for all diagnostic
tests. In this scenario any patient who tests positive is ‘ruled in’ and treated as being asthmatic (as per the
base-case structure), whereas any patient testing negative is assumed to immediately undergo further tests
to confirm the diagnosis. As a consequence, no patient loses health from initially testing FN. The ‘rule-in’
approach was evaluated over three scenarios: scenario D32 – base-case test characteristics for FeNO
monitoring options; scenario D33 – best sensitivity for FeNO monitoring options; and scenario D34 – best
specificity for FeNO monitoring options.
Deterministic sensitivity analyses undertaken using the management model
Scenario M1: point estimates of parameters
The model was evaluated using point estimates of parameters rather than the expectation of the mean.
Scenarios M2 and M3: alternative discount rates
The model was evaluated with discount rates of 0% for costs and QALYs (scenario M2) and 6% for costs
and QALYs (scenario M3).
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Scenario M4: pregnant women subgroup analysis
In this scenario the model was evaluated specifically for a subgroup consisting of women who are pregnant.
This analysis was based on the RCT reported by Powell et al.102 We estimated annual exacerbation rates of
0.58 and 1.26 for the FeNO monitoring and guidelines groups respectively. Mean ICS use over the study
period was estimated to be approximately 77% of the baseline dose for the FeNO group and 102% of the
baseline dose for the guidelines group. These estimates were assumed to apply for the first 5 months
(the observed period in the trial). The final observations of 73% and 105% for the FeNO and guidelines
groups, respectively, were assumed to be carried forward over the remainder of the time horizon.
Scenario M5: alternative source of exacerbation rates and ICS use for children
In scenario M5, the model was evaluated using alternative estimates of exacerbation rates and ICS use over
time, based on the RCT reported by Pijnenburg et al.106 We estimated exacerbation rates of 0.18 and 0.39
for the FeNO and guidelines groups respectively. ICS use over the 1-year follow-up period was similar in
both groups: the RDI compared with the baseline dose was estimated to be 1.16 in both groups. Beyond
the first year, the RDI was estimated to be 1.23 for the FeNO group and 1.22 for the guidelines group.
Scenarios M6 and M7: alternative sources of exacerbation rates and ICS use for adults
In scenarios M6 and M7, the model was evaluated using alternative estimates of exacerbation rates and ICS
use over time, based on the RCTs reported by Smith et al.119 (scenario M6) and Syk et al.99 (scenario M7).
Using data from Smith et al.,119 we estimated severe exacerbation rates of 0.16 and 0,17 for the FeNO and
guidelines groups respectively. ICS use in the first year, relative to the first observation, was estimated to
be 0.85 and 1.08 for the FeNO and guidelines groups respectively. ICS use based on the last observation
was estimated to be 0.90 and 1.30 for the FeNO and guidelines groups respectively.
Using data from Syk et al.,99 we estimated exacerbation rates of 0.09 and 0.07 for the FeNO and
guidelines groups respectively. ICS use in the first year, relative to the first observation, was estimated to
be 0.97 and 0.96 for the FeNO and guidelines groups respectively. ICS use based on the last observation
was estimated to be 0.88 and 0.99 for the FeNO and guidelines groups respectively.
Scenarios M8–M17: alternative assumptions regarding the duration of impact of
FeNO monitoring
A number of scenarios were undertaken to examine the impact of assuming alternative durations over which
FeNO monitoring would impact on ICS use and exacerbations. The durations examined were 1 year, 2 years,
3 years, 4 years, 5 years, 10 years, 15 years, 20 years, 30 years and 40 years (scenarios M8–M17 respectively).
Scenarios M18 and M19: FeNO test costs
The model was evaluated assuming that the marginal per-test costs for all FeNO devices (NIOX MINO,
NIOX VERO and NObreath) are double (scenario M18) or half (scenario M19) those assumed in the
base-case analysis.
Scenarios M20–M22: alternative assumptions concerning the lifetime of the
NObreath device
In scenario M20, the model was evaluated assuming a maximum lifetime for the NObreath device of
3 years (equal to the maximum lifetime of the NIOX MINO device). In scenario M21, the analysis was
repeated assuming a maximum lifetime for the NObreath device of 5 years (equal to the maximum lifetime
of the NIOX VERO device). In scenario M22, the analysis was repeated assuming a maximum lifetime for
the NObreath device of 20 years (double that assumed in the base case). These result in marginal per-test
costs for the NObreath device of £14.32, £8.88 and £2.32 for scenarios M20, M21 and M22 respectively.
Scenarios M23 and M24: nurse visits
The model was evaluated assuming that the number of nurse visits for the FeNO group was double
(scenario M23) or half (scenario M24) the number applied in the base-case analysis.
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Scenarios M25 and M26: alternative assumptions regarding exacerbation rates
The model was evaluated assuming that the exacerbation rates for the FeNO and guidelines groups are
double (scenario M25) or half (scenario M26) those rates assumed in the base-case analysis.
Scenarios M27 and M28: alternative assumptions regarding exacerbation disutility
The model was evaluated assuming that the exacerbation disutilities for the FeNO and guidelines groups
are double (scenario M27) or half (scenario M28) those disutilities assumed in the base-case analysis.
Scenario M29: mean observed inhaled corticosteroid use projected forward
The model was evaluated assuming that mean ICS use observed within the clinical trials is maintained
over the remainder of the model time horizon.
Scenarios M30 and M31: alternative assumptions regarding inhaled
corticosteroid dose change over time
The model was evaluated assuming that the mean RDI for ICSs in the FeNO and guidelines groups is
double (scenario M30) or half (scenario M31) that assumed in the base-case analysis.
With the exception of scenarios M4–M7, all DSAs within the management model were undertaken in both
the child subgroup and the adult subgroup.
Model validation methods
We took a number of measures to ensure the credibility of the models and their results. The conceptual
models were discussed extensively amongst the EAG before implementation. The lead modeller (PT) checked
the integrity of all model calculations and VBA (Visual Basic for Applications) programming whilst developing
the model. The models were rechecked once they were complete. PT also rebuilt deterministic versions of both
models in a more disaggregated form to ensure that all calculations were implemented as intended; these
replicated models gave exactly the same results as the full models. All model input parameters and pre-model
analyses were checked and inputted values were compared against the sources from which they were derived.
The results of the models were compared against our a priori expectations, given the model structures and
input parameters, and any discrepancies were investigated. A large number of sensitivity analyses and
black-box tests were undertaken to ensure that the models were behaving as expected. Finally, the assessment
report was peer reviewed by clinical experts, other researchers within the School of Health and Related
Research (ScHARR), University of Sheffield, and NICE (see Acknowledgements).
De novo model results
Diagnostic model results (all patients)
Central estimates of cost-effectiveness: diagnosis (all patients)
Table 70 presents the central estimates of cost-effectiveness based on the probabilistic version of the
diagnostic model. The results suggest that, across the 17 diagnostic options included in the economic
analysis, the expected difference in QALY gains is likely to be very small. NIOX MINO and NIOX VERO,
alone or in combination with other tests, are expected to be dominated as their marginal per-test cost is
higher than that for NObreath. Airway hyper-responsiveness (MCT) is expected to produce the greatest
QALY gain; this is because this option has both the highest sensitivity and the highest specificity of all of
the tests included in the economic analysis. With the exception of FeNO (NObreath) plus bronchodilator
reversibility, all other options are expected to be ruled out by simple dominance. The incremental
cost-effectiveness of airway hyper-responsiveness compared with FeNO plus bronchodilator reversibility is
expected to be approximately £1.125M per QALY gained. This information is presented on the absolute
cost-effectiveness plane in Figure 27.
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TABLE 70 Central estimates of cost-effectiveness: diagnosis
Option QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£)
Incremental cost per
QALY gained (£)
Airway hyper-responsiveness (MCT) 4.2834 1226.00 0.0005 539.92 1,125,074
FeNO+ bronchodilator reversibility
(NObreath)
4.2829 686.08 – – –
FeNO+ bronchodilator reversibility
(NIOX VERO)
4.2829 687.61 – – Dominated
FeNO+ bronchodilator reversibility
(NIOX MINO)
4.2829 688.33 – – Dominated
FeNO+ sputum induction (NObreath) 4.2812 1265.78 – – Dominated
FeNO+ sputum induction (NIOX VERO) 4.2812 1267.32 – – Dominated
FeNO+ sputum induction (NIOX MINO) 4.2812 1268.03 – – Dominated
FeNO+ FEV1 (NObreath) 4.2783 810.14 – – Dominated
FeNO+ FEV1 (NIOX VERO) 4.2783 811.67 – – Dominated
FeNO+ FEV1 (NIOX MINO) 4.2783 812.38 – – Dominated
Sputum induction 4.2774 1328.28 – – Dominated
FeNO (NObreath) 4.2771 819.94 – – Dominated
FeNO (NIOX VERO) 4.2771 821.47 – – Dominated
FeNO (NIOX MINO) 4.2771 822.18 – – Dominated
PEF 4.2719 877.91 – – Dominated
Bronchodilator reversibility 4.2710 886.27 – – Dominated
FEV1/FVC 4.2686 907.71 – – Dominated
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FIGURE 27 Cost-effectiveness plane: diagnosis (all patients).
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Uncertainty analysis: diagnosis (all patients)
Figure 28 presents CEACs for the diagnostic options. Assuming a willingness-to-pay threshold of £20,000
per QALY gained, FeNO plus bronchodilator reversibility (using NObreath) has the highest probability of
producing the greatest amount of net benefit (probability= 0.98). Assuming a willingness-to-pay threshold
of £30,000 per QALY gained, FeNO plus bronchodilator reversibility (using NObreath) also has the highest
probability of producing the greatest amount of net benefit (probability= 0.95). These results are also
summarised in Table 71.
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FIGURE 28 Cost-effectiveness acceptability curves: diagnosis (all patients).
TABLE 71 Probability of optimality: diagnosis (all patients)
Option
Probability optimal:
λ= £20,000 per QALY gained
Probability optimal:
λ= £30,000 per QALY gained
FeNO (NIOX MINO) 0.00 0.00
FeNO (NIOX VERO) 0.00 0.00
FeNO (NObreath) 0.00 0.00
FeNO+ FEV1 (NIOX MINO) 0.00 0.00
FeNO+ FEV1 (NIOX VERO) 0.00 0.00
FeNO+ FEV1 (NObreath) 0.02 0.05
FeNO+ sputum induction (NIOX MINO) 0.00 0.00
FeNO+ sputum induction (NIOX VERO) 0.00 0.00
FeNO+ sputum induction (NObreath) 0.00 0.00
FeNO+ bronchodilator reversibility (NIOX MINO) 0.00 0.00
FeNO+ bronchodilator reversibility (NIOX VERO) 0.00 0.00
FeNO+ bronchodilator reversibility (NObreath) 0.98 0.95
FEV1/FVC 0.00 0.00
PEF 0.00 0.00
Bronchial reversibility 0.00 0.00
Airway hyper-responsiveness (MCT) 0.00 0.00
Sputum induction 0.00 0.00
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Deterministic sensitivity analysis: diagnosis (all patients)
Tables 72–77 present the results of the DSAs. In all analyses the rank ordering of non-dominated options
is maintained except when indicated by square brackets.
The DSAs indicate the following:
l Across the majority of scenarios, the cost-effectiveness frontier presented in the base-case analysis
[which includes only airway hyper-responsiveness (MCT) and FeNO plus bronchodilator reversibility]
is maintained. In most scenarios the majority of options are expected to be ruled out because of
simple dominance.
l The results based on the point estimates of parameters are similar to the results of the
probabilistic analysis.
l Discounting does not have a substantial effect on the cost-effectiveness of the non-dominated
diagnostic options.
l The disutility associated with loss of control in FNs has a substantial impact on the incremental
cost-effectiveness of airway hyper-responsiveness (MCT) compared with FeNO plus
bronchodilator reversibility.
l The FP exacerbation rate has no impact on the results as both non-dominated options have the
same specificity.
l The cost of the various FeNO devices has only a negligible impact on the cost-effectiveness results for
non-dominated options.
l Longer misdiagnosis correction times substantially improve the cost-effectiveness of airway
hyper-responsiveness (MCT) compared with FeNO plus bronchodilator reversibility.
l The use of other sources for the operating characteristics of FeNO monitoring and standard tests does
not impact on the cost-effectiveness of non-dominated options.
l The use of a ‘rule-out’ decision approach may improve the comparative effectiveness and
cost-effectiveness of FeNO monitoring in combination with either bronchodilator reversibility or FEV1.
l The use of a ‘rule-in’ decision approach may improve the effectiveness of FeNO monitoring plus FEV1;
however, the ICER for this option (compared with FeNO monitoring plus bronchodilator reversibility) is
in excess of £63,000 per QALY gained.
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TABLE 76 Deterministic sensitivity analyses: diagnosis (all patients) – scenarios D26–D28 (cost per QALY gained)
Option
D26: FeNO
operating
characteristics from
Schleich et al.77 (£)
D27: FeNO
operating
characteristics from
Pedrosa et al.85 (£)
D28: other test
operating
characteristics from
Smith et al.86 (£)
Airway hyper-responsiveness (MCT) 1,094,325 1,094,325 1,094,325
FeNO+ bronchodilator reversibility (NObreath) – – –
FeNO+ bronchodilator reversibility (NIOX VERO) Dominated Dominated Dominated
FeNO+ bronchodilator reversibility (NIOX MINO) Dominated Dominated Dominated
FeNO+ sputum induction (NObreath) Dominated Dominated Dominated
FeNO+ sputum induction (NIOX VERO) Dominated Dominated Dominated
FeNO+ sputum induction (NIOX MINO) Dominated Dominated Dominated
FeNO+ FEV1 (NObreath) Dominated Dominated Dominated
FeNO+ FEV1 (NIOX VERO) Dominated Dominated Dominated
FeNO+ FEV1 (NIOX MINO) Dominated Dominated Dominated
Sputum induction Dominated Dominated Dominated
FeNO (NObreath) Dominated Dominated Dominated
FeNO (NIOX VERO) Dominated Dominated Dominated
FeNO (NIOX MINO) Dominated Dominated Dominated
PEF Dominated Dominated Dominated
Bronchodilator reversibility Dominated Dominated Dominated
FEV1/FVC Dominated Dominated Dominated
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Management model results (children)
Central estimates of cost-effectiveness: management (children)
Table 78 presents the central estimates of cost-effectiveness based on the probabilistic version of the child
management model. The results suggest that FeNO testing is expected to produce a small health benefit
compared with guidelines alone (0.05 QALYs). FeNO testing is also expected to be more expensive than
guidelines alone; this is because of the projected ICS use for the FeNO groups. The results also indicate, as
expected, that NIOX MINO and NIOX VERO are expected to be dominated by NObreath because of their
slightly higher marginal per-test cost. The incremental cost-effectiveness of NObreath compared with
guidelines is expected to be approximately £45,213 per QALY gained. This information is presented on the
absolute cost-effectiveness plane in Figure 29.
TABLE 78 Central estimates of cost-effectiveness: management (children)
Option QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£)
Incremental
cost per QALY
gained (£)
Guidelines plus FeNO monitoring
(NObreath)
23.6767 8148.59 0.0506 2288.53 45,213
Guidelines plus FeNO monitoring
(NIOX VERO)
23.6767 8314.30 – – Dominated
Guidelines plus FeNO monitoring
(NIOX MINO)
23.6767 8391.53 – – Dominated
Guidelines 23.6261 5860.06 – – –
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FIGURE 29 Cost-effectiveness plane: management (children).
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Uncertainty analysis: management (children)
Figure 30 presents CEACs for the management options in the child subgroup. These data are also summarised
in Table 79. Assuming a willingness-to-pay threshold of £20,000 per QALY gained, use of guidelines alone
has the highest probability of producing the greatest amount of net benefit (probability= 0.99). Assuming a
willingness-to-pay threshold of £30,000 per QALY gained, use of guidelines alone also has the highest
probability of producing the greatest amount of net benefit (probability= 0.91).
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FIGURE 30 Cost-effectiveness acceptability curves: management (children).
TABLE 79 Probability of optimality: management (children)
Option
Probability optimal: λ= £20,000
per QALY gained
Probability optimal: λ= £30,000
per QALY gained
Guidelines 0.99 0.91
Guidelines plus FeNO monitoring
(NIOX MINO)
0.00 0.00
Guidelines plus FeNO monitoring
(NIOX VERO)
0.00 0.00
Guidelines plus FeNO monitoring
(NObreath)
0.01 0.09
λ, willingness-to-pay threshold.
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Deterministic sensitivity analysis results
Table 80 presents the results of the DSAs.
The DSAs indicate the following:
l The results of the analysis using point estimates of parameters are similar to those produced using the
probabilistic model.
l NIOX MINO and NIOX VERO are expected to be consistently dominated by NObreath because of their
higher marginal per-test costs.
l Although the marginal per-test cost influences which device would be preferred, it does not have a
substantial impact on the overall cost-effectiveness of FeNO monitoring compared with guidelines.
l Discounting has little impact on the cost-effectiveness of FeNO monitoring.
l The duration over which FeNO monitoring is assumed to impact on exacerbations and ICS use is a key
parameter within the child subgroup. Shorter durations of impact improve the cost-effectiveness of
FeNO monitoring.
l The analysis based on data from Pijnenburg et al.106 suggests a considerably more favourable ICER for
FeNO monitoring compared with guidelines in children. This may be explained by the fact that the
Szefler et al.104 study was undertaken in uncontrolled patients and the study protocol did not allow
therapy to be stepped down on the basis of low FeNO levels alone. This may in part explain why ICS
use was higher for FeNO monitoring than for guidelines alone.
l The model is sensitive to the rate of exacerbations (and associated health loss) and assumptions
regarding the number of monitoring visits in which FeNO monitoring is used.
TABLE 80 Deterministic sensitivity analyses: management (children) (cost per QALY gained)
Scenario
Guidelines plus
FeNO (NObreath)
(£)
Guidelines plus
FeNO (NIOX VERO)
(£)
Guidelines plus
FeNO (NIOX MINO)
(£) Guidelines (£)
M1 Point estimates of
parameters
45,138 Dominated Dominated –
M2 Undiscounted costs
and outcomes
46,894 Dominated Dominated –
M3 Discount rate= 6% 44,555 Dominated Dominated –
M5 Analysis based on
Pijnenburg et al.106
18,963 Dominated Dominated –
M8 FeNO impact= 1 year Dominating Dominated Dominated Dominated
M9 FeNO impact= 2 years Dominating Dominated Dominated Dominated
M10 FeNO impact= 3 years Dominating Dominated Dominated Dominated
M11 FeNO impact= 4 years Dominating Dominated Dominated Dominated
M12 FeNO impact= 5 years 7598 Dominated Dominated –
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TABLE 80 Deterministic sensitivity analyses: management (children) (cost per QALY gained) (continued )
Scenario
Guidelines plus
FeNO (NObreath)
(£)
Guidelines plus
FeNO (NIOX VERO)
(£)
Guidelines plus
FeNO (NIOX MINO)
(£) Guidelines (£)
M13 FeNO impact=
10 years
27,660 Dominated Dominated –
M14 FeNO impact=
15 years
34,337 Dominated Dominated –
M15 FeNO impact=
20 years
37,674 Dominated Dominated –
M16 FeNO impact=
30 years
41,025 Dominated Dominated –
M17 FeNO impact=
40 years
42,721 Dominated Dominated –
M18 Marginal per-test
FeNO cost doubled
55,409 Dominated Dominated –
M19 Marginal per-test
FeNO cost halved
40,003 Dominated Dominated –
M20 NObreath lifetime=
3 years
47,780 Dominated Dominated –
M21 NObreath lifetime=
5 years
45,963 Dominated Dominated –
M22 NObreath lifetime=
20 years
45,925 Dominated Dominated –
M23 FeNO nurse visits
doubled
84,564 Dominated Dominated –
M24 FeNO nurse visits
halved
25,425 Dominated Dominated –
M25 Exacerbation rates
doubled
19,891 Dominated Dominated –
M26 Exacerbation rates
halved
95,632 Dominated Dominated –
M27 Exacerbation disutility
doubled
31,479 Dominated Dominated –
M28 Exacerbation disutility
halved
52,844 Dominated Dominated –
M29 ICS observed mean
carried forward
37,452 Dominated Dominated –
M30 ICS change doubled 56,206 Dominated Dominated –
M31 ICS change halved 39,604 Dominated Dominated –
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Management model results (adults)
Central estimates of cost-effectiveness: management (adults)
Table 81 presents the central estimates of cost-effectiveness based on the probabilistic version of the adult
management model. FeNO testing is expected to produce a small incremental health gain compared with
standard guidelines (0.04 QALYs). The results also suggest that NIOX MINO and NIOX VERO are expected
to be dominated by NObreath (again, this is because of the slightly lower marginal per-test cost for this
device). In this population subgroup, the NObreath device plus guidelines compared with guidelines alone
is expected to cost approximately £2146 per QALY gained. This information is presented on the absolute
cost-effectiveness plane in Figure 31.
TABLE 81 Central estimates of cost-effectiveness: management (adults)
Option QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£)
Incremental cost
per QALY gained (£)
Guidelines plus FeNO monitoring
(NObreath)
21.9397 7377.61 0.0379 81.31 2146
Guidelines plus FeNO monitoring
(NIOX VERO)
21.9397 7535.43 – – Dominated
Guidelines plus FeNO monitoring
(NIOX MINO)
21.9397 7608.99 – – Dominated
Guidelines 21.9018 7296.30 – – –
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Guidelines plus FeNO monitoring (NIOX MINO)
Guidelines
FIGURE 31 Cost-effectiveness plane: management (adults).
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Uncertainty analysis: management (adults)
Figure 32 presents CEACs for the management options in the adult subgroup. Assuming a willingness-to-pay
threshold of £20,000 per QALY gained, FeNO monitoring using NObreath plus guidelines has the highest
probability of producing the greatest amount of net benefit (probability= 0.82). Assuming a willingness-to-pay
threshold of £30,000 per QALY gained, FeNO monitoring using NObreath plus guidelines also has the highest
probability of producing the greatest amount of net benefit (probability= 0.87). These results are summarised
in Table 82.
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FIGURE 32 Cost-effectiveness acceptability curves: management (adults).
TABLE 82 Probability of optimality: management (adults)
Option
Probability optimal: λ= £20,000
per QALY gained
Probability optimal: λ= £30,000
per QALY gained
Guidelines 0.18 0.13
Guidelines plus FeNO monitoring
(NIOX MINO)
0.00 0.00
Guidelines plus FeNO monitoring
(NIOX VERO)
0.00 0.00
Guidelines plus FeNO monitoring
(NObreath)
0.82 0.87
λ, willingness-to-pay threshold.
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Deterministic sensitivity analyses
Table 83 presents the results of the DSAs.
The DSAs indicate the following:
l The results of the analysis using point estimates of parameters are very similar to those produced using
the probabilistic version of the model.
l NIOX MINO and NIOX VERO are expected to be consistently dominated by NObreath because of their
higher marginal per-test costs.
l FeNO monitoring using NObreath is expected to dominate standard guidelines in the subgroup of
women who are pregnant.
l Discounting has little impact on the cost-effectiveness of FeNO monitoring.
l Although the marginal per-test cost influences which device would be preferred, it does not have a
substantial impact on the overall cost-effectiveness of FeNO monitoring compared with guidelines.
l The use of exacerbation rates from Syk et al.99 and Smith et al.119 has a substantial negative impact on
the cost-effectiveness of FeNO monitoring.
l The duration over which FeNO monitoring is assumed to impact on exacerbations and ICS use is
a key driver of cost-effectiveness. It is noteworthy that, in the adult subgroup, cost-effectiveness
improves over longer time horizons whereas the opposite is true in the child subgroup, in which
cost-effectiveness worsens over longer time horizons. This is driven entirely by the observed differences
in relative ICS use for FeNO monitoring and guidelines at the last observed time point in the trials.
l The cost-effectiveness of FeNO monitoring is markedly less favourable when projected ICS use is
modelled according to the mean ICS use observed in the trial reported by Shaw et al.98
TABLE 83 Deterministic sensitivity analyses: management (adults) (cost per QALY gained)
Scenario
Guidelines plus
FeNO (NObreath)
(£)
Guidelines plus
FeNO (NIOX VERO)
(£)
Guidelines plus
FeNO (NIOX MINO)
(£) Guidelines (£)
M1 Point estimates of
parameters
2248 Dominated Dominated –
M2 Undiscounted costs
and outcomes
740 Dominated Dominated –
M3 Discount rate= 6% 3534 Dominated Dominated –
M4 Pregnant women
subgroup
Dominating Dominated Dominated –
M6 Analysis based on
Smith et al.119
184,095 Dominated Dominated –
M7 Analysis based on
Syk et al.99
Dominated Dominated Dominated Dominating
M8 FeNO impact= 1 year 885,451 Dominated Dominated –
M9 FeNO impact= 2 years 434,284 Dominated Dominated –
M10 FeNO impact= 3 years 283,954 Dominated Dominated –
M11 FeNO impact= 4 years 208,833 Dominated Dominated –
M12 FeNO impact= 5 years 163,795 Dominated Dominated –
M13 FeNO impact=
10 years
73,975 Dominated Dominated –
M14 FeNO impact=
15 years
44,320 Dominated Dominated –
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TABLE 83 Deterministic sensitivity analyses: management (adults) (cost per QALY gained) (continued )
Scenario
Guidelines plus
FeNO (NObreath)
(£)
Guidelines plus
FeNO (NIOX VERO)
(£)
Guidelines plus
FeNO (NIOX MINO)
(£) Guidelines (£)
M15 FeNO impact=
20 years
29,707 Dominated Dominated –
M16 FeNO impact=
30 years
15,531 Dominated Dominated –
M17 FeNO impact=
40 years
8898 Dominated Dominated –
M18 Marginal per-test
FeNO cost doubled
15,273 Dominated Dominated –
M19 Marginal per-test
FeNO cost halved
Dominating Dominated Dominated –
M20 NObreath lifetime=
3 years
5598 Dominated Dominated –
M21 NObreath lifetime=
5 years
3294 Dominated Dominated –
M22 NObreath lifetime=
20 years
3246 Dominated Dominated –
M23 FeNO nurse visits
doubled
52,246 Dominated Dominated –
M24 FeNO nurse visits
halved
Dominating Dominated Dominated –
M25 Exacerbation rates
doubled
Dominating Dominated Dominated –
M26 Exacerbation rates
halved
9958 Dominated Dominated –
M27 Exacerbation disutility
doubled
1563 Dominated Dominated –
M28 Exacerbation disutility
halved
2634 Dominated Dominated –
M29 ICS observed mean
carried forward
66,453 Dominated Dominated –
M30 ICS change doubled Dominating Dominated Dominated –
M31 ICS change halved 23,392 Dominated Dominated –
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Discussion
Summary of cost-effectiveness evidence
There is very limited evidence available on the cost-effectiveness of FeNO testing for the diagnosis and/or
management of asthma. The systematic review presented in this chapter identified one published UK
model of FeNO testing in the diagnostic setting and one published model of FeNO testing in the
management setting. These models were published within the same paper.147 Aerocrine submitted a
model of FeNO testing for diagnosis and a model of FeNO testing for management; these models were
similar to, but not the same as, the published Price et al.147 models.
The Price et al.147 diagnostic model indicates that NIOX MINO is likely to be cost saving in comparison to
other tests routinely used in the diagnosis of asthma. The model analysis presented by Price et al.147 also
suggests that NIOX MINO is expected to be more expensive than standard diagnostic tests when used in
conjunction with other tests. The EAG critique of this model highlighted a number of problems including
the use of a blended comparison, the questionable selection of evidence used to inform the model’s
parameters and the absence of any quantified health consequences associated with diagnostic test
outcomes. The Aerocrine diagnostic model is similar in structure to the published version but does not use
a blended comparison approach and includes some updated parameter values. However, the Aerocrine
model also fails to reflect the health consequences associated with correct or incorrect diagnostic
outcomes. Because of their limited scope, these diagnostic models do not provide any information
regarding the economic trade-off between potential additional health gains resulting from the more
accurate diagnosis of asthma and the health loss associated with displacing existing services.
The Price et al.147 management model compares FeNO monitoring using NIOX MINO with guidelines.
This model was evaluated within a cost–utility framework and indicates that NIOX MINO produces more
health gain at a lower cost than guidelines; in other words, NIOX MINO dominates management using
guidelines alone. Aerocrine submitted a similar management model that included some different data
and assumptions but ultimately produced the same conclusion as the published analysis reported by
Price et al.147 The EAG critique of these management models highlighted a number of problems including
the use of a short time horizon, the selective use of efficacy evidence, the assumptions made regarding
equivalence between sputum count monitoring and FeNO and invalid assumptions regarding the health
losses associated with exacerbations. No economic evidence was submitted by the manufacturers for either
NIOX VERO or NObreath. The EAG takes the view that neither the published Price et al.147 models nor the
submitted Aerocrine models represent a suitable basis for informing decision-making about the use of
FeNO testing for the diagnosis or management of asthma.
In light of the problems with the available evidence, the EAG developed two de novo models:
1. a model to assess the cost-effectiveness of FeNO testing using NIOX MINO, NIOX VERO and NObreath
in addition to, or in place of, existing tests compared with other diagnostic options commonly used in
the diagnosis of asthma
2. a model to assess the cost-effectiveness of NIOX MINO, NIOX VERO and NObreath plus guidelines
compared with guidelines alone for the management of asthma.
The EAG diagnostic model suggests that, across the diagnostic options included in the economic analysis,
the expected difference in QALY gains is likely to be very small. Airway hyper-responsiveness (MCT) is
expected to produce the greatest QALY gain; this is because this option has the highest sensitivity of all
of the tests included in the economic analysis. All options that include NIOX MINO or NIOX VERO are
expected to be dominated as their marginal per-test cost is higher than that for NObreath (assuming a
device lifetime of 10 years). In the base-case analysis, all options except airway hyper-responsiveness (MCT)
and FeNO monitoring (NObreath) plus bronchodilator reversibility testing are expected to be ruled out by
simple dominance. The incremental cost-effectiveness of airway hyper-responsiveness (MCT) compared
with FeNO monitoring (using NObreath) plus bronchodilator reversibility is expected to be £1.125M per
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QALY gained. The results of the analysis are particularly sensitive to assumptions about the duration of
time required to resolve misdiagnoses, assumptions about health losses incurred by patients who are FNs,
the costs of asthma management and the use of ‘rule-in’ and ‘rule-out’ diagnostic decision rules.
The EAG management model was evaluated across two subgroups: (1) children and (2) adults. Within
both the child and the adult subgroup base-case analyses, FeNO testing is expected to produce a small
incremental QALY gain compared with guidelines alone. In both subgroups, NIOX MINO and NIOX VERO
are expected to be dominated as their marginal per-test costs are higher than that for NObreath. Within
the child subgroup, the incremental cost-effectiveness of guidelines plus FeNO monitoring using NObreath
compared with guidelines alone is expected to be approximately £45,200 per QALY gained. This ICER is
influenced considerably by the assumed change in ICS use, which is applied over a lifetime horizon. Within
the adult subgroup, FeNO monitoring using NObreath compared with guidelines alone is expected to cost
approximately £2100 per QALY gained. A similarly favourable result was produced within a further analysis
based on a subgroup of women who are pregnant.102 Importantly, these positive results are not held when
alternative trials are used to inform the analysis.99,119 The results in the child and adult subgroups are
particularly sensitive to assumptions regarding changes in ICS use over time, the number of nurse visits for
FeNO monitoring and the duration over which FeNO monitoring is assumed to impact on exacerbations
and ICS use.
Limitations of the External Assessment Group models
Although the EAG models presented here do resolve many of the problems identified within the
Price et al.147/Aerocrine models, the results drawn from these models remain subject to considerable
uncertainty. These are briefly discussed in the following sections.
Limitations of the diagnostic model
The following represent the key limitations and uncertainties within the EAG diagnostic model:
l Use of naive indirect comparisons. Limitations in the diagnostic evidence base meant that naive indirect
comparisons across studies that assess the diagnostic accuracy of different tests were used in the
model. The review presented in Chapter 3 highlighted considerable heterogeneity between these
studies. As such, the results of the economic analysis of FeNO monitoring in the diagnostic setting
should be interpreted with caution.
l Non-systematic approach to including non-FeNO comparators. We did not undertake a systematic
review of evidence concerning the diagnostic accuracy of existing tests used in the diagnosis of asthma
but instead relied on studies picked up by our systematic review of FeNO studies.86,163 Although a
formal review of other tests (excluding FeNO monitoring) would be valuable, this was beyond the
scope of the assessment and the time and resources available to the EAG precluded this work. It is
likely that other studies exist and it is possible that these could be considered more relevant than the
studies used in the EAG model.
l Use of a ‘blunt’ model structure. We adopted a similar model structure to that of Price et al.,147 which
assesses options at a particular point in the diagnostic pathway rather than attempting to simulate the
entire sequence of tests used throughout the pathway. This model development decision was taken
because of limitations in the available evidence.
l Uncertainty surrounding health losses associated with misdiagnosis. We crudely elicited estimates of the
duration required to resolve a FN/FP diagnosis. Only one of our experts was able to tentatively quantify
the likely values of these parameters. These estimates are very uncertain. There is also uncertainty
surrounding the magnitude of the HRQoL loss as well as the duration over which this loss is incurred.
It is possible that health losses associated with FP diagnoses in patients with more serious underlying
pathology are underestimated. It is not clear how this uncertainty could be resolved empirically.
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Limitations of the management model
The following represent the key limitations and uncertainties within the EAG management model:
l Use of effectiveness evidence. The model uses individual studies within the child and adult subgroups.
These studies were deemed by the EAG to most closely reflect asthma management in England and
Wales. However, the Szefler et al.104 study was undertaken in the USA and does not fully match
BTS/SIGN guidelines8 on dose titration. Only the use of guidelines in the comparator group within the
Shaw et al.98 study can be considered as ‘standard’ within the UK.
l Uncertainty surrounding the duration over which FeNO monitoring impacts on dose titration. In line
with the NICE reference case, the EAG model reflects a lifetime horizon. There is, however,
considerable uncertainty with respect to the duration over which FeNO monitoring would result in
different exacerbation rates and ICS use compared with guidelines alone. Within the base-case analysis
we assumed that this impact would be sustained indefinitely. The sensitivity analysis shows that this
parameter is a key driver of cost-effectiveness.
Both the EAG diagnostic model and the EAG management model assume that all FeNO devices have
the same diagnostic properties in terms of absolute FeNO measurements and how this translates into
sensitivity and specificity. This necessary assumption may not hold in reality.
Areas for further research
Further research would be valuable to reduce some of the uncertainties detailed in the previous sections.
In particular, comparative studies that include FeNO monitoring alongside the range of existing standard
tests with a common population and a common reference standard of long-term follow-up of at least
1 year would be useful in assessing the comparative accuracies of these alternative diagnostic strategies.
In addition, longer-term studies of FeNO monitoring in combination with standard UK management
guidelines would be beneficial to better understand the long-term impacts on asthma medication use
and exacerbations.
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Chapter 5 Assessment of factors relevant to the
NHS and other parties
Beyond its likely clinical effectiveness and cost-effectiveness, a number of other factors relating to theimplementation of FeNO testing in the NHS require consideration.
Training and education
The introduction of FeNO testing for the diagnosis and/or management of asthma has implications for
training and education in terms of teaching NHS staff how to instruct patients to use the devices correctly
to minimise test failure rates. Repeatability and accuracy of the devices are not dependent on patient
performance as the devices will not produce a measurement if flow rate and length of exhalation limits are
not met. The precise training and education requirements associated with introducing FeNO testing are
dependent on whether it is routinely recommended and, if so, the setting that such recommendations
relate to. Training may be required for primary care nurses and GPs or for secondary care staff or for both.
It should be noted that these additional costs are not reflected in the marginal per-test costs used within
the economic analysis presented in Chapter 4.
Purchasing of equipment and consumables
The diffusion of FeNO testing into routine NHS practice would involve the purchasing of additional
equipment either for GP surgeries or for hospitals. Equipment costs include the costs of the devices, the
replacement parts (NObreath only) and other consumables (test kit mouthpieces). The NIOX MINO and
NIOX VERO devices both have a finite lifetime and would need to be replaced at a maximum of 3 years
and 5 years respectively. The NObreath device does not have a finite lifetime but does require replacement
sensor cells every 2 years. Each FeNO device requires the purchase of test kit mouthpieces; the volume
purchased and the number of tests undertaken will influence the overall marginal per-test cost of each
device for GP surgeries and trusts. Maintenance of the NObreath device is expected to be free of charge
to the NHS. Aerocrine did not mention the cost of maintenance in its cost estimates.
Replacement of the NIOX MINO device with the newer NIOX
VERO device
It is anticipated that the NIOX MINO device will soon be replaced with the newer NIOX VERO device. Both
FeNO devices will be available for some time but, in the long term, the NIOX MINO device will eventually
become redundant. It is likely that the NIOX VERO device will be less expensive (per test) than the NIOX
MINO device and hence the justification for purchasing the NIOX MINO device is unclear.
Impact on the demand for current standard diagnostic tests
The introduction of FeNO testing in a diagnostic setting will likely have an impact on the demand for
other existing standard tests currently used in the diagnosis of asthma. This change in the level of demand
for existing standard tests will be dependent on how FeNO testing is incorporated into the existing asthma
diagnosis pathway.
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FeNO testing in children
The diagnostic and clinical evidence considered in this assessment is restricted to patients aged ≥ 5 years.
The potential diagnostic/management benefit of FeNO use in younger children is unknown.
FeNO testing in older adults
Monitoring of FeNO levels does not seem to be a useful test in the diagnosis or management of older
adults with asthma. In this population, other current standard tests and management approaches may be
more applicable.
Patients with respiratory tract infections
Most studies included in this assessment (see Chapter 3) purposefully excluded patients with a recent
respiratory tract infection. The diagnostic utility of FeNO testing in these patients is unclear. It may be more
appropriate either to use standard diagnostic tests in these patients or to allow a period of recovery before
using FeNO testing.
ASSESSMENT OF FACTORS RELEVANT TO THE NHS AND OTHER PARTIES
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Chapter 6 Discussion
Statement of principal findings
Equivalence of devices
Although there was often a good correlation between FeNO measurement devices, equivalence of
readings could not necessarily be assumed in all situations. Many studies concluded that the comparability
of measurements between devices was within clinically acceptable limits; however, others went on to
produce correction equations to correct for systematic bias in measurements. There was also no common
justified definition of clinically acceptable differences and 95% limits of agreement were sometimes very
wide (around 20 ppb). There seemed to be a generally consistent observation of poorer equivalence
between FeNO devices at higher FeNO levels. The direction of disagreement varied between studies and
between comparator devices.
However, as there is mostly a high degree of correlation between measurements across all devices,
estimates of sensitivity and specificity are likely to be a reasonable indication of the potential diagnostic
accuracy of using FeNO monitoring to guide diagnosis and management, but the derived cut-off points are
not likely to be interchangeable between devices. As such, for the purpose of this assessment, sensitivities
and specificities will be assumed to be interchangeable, but it cannot be assumed that the cut-off points
that should be used to achieve them will be the same in each device, and there is still some doubt whether
the same diagnostic accuracy would be achievable in all devices. This is an important issue that should be
considered in the interpretation of the diagnostic accuracy review and the findings of the health economic
analysis assessment presented within this report.
Test failure rates were generally low for all devices in adults, with the highest reported rate being 3.3%.
With regard to children, there may be some problems with using the NIOX MINO device in younger
children, with failure rates ranging from 5.5% to 27%. One study used the NObreath device with children
and reported no test failures.
Diagnostic accuracy review
This review identified several groups of studies that were similar to one another in terms of the position of the
patients in the UK pathway and the reference standards used. Groups were adults presenting with symptoms
of asthma compared with most of or the entire UK pathway; a subset of adults presenting with symptoms of
asthma compared with airway hyper-responsiveness; difficult-to-diagnose patients compared with airway
hyper-responsiveness; patients with chronic cough who were difficult to diagnose compared with ICS
responsiveness; and children with symptoms of asthma compared with various reference standards.
No meta-analysis was conducted in any group as clinical heterogeneity between studies was generally
extremely high. Estimates of sensitivity and specificity were not consistent within groups and ranged widely
in rule-in scenarios, rule-out scenarios and when the pair with the highest sum of sensitivity and specificity
were selected. Table 84 summarises the results across studies and groups of studies. Given the wide-ranging
estimates of sensitivity and specificity, together with heterogeneous cut-off points, it is difficult to draw
any firm conclusions as to the diagnostic accuracy of FeNO monitoring in any situation and at any given
cut-off point. Interestingly, there did not appear to be an obvious difference between the diagnostic
accuracy of FeNO monitoring compared with the whole or parts of the UK pathway in patients who
present with symptoms of asthma and the diagnostic accuracy of FeNO monitoring compared with airway
hyper-responsiveness in patients who are difficult to diagnose. The large variation in estimates within
groups may obscure any true underlying differences in the accuracy of FeNO monitoring between groups
and compared with different reference standards.
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However, some limited observations can be made. It would appear that FeNO monitoring was more often
able to reach 100% specificity than 100% sensitivity and that ranges of specificity were generally tighter.
This may indicate that it has the most potential for use as a rule-in test. It would also appear that FeNO
cut-off points should probably be lower in children than in adults.
In addition to the above, two studies were found that reported results for FeNO monitoring in conjunction
with another test in adults, one in those difficult to diagnose77 and one in patients of all ages with
symptoms of asthma.87 In both cases the addition of another test to the diagnostic protocol resulted in a
change in diagnostic accuracy, but as this involved the usual trade-off between sensitivity and specificity it
is difficult to tell if this represents an increase or decrease in clinical effectiveness and cost-effectiveness.
Evidence was limited in the subgroups defined a priori, namely pregnant women, the elderly and
smokers/those subjected to environmental tobacco exposure.
l Smokers. FeNO monitoring appeared to be able to distinguish between asthmatic and non-asthmatic
adult smokers with similar accuracy as for non-smokers and ex-smokers. It would seem likely that the
FeNO level is generally lower in smokers than in mixed cohorts and it may be useful to consider a
patient’s smoking status when interpreting results or to select lower cut-off points for smokers. Limited
data in children support the same conclusion as for adults.
l The elderly. Available data were extremely limited and did not always provide appropriate comparisons
between elderly asthmatics and elderly non-asthmatics. A case–control study indicated that FeNO
monitoring is unlikely to be a useful test in the diagnosis of asthma in the elderly.
l Pregnant women. A cross-sectional study indicated that pregnancy does not alter FeNO levels in
asthmatics or non-asthmatics and that FeNO monitoring can distinguish between asthmatic and
non-asthmatic pregnant and healthy women.
FeNO-guided management of asthma
Five studies on FeNO-guided management of asthma in adults were identified. There were high levels of
heterogeneity in multiple study characteristics and outcome definitions and as such it was not possible to
draw any firm conclusions as to which step-up/step-down protocol or cut-off points offer the best efficacy.
All studies reported a fall in exacerbation rates per person-year, although it appeared that this was mostly
driven by mild and moderate exacerbations and was statistically significant in only one study.99 Exploratory
pooled analyses showed no statistically significant difference for severe exacerbations and a statistically
significant decrease in exacerbations in the intervention groups when considering the composite outcome of
any severity of exacerbation. The effects on ICS use were heterogeneous, with two studies showing
statistically significant decreases in ICS use in the FeNO-guided management groups, one study showing a
very minor increase (significance not reported) and another showing very similar levels of use in each arm.
This may indicate that some step-up/step-down protocols were better at decreasing ICS use than others or it
may be because of the characteristics of the study populations. Pooled analysis showed decreased ICS use in
the intervention arm, but the difference was not statistically significant. HRQoL was infrequently reported;
two studies used versions of the AQLQ to measure quality of life and both showed no effect of FeNO
monitoring on the global score, but one investigated domains and found a statistically significant difference
in the symptoms score.
Despite the heterogeneity in the results, and the lack of statistically significant findings in individual studies,
it would seem possible that, on the basis of an exploratory class-effects meta-analysis in adults,
FeNO-guided management protocols of some or most designs may, during the first year of management,
result in better management overall (considering all exacerbations), with either a small or a zero reduction
in ICS use. Further larger studies are needed to clarify any treatment effects. There was no evidence
relating to whether these effects would be maintained over a longer time period.
DOI: 10.3310/hta19820 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 82
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
229
In pregnant women, the use of FeNO monitoring to guide asthma management appears to be as effective
if not more effective than the use of FeNO monitoring to guide asthma management in other adults and
appears to reduce exacerbations and ICS use. This may be because of increased efficacy in pregnant
women or because of differences in step-up/step-down protocols. Notably, this protocol allowed for the
step-down of ICS use on the basis of FeNO levels alone, regardless of whether symptoms were still present
or not. A follow-up study suggests that there may be benefits to the children born to women who had
FeNO-guided asthma management that have not been captured in the economic model.
Studies looking at FeNO-guided asthma management in the elderly were limited by study quality. The
majority of studies suggest that FeNO monitoring is not useful in the elderly because of a lack of difference
in FeNO levels between elderly asthmatics and elderly non-asthmatics and no correlation between FeNO
levels, sputum eosinophils, asthma control, quality of life and so on in elderly asthmatics.
Levels of FeNO in smokers appeared to be generally lower than those in non-smokers but still appeared
to be responsive to changes in control and eosinophils. Lower cut-off values for management might be
necessary in smokers.
Seven studies in children were identified. One study appeared to recruit a group of patients who were
well controlled whereas two others recruited patients who appeared to be poorly controlled. Both reported
fewer severe exacerbations in the intervention arm, but not statistically significantly so. All studies
reported a decrease in exacerbations (however defined) in the intervention arm, but only one reported a
statistically significant reduction. The effects on ICS use were heterogeneous, with two studies showing
a statistically significant increase in ICS use, one showing no difference, one being difficult to interpret and
one further study not reporting this outcome. HRQoL was only reported within one study, although
insufficient details were reported.
Because of the high levels of heterogeneity in multiple study characteristics and outcome definitions, it was
not possible to draw any firm conclusions as to which step-up/step-down protocol or cut-off points offer the
best efficacy for management. Results were generally not statistically significant but this may be because
of small sample sizes in some cases; meta-analysis was precluded by the ability to calculate rate ratios.
However, because all but one study reported numerically smaller numbers or rates of exacerbations in the
intervention arm, it would seem possible that FeNO-guided management protocols of most descriptions
could, during the first year of management, result in better management (fewer exacerbations) overall,
despite the lack of statistically significant results in individual studies. Further larger studies are needed to
clarify any treatment effect. It is unclear whether ICS use is likely to increase or decrease and this may
depend on the details of the step-up/step-down protocols or the characteristics of the patients recruited to
the trials in terms of control and severity.
Independent assessment of cost-effectiveness
The EAG developed two de novo models. The first model assesses the cost-effectiveness of FeNO testing
using NIOX MINO, NIOX VERO and NObreath in addition to, or in place of, existing tests compared
with other diagnostic options commonly used in the diagnosis of asthma. The second model assesses the
cost-effectiveness of NIOX MINO, NIOX VERO and NObreath plus guidelines compared with guidelines
alone for the management of asthma.
The EAG diagnostic model suggests that, across the 17 options included in the analysis, airway
hyper-responsiveness (MCT) is expected to produce the greatest QALY gain. All options that include
NIOX MINO or NIOX VERO are expected to be dominated as their marginal per-test costs are higher than
that for NObreath. The incremental cost-effectiveness of airway hyper-responsiveness (MCT) compared
with FeNO testing (using NObreath) plus bronchodilator reversibility is expected to be £1.125M per QALY
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gained. All other options are ruled out of the analysis because of simple dominance. The results of the
analysis are particularly sensitive to assumptions about the duration of time required to resolve
misdiagnoses, assumptions about health losses incurred by patients who are false-negative, the costs
of asthma management and the use of ‘rule-in’ and ‘rule-out’ diagnostic decision rules.
The EAG management model was evaluated separately for the child and adult subgroups. Within both the
child and adult subgroup analyses, FeNO monitoring plus guidelines is expected to produce a small
incremental QALY gain compared with guidelines alone. NIOX MINO and NIOX VERO are expected to be
dominated as their marginal per-test costs are higher than that for NObreath. Within the adult subgroup,
FeNO monitoring using NObreath compared with guidelines alone is expected to cost approximately
£2100 per QALY gained. A similarly favourable result was produced within a further analysis based on
a subgroup of women who are pregnant.102 Importantly, these positive results for the adult subgroup do
not hold when alternative trials are used to inform the analysis.97,99 Within the child subgroup, the
incremental cost-effectiveness of guidelines plus FeNO monitoring using NObreath compared with
guidelines alone is expected to be approximately £45,200 per QALY gained. A more favourable ICER
was produced when the analysis was based on the trial reported by Pijnenburg et al.;106 this may
reflect differences in the characteristics of patients recruited to these trials, with the former trial being
uncontrolled. The results in the child and adult subgroups are particularly sensitive to assumptions
regarding changes in ICS use over time, the annual number of nurse visits for FeNO monitoring and the
duration over which FeNO monitoring is assumed to impact on exacerbation rates and ICS use.
Generalisability of the results
Generalisability of the evidence relating to FeNO monitoring in the
diagnosis of asthma
l The clinical evidence was heterogeneous in terms of clinical characteristics and results and studies
were selected for modelling based on their similarity to UK practice and similarity to the subgroups of
interest as defined in the protocol (i.e. those who are difficult to diagnose or the wider population
of those presenting with symptoms of asthma). As such, no single study can be generalised to the
whole population and this should be noted when interpreting the results of this assessment.
l Some of the subgroups of interest to the appraisal were not modelled. These groups were the elderly,
pregnant women and smokers/those exposed to environmental tobacco smoke. This was because of
limitations in the identified evidence. Only inferences as to the generalisability of results from other
studies to these populations can be made.
l The EAG model is ‘blunt’ in that it assumes that all misdiagnoses are assumed to be later corrected by
subsequent tests. The model is not specific about what these tests are.
l In addition, all but one95 of the studies used to inform the diagnostic accuracy parameters were
undertaken in adults. As a consequence, the EAG model does not fully capture differences in the likely
diagnostic pathways between child and adult subgroups.
Generalisability of the evidence relating to FeNO monitoring in the
management of asthma
l In adults, the studies used in the model were those by Shaw et al.,98 Smith et al.97 and Syk et al.99
Each study has its own merits in terms of generalisability.
¢ Shaw et al.98 followed UK practice in terms of the comparator arm management strategy. They also
recruited a population from primary care and included mild to severe asthmatics regardless of
atopic status. Smokers were excluded and so it is not clear if the results can be generalised to the
UK smoking population. It was also not clear which FeNO device was used.
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¢ Smith et al.97 recruited what is likely to be a population with mild to moderately severe asthma
and used a different step-up/step-down protocol in the control arm and the intervention arm. It is
unclear to what extent this study could be generalisable to the UK population but it nevertheless
provides some insight into the impact that different but plausible efficacy inputs have on the
cost-effectiveness estimates.
¢ The study by Syk et al.99 is most notable for having recruited only atopic patients, only
non-smokers and only mild to moderate asthmatics. This study is unlikely to have wide generalisability.
However, again, it nevertheless provides some insight into the impact that different but plausible
efficacy inputs have on the cost-effectiveness estimates.
l In children, the two studies that were modelled were those by Szefler et al.104 and Pijnenburg et al.,106
largely because these two studies reported the most complete sets of data and recruited different
populations. Again, each study has its own merits in terms of generalisability.
¢ The study by Szefler et al.104 had the lowest risk of bias amongst the studies available. It also
recruited patients who were difficult to treat, one of the subgroups identified in the scope as being
of special interest, and so generalisability may be limited to this group. However, the step-up/step
down protocol within this trial did not allow for ICS use to be decreased on the basis of low FeNO
levels alone, making it less likely that a decrease in ICS use will be seen in the intervention arm
than in some other protocols. Therefore, the generalisability of this study largely depends on what
type of step-up/step-down protocol is likely to be adopted in the UK.
¢ Pijnenburg et al.106 adopted inclusion criteria that were likely to result in a population of asthmatics
who have more stable disease. The step-up/step-down protocol also does not allow for ICS use to
be decreased on the basis of low FeNO levels alone, requiring that symptoms are also low.
As such, the generalisability of this study also largely depends on what type of step-up/step-down
protocol is likely to be adopted in the UK.
l One study was found that recruited pregnant women. The management strategy allowed step down
of ICS use on the basis of FeNO levels alone. This study can be generalised within the population of
pregnant women.
Equivalence of devices
l As the equivalence of devices is not assured, the generalisability of these results to all three devices is
also not assured.
l It is thought that estimates of diagnostic accuracy and efficacy in managing asthma are probably
achievable by all devices, as correlation between measurements is good. However, the actual values
that should be used as cut-offs in diagnosis and management are much more difficult to generalise
and further research may be required to estimate the most appropriate values.
Strengths and limitations of the assessment
Strengths of the assessment
The assessment includes systematic reviews of the equivalence of devices, diagnostic accuracy, management
efficacy and test failures, which have been undertaken according to robust and high-quality methods.
The scope of the assessment was agreed by NICE and the SCMs during an extensive scoping exercise.
The existing economic evidence base models have been formally critiqued using the Drummond et al.144
checklist and assessed in terms of adherence of the individual studies to the NICE reference case.145
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The two economic models have been developed to a high standard and are based on the decision
problem rather than being limited by the available empirical evidence. Both EAG models explicitly address
the trade-off between expected additional health gains resulting from the more accurate diagnosis of
asthma and the health losses associated with displacing existing services. Although many of the
parameters included in these models are subject to considerable uncertainty, the use of a modelling
framework helps elucidate which parameters are likely to be most important for decision-making.
The assessment report has been peer reviewed by NICE, other experienced HTA researchers and leading
experts in the diagnosis and management of inflammatory airways diseases.
Limitations of the assessment
This assessment is subject to several limitations. It is important to note that these limitations are principally
sourced in the evidence base rather than in the methods used to interrogate and evaluate it. Overall, the
evidence base for this assessment was not of the highest quality. No end-to-end studies were found that
estimated the clinical utility of FeNO testing in the diagnosis of asthma and no studies were found
that used NIOX VERO or NObreath. As such, clinical validity studies were included and a review of the
equivalence of devices was conducted. This leads to the following limitations:
l The benefits and harms associated with the diagnosis of asthma using FeNO testing have been estimated
based on modelling of the consequences of being TP, TN, FP and FN. This includes a large number of
assumptions and extrapolations, many of which cannot be substantiated with empirical evidence.
l The equivalence of devices is assumed and this may not hold true in practice. As such, FeNO cut-off
values reported in the primary research may not be applicable to measurements using other devices.
l The NObreath device will always dominate other devices as its efficacy has been assumed to be
equivalent but its unit cost is less.
No study provided estimates relating to the additional diagnostic value of FeNO testing to the whole UK
diagnostic pathway. This limits the scope of the economic analysis.
No short-term diagnosis of asthma is 100% accurate and as such all diagnostic studies included in the
review had a flawed reference standard. However, in the absence of any alternative, these reference
standards were considered to be 100% accurate. A better reference standard would have been long-term
follow-up of patients; however, only one study95 used such a reference standard.
None of the management studies in children included a step-up/step-down protocol that allowed ICS use
to be stepped down on the basis of FeNO levels alone. This will limit the degree to which ICS use can be
reduced and means that one of the major putative benefits of FeNO management has not actually been
assessed empirically: the identification of ICS non-responsive asthmatics who can be taken off ICS therapy
with no loss of control.
The EAG diagnostic model is based on evidence identified through the systematic review of FeNO
monitoring. The diagnostic accuracy of other non-FeNO comparators [spirometry, airway reversibility (MCT)
and bronchodilator reversibility] was based on comparative studies identified through the review process.
It is possible that other studies not identified within the review could be considered relevant to the model.
The use of the Hunter et al.163 case–control study does, however, mean that all non-FeNO diagnostic
options are assessed consistently within the same study.
The EAG diagnostic model and the Price et al.147/Aerocrine diagnostic models draw a number of
naive indirect comparisons across studies; this is a limitation of the evidence base rather than of the
assessment. It does, however, limit the confidence that can and should be placed in the findings of these
diagnostic models.
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The EAG management model is based on short-term evidence of the comparative efficacy of FeNO testing
compared with guidelines. The extrapolation of these benefits to the longer term is subject to considerable
uncertainty. Again, this limitation reflects the evidence base rather than the model itself.
Two previous systematic reviews of the effectiveness of FeNO monitoring to guide management were
identified. Petsky et al.31 performed a Cochrane review in 2008, which was updated with data from two
new studies in 2009. A total of six studies were included in the update (two adult studies83,98 and four
studies in children/adolescents103,104,106,190), all of which compared adjustments in asthma therapy based on
FeNO monitoring with those based on conventional methods (typically clinical symptoms and spirometry).
A meta-analysis was performed for seven outcomes: number of patients with more than one exacerbation,
exacerbation rates, FEV1% predicted at the final study visit, FeNO level at the final visit, symptom score, ICS
dose at the final visit and geometric mean change in FeNO level from baseline. There was some suggestion
of benefits associated with FeNO monitoring for several outcomes, in particular the number of subjects
with more than one exacerbation, exacerbation rates, FEV1% predicted at the final visit and geometric
mean change in FeNO level from baseline; however, none of these results was statistically conclusive.
There were also some results that suggested inconsistent effects between adult and child cohorts. FeNO
monitoring appeared to have some beneficial effects on the symptom score in adults (mean difference
–0.14, 95% CI –0.42 to 0.14) but not children (mean difference 0.04, 95% CI –0.11 to 0.20) and FeNO
management lowered the ICS dose in adults (mean difference –450.03 µg, 95% CI –676.73 µg to
–223.34 µg) but not children (mean difference 140.18 µg, 95% CI 28.94 µg to 251.43 µg). Furthermore,
there were some limitations to the meta-analysis, particularly with respect to the studies in children. There
was substantial clinical heterogeneity among the study cohorts, with no two studies using exactly the same
step-up/step-down protocols. The study by de Jongste et al.,190 which included a telemedical component,
was not of relevance to our current assessment, making the results of this meta-analysis not directly
applicable to this review.
It can be seen that there is a high degree of agreement between the Petsky et al.31 review and our own
review, especially with relation to the lack of statistically significant effects and some differences between
adults and children. The strength of our review lies in the inclusion of subsequently published studies, the
focus on exacerbation rates rather than the number of people with an exacerbation and the a priori
separation of both children and pregnant women into different subgroups.
The second review was an academic-in-confidence manufacturer’s submission to NICE (Aerocrine. Meta
Analysis of Asthma Exacerbation Rates with FeNO Guided Asthma Management. Aerocrine submission to
NICE, 2013). This review has subsequently been published.191 This review updated the meta-analyses of the
number of patients with more than one exacerbation and exacerbation rates from the aforementioned
Cochrane review31 with a study of FeNO-guided asthma management in pregnant women.102 Inclusion of this
study resulted in improvements on all measures of exacerbations, especially asthma exacerbation rates in
adults (mean difference –0.27, 95% CI –0.42 to –0.12) and relative rate of asthma exacerbations in adults
(relative rate 0.57, 95% CI 0.41 to 0.80). However, as it is known that pregnancy can substantially affect the
course of asthma,192 it was arguably inappropriate to include the cohort of pregnant women in meta-analyses
of adults with asthma. Indeed, in the current review of FeNO-guided management, we have interpreted the
results of the Powell et al.102 study of pregnant women separately from the main results for just this reason.
Research recommendations
This appraisal has been limited by several key evidence gaps that would benefit from further research. It
could be argued that this technology is currently under-researched and that any conclusions drawn at this
stage may be unduly affected by this lack of evidence. However, some of the problems with the evidence
base seem intractable in terms of practicalities and it could also be argued that the available evidence does
point towards some benefits of the technology, albeit benefits that are difficult to quantify with certainty.
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Some key problems and suggested research priorities are listed here:
l The equivalence of devices is not assured. There are several ways that this problem could be addressed,
none of which offers a panacea:
¢ Additional extensive equivalence testing of all devices in relation to one another to ascertain what
is driving the heterogeneity in study results. This may be expensive and time-consuming and may
still reveal high levels of disagreement between studies because of the evidence of variability
between devices of the same design.
¢ A network meta-analysis of the existing evidence. This was precluded in this project because of
time and resource constraints. There is likely to be a high degree of uncertainty in any such analysis
based on current evidence and its results may not be useful.
¢ Derivation and validation studies conducted using the devices in question to develop unique cut-off
points for each device for management and diagnosis. This may also be expensive and
time-consuming.
¢ Exploration of the option of using intrasubject relative change to assess control when managing
asthma. There is already evidence relating to this approach but it appears to be in the
comparatively early stages of development. This is not likely to be a useful option in diagnosis.
l Cut-off values are highly variable and are largely based on derivation studies not validation studies.
This is related to problems with the equivalence of devices. Possible research priorities relating to this
include large validation studies (possibly preceded by derivation studies) to determine cut-off values in
all populations of interest, using a number of available devices. Although expensive and time-consuming,
these studies could be very valuable.
l The clinical utility of the diagnosis of asthma using FeNO monitoring compared with the diagnosis of
asthma using current practice is not informed by direct evidence. Possible research priorities relating to
this include a study that charts the clinical utility of the diagnosis of asthma using FeNO monitoring
compared with the diagnosis of asthma using current guidelines against a reference standard of
long-term follow-up of diagnosis to correct for the misdiagnoses of both diagnostic approaches.
l It is unclear which step-up/step-down protocol offers the best efficacy. Possible research priorities
relating to this include:
¢ Studies that compare different management protocols with one another. It may be that different
protocols are necessary in different populations.
¢ Studies that aim to derive the best cut-off points for management protocols. This may be
influenced by the specifics of the step-up/step-down protocols.
l It is unclear how treatment effects will progress over time. Long-term studies following patients for a
number of years could address this evidence gap.
Larger RCTs of FeNO monitoring for asthma management are needed to clarify whether studies are failing
to report significant effects because of underpowering.
Conclusions
There is considerable uncertainty associated with all analyses within this assessment. This is largely because
of the limitations in the evidence base.
Studies using the devices that are the focus of this review were not available for all analyses and, in the
absence of an alternative, equivalence has been assumed between devices. However, there is not a strong
indication across the literature to support this assumption.
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The clinical evidence relating to the use of FeNO monitoring for the diagnosis of asthma is highly
heterogeneous and difficult to interpret in the context of the insertion of FeNO monitoring into
a diagnostic pathway. This is compounded by a lack of certainty as to the equivalence of the devices
used in the primary research studies to the devices that are the focus of this assessment.
The health economic analysis indicates that FeNO monitoring could have value in both the diagnostic
setting and the management setting. In particular, the diagnostic model indicates that FeNO monitoring
plus bronchodilator reversibility dominates many other diagnostic tests and may render airway
hyper-responsiveness cost-ineffective. In the management setting, FeNO-guided management has the
potential to appear cost-effective, although this is largely dependent on the expected duration over which
it continues to impact on medication decisions. The conclusions drawn from both models require strong
technical value judgements with respect to several aspects of the decision problem in which little or no
empirical evidence exists.
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Appendix 1 Search strategies for the clinical
review
Shading indicates sets of related terms within the search strategy.
Management review: MEDLINE
1. NIOX MINO.mp.
2. aerocrine.mp.
3. (niox adj5 (monitor$ or chemiluminescence or analyser$ or sensor or device$ or desktop)).mp.
4. NObreath.mp.
5. bedfont.mp.
6. or/1-5
7. exp cough/
8. cough$.mp.
9. phlegm.mp.
10. sputum.mp.
11. mucus.mp.
12. wheez$.mp.
13. chest pain/
14. chest pain$.mp.
15. (chest adj5 tight$).tw.
16. ((lower respiratory or lrt) adj5 symptom$).tw.
17. (lower airway adj5 symptom$).tw.
18. ((trache$ or wind pipe or lung$ or bronch$) adj3 symptom$).tw.
19. exp lung/ or trachea/
20. symptom$.tw.
21. 19 and 20
22. or/7-18,21
23. exp asthma/
24. asthma$.mp.
25. exp respiratory hypersensitivity/
26. exp bronchial hyperreactivity/
27. bronchial spasm/
28. bronchospas$.mp.
29. exp Bronchoconstriction/
30. bronchoconstric$.mp.
31. (bronch$ adj3 constrict$).mp.
32. (bronch$ adj5 spas$).mp.
33. (airway$ adj5 (obstruct$ or inflammation$)).mp.
34. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$
or insufficiency)).mp.
35. or/23-34
36. Nitric Oxide/
37. nitric oxide.mp.
38. 36 or 37
39. (exhal$ or expir$ or alveolar or fractional).mp.
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40. 38 and 39 (5228)
41. exhaled NO.mp.
42. eno.mp.
43. fe?no$.mp.
44. (fractional adj2 NO).mp.
45. or/40-44
46. 22 and 45
47. 35 and 45
48. 6 or 46 or 47
49. limit 48 to yr=“2009 -Current”
Systematic reviews search: MEDLINE
1. NIOX MINO.mp.
2. aerocrine.mp.
3. (niox adj5 (monitor$ or chemiluminescence or analyser$ or sensor or device$ or desktop)).mp.
4. NObreath.mp.
5. bedfont.mp.
6. or/1-5
7. exp cough/
8. cough$.mp.
9. phlegm.mp.
10. sputum.mp.
11. mucus.mp.
12. wheez$.mp.
13. chest pain/
14. chest pain$.mp.
15. (chest adj5 tight$).tw.
16. ((lower respiratory or lrt) adj5 symptom$).tw.
17. (lower airway adj5 symptom$).tw.
18. ((trache$ or wind pipe or lung$ or bronch$) adj3 symptom$).tw.
19. exp lung/ or trachea/
20. symptom$.tw.
21. 19 and 20
22. or/7-18,21
23. exp asthma/
24. asthma$.mp.
25. exp respiratory hypersensitivity/
26. exp bronchial hyperreactivity/
27. bronchial spasm/
28. bronchospas$.mp.
29. exp Bronchoconstriction/
30. bronchoconstric$.mp.
31. (bronch$ adj3 constrict$).mp.
32. (bronch$ adj5 spas$).mp.
33. (airway$ adj5 (obstruct$ or inflammation$)).mp.
34. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$
or insufficiency)).mp.
35. or/23-34
36. Nitric Oxide/
37. nitric oxide.mp.
38. 36 or 37
39. (exhal$ or expir$ or alveolar or fractional).mp.
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40. 38 and 39 (5228)
41. exhaled NO.mp.
42. eno.mp.
43. fe?no$.mp.
44. (fractional adj2 NO).mp.
45. or/40-44
46. 22 and 45
47. 35 and 45
48. 6 or 46 or 47
49. meta-analysis as topic/
50. (meta analy$ or metaanaly$).tw.
51. Meta-Analysis/
52. (systematic adj (review$1 or overview$1)).tw.
53. “Review Literature as Topic”/
54. or/49-53 (96944)
55. (cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or cinhal or science
citation index or bids or cancerlit).ab.
56. ((reference adj list$) or bibliograph$ or hand-search$ or (relevant adj journals) or (manual adj
search$)).ab.
57. ((selection adj criteria) or (data adj extraction)).ab.
58. “review”/
59. 57 and 58
60. comment/ or editorial/ or letter/
61. Animals/
62. Humans/
63. 61 not (61 and 62)
64. 60 or 63
65. 54 or 55 or 56 or 59
66. 65 not 64
67. 48 and 66
Randomised controlled trials search: MEDLINE
1. NIOX MINO.mp.
2. aerocrine.mp.
3. (niox adj5 (monitor$ or chemiluminescence or analyser$ or sensor or device$ or desktop)).mp.
4. NObreath.mp.
5. bedfont.mp.
6. or/1-5
7. exp cough/
8. cough$.mp.
9. phlegm.mp.
10. sputum.mp.
11. mucus.mp.
12. wheez$.mp.
13. chest pain/
14. chest pain$.mp.
15. (chest adj5 tight$).tw.
16. ((lower respiratory or lrt) adj5 symptom$).tw.
17. (lower airway adj5 symptom$).tw.
18. ((trache$ or wind pipe or lung$ or bronch$) adj3 symptom$).tw.
19. exp lung/ or trachea/
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20. symptom$.tw.
21. 19 and 20
22. or/7-18,21
23. exp asthma/
24. asthma$.mp.
25. exp respiratory hypersensitivity/
26. exp bronchial hyperreactivity/
27. bronchial spasm/
28. bronchospas$.mp.
29. exp Bronchoconstriction/
30. bronchoconstric$.mp.
31. (bronch$ adj3 constrict$).mp.
32. (bronch$ adj5 spas$).mp.
33. (airway$ adj5 (obstruct$ or inflammation$)).mp.
34. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$
or insufficiency)).mp.
35. or/23-34
36. Nitric Oxide/
37. nitric oxide.mp.
38. 36 or 37
39. (exhal$ or expir$ or alveolar or fractional).mp.
40. 38 and 39 (5228)
41. exhaled NO.mp.
42. eno.mp.
43. fe?no$.mp.
44. (fractional adj2 NO).mp.
45. or/40-44
46. 22 and 45
47. 35 and 45
48. 6 or 46 or 47
49. Randomized controlled trials as Topic/
50. Randomized controlled trial/
51. Random allocation/
52. randomized controlled trial.pt.
53. Double blind method/
54. Single blind method/
55. Clinical trial/
56. exp Clinical Trials as Topic/
57. controlled clinical trial.pt.
58. or/49-57
59. (clinic$ adj25 trial$).ti,ab.
60. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$ or mask$)).tw.
61. Placebos/
62. Placebo$.tw.
63. (allocated adj2 random).tw.
64. or/59-63
65. 58 or 64
66. Case report.tw.
67. Letter/
68. Historical article/
69. 66 or 67 or 68
70. exp Animals/
71. Humans/
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72. 70 not (70 and 71)
73. 69 or 72
74. 65 not 73
75. 48 and 74
Diagnostic studies search: MEDLINE
1. NIOX MINO.mp.
2. aerocrine.mp.
3. (niox adj5 (monitor$ or chemiluminescence or analyser$ or sensor or device$ or desktop)).mp.
4. NObreath.mp.
5. bedfont.mp.
6. or/1-5
7. exp cough/
8. cough$.mp.
9. phlegm.mp.
10. sputum.mp.
11. mucus.mp.
12. wheez$.mp.
13. chest pain/
14. chest pain$.mp.
15. (chest adj5 tight$).tw.
16. ((lower respiratory or lrt) adj5 symptom$).tw.
17. (lower airway adj5 symptom$).tw.
18. ((trache$ or wind pipe or lung$ or bronch$) adj3 symptom$).tw.
19. exp lung/ or trachea/
20. symptom$.tw.
21. 19 and 20
22. or/7-18,21
23. exp asthma/
24. asthma$.mp.
25. exp respiratory hypersensitivity/
26. exp bronchial hyperreactivity/
27. bronchial spasm/
28. bronchospas$.mp.
29. exp Bronchoconstriction/
30. bronchoconstric$.mp.
31. (bronch$ adj3 constrict$).mp.
32. (bronch$ adj5 spas$).mp.
33. (airway$ adj5 (obstruct$ or inflammation$)).mp.
34. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$
or insufficiency)).mp.
35. or/23-34
36. Nitric Oxide/
37. nitric oxide.mp.
38. 36 or 37
39. (exhal$ or expir$ or alveolar or fractional).mp.
40. 38 and 39 (5228)
41. exhaled NO.mp.
42. eno.mp.
43. fe?no$.mp.
44. (fractional adj2 NO).mp.
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45. or/40-44
46. 22 and 45
47. 35 and 45
48. 6 or 46 or 47
49. exp “Sensitivity and Specificity”/
50. sensitivity.tw.
51. specificity.tw.
52. ((pre-test or pretest) adj probability).tw.
53. post-test probability.tw.
54. predictive value$.tw.
55. likelihood ratio$.tw.
56. or/49-55
57. 48 and 56
Analytical validity studies search: MEDLINE
1. NIOX MINO.mp.
2. aerocrine.mp.
3. (niox adj5 (monitor$ or chemiluminescence or analyser$ or sensor or device$ or desktop)).mp.
4. NObreath.mp.
5. bedfont.mp.
6. or/1-5
Trial registers and websites search
ClinicalTrials.gov (www.clinicaltrials.gov/)
21 March 2013
16 studies found for niox
10 studies found for mino | asthma
12 studies found for aerocrine
No studies found for NObreath
No studies found for bedfont
31 studies found for fractional exhaled nitric oxide | asthma
metaRegister of Controlled Trials (www.controlled-trials.com/mrct/)
Three studies found for niox
Three studies found for mino
Two studies found for aerocrine
No studies found for NObreath
One study found for bedfont
Two studies found for fractional exhaled nitric oxide
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Manufacturer and User Facility Device Experience (MAUDE) database
(www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm)
Report date 1 January 2010–28 February 2013
No records were found with NIOX MINO
No records were found with aerocrine
No records were found with NObreath
No records were found with bedfont
EuroScan International Network (http://euroscan.org.uk/)
Two results for NIOX MINO
No records were found with aerocrine
No records were found with bedfont
No records were found with NObreath
13 results for fractional exhaled nitric oxide asthma
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Appendix 2 Clarification of the scope:
communication with specialist committee
member clinicians
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Appendix 4 Quality assessment scoring criteria
Diagnostic studies
Risk of bias in diagnostic studies (for both child and adult populations) was assessed and described using
the Bristol University QUADAS-2 tool.38 The QUADAS-2 tool is structured around four domains of potential
sources of bias in primary diagnostic studies: patient selection, index test, reference standard and flow and
timing. There are signalling questions within each of these domains that allow researchers to overview the
potential sources of bias therein and a summary domain score can be generated to provide an indication
of the overall potential for bias in each aspect of a study’s methodology. These signalling questions, and
our approach to scoring them, are detailed in the following sections. It should be noted that, in our risk of
bias tables, we report only the domain summary scores, although we also narratively summarise our
responses to signalling questions in the review text to support these judgements.
Domain 1: patient selection
Signalling question 1: Was a consecutive or a random sample of patients enrolled?
l Score ‘yes’ if the report states that enrolment was consecutive or random.
l Score ‘no’ if the report states that another method of sampling was used.
l Score ‘unclear’ if insufficient information was provided to make a judgement.
Signalling question 2: Was a case–control design avoided?
l Score ‘yes’ if the study was not a case–control study.
l Score ‘no’ if the study was a case–control study.
l Score ‘unclear’ if insufficient information was provided to make a judgement.
Signalling question 3: Did the study avoid inappropriate exclusions?
With respect to the current review, the population of interest was patients presenting with clinical
characteristics of asthma or those who are ‘difficult to diagnose’, that is, patients who have already
undergone some of the tests for asthma in the UK pathway and who have not yet been confirmed to have
asthma. The review scope also sought data on subgroups, in particular women during pregnancy, older
people and smokers/passive smokers. Hence, this question was answered with respect to these groups.
When there were ambiguities, two reviewers would discuss whether the population was appropriate.
l Score ‘yes’ if the study had appropriately selected patients conforming to the groups outline above.
l Score ‘no’ if the study made inappropriate exclusions from the group it set out to select.
l Score ‘unclear’ if insufficient information was provided to make a judgement.
Summary domain score: Could the selection of patients have introduced bias?
l Score as ‘low risk’ if the study scored ‘yes’ on all of signalling questions above.
l Score as ‘high risk’ if the study scored ‘no’ or ‘unclear’ on two or more of the individual items or on
either of the case–control design or inappropriate exclusions questions.
l Score as ‘unclear risk’ if the study scored ‘no’ or ‘unclear’ on signalling question 1.
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Domain 2: index test
Signalling question 1: Were the index test results interpreted without knowledge of the results of the
reference standard?
l Score ‘yes’ if the index test results were interpreted blind to the reference standard results or the index
test results were clearly interpreted before the reference standard results were known.
l Score ‘no’ if the results of the reference standard (UK guidelines pathway) were already known or if
parts of the reference standard results downstream of the position of the test in the UK pathway were
already known. This will need to be scored with reference to the patient population.
l Score ‘unclear’ if unclear.
Signalling question 2: If a threshold was used, was it prespecified?
l Score ‘yes’ if prespecified cut-off values were used (validation study).
l Score ‘no’ if cut-off values were fitted to the data (derivation study).
l Score ‘unclear’ if unclear.
Summary domain score: Could the conduct or interpretation of the index test have introduced bias?
l Score as ‘low risk’ if the study scored ‘yes’ on both signalling questions.
l Score as ‘high risk’ if cut-off values were fitted to the data (as derivation studies are likely to
overestimate the true diagnostic accuracy of a technology relative to clinical practice) or if the
study scored ‘no’ or ‘unclear’ on both signalling questions.
l Score as ‘unclear’ if the study scored ‘no’ or ‘unclear’ on signalling question 1 only.
Domain 3: reference standard
Signalling question 1: Is the reference standard likely to correctly classify the target condition?
No reference standard for asthma is 100% sensitive or specific. Possibly the only way that this could be
achieved is with long-term follow-up, but even this might be confounded by the fact that asthma can
remiss and develop (e.g. as a comorbidity) over time. Hence, this item was scored with respect to
UK guidelines:
l Score ‘yes’ if the reference standard conforms with all or part of the UK guidelines.
l Score ‘no’ if the reference standard does not conform with UK guidelines, that is, it uses a test that is
not within the UK guidelines.
l Score ‘unclear’ if unclear.
Signalling question 2: Were the reference standard results interpreted without knowledge of the results of
the index test?
l Score ‘yes’ if the reference standard results were interpreted blind to the index test results or the
reference standard results were clearly interpreted before the index test results were known.
l Score ‘no’ if the results of the index test were known.
l Score ‘unclear’ if unclear.
Summary domain score: Could the conduct or interpretation of the index test have introduced bias?
l Score as ‘low risk’ if the study scored ‘yes’ on both signalling questions.
l Score as ‘high risk’ if the study scored ‘no’ or ‘unclear’ on both signalling questions.
l Score as ‘unclear’ if the study scored ‘no’ or ‘unclear’ on either of the two signalling questions.
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Domain 4: flow and timing
Signalling question 1: Was there an appropriate interval between the index test(s) and the
reference standard?
l Score ‘yes’ if the tests were conducted consecutively.
l Score ‘no’ if the index test and the reference test were conducted > 1 week apart.
l Score ‘unclear’ if unclear.
Signalling question 2: Did all patients receive a reference standard?
l Score ‘yes’ if yes.
l Score ‘no’ if no.
l Score ‘unclear’ if unclear.
Signalling question 3: Did patients receive the same reference standard?
l Score ‘yes’ if yes.
l Score ‘no’ if no.
l Score ‘unclear’ if unclear.
Signalling question 4: Were all patients included in the analysis?
l Score ‘yes’ if yes.
l Score ‘no’ if no.
l Score ‘unclear’ if unclear.
Summary domain score: Could the patient flow have introduced bias?
l Score as ‘low risk’ if the study scored ‘yes’ on all signalling questions.
l Score as ‘high risk’ if the study scored ‘no’ or ‘unclear’ on three or more items.
l Score as ‘unclear risk’ if the study scored ‘no’ or ‘unclear’ on up to two items.
Management studies
The quality of the FeNO-guided management studies in adults and children was assessed using the
Cochrane Collaboration’s tool for assessing risk of bias in RCTs.36 The tool is designed to address seven
domains of bias: sequence generation, allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selective outcome reporting and ‘other issues’.
The tool provides a two-part assessment for risk of bias: the first part describes what was reported in the
study for each domain and the second part consists of the review authors’ categorisation of the study as
‘low’, ‘high’ and ‘uncertain’ risk of bias (Table 85).
The criteria for risk of bias judgements as outlined in the Cochrane Handbook36 (Table 86) were used to
assign study ratings. As recommended by the Cochrane Handbook,36 we did not assign an overall
numerical score for risk of bias in each study but discussed how potential sources of bias may be likely to
affect the outcomes of the study.
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TABLE 85 The Cochrane Collaboration’s tool for assessing risk of bias36
Domain Description Review authors’ judgement
Sequence generation Describe the method used to generate the
allocation sequence in sufficient detail to
allow an assessment of whether it should
produce comparable groups
Was the allocation sequence
adequately generated?
Allocation concealment Describe the method used to conceal the
allocation sequence in sufficient detail to
determine whether intervention allocations
could have been foreseen in advance of,
or during, enrolment
Was allocation adequately
concealed?
Blinding of participants, personnel
and outcome assessors [assessments
should be made for each main
outcome (or class of outcomes)]
Describe all measures used, if any, to blind
study participants and personnel from
knowledge of which intervention a participant
received. Provide any information relating to
whether the intended blinding was effective
Was knowledge of the
allocated intervention
adequately prevented during
the study?
Incomplete outcome data
[assessments should be made for each
main outcome (or class of outcomes)]
Describe the completeness of outcome data
for each main outcome, including attrition
and exclusions from the analysis. State
whether attrition and exclusions were
reported, the numbers in each intervention
group (compared with the total number of
randomised participants), reasons for attrition/
exclusions when reported and any re-inclusions
in analyses performed by the review authors
Were incomplete outcome data
adequately addressed?
Selective outcome reporting State how the possibility of selective outcome
reporting was examined by the review
authors and what was found
Are reports of the study free of
the suggestion of selective
outcome reporting?
Other sources of bias State any important concerns about bias not
addressed in the other domains of the tool. If
particular questions/entries were prespecified
in the review’s protocol, responses should be
provided for each question/entry
Was the study apparently free
of other problems that could
put it at a high risk of bias?
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TABLE 86 Criteria for judging risk of bias in the risk of bias assessment tool (from the Cochrane Handbook)36
Sequence generation: Was the allocation sequence adequately generated? (Short form: Adequate sequence generation?)
Criteria for a judgement of ‘yes’
(i.e. low risk of bias)
The investigators describe a random component in the sequence generation
process such as:
l referring to a random number table
l using a computer random number generator
l coin tossing
l shuffling cards or envelopes
l throwing dice
l drawing of lots
l minimisation*
*Minimisation may be implemented without a random element, and this is
considered to be equivalent to being random
Criteria for the judgement of ‘no’
(i.e. high risk of bias)
The investigators describe a non-random component in the sequence generation
process. Usually, the description would involve some systematic, non-random
approach, e.g.:
l sequence generated by odd or even date of birth
l sequence generated by some rule based on date (or day) of admission
l sequence generated by some rule based on hospital or clinic record number
Other non-random approaches happen much less frequently than the systematic
approaches mentioned above and tend to be obvious. They usually involve
judgement or some method of non-random categorisation of participants, e.g.:
l allocation by judgement of the clinician
l allocation by preference of the participant
l allocation based on the results of a laboratory test or a series of tests
l allocation by availability of the intervention
Criteria for the judgement of ‘unclear’
(uncertain risk of bias)
Insufficient information about the sequence generation process to permit
judgement of ‘yes’ or ‘no’
Allocation concealment: Was allocation adequately concealed? (Short form: Allocation concealment?)
Criteria for a judgement of ‘yes’
(i.e. low risk of bias)
Participants and investigators enrolling participants could not foresee assignment
because one of the following, or an equivalent method, was used to conceal
allocation:
l central allocation (including telephone, web-based and pharmacy-
controlled randomisation)
l sequentially numbered drug containers of identical appearance
l sequentially numbered, opaque sealed envelopes
Criteria for the judgement of ‘no’
(i.e. high risk of bias)
Participants or investigators enrolling participants could possibly foresee
assignments and thus introduce selection bias, such as allocation based on:
l using an open random allocation schedule (e.g. a list of random numbers)
l assignment envelopes used without appropriate safeguards (e.g. if envelopes
were unsealed or non-opaque or not sequentially numbered)
l alternation or rotation
l date of birth
l case record number
l any other explicitly unconcealed procedure
Criteria for the judgement of ‘unclear’
(uncertain risk of bias)
Insufficient information to permit judgement of ‘yes’ or ‘no’. This is usually the
case if the method of concealment is not described or not described in sufficient
detail to allow a definite judgement, e.g. if the use of assignment envelopes is
described but it remains unclear whether envelopes were sequentially numbered,
opaque and sealed
Blinding of participants, personnel and outcome assessors: Was knowledge of the allocated interventions adequately
prevented during the study? (Short form: Blinding?)
continued
DOI: 10.3310/hta19820 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 82
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
283
TABLE 86 Criteria for judging risk of bias in the risk of bias assessment tool (from the Cochrane
Handbook)36 (continued )
Criteria for a judgement of ‘yes’
(i.e. low risk of bias)
Any one of the following:
l no blinding but the review authors judge that the outcome and the outcome
measurement are not likely to be influenced by lack of blinding
l blinding of participants and key study personnel ensured and unlikely that
the blinding could have been broken
l the participants or some key study personnel were not blinded but the
outcome assessment was blinded and the non-blinding of others is unlikely
to introduce bias
Criteria for the judgement of ‘no’
(i.e. high risk of bias)
Any one of the following:
l no blinding or incomplete blinding and the outcome or outcome
measurement is likely to be influenced by lack of blinding
l blinding of key study participants and personnel attempted but likely that
the blinding could have been broken
l participants or some key study personnel were not blinded and the
non-blinding of others is likely to introduce bias
Criteria for the judgement of ‘unclear’
(uncertain risk of bias)
Any one of the following:
l insufficient information to permit judgement of ‘yes’ or ‘no’
l the study did not address this outcome
Incomplete outcome data: Were incomplete outcome data adequately addressed? (Short form: Incomplete outcome
data addressed?)
Criteria for a judgement of ‘yes’
(i.e. low risk of bias)
Any one of the following:
l no missing outcome data
l reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias)
l missing outcome data balanced across intervention groups, with similar
reasons for missing data across groups
l for dichotomous outcome data, the proportion of missing outcomes
compared with the observed event risk not enough to have a clinically
relevant impact on the intervention effect estimate
l for continuous outcome data, plausible effect size (difference in means or
standardised difference in means) among missing outcomes not enough to
have a clinically relevant impact on the observed effect size
l missing data have been imputed using appropriate methods
Criteria for the judgement of ‘no’ (i.e.
high risk of bias)
Any one of the following:
l reasons for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
intervention groups
l for dichotomous outcome data, the proportion of missing outcomes
compared with the observed event risk enough to induce clinically relevant
bias in the intervention effect estimate
l for continuous outcome data, plausible effect size (difference in means or
standardised difference in means) among missing outcomes enough to
induce clinically relevant bias in the observed effect size
l ‘as-treated’ analysis carried out with substantial departure of the intervention
received from that assigned at randomisation
l potentially inappropriate application of simple imputation
Criteria for the judgement of ‘unclear’
(uncertain risk of bias)
Any one of the following:
l insufficient reporting of attrition/exclusions to permit judgement of ‘yes’ or
‘no’ (e.g. number randomised not stated, no reasons for missing
data provided)
l the study did not address this outcome
Selective outcome reporting: Are reports of the study free of the suggestion of selective outcome reporting? (Short form:
Free of selective reporting?)
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TABLE 86 Criteria for judging risk of bias in the risk of bias assessment tool (from the Cochrane
Handbook)36 (continued )
Criteria for the judgement of ‘yes’
(i.e. high risk of bias)
Any of the following:
l the study protocol is available and all of the study’s prespecified (primary and
secondary) outcomes that are of interest in the review have been reported in
the prespecified way
l the study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were prespecified
(convincing text of this nature may be uncommon)
Criteria for the judgement of ‘no’
(i.e. high risk of bias)
Any one of the following:
l not all of the study’s prespecified primary outcomes have been reported
l one or more of the primary outcomes are reported using measurements,
analysis methods or subsets of the data (e.g. subscales) that were
not prespecified
l one or more of the reported primary outcomes are not prespecified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect)
l one or more outcomes of interest in the review are reported incompletely so
that they cannot be entered in a meta-analysis
l the study report fails to include results for a key outcome that would be
expected to have been reported for such a study
Criteria for the judgement of ‘unclear’
(uncertain risk of bias)
Insufficient information to permit judgement of ‘yes’ or ‘no’. It is likely that the
majority of studies will fall into this category
Other potential threats to validity: Was the study apparently free of other problems that could put it at a risk of bias?
(Short form: Free of other bias?)
Criteria for a judgement of ‘yes’
(i.e. low risk of bias)
The study appears to be free of other sources of bias
Criteria for the judgement of ‘no’
(i.e. high risk of bias)
There is at least one important risk of bias, e.g. the study:
l had a potential source of bias related to the specific study design used or
l stopped early because of some data-dependent process (including a formal
stopping rule) or
l had an extreme baseline imbalance or
l has been claimed to have been fraudulent or
l had some other problem
Criteria for the judgement of ‘unclear’
(uncertain risk of bias)
There may be a risk of bias but there is either:
l insufficient information to assess whether an important risk of bias exists or
l insufficient rationale or evidence that an identified problem will introduce bias
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Appendix 5 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA)193 flow diagram (adapted) for the
reviews of clinical evidence and for the update of clinical
evidence conducted in September 2013. Additional search for
NIOX Vero included in numbers for original search
Citations identified through
database searching
(original search, n = 4853)
(update, n = 490)
Citations screened by title
(original search, n = 4859)
(update search, n = 495)
Citations screened by
abstract
(original search, n = 1685)
(update search, n = 94)
Citations excluded by title
(original search, n = 3174)
(update search, n = 401)
Full-text citations assessed
for eligibility
(original search, n = 405)
(update search, n = 17) Full-text articles excluded
(original search, n = 338, see 
Table 87 for details)
(update search, n = 11, see 
Table 88 for details)
Citations excluded by abstract
(original search, n = 1280)
(update search, n = 77)
Studies included in synthesis
(n = 65 studies, 73 citations)
• Equivalence review (n = 27 studies, 32 citations)
• Diagnostic review (n = 26 studies, 30 citations)
• Management review (n = 13 studies, 13 citations)
[Note: n = 1 study (2 citations) appeared in 2 reviews]
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Additional citations identified
through other sources
(original search, n = 6)
(update search, n = 5)
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale
Study Reason for exclusion
1 National Institute of Allergy and Infectious Diseases. Evaluation of an asthma
treatment strategy based on exhaled nitric oxide measurements in adolescents.
ClinicalTrials.gov 2005
Trial protocol
2 Abba AA, Habib SS, Beg MFS, Al Zoghaibi M. A comparative study of fraction of
exhaled nitric oxide in stable chronic obstructive pulmonary disease and steroid naive
asthma. In New Horizons Allergy Asthma Immunology 2009. pp. 199–204
Not a RCT
3 Acembekiroglu S, Altintas D, Seydaoglu G, Ceter T, Yilmaz M, Bingol KG, et al.
Seasonal variation of exhaled nitric oxide levels in children with allergic asthma that is
sensitive to inhaled allergens. Allergy 2011;66:201
Not a RCT
4 Agache I, Ciobanu C. Predictive value of lung function trend and FeNO for difficult
asthma in children. J Invest Allergol Clin Immunol 2012;22:419–26
Not a RCT
5 Alvarez-Gutierrez FJ, Medina-Gallardo JF, Perez-Navarro P, Martin-Villasclaras JJ,
Etchegoren BM, Romero-Romero B, et al. Comparison of the Asthma Control Test
(ACT) with lung function, levels of exhaled nitric oxide and control according to the
Global Initiative for Asthma (GINA). Arch Bronconeumol 2010;46:370–7
Foreign language
6 Anderson WJ, Lipworth BJ. Does body mass index influence responsiveness to inhaled
corticosteroids in persistent asthma? Ann Allergy Asthma Immunol 2012;108:237–42
Not a RCT
7 Andregnette-Roscigno V, Fernandez-Nieto M, Garcia Del Potro M, Aguado E,
Sastre J. Correlation between tests to measure bronchial hyperreactivity and exhaled
nitric oxide levels in asthmatic children. Allergy 2011;66:154
No useable diagnostic data
8 Arnold DH, Gebretsadik T, Abramo TJ, Hartert TV, Arnold DH, Gebretsadik T, et al.
Noninvasive testing of lung function and inflammation in pediatric patients with
acute asthma exacerbations. J Asthma 2012;49:29–35
Emergency care
9 Arochena L, Fernandez-Nieto M, Andregnette V, Garcia Del PM, Aguado E, Sastre J.
Bronchial hyperresponsiveness in sportschildren; different methods to reach a
diagnosis. J Allergy Clin Immunol 2012;129(2 Suppl. 1):AB2
No useable diagnostic data
10 Artlich A, Hagenah JU, Jonas S, Ahrens P, Gortner L. Exhaled nitric oxide in childhood
asthma. Eur J Pediatr 1996;155:698–701
Wrong flow rate
11 Avital A, Uwyyed K, Berkman N, Godfrey S, Bar-Yishay E, Springer C. Exhaled nitric
oxide and asthma in young children. Pediatr Pulmonol 2001;32:308–13
Offline
12 Awabdy B, Balasubramanyam V, Parikh B, Peled N. Performance of the new insight
ENO system to measure exhaled nitric oxide – comparison to chemiluminescence
technologies. Am J Respir Crit Care Med 2010;181:A4283
Wrong device
13 Ayars AG, Potter-Perigo S, Wight TN, Tilles SA, Altman LC. Comparative sensitivity of
various indices in evaluating improvement in mild persistent asthma. J Allergy Clin
Immunol 2012;129(2 Suppl. 1):AB75
Not a RCT
14 Badzakova MG, Obocki K. Exhaled nitric oxide fraction in asthmatic children – well
correlated with clinical control of asthma (in primary care). Allergy 2011;66:588
Not a RCT
15 Baek HS, Kim HJ, Kim YD, Oh JW, Shin JH, Lee HB. Exhaled nitric oxide correlates
with post-betaronchodilator improvement of FEV1 in chronic childhood asthma.
J Allergy Clin Immunol 2010;125(2 Suppl. 1):AB50
Not a RCT
16 Balinotti JE, Colom A, Kofman C, Teper AM. Association between nitric oxide and
a clinical index to define risk of asthma in young children with recurrent wheezing.
Am J Respir Crit Care Med 2011;183:A5475
Infants
17 Baptist AP, Sengupta R, Pranathiageswaran S, Wang Y, Ager J. Evaluation of exhaled
nitric oxide measurements in the emergency department for patients with acute
asthma. Ann Allergy Asthma Immunol 2008;100:415–19
Emergency care
18 Baptist AP, Shah B, Wang Y, Ager J, Badr MS. Exhaled nitric oxide levels during
treatment in patients hospitalized with asthma. Allergy Asthma Proc 2008;29:171–6
Emergency care
19 Baptist AP, Khan FI, Wang Y, Ager J. Exhaled nitric oxide measurements in
hospitalized children with asthma. J Asthma 2008;45:670–4
Emergency care
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
20 Bar-Yishay E, Matyashchuk E, Mussaffi H, Prais D, Steuer G, Mei-Zahav M, et al.
Fractional exhaled nitric oxide does not correlate with functional measures in
pre-school wheezy children. Am J Respir Crit Care Med 2010;181:A3922
No usable diagnostic data
21 Baraldi E, Scollo M, Zaramella C, Zanconato S, Zacchello F. A simple flow-driven
method for online measurement of exhaled NO starting at the age of 4 to 5 years.
Am J Respir Crit Care Med 2000;162:1828–32
NO analytical data
22 Baraldi E, Azzolin NM, Zanconato S, Dario C, Zacchello F. Corticosteroids decrease
exhaled nitric oxide in children with acute asthma. J Pediatr 1997;131:381–5
Not a RCT
23 Baraldi E, Azzolin NM, Cracco A, Zacchello F. Reference values of exhaled nitric oxide
for healthy children 6–15 years old. Pediatr Pulmonol 1999;27:54–8
Tidal breathing
24 Barben J, Strippoli MP, Trachsel D, Schiller B, Hammer J, Kuehni CE, et al. Effect of
mannitol dry powder challenge on exhaled nitric oxide in children. PLOS ONE
2013;8:e54521
Not FeNO testing for
diagnosis
25 Barreto M, Villa MP, Olita C, Martella S, Ciabattoni G, Montuschi P, et al.
8-Isoprostane in exhaled breath condensate and exercise-induced bronchoconstriction
in asthmatic children and adolescents. Chest 2009;135:66–73
Not a RCT
26 Barreto M, La Penna F, Prete A, Bonafoni S, Negro V, Chialant D, et al. Exhaled
breath temperature and other exhaled markers in children with asthma and rhinitis.
Am J Respir Crit Care Med 2011;183:A1897
No useable diagnostic data
27 Bastain TM, Islam T, Berhane KT, McConnell RS, Rappaport EB, Salam MT, et al.
Exhaled nitric oxide, susceptibility and new-onset asthma in the Children's Health
Study. Eur Respir J 2011;37:523–31
Offline
28 Bautista AP, Eisenlohr CP, Lanz MJ. Nasal nitric oxide and nasal eosinophils decrease
with levocetirizine in subjects with perennial allergic rhinitis. Am J Rhinol Allergy
2011;25:383–7
Not asthma
29 Bayo AL, Tordera MP, Perez EM, Gisbert VM. Contribution of exhaled nitric oxide
measurements to abbreviated bronchial challenge test protocols. Arch Bronconeumol
2008;44:402–7
Population asthma and
non-asthma
30 Becher G, Dietze S, Steinhaeusser W, Schmidtmann S, Beck E, Timm-Labsch B. Can
we measure exhaled NO accurate and reproducible? Am J Respir Crit Care Med
2010;181:A4280
No analytical data
31 Beigelman A, Mauger DT, Phillips BR, Zeiger RS, Taussig LM, Strunk RC, et al.
Effect of elevated exhaled nitric oxide levels on the risk of respiratory tract illness
in preschool-aged children with moderate-to-severe intermittent wheezing.
Ann Allergy Asthma Immunol 2009;103:108–13
Offline
32 Belda J, Parameswaran K, Lemiere C, Kamada D, O’Byrne PM, Hargreave FE, et al.
Predictors of loss of asthma control induced by corticosteroid withdrawal.
Can Respir J 2006;13:129–33
Not a RCT
33 Bell MC, Evans MD, Tisler CJ, Gern J, Lemanske J, Jackson DJ. Early aeroallergen
sensitization is associated with higher fractional exhaled nitric oxide levels in
school age children independent of asthma diagnosis. J Allergy Clin Immunol
2013;131(2 Suppl. 1):AB46
No useable diagnostic data
34 Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S. Exhaled nitric oxide
in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax
2005;60:383–8
Wrong flow rate
35 Berlyne GS, Parameswaran K, Kamada D, Efthimiadis A, Hargreave FE.
A comparison of exhaled nitric oxide and induced sputum as markers of airway
inflammation. J Allergy Clin Immunol 2000;106:638–44
Wrong flow rate
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
36 Bernstein JA, Davis B, Alvarez-Puebla MJ, Nguyen D, Levin L, Olaguibel JM, et al.
Is exhaled nitric oxide a useful adjunctive test for assessing asthma? J Asthma
2009;46:955–60
No useable diagnostic data
37 Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID, et al. The use
of exhaled nitric oxide concentration to identify eosinophilic airway inflammation:
an observational study in adults with asthma. Clin Exp Allergy 2005;35:1175–9
Wrong flow rate
38 Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by
the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med
1999;160:1227–31
Wrong flow rate
39 Bivins J, Ownby D, Waller J, Tingen M. Exhaled nitric oxide level and school
absenteeism in rural high school students with current asthma. J Allergy Clin
Immunol 2013;131(2 Suppl. 1):AB64
No useable diagnostic data
40 Blain EA, Craig T, Weyant K. Exhaled nitric oxide (eNO) should not be
used to exclude the diagnosis of asthma. Ann Allergy Asthma Immunol
2009;103(5 Suppl. 3):A60
Case study
41 Bloemen K, Koppen G, Govarts E, Colles A, Van Den Heuvel R, Nelen V, et al.
Application of non-invasive biomarkers in a birth cohort follow-up in relation
to respiratory health outcome. Biomarkers 2010;15:583–93
No useable diagnostic data
42 Bodini A, Peroni DG, Zardini F, Corradi M, Alinovi R, Boner AL, et al. Flunisolide
decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children.
Mediators Inflamm 2006;2006:31919
Not a RCT
43 Bodini A, Peroni D, Loiacono A, Costella S, Pigozzi R, Baraldi E, et al. Exhaled nitric
oxide daily evaluation is effective in monitoring exposure to relevant allergens in
asthmatic children. Chest 2007;132:1520–5
Not a RCT
44 Bohadana AB, Hannhart B, Ghezzo H, Teculescu D, Zmirou-Navier D. Exhaled nitric
oxide and spirometry in respiratory health surveillance. Occup Med (Oxford)
2011;61:108–14
Unselected population
45 Bommarito L, Migliore E, Bugiani M, Heffler E, Guida G, Bucca C, et al. Exhaled nitric
oxide in a population sample of adults. Respiration 2008;75:386–92
Offline
46 Boon M, Meyts I, Warnier G, Boeck KD. Exhaled nitric oxide: offline tidal breathing
measurements are feasible in children and correlate with online single breath
measurements. Pediatr Allergy Immunol Pulmonol 2010;23:201–6
Online vs. offline
47 Boon M, Proesmans M, Meyts I, De Boeck K. Do composite scores of nNO and FENO
improve diagnostic value? J Cyst Fibrosis 2012;11:S96
Case–control study
48 Boot JD, de Kam ML, Mascelli MA, Miller B, van Wijk RG, de Groot H, et al. Nasal
nitric oxide: longitudinal reproducibility and the effects of a nasal allergen challenge
in patients with allergic rhinitis. Allergy 2007;62:378–84
Nasal NO
49 Bora M, Alpaydin AO, Yorgancioglu A, Akkas G, Isisag A, Coskun AS, et al. Does
asthma control as assessed by the asthma control test reflect airway inflammation?
Multidiscip Resp Med 2011;6:291–8
Not a RCT
50 Bosque-Garcia M, Asensio-De La Cruz O, Jaramillo-Hidalgo D, Valdesoiro-Navarrete L,
Costa-Colomer J, Penas-Aguilera A, et al. Exhaled nitric oxide and asthma control
measured by clinical score and exerciseinduced bronchoconstriction. Allergy Eur J
Allergy Clin Immunol 2011;66:577–8
Not a RCT
51 Bossley CJ, Saglani S, Kavanagh C, Payne DN, Wilson N, Tsartsali L, et al.
Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma.
Eur Respir J 2009;34:1052–9
Not a RCT
52 Bozek A, Jarzab J. Nasal nitric oxide measurements in patients with seasonal allergic
rhinitis. Allergy Eur J Allergy Clin Immunol 2010;65:155
No usable diagnostic data
53 Bozek A, Filipowska-Gronska A, Werynska-Kalemba M, Jarzab J. Nasal nitric oxide
measurements in patients with seasonal allergic rhinitis of different age groups.
Postepy Dermatol Alergol 2010;27:96–100
Foreign language
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
54 Bozek A, Krajewska J, Jarzab J. Nasal nitric oxide and other diagnostic procedures
in seasonal allergic rhinitis: elderly vs juvenile patients. Am J Otolaryngol
2011;32:105–8
Nasal NO
55 Bratton DL, Lanz MJ, Miyazawa N, White CW, Silkoff PE. Exhaled nitric oxide before
and after montelukast sodium therapy in school-age children with chronic asthma:
a preliminary study. Pediatr Pulmonol 1999;28:402–7
Wrong flow rate
56 Brightling CE, Green RH, Pavord ID. Biomarkers predicting response to corticosteroid
therapy in asthma. Treat Respir Med 2005;4:309–16
Review
57 Brindicci C, Ito K, Barnes PJ, Kharitonov SA. Differential flow analysis of exhaled nitric
oxide in patients with asthma of differing severity. Chest 2007;131:1353–62
FeNO testing did not guide
step-up/step-down therapy
58 Brooks CR, Brogan SB, van Dalen CJ, Lampshire PK, Crane J, Douwes J, et al.
Measurement of exhaled nitric oxide in a general population sample: a comparison of
the Medisoft HypAir FE(NO) and Aerocrine NIOX analyzers. J Asthma 2011;48:324–8
Wrong device
59 Bruce CT, Zhao D, Yates DH, Thomas PS. AMP challenge induces a decrease in
FE(NO) in asthmatic subjects modulated by nedocromil. Eur J Clin Invest
2006;36:899–905
FeNO testing did not guide
step-up/step-down therapy
60 Bruce CT, Zhao D, Yates DH, Thomas PS. L-arginine reverses cigarette-induced
reduction of fractional exhaled nitric oxide in asthmatic smokers.
Inflammopharmacology 2010;18:9–16
FeNO testing did not guide
step-up/step-down therapy
61 Brusselle GG, Kardos P, Louis R, Schmoller T, Jorgensen L, Aubier M, et al.
Budesonide/formoterol maintenance and reliever therapy at two different
maintenance doses: effect on fractional excretion of nitric oxide (FENO). Am J
Respir Crit Care Med 2010;181:A5407
No useable diagnostic data
62 Buchvald F, Eiberg H, Bisgaard H. Heterogeneity of FeNO response to inhaled steroid
in asthmatic children. Clin Exp Allergy 2003;33:1735–40
FeNO testing did not guide
step-up/step-down therapy
63 Buchvald F, Hermansen MN, Nielsen KG, Bisgaard H. Exhaled nitric oxide predicts
exercise-induced bronchoconstriction in asthmatic school children. Chest
2005;128:1964–7
All asthmatic not
diagnostic
64 Buchvald F, Baraldi E, Carraro S, Gaston B, De Jongste J, Pijnenburg MW, et al.
Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years.
J Allergy Clin Immunol 2005;115:1130–6
Measurement in healthy
subjects
65 Bukstein D, Luskin AT, Brooks EA. Exhaled nitric oxide as a tool in managing and
monitoring difficult-to-treat asthma. Allergy Asthma Proc 2011;32:185–92
Not a RCT
66 Bukstein DA. Individualized dynamic phenotyping using fractional exhaled nitric oxide
levels in children with asthma. Ann Allergy Asthma Immunol 2012;109:A52
Not a RCT
67 Burnett M, Wegienka G, Havstad S, Ownby D, Cole JC, Zoratti E. The relationship
of fractional exhaled nitric oxide levels to allergy and asthma biomarkers in young
adults. J Allergy Clin Immunol 2011;127(2 Suppl. 1):AB58
68 Bush A. The use of inflammatory markers to guide therapy in children with severe
asthma. ClinicalTrials.gov 2005
Trial protocol
69 Byrnes CA, Dinarevic S, Busst CA, Shinebourne EA, Bush A. Effect of measurement
conditions on measured levels of peak exhaled nitric oxide. Thorax 1997;52:697–701
No analytical data
70 Cabral AL, Vollmer WM, Barbirotto RM, Martins MA. Exhaled nitric oxide as a
predictor of exacerbation in children with moderate-to-severe asthma: a prospective,
5-month study. Ann Allergy Asthma Immunol 2009;103:206–11
Not a RCT
71 Canady RG, Platts-Mills T, Murphy A, Johannesen R, Gaston B. Vital capacity reservoir
and online measurement of childhood nitrosopnea are linearly related. Clinical
implications. Am J Respir Crit Care Med 1999;159:311–14
Online vs. offline
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
72 Cardinale F, De Benedictis FM, Muggeo V, Giordano P, Loffredo MS, Iacoviello G,
et al. Exhaled nitric oxide, total serum IgE and allergic sensitization in childhood
asthma and allergic rhinitis. Pediatr Allergy Immunol 2005;16:236–42
Wrong flow rate
73 Carlstedt F, Lazowska D, Bornehag CG, Olin AC, Hasselgren M. Exhaled nitric oxide
and urinary EPX levels in infants: a pilot study. Clin Mol Allergy 2011;9:8
No useable diagnostic data
74 Carra S, Gagliardi L, Zanconato S, Scollo M, Azzolin N, Zacchello F, et al. Budesonide
but not nedocromil sodium reduces exhaled nitric oxide levels in asthmatic children.
Respir Med 2001;95:734–9
Wrong flow rate
75 Carter R, Murphy A, Hargadon B, Agbetile J, Pavord ID, Wardlaw AJ, et al. Evaluating
the role of triamcinolone in a difficult asthma service. Thorax
2010;65:A152
Not a RCT
76 Carvalho-Pinto RM, Stelmach R, Angelini L, Santos DO, Dias-Junior S, Cukier A,
et al. Is there a good tool to measure asthma control on severe asthma patients?
Am J Respir Crit Care Med 2010;181:A2560
Not a RCT
77 Castano R, Miedinger D, Malo JL, Desrosiers M. Nasal and exhaled nitric oxide
monitoring during specific inhalation challenge using a portable analyser. J Allergy
Clin Immunol 2011;127(2 Suppl. 1):AB53
No analytical data
78 Castell B, Pike D, Masoli M. Difficult asthma: the Plymouth experience. Thorax
2011;66:A114
Not a RCT
79 Castro-Rodriguez JA, Sardon O, Perez-Yarza EG, Korta J, Aldasoro A, Corcuera P,
et al. Young infants with recurrent wheezing and positive asthma predictive index
have higher levels of exhaled nitric oxide. J Asthma 2013;50:162–5
Age < 5 years
80 Caudri D, Wijga AH, Hoekstra MO, Kerkhof M, Koppelman GH, Brunekreef B, et al.
Prediction of asthma in symptomatic preschool children using exhaled nitric oxide,
Rint and specific IgE. Thorax 2010;65:801–7
Offline
81 Chai J-J, Cai B-Q. The normal value measurement of fractional concentration of
exhaled nitric oxide in Chinese adults. Respirology 2011;16:196–7
No analytical data
82 Chatkin JM, Ansarin K, Silkoff PE, McClean P, Gutierrez C, Zamel N, et al. Exhaled
nitric oxide as a noninvasive assessment of chronic cough. Am J Respir Crit Care Med
1999;159:1810–13
Wrong flow rate
83 Chawes BL, Buchvald F, Bischoff AL, Loland L, Hermansen M, Halkjaer LB, et al.
Elevated exhaled nitric oxide in high-risk neonates precedes transient early but not
persistent wheeze. Am J Respir Crit Care Med 2010;182:138–42
Wrong flow rate
84 Chen E, Strunk RC, Bacharier LB, Chan M, Miller GE. Socioeconomic status
associated with exhaled nitric oxide responses to acute stress in children with asthma.
Brain Behav Immunity 2010;24:444–50
Not a RCT
85 Cherot-Kornobis N, Hulo S, Edme JL, de Broucker V, Matran R, Sobaszek A. Analysis
of nitrogen oxides (NOx) in the exhaled breath condensate (EBC) of subjects with
asthma as a complement to exhaled nitric oxide (FeNO) measurements:
a cross-sectional study. BMC Res Notes 2011;4:202
No useable diagnostic data
86 Chinellato I, Piazza M, Peroni D, Sandri M, Chiorazzo F, Boner AL, et al. Bronchial
and alveolar nitric oxide in exercise-induced bronchoconstriction in asthmatic
children. Clin Exp Allergy 2012;42:1190–6
Not a RCT
87 Chladkova J, Senkerik M, Havlinova Z, Krcmova I, Chladek J. Alveolar concentration
and bronchial flux of nitric oxide: two linear modeling methods evaluated in children
and adolescents with allergic rhinitis and atopic asthma. Pediatr Pulmonol
2012;47:1070–9
Alveolar NO
88 Choi B, Jee H, Park Y, Kim C, Sohn M, Kim K. Relationship between exhaled nitric
oxide and allergic inflammation or sensitization in children. J Allergy Clin Immunol
2009;123(2 Suppl. 1):S207
No useable diagnostic data
89 Choi BS, Kim KW, Lee YJ, Baek J, Park HB, Kim YH, et al. Exhaled nitric oxide is
associated with allergic inflammation in children. J Korean Med Sci 2011;26:1265–9
Not FeNO testing for
diagnosis
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
292
TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
90 Chow JS, Leung AS, Li WW, Tse TP, Sy HY, Leung TF, et al. Airway inflammatory and
spirometric measurements in obese children. Hong Kong Med J 2009;15:346–52
No useable diagnostic data
91 Cibella F, Cuttitta G, La Grutta S, Melis MR, Bucchieri S, Viegi G. A cross-sectional
study assessing the relationship between BMI, asthma, atopy, and eNO among
schoolchildren. Ann Allergy Asthma Immunol 2011;107:330–6
No useable diagnostic data
92 Ciprandi G, Tosca MA, Capasso M. Exhaled nitric oxide in children with allergic
rhinitis and/or asthma: a relationship with bronchial hyperreactivity. J Asthma
2010;47:1142-7
Data for both asthma and
rhinitis
93 Ciprandi G, Tosca MA, Capasso M. High exhaled nitric oxide levels may predict
bronchial reversibility in allergic children with asthma or rhinitis. J Asthma
2013;50:33–8
Data for both asthma and
rhinitis
94 Cirillo I, Ricciardolo FLM, Medusei G, Signori A, Ciprandi G. Exhaled nitric oxide may
predict bronchial hyperreactivity in patients with allergic rhinitis. Int Arch Allergy
Immunol 2013;160:322–8
Not diagnosis of asthma
95 Clearie KL, Williamson PA, Vaidyanathan S, Short P, Goudie A, Burns P, et al.
Disconnect between standardized field-based testing and mannitol challenge in
Scottish elite swimmers. Clin Exp Allergy 2010;40:731–7
Not FeNO for diagnosis
96 Clearie KL, Vaidyanathan S, Williamson PA, Goudie A, Short P, Schembri S, et al.
Effects of chlorine and exercise on the unified airway in adolescent elite Scottish
swimmers. Allergy 2010;65:269–73
No useable diagnostic data
97 Clearie KL, Jackson CM, Fardon TC, Williamson PA, Vaidyanathan S, Burns P, et al.
Supervised step-down of inhaled corticosteroids in the community – an observational
study. Respir Med 2011;105:558–65
Not a RCT
98 Cleveland C, Monforte SE, Spahn JD. Establishing normal exhaled nitric oxide (FeNO)
values in young children. J Allergy Clin Immunol 2013;131(2 Suppl. 1):AB195
No useable diagnostic data
99 Cohen J, Douma WR, Ten Hacken NH, Vonk JM, Oudkerk M, Postma DS, et al.
Ciclesonide improves measures of small airway involvement in asthma.
Eur Respir J 2008;31:1213–20
Alveolar NO
100 Colon-Semidey AJ, Marshik P, Crowley M, Katz R, Kelly HW. Correlation between
reversibility of airway obstruction and exhaled nitric oxide levels in children with
stable bronchial asthma. Pediatr Pulmonol 2000;30:385–92
Not a RCT
101 Columbo M, Wong B, Panettieri RA, Rohr AS. Asthma in the elderly: the role of
exhaled nitric oxide measurements. J Allergy Clin Immunol 2012;129(2 Suppl. 1):AB8
No useable diagnostic data
102 Consilvio NP, Di Pillo S, Verini M, de Giorgis T, Cingolani A, Chiavaroli V, et al.
The reciprocal influences of asthma and obesity on lung function testing, AHR, and
airway inflammation in prepubertal children. Pediatr Pulmonol 2010;45:1103–10
Population obese
103 Consilvio NP, Di Pillo S, de Giorgis T, Cingolani A, Scaparrotta A, Rapino D, et al.
The reciprocal influences of asthma and obesity on lung function, AHR and bronchial
inflammation in prepubertal children. Paediatr Respir Rev 2010;11:S2–3
No useable diagnostic data
104 Corradi M. What is new in the air? Monaldi Arch Chest Dis Pulm Ser 2002;57:227-8 Editorial
105 Corradi M, Zinelli C, Caffarelli C. Exhaled breath biomarkers in asthmatic children.
Inflamm Allergy Drug Targets 2007;6:150–9
Review
106 Covar RA, Szefler SJ, Martin RJ, Sundstrom DA, Silkoff PE, Murphy J, et al. Relations
between exhaled nitric oxide and measures of disease activity among children with
mild-to-moderate asthma. J Pediatr 2003;142:469-75
Not a RCT
107 Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy
on inflammatory cell subtypes in asthma. Thorax 2010;65:384–90
FeNO testing did not guide
step-up/step-down therapy
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
108 Cowan DC, Hewitt RS, Cowan JO, Palmay R, Williamson A, Lucas SJ, et al.
Exercise-induced wheeze: fraction of exhaled nitric oxide-directed management.
Respirology 2010;15:683–90
Not randomised to FeNO
109 Craig TJ, King TS, Lemanske RF Jr, Wechsler ME, Icitovic N, Zimmerman RR Jr, et al.
Aeroallergen sensitization correlates with PC(20) and exhaled nitric oxide in subjects
with mild-to-moderate asthma. J Allergy Clin Immunol 2008;121:671–7
FeNO testing did not guide
step-up/step-down therapy
110 Crane J, Wickens K, Beasley R, Fitzharris P. Asthma and allergy: a worldwide problem
of meanings and management? Allergy Eur J Allergy Clin Immunol 2002;57:663–72
Review
111 Crane J, Lampshire P, Wickens K, Epton M, Siebers R, Ingham T, et al. Asthma, atopy
and exhaled nitric oxide in a cohort of 6-yr-old New Zealand children. Pediatr
Allergy Immunol 2012;23:59–64
No useable diagnostic data
112 Crater SE, Peters EJ, Martin ML, Murphy AW, Platts-Mills TAE. Expired nitric oxide
and airway obstruction in asthma patients with an acute exacerbation. Am J Respir
Crit Care Med 1999;159:806–11
Wrong flow rate
113 Cristescu SM, Mandon J, Harren FJM, Merilainen P, Hogman M. Methods of NO
detection in exhaled breath. J Breath Res 2013;7:017104
Review
114 Crothall H, Custovic A, Simpson A, Kerry G, Belgrave D, Murray C. The relationship
between exhaled nitric oxide, atopy and asthma in school aged children. Clin Exp
Allergy 2012;42:1846
No useable diagnostic data
115 Currie GP, Bates CE, Lee DKC, Jackson CM, Lipworth BJ. Effects of fluticasone plus
salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin
Pharmacol 2003;59:11–15
FeNO testing did not guide
step-up/step-down therapy
116 Currie GP, Syme-Grant NJ, McFarlane LC, Carey FA, Lipworth BJ. Effects of low dose
fluticasone/salmeterol combination on surrogate inflammatory markers in moderate
persistent asthma. Allergy 2003;58:602–7
Not a RCT
117 Currie GP, Lee DKC, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on
surrogate inflammatory markers in corticosteroid-treated patients with asthma.
Am J Respir Crit Care Med 2003;167:1232–8
Wrong flow rate
118 Dahlen B, Lantz AS, Ihre E, Skedinger M, Henriksson E, Jorgensen L, et al. Effect of
formoterol with or without budesonide in repeated low-dose allergen challenge.
Eur Respir J 2009;33:747–53
FeNO testing did not guide
step-up/step-down therapy
119 Dal Negro R, Micheletto C, Tognella S, Turco P, Rossetti A, Cantini L. Assessment
of inhaled BDP-dose dependency of exhaled nitric oxide and local and serum
eosinophilic markers in steroids-naive nonatopic asthmatics. Allergy 2003;58:1018–22
Wrong flow rate
120 Dallinga JW, Robroeks CMHH, van Berkel JJBN, Moonen EJC, Godschalk RWL,
Jobsis Q, et al. Volatile organic compounds in exhaled breath as a diagnostic tool for
asthma in children. Clin Exp Allergy 2010;40:68–76
No useable diagnostic data
121 de Bot CM, Moed H, Bindels PJ, van Wijk RG, Berger MY, de Groot H, et al. Exhaled
nitric oxide measures allergy not symptoms in children with allergic rhinitis in primary
care: a prospective cross-sectional and longitudinal cohort study. Prim Care Respir J
2013;22:44–50
No useable diagnostic data
122 de Gouw HW, Hendriks J, Woltman AM, Twiss IM, Sterk PJ. Exhaled nitric oxide (NO)
is reduced shortly after bronchoconstriction to direct and indirect stimuli in asthma.
Am J Respir Crit Care Med 1998;158:315–19
FeNO testing did not guide
step-up/step-down therapy
123 de Gouw HW, Grunberg K, Schot R, Kroes AC, Dick EC, Sterk PJ, et al. Relationship
between exhaled nitric oxide and airway hyperresponsiveness following experimental
rhinovirus infection in asthmatic subjects. Eur Respir J 1998;11:126–32
Not RCT study
124 de Gouw HW, Marshall-Partridge SJ, Van der Veen H, Van Den Aardweg JG,
Hiemstra PS, Sterk PJ. Role of nitric oxide in the airway response to exercise in healthy
and asthmatic subjects. J Appl Physiol 2001;90:586–92
Wrong flow rate
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
125 de Groot EP, Nijkamp A, Duiverman EJ, Brand PL. Allergic rhinitis is associated with
poor asthma control in children with asthma. Thorax 2012;67:582–7
Not a RCT
126 de Jongste JC, Carraro S, Hop WC, CHARISM Study Group, Baraldi E. Daily
telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood
asthma. Am J Respir Crit Care Med 2009;179:93–7
Daily monitoring
127 de Meer G, van Amsterdam JGC, Janssen NAH, Meijer E, Steerenberg PA, Brunekreef B.
Exhaled nitric oxide predicts airway hyper-responsiveness to hypertonic saline in children
that wheeze. Allergy 2005;60:1499–504
Offline
128 de Winter-de Groot K, van der Ent CK. Measurement of nasal nitric oxide: evaluation
of six different sampling methods. Eur J Clin Invest 2009;39:72–7
Nasal NO
129 de Kluijver J, Evertse CE, Schrumpf JA, van der Veen H, Zwinderman AH, Hiemstra PS,
et al. Asymptomatic worsening of airway inflammation during low-dose allergen
exposure in asthma: protection by inhaled steroids. Am J Respir Crit Care Med
2002;166:294–300
FeNO testing did not guide
step-up/step-down therapy
130 Debley JS, Stamey DC, Cochrane ES, Gama KL, Redding GJ. Exhaled nitric oxide, lung
function, and exacerbations in wheezy infants and toddlers. J Allergy Clin Immunol
2010;125:1228–34
Infants aged < 2 years
131 Debley J, Stamey D, Cochrane E, Elliot M, Redding G. Exhaled nitric oxide predicts
persistence of wheezing, exacerbations, and decline in lung function in wheezy
infants and toddlers. Am J Respir Crit Care Med 2011;183:A1033
Infants
132 Debley JS, Cochrane ES, Redding GJ, Carter ER. Lung function and biomarkers of
airway inflammation during and after hospitalization for acute exacerbations of
childhood asthma associated with viral respiratory symptoms. Ann Allergy Asthma
Immunol 2012;109:114–20
Not a RCT
133 Decimo F, Capristo C, Amelio R, Maiello N, Capristo AF, Miraglia Del GM, et al.
Evaluation of bronchial hyperreactivity with mannitol dry powder challenge test in a
paediatric population with intermittent allergic asthma or allergic rhinitis. Int J
Immunopathol Pharmacol 2011;24:1069–74
No useable diagnostic data
134 del Giudice MM, Brunese FP, Piacentini GL, Pedulla M, Capristo C, Decimo F, et al.
Fractional exhaled nitric oxide (FENO), lung function and airway hyperresponsiveness
in naive atopic asthmatic children. J Asthma 2004;41:759–65
Unselected population
135 Delclaux C, Mahut B, Zerah-Lancner F, Delacourt C, Laoud S, Cherqui D, et al.
Increased nitric oxide output from alveolar origin during liver cirrhosis versus
bronchial source during asthma. Am J Respir Crit Care Med 2002;165:332–7
Case–control study
136 Delclaux C, Sembach N, Claessens YE, Dolbeau G, Chevalier-Bidaud B, Renaud B,
et al. Offline exhaled nitric oxide in emergency department and subsequent acute
asthma control. J Asthma 2008;45:867–73
Offline
137 Delgado-Corcoran C, Kissoon N, Murphy SP, Duckworth LJ. Exhaled nitric oxide
reflects asthma severity and asthma control. Pediatr Crit Care Med 2004;5:48–52
Not a RCT
138 Demange V, Bohadana A, Massin N, Wild P. Exhaled nitric oxide and airway
hyperresponsiveness in workers: a preliminary study in lifeguards. BMC Pulm Med
2009;9:53
Unselected population
139 Demange V, Wild P, Zmirou-Navier D, Tossa P, Bohadana A, Barbaud A, et al.
Associations of airway inflammation and responsiveness markers in non asthmatic
subjects at start of apprenticeship. BMC Pulm Med 2010;10:37
Unselected population
140 Dente FL, Melosini L, Novelli F, Bacci E, Cianchetti S, Di Franco A, et al. Asthma
control test (ACT) score is related to PEF variability and markers of airway
inflammation in corticosteroids naives asthmatics. Am J Respir Crit Care Med
2010;181:A2738
No useable diagnostic data
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
141 Deykin A, Massaro AF, Drazen JM, Israel E. Exhaled nitric oxide as a diagnostic test
for asthma: online versus offline techniques and effect of flow rate. Am J Respir Crit
Care Med 2002;165:1597–601
Wrong flow rate
142 Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, et al.
Sputum eosinophil counts predict asthma control after discontinuation of inhaled
corticosteroids. J Allergy Clin Immunol 2005;115:720–7
Offline
143 Diaconu R, Diaconu C, Bica C, Bulucea D. Bronchial responsiveness and airway
inflammation in various sports. Allergy 2010;65:195
No useable diagnostic data
144 Diamant Z, Kuperus J, Baan R, Nietzmann K, Millet S, Mendes P, et al. Effect of a
very late antigen-4 receptor antagonist on allergen-induced airway responses
and inflammation in asthma. Clin Exp Allergy 2005;35:1080–7
FeNO testing did not guide
step-up/step-down therapy
145 Dichiaro CA, Baptist AP. Exhaled nitric oxide levels in African American children.
Ann Allergy Asthma Immunol 2009;103(5 Suppl. 3):A71
No useable diagnostic data
146 Dichiaro CA, Joiner TA, Hudson SA, Baptist AP. Factors influencing asthma control
and quality of life in African American children. J Allergy Clin Immunol
2010;125(2 Suppl. 1):AB138
No useable diagnostic data
147 Divjan A, Rosa M, Just AC, Sheares BJ, Perera FP, Miller RL, et al. IgE and symptoms
by age 2 years predict FENO at age 5-7 years in a low-income urban New York City
population. J Allergy Clin Immunol 2009;123(2 Suppl. 1):S19
No useable diagnostic data
148 Divjan A, Rosa M, Reyes M, Hoepner L, Sheares BJ, Zhang H, et al. Exhaled NO at
age 7–11 years is elevated with early life but not recent onset of allergic sensitization.
Am J Respir Crit Care Med 2011;183:A4472
No useable diagnostic data
149 Domingo C, Moreno A, Amengual MJ, Monton C, Suarez D, Pomares X.
Omalizumab in the management of oral corticosteroid-dependent IGE-mediated
asthma patients. Curr Med Res Opin 2011;27:45–53
Not a RCT
150 Donohue KM, Miller RL, Perzanowski MS, Just AC, Hoepner LA, Arunajadai S, et al.
Prenatal and postnatal bisphenol A exposure and asthma development among
inner-city children. J Allergy Clin Immunol 2013;131:736–42
Not FeNO testing for
diagnosis
151 Dressel H, Gross C, de la Motte D, Sultz J, Jorres RA, Nowak D. Educational
intervention decreases exhaled nitric oxide in farmers with occupational asthma.
Eur Respir J 2007;30:545–8
Not a RCT
152 Dressel H, Gross C, de la Motte D, Sultz J, Jorres RA, Nowak D, et al. Educational
intervention in farmers with occupational asthma: long-term effect on exhaled nitric
oxide. J Invest Allergol Clin Immunol 2009;19:49–53
Not a RCT
153 Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation of the validity of
exhaled nitric oxide for the diagnosis of asthma. Chest 2003;123:751–6
Wrong flow rate
154 Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, et al.
Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype
among patients with asthma. Am J Respir Crit Care Med 2010;181:1033–41
Not a RCT
155 Ekerljung L, Bossios A, Lotvall J, Olin AC, Ronmark E, Wennergren G, et al.
Multi-symptom asthma as an indication of disease severity in epidemiology.
Eur Respir J 2011;38:825–32
No useable diagnostic data
156 Fernandez-Nieto M, Sastre B, Sastre J, Lahoz C, Quirce S, Madero M, et al. Changes
in sputum eicosanoids and inflammatory markers after inhalation challenges with
occupational agents. Chest 2009;136:1308–15
No data on FeNO testing
for diagnosis
157 Fireman E, Toledano B, Soferman R, Moshe S, Sivan Y, Kivity S, et al. Airways
eosiniphilic inflammation in the airways of astmatic children is correlated to
particulate matter in induced sputum. Am J Respir Crit Care Med 2010;181:A1156
No useable diagnostic data
158 Fortuna A, Feixas T, Gonzalez M, Casan P. Portable equipment (NIOX MINO,
aerocrine) for determination of NO in respiratory air (FENO). Arch Bronconeumol
2006;42:420
Foreign language
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
159 Franklin PJ, Turner SW, Le Souef PN, Stick SM. Exhaled nitric oxide and asthma:
complex interactions between atopy, airway responsiveness, and symptoms in a
community population of children. Thorax 2003;58:1048–52
Wrong flow rate
160 Fuchs O, Latzin P, Singer F, Petrus N, Proietti E, Kieninger E, et al. Comparison of
online single-breath vs. online multiple-breath exhaled nitric oxide in school-age
children. Pediatr Res 2012;71:605–11
Single breath vs. multiple
breaths
161 Fujimura M, Ohkura N, Abo M, Furusho S, Waseda Y, Ichikawa Y, et al. Exhaled nitric
oxide levels in patients with atopic cough and cough variant asthma. Respirology
2008;13:359–64
Case–control study
162 Gill M, Graff GR, Adler AJ, Dweik RA. Validation study of fractional exhaled nitric
oxide measurements using a handheld monitoring device. J Asthma 2006;43:731–4
Inter-reliability
163 Grzelewski T, Grzelewska A, Majak P, Stelmach W, Kowalska A, Stelmach R, et al.
Fractional exhaled nitric oxide (FeNO) may predict exercise-induced
bronchoconstriction (EIB) in schoolchildren with atopic asthma. Nitric Oxide Biol
Chem 2012;27:82–7
Diagnosing EIB in
asthmatics, i.e. not
diagnostic of asthma
164 Hafkamp-de-Groen E, Mohangoo AD, de Jongste JC, van der Wouden JC, Moll HA,
Jaddoe VW, et al. Early detection and counselling intervention of asthma symptoms
in preschool children: study design of a cluster randomised controlled trial. BMC
Public Health 2010;10:555
Study design only
165 Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al.
Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med
2008;178:218–24
Not a RCT
166 Hardaker K, Downie S, Kermode J, Farah C, Berend N, King G, et al. The predictors
of airway hyperresponsiveness are different in younger and older asthmatics.
Respirology 2010;15:A37
No useable diagnostic data
167 Hardaker KM, Downie SR, Kermode JA, Farah CS, Brown NJ, Berend N, et al.
Predictors of airway hyperresponsiveness differ between old and young patients with
asthma. Chest 2011;139:1395–401
No useable diagnostic data
168 Hemmingsson T, Horn A, Linnarsson D. Measuring exhaled nitric oxide at high
altitude. Respir Physiol Neurobiol 2009;67:292–8
Not in humans
169 Högman M, Malinovschi A, Norbäck D, Janson C. Added value with extended NO
analysis in atopy and asthma. Clin Physiol Funct Imaging 2011;31:294–9
No useable diagnostic data
170 Honkoop PJ, Loymans RJ, Termeer EH, Snoeck-Stroband JB, Bakker MJ, Assendelft WJ,
et al. Asthma control cost–utility randomized trial evaluation (ACCURATE): the goals
of asthma treatment. BMC Pulm Med 2011;11:53
Ongoing study
171 Huang J, Yao T, Yeh K. Exhaled nitric oxide discriminates children with and without
allergic sensitisation in a population-based study. Allergy 2011;66:198
Unselected population
172 Hur G-Y, Oh JY, Choi J-H, Sim J-K, Min KH, Lee S-Y, et al. Mannitol challenge test,
sputum eosinophils and exhaled nitric oxide (FENO) for diagnosis of asthma.
J Allergy Clin Immunol 2013;131(2 Suppl. 1):AB64
No useable diagnostic data
173 Imaoka M, Tanahashi T, Kishikawa R, Shimoda T, Iwanaga T. Gender-specific effect
of overweight and obesity on airway inflammation in adults with asthma. J Allergy
Clin Immunol 2011;127(2 Suppl. 1):AB98
No useable diagnostic data
174 Imaoka M, Tanahashi T, Kishikawa R, Shimoda T, Iwanaga T. Overweight and obesity
reduce exhaled nitric oxide levels in Japanese women with asthma. Allergy
2011;66:515
No useable diagnostic data
175 Inoue H, Niimi A, Takeda T, Matsumoto H, Ito I, Otsuka K, et al. Pathophysiological
characteristics of asthma in the elderly. Am J Respir Crit Care Med 2010;181:A5096
No useable diagnostic data
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
176 Ishizuka T, Matsuzaki S, Aoki H, Yatomi M, Kamide Y, Hisada T, et al. Prevalence of
asthma symptoms based on the European Community Respiratory Health Survey
questionnaire and FENO in university students: gender differences in symptoms and
FENO. Allergy Asthma Clin Immunol 2011;7:15
No useable diagnostic data
177 Ito Y, Adachi Y, Itazawa T, Okabe Y, Adachi YS, Katsumuma T, et al. Comparison of
exhalation time methods (6 sec vs. 10 sec) of a hand-held exhaled nitric oxide
analyzer. Pediatr Pulmonol 2010;45:1005–8
Measurement not in
accordance with ATS 2005
guidelines35
178 Jackson DJ, Virnig CM, Gangnon RE, Evans MD, Roberg KA, Anderson EL, et al.
Fractional exhaled nitric oxide measurements are most closely associated with allergic
sensitization in school-age children. J Allergy Clin Immunol 2009;124:949–53
No useable diagnostic data
179 Jobsis Q, Raatgeep HC, Hop WC, Jongste JC. Controlled low flow off line sampling
of exhaled nitric oxide in children. Thorax 2001;56:285–9
Offline
180 Jobsis Q, Schellekens SL, Kroesbergen A, Hop WCJ, de Jongste JC. Off-line sampling
of exhaled air for nitric oxide measurement in children: methodological aspects.
Eur Respir J 2001;17:898–903
Offline
181 Jung A, Summermatter S, Geidel C, Moller A, Menz G, Lauener R. Diagnostic value
of nasal NO measurement using the NIOX MINO device. Atemwegs Lungenkr
2012;38:57–8
Nasal NO
182 Jung M, Korn S, Taube C, Buhl R. Short-term reproducibility of non-invasive
clinical and inflammatory parameters in asthma. Am J Respir Crit Care Med
2011;183:A4481
No analytical data
183 Kelso JM. Titrating steroids on exhaled nitric oxide in children with asthma:
a randomized, controlled trial: commentary. Pediatrics 2006;118(Suppl. 1):S33
Commentary
184 Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ, et al.
Dose-dependent onset and cessation of action of inhaled budesonide on exhaled
nitric oxide and symptoms in mild asthma. Thorax 2002;57:889–96
FeNO testing did not guide
step-up/step-down therapy
185 Khurana S, Larj M, Saatian B, Lerner LB, Smith S, Pietropaoli A, et al. Correlation of
bronchodilator reversibility with exhaled nitric oxide levels and asthma severity.
Am J Respir Crit Care Med 2011;183:A4474
No useable diagnostic data
186 Kim S, Kim T, Sohn J, Yoon H, Shin D, Park S. Measurement of the exhaled
nitric oxide in the assessment of chronic cough. J Allergy Clin Immunol
2009;123(2 Suppl. 1):S6
No useable diagnostic data
187 Kim S-H, Kim TH, Sohn JW, Yoon HJ, Shin DH, Park SS. Measurement of exhaled and
nasal nitric oxide in the diagnosis of chronic cough. Respirology 2009;14:A160
No useable diagnostic data
188 Kim YH, Kim KW, Baek J, Park HB, Kim H, Song K-J, et al. Usefulness of impulse
oscillometry and fractional exhaled nitric oxide in children with eosinophilic
bronchitis. Pediatr Pulmonol 2013;48:221–8
No useable diagnostic data
189 Klaassen EM, van de Kant KD, Jobsis Q, Hovig ST, van Schayck CP, Rijkers GT, et al.
Symptoms, but not a biomarker response to inhaled corticosteroids, predict asthma in
preschool children with recurrent wheeze. Mediators Inflamm 2012;2012:162571
No useable diagnostic data
190 Konstantinou G, Xepapadaki P, Manousakis E, Makrinioti C, Kouloufakou-Gratsia K,
Chatziioannou A, et al. Non-invasive evaluation of airway inflammation during
virus-induced asthma exacerbations in atopic and non-atopic preschool-children.
Allergy 2009;64:432–3
FeNO testing in
exacerbations
191 Konstantinou GN, Xepapadaki P, Manousakis E, Makrinioti H, Kouloufakou-Gratsia K,
Saxoni-Papageorgiou P, et al. Assessment of airflow limitation, airway inflammation,
and symptoms during virus-induced wheezing episodes in 4- to 6-year-old children.
J Allergy Clin Immunol 2013;131:87–93
No useable diagnostic data
192 Koopman M, Arets HG, Uiterwaal CS, van der Ent CK. Comparing 6 and 10 sec
exhalation time in exhaled nitric oxide measurements in children. Pediatr Pulmonol
2009;44:340–4
Measurement not in
accordance with ATS 2005
guidelines35
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
193 Kotaniemi-Syrjanen A, Malmberg LP, Malmstrom K, Pelkonen AS, Makela MJ. Factors
associated with elevated exhaled nitric oxide fraction in infants with recurrent
respiratory symptoms. Eur Respir J 2013;41:189–94
Infants aged < 3 years
194 Krcmova I, Novosad J, Kralickova P, Kleiberova M, Chladkova J, Melicharova J.
Asthma control test, FeNO, functional parameters, ECP and their correlation.
Allergy 2009;64:301–2
Not a RCT
195 Kumor M, Przybylowski T, Maskey-Warzechowska M, Hildebrand K, Fangrat A,
Bielicki P, et al. [Reproducibility of exhaled nitric oxide (FENO) measurements in
healthy subjects]. Pneumonol Alergol Pol 2004;72:395–9
Foreign language
196 Larj MJ, Khurana S, Lerner LB, Smith SM, Aung T, Pietropaoli A, et al. Alveolar
and airway nitric oxide correlations in asthma. Am J Respir Crit Care Med
2010;181:A4282
Alveolar NO
197 Larson JL, Zeidler MR, Kleerup EC, Kim HJG, Tashkin DP. Correlation of alveolar nitric
oxide with methacholine responsiveness in asthmatic subjects following a naturalistic
cat challenge. Am J Respir Crit Care Med 2011;183:A4471
Alveolar NO
198 Larson JL, Zeidler M, Kleerup E, Tashkin D. Evaluation of exhaled nitric oxide as a
surrogate for airways hyperresponsiveness. J Invest Med 2011;59:214
No useable diagnostic data
199 Latzin P, Kuehni CE, Baldwin DN, Roiha HL, Casaulta C, Frey U. Elevated exhaled
nitric oxide in newborns of atopic mothers precedes respiratory symptoms.
Am J Respir Crit Care Med 2006;174:1292–8
No useable diagnostic data
200 Lee J, Lee BH, Lee S-H. Repeatability of successive measurements with a portable
nitric oxide analyser in healthy Koreans. Chest 2011;140:213A
Repeatability
201 Lehtimaki L, Turjanmaa V, Kankaanranta H, Saarelainen S, Hahtola P, Moilanen E.
Increased bronchial nitric oxide production in patients with asthma measured with a
novel method of different exhalation flow rates. Ann Med 2000;32:417–23
Device not in scope
202 Lemiere C, D’Alpaos V, Chaboillez S, Cesar M, Wattiez M, Chiry S, et al. Investigation
of occupational asthma: sputum cell counts or exhaled nitric oxide? Chest
2010;137:617–22
Offline
203 Lemiere C, Tremblay C, Bohadana A, Chaboillez S. Prognosis of the workers with
non-eosinophilic occupational asthma. Am J Respir Crit Care Med 2011;183:A1172
Not FeNO testing
204 Lex C, Dymek S, Heying R, Kovacevic A, Kramm CM, Schuster A. Value of surrogate
tests to predict exercise-induced bronchoconstriction in atopic childhood asthma.
Pediatr Pulmonol 2007;42:225–30
Diagnosis of EIB not
asthma
205 Li S, Lou XS, Ma Y, Han SL, Liu CH, Chen YZ, et al. [Exhaled nitric oxide levels in
school children of Beijing]. Zhonghua Erke Zazhi 2010;48:148–52
Foreign language
206 Linkosalo L, Lehtimaki L, Holm K, Kaila M, Moilanen E. Increased bronchial nitric
oxide output is associated with exercise-induced bronchoconstriction in atopic
children. Allergy 2009;64:72–3
No useable diagnostic data
207 Linn WS, Rappaport EB, Berhane KT, Bastain TM, Avol EL, Gilliland FD. Exhaled nitric
oxide in a population-based study of southern California schoolchildren. Respir Res
2009;10:28
Wrong device
208 Linn WS, Rappaport EB, Berhane KT, Bastain TM, Salam MT, Gilliland FD, et al.
Extended exhaled nitric oxide analysis in field surveys of schoolchildren: a pilot test.
Pediatr Pulmonol 2009;44:1033–42
No useable diagnostic data
209 Linn WS, Berhane KT, Rappaport EB, Bastain TM, Avol EL, Gilliland FD. Relationships
of online exhaled, offline exhaled, and ambient nitric oxide in an epidemiologic
survey of schoolchildren. J Expo Sci Environ Epidemiol 2009;19:674–81
No useable diagnostic data
210 Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive
markers of airway inflammation as predictors of oral steroid responsiveness in
asthma. Thorax 2000;55:232–4
Wrong flow rate
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
211 Lonnkvist K, Anderson M, Hedlin G, Svartengren M. Exhaled NO and eosinophil
markers in blood, nasal lavage and sputum in children with asthma after withdrawal
of budesonide. Pediatr Allergy Immunol 2004;15:351–8
FeNO testing did not guide
step-up/step-down therapy
212 Lund TK. Asthma in elite athletes: how do we manage asthma-like symptoms and
asthma in elite athletes? Clin Respir J 2009;3:123
Case–control study
213 Magori E, Hiltawsky K, Fleischer M, Simon E, Pohle R, von Sicard O, et al. Fractional
exhaled nitric oxide measurement with a handheld device. J Breath Res 2011;5:027104
Device not in scope
214 Mahut B, Peyrard S, Delclaux C. Exhaled nitric oxide and clinical phenotypes of
childhood asthma. Respir Res 2011;12:65
No useable diagnostic data
215 Malby Schoos AM, Chawes BL, Bonnelykke K, Bisgaard H. Fraction of exhaled nitric
oxide and bronchial responsiveness are associated and continuous traits in young
children independent of asthma. Chest 2012;142:1562–8
No useable diagnostic data
216 Malik G, Turner SW. Deselecting the instant flow option on the NIOX© analyser
increases the number of successful FENO measurements without altering the results.
Eur Respir J 2005;26:Abstract 3907
No comparison between
devices
217 Malik G, Turner S. Is the ‘instant flow’ option on the NIOX analyser needed? Med
Eng Physics 2007;29:72–5
Wrong device
218 Malinovschi A, Janson C, Hogman M, Rolla G, Toren K, Norback D, et al. Both
allergic and nonallergic asthma are associated with increased FE(NO) levels, but only
in never-smokers. Allergy 2009;64:55–61
No useable diagnostic data
219 Malinovschi A, Backer V, Harving H, Porsbjerg C. The value of exhaled nitric oxide to
identify asthma in smoking patients with asthma-like symptoms. Respir Med
2012;106:794–801
Incorrect reference
standard
220 Malka-Rais J, Krawiec ME, Spahn JD. Are there differences in levels of impairment,
risk, and biomarkers of inflammation in children vs. adults with severe persistent
asthma? J Allergy Clin Immunol 2010;125(2 Suppl. 1):AB6
No useable diagnostic data
221 Malka-Rais J, Davidson J, Krawiec ME, Spahn JD. Which parameters are useful in
the determining asthma severity in childhood? Am J Respir Crit Care Med
2010;181:A2556
No useable diagnostic data
222 Malmberg LP, Pelkonen AS, Mattila PS, Hammaren-Malmi S, Makela MJ. Exhaled
nitric oxide and exercise-induced bronchoconstriction in young wheezy children –
interactions with atopy. Pediatr Allergy Immunol 2009;20:673–8
Age 3–7 years
223 Malmberg LP, Laatikainen T, von Hertzen L, Makela MJ, Vartiainen E, Haahtela T,
et al. Exhaled nitric oxide in contrasting population samples of Finnish and Russian
Karelia. Eur Respir J 2010;35:1416–18
No useable diagnostic data
224 Maniscalco M, Lundberg JO. Hand-held nitric oxide sensor NIOX MINO for the
monitoring of respiratory disorders. Expert Rev Respir Med 2010;4:715–21
Review
225 Martin N, Lindley MR, Hargadon B, Monteiro W, Pavord ID. Airway dysfunction
and inflammation in pool and non-pool based elite endurance athletes.
Thorax 2010;65:A60–1
No useable diagnostic data
226 Martin N, Lindley MR, Hargadon B, Monteiro W, Pavord ID. Airway dysfunction and
inflammation in pool and non-pool based elite international athletes with symptoms
suggesting exercise-induced asthma. Am J Respir Crit Care Med 2010;181:A3970
No useable diagnostic data
227 Martin N, Lindley MR, Hargadon B, Monteiro W, Pavord ID. Airways dysfunction
and eosinophilic inflammation in elite athletes with symptoms suggesting
exercise-induced asthma. Thorax 2009;64:A72
No useable diagnostic data
228 Martin N, Lindley MR, Hargadon B, Monteiro WR, Pavord ID. Airway dysfunction and
inflammation in pool- and non-pool-based elite athletes. Med Sci Sports Exerc
2012;44:1433–9
No useable diagnostic data
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
229 Martin RJ, Szefler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, et al. The
Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin
Immunol 2007;119:73–80
No useable diagnostic data
230 Martins P, Caires I, Pinto JR, da Mata PL, Torres S, Valente J, et al. The clinical use of
exhaled nitric oxide in wheezing children. Rev Port Pneumol 2008;14:195–218
Population not self-
presenting for assessment
231 Matsunaga K, Hirano T, Akamatsu K, Koarai A, Sugiura H, Minakata Y, et al. Exhaled
nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking
status in Japanese subjects. Allergol Int 2011;60:331–7
Case–control study
232 McCurdy MR, Bakhirkin YA, Tittel FK. Quantum cascade laser-based integrated cavity
output spectroscopy of exhaled nitric oxide. Appl Physics B Lasers Optics
2006;85:445–52
Laser spectroscopy
233 McCurdy MR, Bakhirkin Y, Wysocki G, Tittel FK. Performance of an exhaled nitric
oxide and carbon dioxide sensor using quantum cascade laser-based integrated cavity
output spectroscopy. J Biomed Optics 2007;12:034034
Laser spectroscopy
234 McKinlay L, Williamson PA, Short PM, Fardon TC, Lipworth BJ. Proof of concept study
to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy
on surrogate inflammatory markers in asthma. Br J Clin Pharmacol 2011;71:128–31
FeNO testing did not guide
step-up/step-down therapy
235 Menzies D, Jackson C, Mistry C, Houston R, Lipworth BJ. Symptoms, spirometry,
exhaled nitric oxide, and asthma exacerbations in clinical practice. Ann Allergy
Asthma Immunol 2008;101:248–55
FeNO testing did not guide
step-up/step-down therapy
236 Meyts I, Proesmans M, Van Gerven V, Hoppenbrouwers K, De Boeck K. Tidal
off-line exhaled nitric oxide measurements in a pre-school population. Eur J Pediatr
2003;162:506–10
No useable diagnostic data
237 Mgaloblishvili N, Gotua M, Rukhadze M, Dolidze N, Lomidze N, Abramidze T, et al.
Exhaled nitric oxide and respiratory symptoms in the diagnosis of atopic asthma.
Allergy 2009;64:179–80
No useable diagnostic data
238 Mgaloblishvili N, Gotua M, Gamkrelidze A. Exhaled nitric oxide and asthma severity
in georgian population. Allergy 2010;65:549
No useable diagnostic data
239 Mi Q, Balzar S, Wenzel SE. Distinguishing the features of severe asthma: feature
selection in the asthma dataset using linear support vector machines (SVM) approach.
Am J Respir Crit Care Med 2011;183:A4301
No useable diagnostic data
240 Miedinger D, Chhajed PN, Tamm M, Stolz D, Surber C, Leuppi JD. Diagnostic tests
for asthma in firefighters. Chest 2007;131:1760–7
Unselected population
241 Monforte S, Malka-Rais J, Spahn JD. The use of exhaled nitric oxide (FeNO) in the
outpatient management of children with asthma. J Allergy Clin Immunol
2009;123:727
No useable diagnostic data
242 Monforte S, Malka-Rais J, Spahn JD. The association of exhaled nitric oxide (FeNO)
with asthma control and severity in children. J Allergy Clin Immunol
2010;125(2 Suppl. 1):AB186
Not RCT study
243 Montella S, Alving K, Maniscalco M, Sofia M, De Stefano S, Raia V, et al.
Measurement of nasal nitric oxide by hand-held and stationary devices. Eur J Clin
Invest 2011;41:1063–70
Nasal NO
244 Motomura C, Odajima H, Tezuka J, Murakami Y, Moriyasu Y, Kando N, et al. Effect
of age on relationship between exhaled nitric oxide and airway hyperresponsiveness
in asthmatic children. Chest 2009;136:519–25
No useable diagnostic data
245 Motomura C, Odajima H, Tezuka J, Kodama T, Amimoto Y, Murakami Y, et al.
Exhaled nitric oxide predicts bronchial responsiveness according to age in asthmatic
children. Am J Respir Crit Care Med 2010;181:A3294
No useable diagnostic data
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
246 Motomura C, Odajima H, Higashi N, Tezuka J, Honjo S, Okada K, et al.
Exercise-induced bronchoconstriction in children with asthma: is there an association
with urinary leukotriene E4 or exhaled nitric oxide. Pediatr Allergy Immunol Pulmonol
2012;25:208–12
No useable diagnostic data
247 Muller KC, Jorres RA, Magnussen H, Holz O. Comparison of exhaled nitric oxide
analysers. Respir Med 2005;99:631–7
Wrong device
248 Munnik P, van der Lee I, Fijn J, van Eijsden LJ, Lammers JW, Zanen P. Comparison of
eNO and histamine hyperresponsiveness in diagnosing asthma in new referrals. Respir
Med 2010;104:801–7
Not comparing relevant
devices
249 Murata A, Kida K, Hasunuma H, Kanegae H, Ishimaru Y, Motegi T, et al.
Environmental influence on the measurement of exhaled nitric oxide concentration in
school children: special reference to methodology. J Nippon Med School 2007;74:30–6
No useable diagnostic data
250 Musk AWB, Knuiman M, Hunter M, Hui J, Palmer L, Beilby J, et al. Patterns of airway
disease and the clinical diagnosis of asthma in the Busselton population. Respirology
2010;15:A46
No useable diagnostic data
251 Musk AW, Knuiman M, Hunter M, Hui J, Palmer LJ, Beilby J, et al. Patterns of airway
disease and the clinical diagnosis of asthma in the Busselton population. Eur Respir J
2011;38:1053–9
No useable diagnostic data
252 Nagase H, Toda T, Kamiyama A, Nakase Y, Sugimoto N, Yoshihara H, et al.
Usefulness of measuring fractional exhaled nitric oxide (FeNO) in various respiratory
diseases. J Allergy Clin Immunol 2011;127(2 Suppl. 1):AB7
Unclear how patients
recruited
253 Nakajima N, Mochizuki H, Muramatsu R, Hagiwara S, Mizuno T, Arakawa H, et al.
Relationship between exhaled nitric oxide and small airway lung function in normal
and asthmatic children. Allergol Int 2011;60:53–9
No useable diagnostic data
254 Narang I, Ersu R, Wilson NM, Bush A. Nitric oxide in chronic airway inflammation in
children: diagnostic use and pathophysiological significance. Thorax 2002;57:586–9
Case–control study
255 Nelson BV, Sears S, Woods J, Ling CY, Hunt J, Clapper LM, et al. Expired nitric oxide
as a marker for childhood asthma. J Pediatr 1997;130:423–7
Case–control study
256 Nikasinovic L, Rouffai L, Dassonville C, Momas I, Just J. Nasal lavage fluid IL8 and
fractional exhaled nitric oxide (FeNO) association in untreated asthmatic children.
Allergy 2011;66:643–4
No useable diagnostic data
257 Nishio K, Odajima H, Motomura C, Nakao F, Nishima S, Nishio K, et al. Exhaled nitric
oxide and exercise-induced bronchospasm assessed by FEV1, FEF25–75% in
childhood asthma. J Asthma 2007;44:475–8
No useable diagnostic data
258 Obata H, Dittrick M, Chan H, Chan-Yeung. Sputum eosinophils and exhaled nitric
oxide during late asthmatic reaction in patients with western red cedar asthma.
Eur Respir J 1999;3:489–95
Wrong flow rate
259 Olaguibel JM, Parra A, Alvarez MJ, Quirce S, Lopez R. Measurements of fractional
exhaled nitric oxide with 2 portable electrochemical sensors: a comparative study.
J Invest Allergol Clin Immunol 2011;21:322–3
Healthy volunteers
260 Oros M, Codleanu C, Calapod L, Bogdan R, Bulacu E, Momarla C, et al. Is FENO of
some help for pediatric outpatients with asthma? Am J Respir Crit Care Med
2010;181:A3301
No useable diagnostic data
261 Oshikata C, Tsuburai T, Tsurikisawa N, Ono E, Higashi A, Fukutomi Y, et al. Cutoff
point of the fraction of exhaled nitric oxide (FeNO) with the off-line method for
diagnosing asthma and the effect of smoking on FeNO. Nihon Kokyuki Gakkai Zasshi
2008;46:356–62
Foreign language
262 Perez-de-Llano LA, Carballada F, Castro AO, Pizarro M, Golpe R, Baloira A, et al.
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma.
Eur Respir J 2010;35:1221–7
FeNO testing did not guide
step-up/step-down therapy
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
263 Perzanowski MS, Divjan A, Mellins RB, Canfield SM, Rosa MJ, Chew GL, et al.
Exhaled NO among 7-year-old children who attended Head Start in New York City.
J Allergy Clin Immunol 2009;123(2 Suppl. 1):S171
No useable diagnostic data
264 Perzanowski MS, Divjan A, Mellins RB, Canfield SM, Rosa MJ, Chew GL, et al.
Exhaled NO among inner-city children in New York City. J Asthma 2010;47:1015–21
No useable diagnostic data
265 Pijnenburg MW, Lissenberg ET, Hofhuis W, Ghiro L, Ho WC, Holland WP, et al.
Exhaled nitric oxide measurements with dynamic flow restriction in children
aged 4–8 yrs. Eur Respir J 2002;20:919–24
Online vs. offline
266 Porsbjerg C, Brannan JD, Anderson SD, Backer V. Relationship between airway
responsiveness to mannitol and to methacholine and markers of airway
inflammation, peak flow variability and quality of life in asthma patients. Clin Exp
Allergy 2008;38:43–50
Diagnosis of airway
hyper-responsiveness
267 Porsbjerg C, Lund TK, Pedersen L, Backer V. Inflammatory subtypes in asthma are
related to airway hyperresponsiveness to mannitol and exhaled NO. J Asthma
2009;46:606–12
Population all asthmatics
268 Porsbjerg C, Sverrild A, Thomsen SF, Backer V. The association between AHR to
mannitol and to methacholine and exhaled NO in a random sample population.
Respirology 2010;15:A47
Unselected population
269 Prasad A, Langford B, Stradling JR, Ho LP. Exhaled nitric oxide as a screening tool for
asthma in school children. Respir Med 2006;100:167–73
No useable diagnostic data
270 Profita M, Montuschi P, Bonanno A, Riccobono L, Montalbano AM, Ciabattoni G,
et al. Nasobronchial markers of oxidative stress and inflammation in atopic airway
diseases. Pediatr Allergy Immunol 2009;20:58
No useable diagnostic data
271 Puckett JL, Galant SP, Taylor RWE, Cirson LC, Warren JL, Guijon OL, et al.
Bronchodilator response and airway nitric oxide flux correlate in a pediatric asthma
population. J Allergy Clin Immunol 2009;123(2 Suppl. 1):S78
No useable diagnostic data
272 Raulf-Heimsoth M, van Kampen V, Sucker K, Heinze E, Eliakopoulos C, Bruning T,
et al. Application of non-invasive methods to assess current airway inflammation in
health care workers 10 years after the latex ban in Germany. Allergy 2010;65:56
No useable diagnostic data
273 Raulf-Heimsoth M, van Kampen V, Heinze E, Bernard S, Borowitzki G, Freundt S,
et al. Comparison of different non-invasive methods for detection of allergic asthma.
Adv Exp Med Biol 2013;755:55–63
No useable diagnostic data
274 Rees PJ. Using exhaled NO concentrations to adjust inhaled corticosteroid dose
maintained asthma control and reduced the dose. Evid Based Med 2006;11:20
Commentary
275 Reyes RL, Tordera MP, Gisbert VM. Relationship between values for exhaled nitric
oxide at a flow rate of 250ml/s and levels obtained from a linear regression equation.
Am J Respir Crit Care Med 2011;183:A4374
Wrong flow rate
276 Robroeks CM, van de Kant KD, Jobsis Q, Hendriks HJ, van Gent R, Wouters EF, et al.
Exhaled nitric oxide and biomarkers in exhaled breath condensate indicate the
presence, severity and control of childhood asthma. Clin Exp Allergy 2007;37:1303–11
Case–control study
277 Rosa M, Divjan A, Johnson A, Hoepner L, Sheares B, Perera FP, et al. Flow-dependent
and independent parameters of exhaled nitric oxide in 9 year-old children living in
low-income NYC communities. J Allergy Clin Immunol 2009;123(2 Suppl. 1):S5
No useable diagnostic data
278 Rosa MJ, Divjan A, Hoepner L, Sheares BJ, Diaz D, Gauvey-Kern K, et al. Fractional
exhaled nitric oxide exchange parameters among 9-year-old inner-city children.
Pediatr Pulmonol 2011;46:83–91
Offline measurement
279 Rutgers SR, Meijer RJ, Kerstjens HA, van der Mark TW, Koeter GH, Postma DS, et al.
Nitric oxide measured with single-breath and tidal-breathing methods in asthma and
COPD. Eur Respir J 1998;12:816–19
Case–control study
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
280 Ryan D, Thomas MD, Dorinsky PM, Burden A, Von Ziegenweidt J, Hutton C, et al.
The role of exhaled nitric oxide in guiding asthma. J Allergy Clin Immunol
2013;131(2 Suppl. 1):AB205
Not diagnostic study
281 Sachs-Olsen C, Lodrup Carlsen KC, Mowinckel P, Haland G, Devulapalli CS,
Munthe-Kaas MC, et al. Diagnostic value of exhaled nitric oxide in childhood asthma
and allergy. Pediatric Allergy Immunol 2010;21:e213–21
Unselected population
282 Saito J, Fukuhara A, Sato Y, Sato S, Saito K, Nakagawa N, et al. [Differences of
fractional exhaled nitric oxide (FeNO) levels performed using two different analyzers].
Nihon Kokyuki Gakkai Zasshi 2010;48:17–22
Foreign language
283 Sakai T, Sugiyama N, Hirai K, Muramatsu R, Hagiwara S, Oh Y, et al. Consistently
high levels of exhaled nitric oxide in children with asthma. Pediatr Int 2010;52:801–5
No useable diagnostic data
284 Sanchez-Vidaurre S, Cruz MJ, Gomez-Olles S, Morell F, Munoz X. Diagnostic utility of
exhaled breath condensate analysis in conjunction with specific inhalation challenge
in individuals with suspected work-related asthma. Ann Allergy Asthma Immunol
2012;108:151–6
No data on FeNO testing
285 Sardon PO, Aldasoro RA, Korta MJ, Mintegui AJ, Emparanza Knorr JI, Perez-Yarza EG,
et al. [Agreement between two devices for measuring exhaled nitric oxide].
An Pediatr 2007;67:572–7
Foreign language
286 Sardon PO, Perez-Yarza EG, Aldasoro RA, Korta MJ, Mintegui AJ, Emparanza Knorr JI,
et al. [Fractional exhaled nitric oxide: validation of a 6 second exhalation time with
two different analysers]. An Pediatr 2008;69:221–6
Foreign language
287 Schleich FN, Seidel L, Sele J, Manise M, Quaedvlieg V, Michils A, et al. Exhaled nitric
oxide thresholds associated with a sputum eosinophil count ≥ 3% in a cohort of
unselected patients with asthma. Thorax 2010;65:1039–44
Population all asthmatic
288 Scollo M, Zanconato S, Ongaro R, Zaramella C, Zacchello F, Baraldi E, et al. Exhaled
nitric oxide and exercise-induced bronchoconstriction in asthmatic children.
Am J Respir Crit Care Med 2000;161:1047–50
Case–control study
289 Selby A, Clayton B, Grundy J, Pike K, Drew K, Raza A, et al. Are exhaled nitric oxide
measurements using the portable NIOX MINO repeatable? Respir Res 2010;11:43
Repeatability
290 Silkoff PE, Lent AM, Busacker AA, Katial RK, Balzar S, Strand M, et al. Exhaled nitric
oxide identifies the persistent eosinophilic phenotype in severe refractory asthma.
J Allergy Clin Immunol 2005;116:1249–55
Diagnosis of Eosinophilic
airway inflammation+
phenotype
291 Simpson JL, McDonald VM, Gibson PG. Exhaled nitric oxide is not a marker of
eosinophilic inflammation in older Australians. Respirology 2010;15:A53
No useable diagnostic data
292 Smith AM, Villareal M, Bernstein DI, Swikert DJ. Asthma in the elderly: risk factors
and impact on physical function. Ann Allergy Asthma Immunol 2012;108:305–10
No useable diagnostic data
293 Sobrevia M, Segura N, Ferrer L, Lezaun A, Cubero J, Sierra J, et al. Influence of
positive skin prick tests in FeNO measurement. Allergy 2010;65:675
No useable diagnostic data
294 Sordillo J, Milton DK, Platts-Mills TA, Gold DR. Asthma symptoms, sensitization,
and allergen exposure as predictors of exhaled NO. J Allergy Clin Immunol
2009;123(2 Suppl. 1):S22
No useable diagnostic data
295 Sordillo JE, Webb T, Kwan D, Kamel J, Hoffman E, Milton DK, et al. Allergen
exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels
in children at risk for allergy and asthma. J Allergy Clin Immunol 2011;127:1165–72
FeNO testing did not guide
step-up/step-down therapy
296 Stahl MC, Arora R, Tucker M, Johnson T, Calabria C. A prospective evaluation of the
fraction of exhaled nitric oxide and the subsequent diagnosis of asthma in military
basic trainees. Ann Allergy Asthma Immunol 2009;103(5 Suppl. 3):A72
Unselected population
297 Sverrild A, Porsbjerg C, Thomsen SF, Backer V. Airway hyperresponsiveness to
mannitol and methacholine and exhaled nitric oxide: a random-sample population
study. J Allergy Clin Immunol 2010;126:952–8
Unselected population
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
304
TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
298 Sverrild A, Malinovschi A, Porsbjerg C, Backer V, Alving K. Predicting airway
hyperreactivity to mannitol using exhaled nitric oxide in an unselected sample of
adolescents and young adults. Respir Med 2013;107:150–2
Unselected population
299 Syed A, Rehman A, Akram M, Bukhari R. Role of FeNO in predicting asthma relapse
and clinical relevance in children on inhaled corticosteroid. J Allergy Clin Immunol
2011;127(2 Suppl. 1):AB158
No relevant outcomes
300 Tanaka H, Kitada J, Fujii M, Takahashi H. Diagnostic strategy for chorinic cough using
FENO and impulse oscillometry. Am J Respir Crit Care Med 2011;183:A4386
No useable diagnostic data
301 Tatyana S, Mitrova R, Ganeva M, Boyadjieva L, Markova R. Fractional exhaled nitric
oxide and bronchodilator responsiveness in preschool children with asthma.
Allergy 2011;66:197
Age < 5 years
302 Taylor DR, Palmay R, Cowan JO, Herbison GP. Long term performance characteristics of
an electrochemical nitric oxide analyser. Respir Med 2011;105:211–17
Reproducibility and
long-term performance in
NIOX MINO only
303 Taylor DR, de la Barra SL, Herbison GP, Cowan JO, Smith AD. Predicted versus
absolute values in the interpretation of exhaled nitric oxide measurements.
Am J Respir Crit Care Med 2011;183:A4476
No usable diagnostic data
304 Taylor ES, Smith AD, Cowan JO, Herbison GP, Taylor DR. Effect of caffeine ingestion
on exhaled nitric oxide measurements in patients with asthma. Am J Respir Crit Care
Med 2004;169:1019–21
FeNO testing did not guide
step-up/step-down therapy
305 Terada A, Fujisawa T, Iguchi K, Astuta J, Togari H. [Exhaled nitric oxide of childhood
asthma]. Arerugi 1999;48:466–71
Foreign language
306 Thijs W, Middeldorp S, Hiemstra PS, Rosendaal FR, Rabe KF. Reproducibility of
exhaled NO measurements in overweight subjects. Am J Respir Crit Care Med
2010;181:A2530
No comparison between
devices
307 Thomas PS, Gibson PG, Wang H, Shah S, Henry RL. The relationship of exhaled nitric
oxide to airway inflammation and responsiveness in children. J Asthma 2005;42:291–5
Unselected population
308 Tossa P, Bohadana A, Demange V, Wild P, Michaely JP, Hannhart B, et al. Early
markers of airways inflammation and occupational asthma: rationale, study design
and follow-up rates among bakery, pastry and hairdressing apprentices. BMC Public
Health 2009;9:113
Study design only
309 Travers J, Marsh S, Aldington S, Williams M, Shirtcliffe P, Pritchard A, et al. Reference
ranges for exhaled nitric oxide derived from a random community survey of adults.
Am J Respir Crit Care Med 2007;176:238–42
Unselected population
310 Tseliou E, Bessa V, Hillas G, Delimpoura V, Papadaki G, Roussos C, et al. Exhaled
nitric oxide and exhaled breath condensate pH in severe refractory asthma.
Chest 2010;138:107–13
Population – severe
refractory asthma
311 Tsuburai T, Tsurikisawa N, Higashi N, Tatsuno S, Fukutomi Y, Tanimoto H, et al.
[Differences in fraction of exhaled nitric oxide values measured by two offline
methods or NIOXmino in adult Japanese asthmatics]. Arerugi 2010;59:956–64
Offline
312 Tsuburai T, Tsurikisawa N, Higashi N, Tatsuno S, Fukutomi Y, Tanimoto H, et al.
The difference of the fraction of exhaled nitric oxide (FeNO) levels measured by
off-line methods or NIOXmino in adult Japanese asthmatics. Nitric Oxide Biol Chem
2010;22:S93
Foreign language
313 Turner SW, McSweeny C, Malik G. Comparisons of exhaled nitric oxide
measurements using the NIOX and MINO analysers in children. Proc Am Thorac Soc
2006;A484
Unable to obtain
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
314 Tworek D, Bochenska-Marciniak M, Kupczyk M, Kuprys-Lipinska I, Kuna P. [Lack of
correlation between exhaled nitric oxide (eNO) and clinical indicators of the disease
activity and quality of life in mild and moderate asthmatics]. Pneumonol Alergol Pol
2006;74:391–5
Foreign language
315 van Amsterdam JGC, Zanen P, Somer S, van Loveren H, Opperhuizen A, Steerenberg PA.
Flow dependency and off-line measurement of exhaled NO in children. Pediatr Allergy
Immunol 2003;14:266–71
Wrong flow rate
316 van de Kant KD, Koers K, Rijkers GT, Lima Passos V, Klaassen EMM, Mommers M,
et al. Can exhaled inflammatory markers predict the response to inhaled corticosteroids
in wheezing preschool children? Am J Respir Crit Care Med 2011;183:A4465
Age < 5 years
317 van der Valk RJ, Caudri D, Savenije O, Koppelman GH, Smit HA, Wijga AH, et al.
Childhood wheezing phenotypes and FeNO in atopic children at age 8. Clin Exp
Allergy 2012;42:1329–36
No useable diagnostic data
318 van Wonderen KE, van der Mark LB, Mohrs J, Geskus RB, van der Wal WM, van
Aalderen WM, et al. Prediction and treatment of asthma in preschool children at risk:
study design and baseline data of a prospective cohort study in general practice
(ARCADE). BMC Pulm Med 2009;9:13
Study design only
319 Vieira T, Fonseca J, Cruz L, Silva R, Ferreira A, Leblanc A, et al. Results of a
school-based asthma assessment from the upKids questionnaire validation study.
Allergy 2009;64:441–2
No useable diagnostic data
320 Vieira T, Fonseca JA, Silva R, Cruz L, Ferreira AR, Leblanc A, et al. Validity of a
questionnaire in a school-based allergic asthma screening- comparison with exhaled
nitric oxide fraction and skin prick tests. Rev Port Imunoalergologia 2011;19:215–21
Population – children with
positive skin prick test
321 Vitruba J, Cap P. [Fractional exhaled nitric oxide and its correlation with bioptic results
in chronic cough patients]. Cas Lek Cesk 2009;148:429–33
Foreign language
322 Vitruba J, Cap P, Statsny B. Fractional exhaled nitric oxide and its correlation with
biopsy results in chronic cough patients. Allergy 2011;66:575
Not valid reference
standard (biopsy results)
323 Wang C-C, Wang C-Y, Hsu J-Y. Evaluation the causes of chronic cough of unknown
origin by a protocol based on result of fractional exhaled nitric oxide. Respirology
2009;14:A132
No useable diagnostic data
324 Wanich NH, Kaplan MS. Management of asthma based on exhaled nitric oxide in
addition to guideline-based treatment for inner-city adolescents and young adults: a
randomised controlled trial. Pediatrics 2009;124(Suppl. 2):S147
Commentary
325 Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, et al. Exhaled nitric oxide
correlates with airway eosinophils in childhood asthma. Thorax 2002;57:383–7
Population is mix of
asthmatics and healthy
people
326 Wedes SH, Khatri SB, Zhang R, Wu W, Comhair SA, Wenzel S, et al. Noninvasive
markers of airway inflammation in asthma. Clin Transl Sci 2009;2:112–17
Case–control study
327 Wildhaber JH, Hall GL, Stick SM. Measurements of exhaled nitric oxide with the
single-breath technique and positive expiratory pressure in infants. Am J Respir Crit
Care Med 1999;159:74–8
No useable diagnostic data
328 Wildhaber JH, Moller A, Hall GL, Sennhauser FH, Stick S. Levels of exhaled nitric
oxide in recurrently wheezy infants are decreased following inhaled steroid therapy.
Schweiz Med Wochenschr 2000;130:529–34
No useable diagnostic data
329 Yang CL, Simons E, Foty RG, To T, Dell SD. Parental report of asthma diagnosis
superior to exhaled nitric oxide for measuring childhood asthma prevalence.
Am J Respir Crit Care Med 2011;183:A6361
Not FeNO
330 Yang CL, Simons E, Foty RG, Marshall L, Nelligan K, To T, et al. Questionnaire
diagnosis of asthma leads to misclassification compared to guideline-based diagnosis.
Am J Respir Crit Care Med 2011;183:A5466
Case–control
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TABLE 87 Analytical validity review, management review and diagnostic review: table of excluded studies
with rationale (continued )
Study Reason for exclusion
331 Yao TC, Ou LS, Lee WI, Yeh KW, Chen LC, Huang JL, et al. Exhaled nitric oxide
discriminates children with and without allergic sensitization in a population-based
study. Clin Exp Allergy 2011;41:556–64
Unselected population
332 Yawn B, Rickard K, Herje N, Dorinsky PM. Clinical outcomes of subjects with
non-specific respiratory symptoms and high FENO who were not diagnosed with
asthma: a retrospective review of outcomes 6 months following the initial evaluation.
J Allergy Clin Immunol 2013;131(2 Suppl. 1):AB64
Non-specific respiratory
symptoms
333 Yoo Y, Bauer S, La KS, Seo HS, Seo SC, Song DJ, et al. Relationships between airway
hyperresponsiveness to methacholine, blood eosinophil markers and FENO
in asthmatic children. J Allergy Clin Immunol 2012;129(2 Suppl. 1):AB211
No useable diagnostic data
334 Yoo Y, Bauer S, Harmin S, Seo S, Yoon W, Choung JT. Relationships between
exhaled nitric oxide and atopy profiles (mono-sensitization/poly-sensitization) in
children with asthma. J Allergy Clin Immunol 2013;131(2 Suppl. 1):AB62
No useable diagnostic data
335 Zhang Y-M, Lin J-T, Su N, Chen X, Liu G-L, Yu H-X, et al. Values of fractional exhaled
nitric oxide in the diagnosis of chronic cough. Nat Med J China 2011;91:1254–8
Foreign language
336 Zhang YM, Lin JT. [The values of fractional exhaled nitric oxide in the diagnosis
and treatment of chronic cough]. Chung-Hua Chieh Ho Ho Hu Hsi Tsa Chih
2011;34:504–8
Foreign language
337 Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Mroczko B, Szmitkowski M,
Bodzenta-Lukaszyk A, et al. RANTES in exhaled breath condensate of allergic asthma
patients with exercise-induced bronchoconstriction. Respiration 2010;80:463–71
Case–control study
338 Zietkowski Z, Skiepko R, Tomasiak-Lozowska M, Bodzenta-Lukaszyk A. RANTES in
exhaled breath condensate of allergic asthma patients with exercise-induced
bronchoconstriction. Allergy 2010;65:148
No useable diagnostic data
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TABLE 88 Studies excluded from the update search
Study Reason for exclusion
1 Adachi Y. [Biomarkers in childhood asthma]. Arerugi 2013;62:124–30 Not English language
2 Bozek A, Filipowski M, Fischer A, Jarzab J. Characteristics of atopic
bronchial asthma in seniors over 80 years of age. Biomed Res Int
2013;2013:689782
Not a diagnostic accuracy study –
included in subgroup review of elderly
3 Columbo M, Wong B, Panettieri RA Jr, Rohr AS. Asthma in the elderly:
the role of exhaled nitric oxide measurements. Respir Med
2013;107:785–7
Not a diagnostic accuracy study –
included in subgroup review of elderly
4 Gregoriano C, Abu HN, Maier S, Zogg S, Margelli HD, Miedinger D,
et al. Predictive value of exhaled nitric oxide to predict exercise induced
bronchoconstriction. Respiration 2013;85:605
Unselected population
5 Grzelewski T, Witkowski K, Makandjou-Ola E, Grzelewska A, Majak P,
Jerzynska J, et al. Diagnostic value of lung function parameters and
FeNO for asthma in schoolchildren in large, real-life population.
Pediatr Pulmonol 2014;49:632–40
Unable to extract reliable data
6 Hsu JY, Wang CY, Cheng YW, Chou MC. Optimal value of fractional
exhaled nitric oxide in inhaled corticosteroid treatment for patients with
chronic cough of unknown cause. J Chin Med Assoc 2013;76:15–19
Already included
7 Hur G-Y, Oh JY, Choi J-H, Sim J-K, Min KH, Lee S-Y, et al. Mannitol
challenge test, sputum eosinophils and exhaled nitric oxide (FENO) for
diagnosis of asthma. J Allergy Clin Immunol 2013;131(2 Suppl. 1):AB64
Not enough information to data extract
8 Raulf-Heimsoth M, van Kampen V, Heinze E, Bernard S, Borowitzki G,
Freundt S, et al. Comparison of different non-invasive methods for
detection of allergic asthma. Adv Exp Med Biol 2013;755:55–63
Wrong patient cohort – not symptoms of
asthma
9 Ryan D, Thomas MD, Dorinsky PM, Burden A, Von Ziegenweidt J,
Hutton C, et al. The role of exhaled nitric oxide in guiding asthma.
J Allergy Clin Immunol 2013;131(2 Suppl. 1):AB205
Not enough information to data extract
10 Schneider A, Schwarzbach J, Faderl B, Welker L, Karsch-Volk M, Jorres
RA. FENO measurement and sputum analysis for diagnosing asthma in
clinical practice. Respir Med 2013;107:209–16
Already included
11 Voorend-van Bergen S, Vaessen-Verberne A, Landstra A, Brackel H,
van den Berg N, de Jongste J, et al. FeNO and web-based monitoring in
paediatric asthma managemant; the BATMAN study. Eur Respir J
2013;42(Suppl. 57):3014
Not enough information to data extract
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Appendix 6 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA)193 flow diagram (adapted) of lower levels of evidence
identified during database interrogation for the subgroups relating to
the elderly, smokers and pregnant women
Citations identified through
database searching
(n = 4853)
Sc
re
en
in
g
In
cl
u
d
ed
El
ig
ib
ili
ty
Id
en
ti
fi
ca
ti
o
n
Additional citations identified
through other sources
(n = 6)
Citations interrogated
(n = 4859)
Citations identified by
interrogation search
(n = 162)
Citations excluded by title
and abstract
(n = 111)
Full-text articles assessed
for eligibility
(n = 51)
Full-text articles excluded
(n = 36)
Studies included in narrative
synthesis
(n = 17 studies, n = 17 references)
• Elderly management, n = 5 studies, n = 5 references
• Elderly diagnostic, n = 1 study, n = 1 reference
• Smokers management, n = 7 studies, n = 7 references
• Smokers diagnostic, n = 5 studies, n = 5 references
• Pregnant women management, n = 1 study, n = 1 reference
• Pregnant women diagnostic, n = 1 study, n = 1 reference
Full-text articles included
from update search
(n = 3)
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TABLE 89 Smokers management review, elderly management and diagnostic review and pregnancy diagnostic
review: table of excluded studies with rationale
Study Reason for exclusion
1 Baur X, Barbinova L. Latex allergen exposure increases exhaled nitric oxide in
symptomatic healthcare workers. Eur Respir J 2005;25:309–316
Non-asthmatics
2 Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID, et al.
The use of exhaled nitric oxide concentration to identify eosinophilic airway
inflammation: an observational study in adults with asthma. Clin Exp Allergy
2005;35:1175–9
Wrong flow rate
3 Bivins J, Ownby D, Waller J, Tingen M. Exhaled nitric oxide level and school
absenteeism in rural high school students with current asthma. J Allergy Clin
Immunol 2013;131(2 Suppl. 1):AB64
No data for smokers vs.
non-smokers
4 Bohadana AB, Hannhart B, Ghezzo H, Teculescu D, Zmirou-Navier D. Exhaled
nitric oxide and spirometry in respiratory health surveillance. Occup Med
(Oxford) 2011;61:108–14
Not all asthmatics
5 Bommarito L, Migliore E, Bugiani M, Heffler E, Guida G, Bucca C, et al. Exhaled
nitric oxide in a population sample of adults. Respiration 2008;75:386–92
Diagnostic – not all asthmatic
6 Bozek A, Krajewska J, Jarzab J. Nasal nitric oxide and other diagnostic
procedures in seasonal allergic rhinitis: elderly vs juvenile patients. Am J
Otolaryngol 2011;32:105–8
Population not asthmatic
7 de la Barra SL, Smith AD, Cowan JO, Herbison GP, Taylor DR. Predicted versus
absolute values in the application of exhaled nitric oxide measurements. Respir
Med 2011;105:1629–34
No data for smokers vs.
non-smokers
8 Dinakar C, Lapuente M, Barnes C, Garg U. Real-life environmental tobacco
exposure does not affect exhaled nitric oxide levels in asthmatic children.
J Asthma 2005;42:113–18
Offline
9 Gaku I, Risako S, Hiroyoshi W, Nene K, Mayuko T, Masanori W, et al. Smoking
exacerbates airway inflammation in patients with asthma. Respirology
2010;15:61
Mean FeNO levels only
10 Gemicioglu B, Guven K, Dogan I. FeNO in different asthma phenotypes.
Allergy 2009;64:560
Mean FeNO levels only
11 Gibson PG, Powell H, Giles W, Clifton V, Hensley M, Taylor DR, et al. Asthma
exacerbations during pregnancy are reduced by inflammometry (FENO) guided
asthma management: a randomised controlled trial. Am J Respir Crit Care Med
2011;183:A6414
Management study
12 Gouvis-Echraghi R, Nikasinovic L, Bernard A, Herr-Breget M, Momas I, Just J.
Passive smoke exposure lowers the fraction of exhaled nitric oxide in preschool
children with recurrent wheeze. Allergy 2012;67:479
Preschool
13 Hardaker K, Downie S, Kermode J, Farah C, Berend N, King G, et al. The
predictors of airway hyperresponsiveness are different in younger and older
asthmatics. Respirology 2010;15:A37
Wrong flow rate
14 Hardaker KM, Downie SR, Kermode JA, Farah CS, Brown NJ, Berend N, et al.
Predictors of airway hyperresponsiveness differ between old and young patients
with asthma. Chest 2011;139:1395–1401
Wrong flow rate
15 Hillas G, Kostikas K, Mantzouranis K, Bessa V, Kontogianni K, Papadaki G,
et al. Exhaled nitric oxide and exhaled breath condensate pH as predictors of
sputum cell counts in optimally treated asthmatic smokers. Respirology
2011;16:811–18
Mean FeNO levels only
16 Jung A, Summermatter S, Geidel C, Moller A, Menz G, Lauener R. Diagnostic
value of nasal NO measurement using the NIOX MINO device. Atemwegs
Lungenkr 2012;38:57–8
Nasal NO
17 Kostikas K, Papaioannou AI, Tanou K, Koutsokera A, Papala M, Gourgoulianis
KI, et al. Portable exhaled nitric oxide as a screening tool for asthma in young
adults during pollen season. Chest 2008;133:906–13
Diagnostic AUCs reported for
smokers vs. non-smokers
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
310
TABLE 89 Smokers management review, elderly management and diagnostic review and pregnancy diagnostic
review: table of excluded studies with rationale (continued )
Study Reason for exclusion
18 Leblanc A, Castro E, Castel-Branco M. Evolution and asthma control in
pregnant women followed in an allergy Division. Allergy 2009;64:194–5
Not diagnostic study
19 Lehtimaki L, Turjanmaa V, Kankaanranta H, Saarelainen S, Hahtola P,
Moilanen E. Increased bronchial nitric oxide production in patients with asthma
measured with a novel method of different exhalation flow rates. Ann Med
2000;32:417–23
Wrong flow rate
20 Mahut B, Trinquart L, Le Bourgeois M, Becquemin MH, Beydon N, Aubourg F,
et al. Multicentre trial evaluating alveolar NO fraction as a marker of asthma
control and severity. Allergy 2010;65:636–44
Adults mean FeNO levels only
21 Malinovschi A, Janson C, Hogman M, Rolla G, Toren K, Norback D, et al. Both
allergic and nonallergic asthma are associated with increased FE(NO) levels,
but only in never-smokers. Allergy 2009;64:55–61
Diagnostic adults
22 Matsunaga K, Hirano T, Akamatsu K, Koarai A, Sugiura H, Minakata Y, et al.
Differences in cutoff values of exhaled nitric oxide for asthma diagnosis
according to rhinitis and smoking status. Am J Respir Crit Care Med
2011;183:A4480
Diagnostic adults
23 Matsunaga K, Hirano T, Akamatsu K, Koarai A, Sugiura H, Minakata Y, et al.
Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and
smoking status in Japanese subjects. Allergol Int 2011;60:331–7
Diagnostic adults
24 McCallister JW. Asthma in pregnancy: management strategies. Curr Opin Pulm
Med 2013;19:13–17
Review
25 Munnik P, van der Lee I, Fijn J, van Eijsden LJ, Lammers JW, Zanen P, et al.
Comparison of eNO and histamine hyperresponsiveness in diagnosing asthma
in new referrals. Respir Med 2010;104:801–7
Diagnostic in adults, correction for
smoking only
26 Nadif R, Matran R, Maccario J, Bechet M, Le Mouai N, Scheinmann P, et al.
Passive and active smoking and exhaled nitric oxide levels according to asthma
and atopy in adults. Ann Allergy Asthma Immunol 2010;104:385–93.
[Erratum published in Ann Allergy Asthma Immunol 2010;105:97–8]
Mean FeNO levels only
27 Nadif R, Matran R, Maccario J, Bechet M, Le Moual N, Scheinmann P, et al.
Passive and active smoking and exhaled nitric oxide levels according to asthma
and atopy in adults. Ann Allergy Asthma Immunol 2010;105:97–8
Mean FeNO levels only
28 Oshikata C, Tsuburai T, Tsurikisawa N, Ono E, Higashi A, Fukutomi Y, et al.
Cutoff point of the fraction of exhaled nitric oxide (FeNO) with the off-line
method for diagnosing asthma and the effect of smoking on FeNO.
Nihon Kokyuki Gakkai Zasshi 2008;46:356–62
Diagnostic adults
29 Persson MG, Zetterstrom O, Agrenius V, Ihre E, Gustafsson LE. Single-breath
nitric oxide measurements in asthmatic patients and smokers. Lancet
1994;343:146–7
Healthy only
30 Perzanowski MS, Divjan A, Mellins RB, Canfield SM, Rosa MJ, Chew GL, et al.
Exhaled NO among inner-city children in New York City. J Asthma
2010;47:1015–21
Wheeze not asthma
31 Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, et al.
Management of asthma in pregnancy guided by measurement of fraction of
exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet
2011;378:983–90
Management study
32 Rouhos A, Ekroos H, Karjalainen J, Sarna S, Haahtela T, Sovijarvi AR, et al.
Smoking attenuates increase in exhaled nitric oxide in atopic but not in
nonatopic young adults with asthma. Int Arch Allergy Immunol
2010;152:226–32
Mean FeNO levels only
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TABLE 89 Smokers management review, elderly management and diagnostic review and pregnancy diagnostic
review: table of excluded studies with rationale (continued )
Study Reason for exclusion
33 Rutgers SR, Meijer RJ, Kerstjens HA, van der Mark TW, Koeter GH, Postma DS,
et al. Nitric oxide measured with single-breath and tidal-breathing methods
in asthma and COPD. Eur Respir J 1998;12:816–19
Mean FeNO levels only
34 Shimoda T, Obase Y, Imaoka M, Kishikawa RT, Iwanaga T. Influence of
cigarette smoking on airway inflammation and inhaled corticosteroid treatment
in asthmatic patients. J Allergy Clin Immunol 2013;131(2 Suppl. 1):AB52
Mean FeNO levels only
35 Spears M, Weir CJ, Smith AD, McSharry C, Chaudhuri R, Johnson M, et al.
Bronchial nitric oxide flux (J'aw) is sensitive to oral corticosteroids in smokers
with asthma. Respir Med 2011;105:1823–30
Wrong flow rate
36 Taylor DR, de la Barra SL, Herbison GP, Cowan JO, Smith AD. Predicted versus
absolute values in the interpretation of exhaled nitric oxide measurements.
Am J Respir Crit Care Med 2011;183:A4476
No data for smokers vs.
non-smokers
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Appendix 7 Table of study characteristics for
non-relevant adult diagnostics
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Appendix 8 Table of the highest sum of
sensitivity and specificity, highest sensitivity and
highest specificity for non-relevant studies
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Appendix 9 Table detailing the reference
standards used in relevant adult diagnostic studies
Author, year Details of reference standard Summarised as
Position A vs. whole pathway
Schneider 200971,72 l FEV1/FVC < 0.7 or FEV1% < 80% plus positive
bronchodilator response= asthma
l FEV1/FVC > 0.7 or FEV1% > 80% plus
positive MCT= asthma
FEV1, FEV1/FVC, airway reversibility,
airway hyper-responsiveness (MCT)
Schneider 201369 If FEV1 < 80% predicted, patient received salbutamol
plus whole-body plethysmography 20 minutes later.
Obstructive airway disease diagnosed if FEV1/FVC was
≤ 0.70. Classified as asthma according to clinical
symptoms and history plus change in FEV1 ≥ 12%
compared with baseline and ≥ 200 ml and if lung
function increased to predicted normal range.
Classified as incomplete bronchodilator response if
response was ≤ 12% compared with baseline and
≥ 200 ml and lung volumes remained below predicted.
Classified as COPD according to clinical symptoms
and history plus FEV1 after salbutamol < 12%
compared with baseline and < 200ml. If FEV1 ≥ 80%
predicted, bronchial provocation performed to
determine bronchial hyper-responsiveness to
methacholine according to the 1-concentration–4-step
dosimeter protocol. Asthma diagnosed if 20% fall
in FEV1 from baseline after inhaling methacholine
stepwise until the maximum concentration (16mg/ml)
or doubling of airway resistance (Raw) and its increase
to ≥ 2.0 kPa/second. The pneumologist was blinded
to the FeNO results and made diagnostic decisions
on basis of medical history, physical examination,
spirometry, whole-body plethysmography and
bronchial provocation results
FEV1, FEV1/FVC, airway reversibility,
hyper-responsiveness (MCT)
Smith 200486 Relevant symptom history (ATS 1987 guidelines113) and
a positive test for bronchial hyper-responsiveness
(provocative dose of hypertonic saline resulting in a
15% fall in FEV1 of < 20ml) and/or a positive response
to bronchodilator (increase in FEV1 of ≥ 12% from
baseline 15 minutes after inhaled albuterol)
Airway reversibility, positive
response to ICS, airway
hyper-responsiveness (MCT)
Smith 200583 ATS 1987113 diagnostic criteria plus one or more of:
1. positive response to bronchodilator (increase in
FEV1 of ≥ 12% from baseline 15 minutes after
inhaled albuterol)
2. positive response to ICS (increase in FEV1 of ≥ 12%
or an increase in mean morning peak flow over
previous 7 days of ≥ 15%)
3. positive test for airway hyper-responsiveness
(defined as a provocative dose of methacholine,
resulting in a 20% reduction in FEV1 of < 8 µmol)
Airway reversibility, positive
response to ICS, airway
hyper-responsiveness (MCT)
Position A vs. airway reversibility
de la Barra 201184 Positive response to bronchodilator (increase in FEV1
of ≥ 12% from baseline 15 minutes after inhaled
albuterol)
Airway reversibility
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Author, year Details of reference standard Summarised as
Subset of Position A vs. airway reversibility or airway hyper-responsiveness
Cordeiro 201187 History of typical respiratory symptoms and FEV1%
improvement of > 12% and > 200ml or PC20 histamine
of ≤ 8mg/ml, according to GINA guidelines129
Airway reversibility, airway
hyper-responsiveness (histamine)
Heffler 200682 Asthma confirmed based on typical symptoms and
> 12% improvement in FEV1 in response to salbutamol
or a dose of methacholine needed to cause a 20% fall
from baseline in FEV1 (PD20) of < 800 µg
Airway hyper-responsiveness (MCT)
or airway reversibility
Difficult to diagnose vs. airway hyper-responsiveness
Bobolea 201288 Adenosine challenge test (PC20 < 400mg/ml) Adenosine challenge test
Katsoulis 201381 Dose of methacholine needed to cause a 20% fall
from baseline in FEV1 (PD20) according to ATS
guidelines133
Airway hyper-responsiveness (MCT)
Pedrosa 201085 Consistent symptoms and a positive methacholine
bronchial challenge. Patients stopped asthma
medication before the test. The test was performed
according to ATS 1999 guidelines133 and was
considered positive when a decrease in FEV1 from
baseline of ≥ 20% or higher was obtained after
methacholine inhalation
Airway hyper-responsiveness (MCT)
Schleich 201277 Asthma diagnosed based on airway hyper-responsiveness
(MCT) provoking a 20% fall in FEV1 of <16mg/ml.
Subjects were characterised as atopic if they had at least
one positive skin prick test (wheal >3mm compared
with negative control) or specific IgE (>0.35 kU/l) for at
least one common aeroallergen (cat, dog, house dust
mites, grass pollen, tree pollen and a mixture of moulds)
Airway hyper-responsiveness (MCT)
Suspected EIB vs. exercise challenge test
El Halawani 200378 Exercise challenge test was performed on a treadmill
with an incremental work rate (up to 14 minutes of
symptom-limited exercise). Treadmill speed began at
2 miles/hour and increased by 1 mile/hour every
2 minutes. Treadmill grade began at 10%, increasing
to 15% after 8 minutes. The targeted heart rate
was 85% predicted maximum and maintained for
2 minutes. Spirometry was performed every 5 minutes
after exercise for a total of 30 minutes. Pulmonary
functioning discontinued when a fall in FEV1 of 15%
from baseline was demonstrated
Exercise challenge
Position F with chronic cough vs. ICS responsiveness
Hahn 200774 ICS responsiveness assessed 1–16 months after
diagnostic tests
ICS responsiveness
Hsu 201373 Complete improvement of cough on ICS treatment
with 250 µg twice per day for at least 2 weeks
ICS responsiveness
Prieto 200976 Responsiveness to FP was identified by a reduction of
> 50% in the mean daily cough symptom scores
during the 4 weeks of the fluticasone propionate trial
compared with the baseline period
ICS responsiveness
IgE, immunoglobulin E; PC20, provocative concentration that cause a positive reaction; PD20, dose of methacholine needed
to cause a 20% fall from baseline in FEV1.
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Appendix 10 Table detailing the inclusion and
exclusion criteria of the studies considered of most
relevance to the review
Author, year Details of inclusion and exclusion criteria Categorised as
Position A vs. whole pathway
Schneider 200971,72 Patients presenting to their GP for the first time with complaints
suggestive of obstructive airway disease; presentation of symptoms such
as dyspnoea, coughing or expectoration for > 2 months, thus leading
to clinical suspicion of obstructive or restrictive airway disease as most
important differential diagnoses (‘indicated population’). GPs were
advised to exclude patients with respiratory tract infections preceding the
evaluation by 6 weeks. Patients with a previously established diagnosis
of obstructive airway disease were excluded. Other exclusion criteria
related to well-known contraindications for bronchodilator reversibility
testing or bronchial provocation, namely untreated hyperthyreosis,
unstable coronary artery disease and cardiac arrhythmia. Pregnancy also
led to exclusion
Position A
Schneider 201369 Patients presenting for the first time with symptoms such as dyspnoea,
cough or phlegm for > 2 months, leading to the clinical suspicion of
obstructive or restrictive airway disease (‘indicated population’). Patients
were advised not to smoke on the day of investigation and not to use
inhaler medication for 12 hours before lung function testing. Exclusions:
patients with respiratory tract infections within the last 6 weeks;
previously established diagnosis of chronic obstructive airway disease;
known contraindications for bronchodilator reversibility testing or
bronchial provocation, namely untreated hyperthyreosis, unstable
coronary artery disease and cardiac arrhythmia; pregnancy
Position A
Smith 200486 Patients referred by their GP for investigation of possible bronchial asthma
with symptoms for a minimum of 6 weeks. No patient had been referred
for specialist consultation. Exclusions: those who used oral or inhaled
corticosteroids in the previous 4 weeks and those with a respiratory tract
infection in the previous 6 weeks
Position A
Smith 200583 Patients referred by their GP for investigation of persistent, undiagnosed
respiratory symptoms lasting for at least 6 weeks. Exclusions: use of ICSs
or OCSs in the previous 4 weeks, respiratory tract infection in the previous
6 weeks, other established respiratory diagnosis or significant comorbidity;
smokers were not excluded
Position A
Position A vs. airway reversibility
de la Barra 201184 New undiagnosed symptoms of cough, wheeze or dyspnoea of
≥ 6 weeks in duration
Position A
Subset of Position A vs. airway reversibility or airway hyper-responsiveness
Cordeiro 201187 All new patients who were referred to a general outpatient allergy clinic
from January 2007 to September 2007. Patients using ICSs or oral
corticosteroids within 6 weeks of the first visit were excluded from data
analysis
Position A
Heffler 200682 Nasal symptoms for > 4 days per week over > 8 weeks; asthma-like
symptoms during the past 2 months. Exclusions: use of steroids or any
other anti-inflammatory drugs in the last 2 months, current smoker
(within the past 12 months), previous diagnosis of asthma, respiratory
infection within the past 6 weeks
Position A
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Author, year Details of inclusion and exclusion criteria Categorised as
Difficult to diagnose vs. airway hyper-responsiveness
Bobolea 201288 Patients with suspected asthma who had normal spirometry, a negative
bronchodilator test, a negative methacholine challenge [provocative
concentration inducing a 20% fall in FEV1 (PC20) > 16mg/ml)]
Difficult to diagnose
Katsoulis 201381 Patients with one positive answer for respiratory symptoms. Exclusions:
pre-existing asthma diagnosis, treatment with asthma-related medication,
12% reversibility after bronchodilation and 200ml FEV1, respiratory
infection within the last 8 weeks, recent ex-smokers
Difficult to diagnose
Pedrosa 201085 Those reporting persistent symptoms consistent with asthma (shortness of
breath, wheezing and/or cough) regardless of atopic status who showed
normal spirometry and who had a negative bronchodilator test.
Exclusions: as per ATS 1999 guidelines133 for bronchial challenge test
Difficult to diagnose
Schleich 201277 Patients were referred to a respiratory physician for a methacholine
challenge to detect asthma. Subjects referred to methacholine challenge
were those in whom the bronchodilating test failed to demonstrate
reversible airways obstruction or those in whom baseline spirometric
values were normal giving a low probability for a bronchodilating test to
be significant. Patients had either (1) baseline FEV1 ≥ 80% predicted
and a FEV1/FVC ratio ≥ 70% or (2) baseline FEV1 < 80% predicted and a
FEV1/FVC ratio < 70% plus bronchodilation < 12% from baseline and
200ml after 400 µg inhaled salbutamol Exclusions: patients already
receiving ICSs
Difficult to diagnose
Suspected EIB vs. exercise challenge test
El Halawani 200378 Patients with suspected asthma who had normal spirometry, a negative
bronchodilator test, negative methacholine challenge [provocative
concentration inducing a 20% fall in FEV1 (PC20) > 16mg/ml]
EIB
Position F with chronic cough vs. ICS responsiveness
Hahn 200774 Age > 18 years, uncontrolled chronic cough (>8 weeks), normal/
non-localising chest radiograph, documented MCT results and measurement
of NO levels within 1 day of each other. Only patients who had started
ICS therapy or who had their current ICS doses altered were included.
Exclusions: current smokers and users of angiotensin-converting enzyme
inhibitors
Difficult to diagnose
with chronic cough
Hsu 201373 Patients with a history of chronic cough of > 8 weeks’ duration and who
did not stop coughing after treatment for upper airway cough syndrome
or gastro-oesophageal reflux disease. Exclusions: obvious chest radiograph
abnormalities, current smokers/smoking history of > 10 pack-years
Difficult to diagnose
with chronic cough
Prieto 200976 Chronic cough of at least 8 weeks’ duration with no evidence of any
other lung disease, non-smokers, not currently being treated with
angiotensin-converting enzyme inhibitors or beta-blockers, not previously
received treatment with ICSs or OCSs or not experienced a respiratory
tract infection in the previous 4 weeks. Each subject required to have a
FEV1 of at least 80% predicted
Difficult to diagnose
with chronic cough
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Appendix 11 Table of results for all diagnostic
studies in adults
Author, year
Prevalence of
positive result
by reference
standard, n/N (%)
FeNO
cut-off
(ppb) TP (n) FP (n) FN (n) TN (n)
Sensitivity
asthma
(95% CI) (%)
Specificity
asthma
(95% CI) (%)
Position A
de la Barra 201184 NR 25 10 17 2 23 83.3 57.5
40 9 12 3 28 75 70
50 7 8 5 32 58.3 80
70 5 5 7 35 41.7 87.5
90 5 3 7 37 41.7 92.5
110 3 2 9 38 25 95
130 2 2 10 38 16.7 95
150 2 2 10 38 16.7 95
Fortuna 200770 Induced sputum
(Eos%) 16/50 (32.0);
bronchodilator test
13/50 (26.0); FEV1
< 80% 5/50 (10.0)
≥ 20 ppb 17 10 5 18 77 64
Fukuhara 201154 42/61 (68.9) 40 33 2 9 17 78.6 89.5
Schneider 200971,72 75/160 (46.9) > 20 48 36 27 49 64 (53 to 74) 58 (47 to 77)
> 12 64 65 11 20 85 (76 to 92) 24 (16 to 34)
> 16 52 40 23 45 69 (58 to 79) 53 (42 to 63)
> 35 24 14 51 71 32 (25 to 42) 84 (74 to 90)
> 46 24 6 51 79 32 (23 to 43) 93 (85 to 97)
> 76 10 0 65 85 13 (7 to 23) 100 (96 to 100)
Schneider 201369 154/393 (39.2) > 9 146 209 7 31 96 (91 to 98) 13 (9 to 18)
> 12 135 167 23 68 85 (79 to 90) 29 (23 to 35)
> 16 105 128 46 114 70 (62 to 76) 47 (41 to 54)
> 20 91 89 62 151 60 (52 to 67) 63 (57 to 69)
> 25 75 59 79 180 49 (41 to 57) 75 (69 to 80)
> 35 50 29 104 210 33 (26 to 40) 88 (83 to 91)
> 41 42 20 112 219 27 (21 to 35) 92 (87 to 94)
> 42 40 20 114 219 26 (20 to 33) 92 (87 to 94)
> 43 39 19 115 220 25 (19 to 32) 92 (88 to 95)
> 44 39 19 115 220 25 (19 to 32) 92 (88 to 95)
> 45 38 19 116 220 23 (17 to 31) 92 (88 to 95)
> 46 38 17 116 222 27 (21 to 35) 92 (87 to 94)
> 71 27 7 127 232 18 (12 to 24) 97 (94 to 99)
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Author, year
Prevalence of
positive result
by reference
standard, n/N (%)
FeNO
cut-off
(ppb) TP (n) FP (n) FN (n) TN (n)
Sensitivity
asthma
(95% CI) (%)
Specificity
asthma
(95% CI) (%)
Smith 200486 17/47 (36.2) > 20 14 6 2 22 88 79
Smith 200583 27/52 (51.9) ≥ 15 22 13 5 12 81.5 48
> 47 15 2 12 23 55.6 92
< 15 5 12 22 13 18.5 52
Subset of Position A
Cordeiro 201187 42/114 (36.8) 27 33 6 9 66 78 92
Heffler 200682 18/48 (37.5) > 10 18 29 0 1 100 3.3
> 15 18 26 0 4 100 13.3
> 20 18 20 0 10 100 33.3
> 25 18 16 0 14 100 46.7
> 30 14 15 4 15 77.8 50
> 34 14 14 4 16 77.8 53.3
> 36 14 12 4 18 77.8 60
> 40 11 11 7 19 61.1 63.3
> 45 11 8 7 22 61.1 73.3
> 50 10 7 8 23 55.6 76.7
> 55 9 6 9 24 50 80
> 60 9 4 9 26 50 86.7
> 65 8 4 10 26 44.4 86.7
> 75 8 3 10 27 44.4 90
> 80 7 1 11 29 38.9 96.7
> 85 5 1 13 29 27.8 96.7
> 100 5 0 13 30 27.8 100
Pizzimenti 200990 14/156 (9.0) 55 11 17 3 125 78 88
Difficult to diagnose
Bobolea 201288 6/30 (20.0) > 30 6 17 0 7 100 29.2
Katsoulis 201381 48/112 (42.9) > 30 24 12 24 52 49 (34 to 64) 82 (71 to 90)
> 25 24 16 24 48 51 (36 to 66) 75 (63 to 85)
> 20 31 26 17 38 64 (49 to 78) 60 (47 to 72)
> 15 35 33 13 31 73 (58 to 85) 49 (37 to 62)
> 10 39 39 9 25 81 (64 to 91) 39 (29 to 50)
Mathew 201191 20/84 (23.8) NR 2 21 18 43 10 67.2
Pedrosa 201085 35/114 (30.7) 40 26 22 9 57 74.3 72.5
Schleich 201277 82/174 (47.1) 34 29 4 53 88 35.4 95.4
Schneider 200971,72 Subjects with
unsuspicious
spirometric results:
49/101 (48.5)
> 46 17 5 32 47 35 (23 to 49) 90 (79 to 96)
> 15 38 29 11 23 78 (63 to 89) 45 (34 to 57)
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Author, year
Prevalence of
positive result
by reference
standard, n/N (%)
FeNO
cut-off
(ppb) TP (n) FP (n) FN (n) TN (n)
Sensitivity
asthma
(95% CI) (%)
Specificity
asthma
(95% CI) (%)
Difficult to diagnose with chronic cough
aHahn 200774 38/64 (59.4) 35 36 5 2 21 95 (83 to 99) 80 (62 to 92)
38 34 4 4 22 90 (76 to 96) 85 (76 to 96)
aHsu 201373 38/81 (46.9) 33.9 36 9 2 34 94.7 76.3
30 37 14 1 29 97.4 65.8
Prieto 200976 19/43 (44.2) 20 10 9 9 15 53 63
Sato 200875 48/71 (67.6) 38.8 38 2 10 21 79.2 91.3
Zhang 201189 39/106 (36.8) 40 29 9 10 58 75 86
36a 32 5 7 62 82 93
EIB
El Halawani 200378 7/49 (14.3)b < 12 7 29 0 13 100 31
Other
Arora 200679 138/172 (80.2) > 6 133 34 5 0 96.4 0
> 7 131 33 7 1 94.6 2.9
> 8 130 31 8 3 94.2 8.8
> 9 127 30 11 4 92 11.8
> 10 119 28 19 6 86.2 17.6
> 11 115 26 23 8 83.3 23.5
> 12 113 25 25 9 81.9 26.5
> 13 110 21 28 13 79.7 38.2
> 14 102 19 36 15 73.9 44.1
> 15 98 19 40 15 71 44.1
> 16 92 17 46 17 66.7 50
> 17 87 14 51 20 63 58.8
> 18 83 14 55 20 60.1 58.8
> 19 78 13 60 21 56.5 61.8
> 20 73 11 65 23 52.9 67.6
> 25 56 7 82 27 40.6 79.4
> 30 45 7 93 27 32.6 79.4
> 40 32 3 106 31 23.2 91.2
> 46 23 0 115 34 16.7 100
Brannan 201392 76/401 (19.0) 47 23 12 44 322 30.2 96.3
Chancafe-Morgan
201380
12/30 (40.0) 35 9 3 3 15 75 83.3
Eos%, eosinophil count expressed as a percentage.
a Data are for ICS responsiveness.
b Test for EIB.
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Appendix 12 Table of results for all diagnostic
studies in children
Author, year
Prevalence of
positive result
by reference
standard, n/N (%)
FeNO
cut-off
(ppb) TP (n) FP (n) FN (n) TN (n)
Sensitivity
asthma (%)
Specificity
asthma (%)
Linkosalo 201293 18/30 (60.0) 10 16 8 2 4 89 33
20 13 2 5 10 72 83
30 9 1 9 11 50 92
40 7 1 11 11 39 92
50 2 1 16 11 11 92
Ramser 200894 105/169 (62.1) 10 75 24 45 25 76 36
20 49 50 17 53 49 76
30 33 66 12 58 33 83
40 23 76 7 63 23 90
50 20 79 5 65 20 93
Sivan 200995 106/150 (70.7) 15 62 13 7 31 90 70
18 87 7 19 37 82 84
19 59 5 10 39 86 89
25 52 5 17 39 75 89
> 20 or
< 15
58 4 7 32 89 88
Woo 201296 167/245 (68.2) > 50 24 0 143 78 14.4 100
> 45 29 0 138 78 17.4 100
> 41 39 0 128 78 23.4 100
> 40 41 1 126 77 24.6 98.7
> 35 54 1 113 77 32.3 98.7
> 30 71 4 96 74 42.5 94.9
> 25 83 6 84 72 49.7 92.3
> 24 84 7 83 71 50.3 91
> 23 86 7 81 71 51.5 91
> 22 90 10 68 68 53.9 87.2
> 21 95 10 68 68 56.9 87.2
> 20 101 15 63 63 60.5 80.8
> 15 120 26 52 52 71.9 66.7
> 10 134 43 35 35 80.2 44.9
> 5 157 67 11 11 94 14.1
22 93 9 51 51 72.1 85
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Appendix 13 MEDLINE search strategies for the
economic review
Use of NIOX MINO/NObreath for either the diagnosis or the
management of asthma (30 May 2013)
1. niox mino.mp.
2. aerocrine.mp.
3. (niox adj5 (monitor$ or chemiluminescence or analyser$ or sensor or device$ or desktop)).mp.
4. nobreath.mp.
5. bedfont.mp.
6. or/1-5
7. exp “Costs and Cost Analysis”/
8. Economics/
9. exp Economics, Hospital/
10. exp Economics, Medical/
11. Economics, Nursing/
12. exp models, economic/
13. Economics, Pharmaceutical/
14. exp “Fees and Charges”/
15. exp Budgets/
16. budget$.tw.
17. ec.fs.
18. cost$.ti.
19. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
20. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
21. (price$ or pricing$).tw.
22. (financial or finance or finances or financed).tw.
23. (fee or fees).tw.
24. (value adj2 (money or monetary)).tw.
25. quality-adjusted life years/
26. (qaly or qalys).af.
27. (quality adjusted life year or quality adjusted life years).af.
28. or/7-28
29. 6 and 28
Models of asthma and FENO testing (30 May 2013)
1. niox mino.mp.
2. aerocrine.mp.
3. (niox adj5 (monitor$ or chemiluminescence or analyser$ or sensor or device$ or desktop)).mp.
4. nobreath.mp.
5. bedfont.mp.
6. or/1-5
7. exp cough/
8. cough$.mp.
9. phlegm.mp.
10. sputum.mp.
11. mucus.mp.
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12. wheez$.mp.
13. chest pain/
14. chest pain$.mp.
15. (chest adj5 tight$).tw.
16. ((lower respiratory or lrt) adj5 symptom$).tw.
17. (lower airway adj5 symptom$).tw.
18. ((trache$ or wind pipe or lung$ or bronch$) adj3 symptom$).tw.
19. exp lung/ or trachea/
20. symptom$.tw.
21. 19 and 20
22. or/7-18,21
23. exp asthma/
24. asthma$.mp.
25. exp respiratory hypersensitivity/
26. exp bronchial hyperreactivity/
27. bronchial spasm/
28. bronchospas$.mp.
29. exp Bronchoconstriction/
30. bronchoconstric$.mp.
31. (bronch$ adj3 constrict$).mp.
32. (bronch$ adj5 spas$).mp.
33. (airway$ adj5 (obstruct$ or inflammation$)).mp.
34. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$
or insufficiency)).mp.
35. or/23-34
36. Nitric Oxide/
37. nitric oxide.mp.
38. 36 or 37
39. (exhal$ or expir$ or alveolar or fractional).mp.
40. 38 and 39
41. exhaled NO.mp.
42. eno.mp.
43. fe?no$.mp.
44. (fractional adj2 NO).mp.
45. or/40-44
46. 22 and 45
47. 35 and 45
48. 6 or 46 or 47
49. exp “Costs and Cost Analysis”/
50. Economics/
51. exp Economics, Hospital/
52. exp Economics, Medical/
53. Economics, Nursing/
54. exp models, economic/
55. Economics, Pharmaceutical/
56. exp “Fees and Charges”/
57. exp Budgets/
58. budget$.tw.
59. ec.fs.
60. cost$.ti.
61. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
62. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
63. (price$ or pricing$).tw.
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64. (financial or finance or finances or financed).tw.
65. (fee or fees).tw.
66. (value adj2 (money or monetary)).tw.
67. quality-adjusted life years/
68. (qaly or qalys).af.
69. (quality adjusted life year or quality adjusted life years).af.
70. or/49-69
71. 48 and 70
Asthma management models (3 June 2013)
1. exp asthma/
2. asthma$.mp.
3. exp respiratory hypersensitivity/
4. exp bronchial hyperreactivity/
5. bronchial spasm/
6. bronchospas$.mp.
7. exp Bronchoconstriction/
8. bronchoconstric$.mp.
9. (bronch$ adj5 spas$).mp.
10. (airway$ adj5 (obstruct$ or inflammation$)).mp.
11. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$
or insufficiency)).mp.
12. exp models, economic/
13. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ti.
14. ((cost$ or economic) adj5 model$).ti.
15. or/1-11
16. or/12-14
17. 15 and 16
Asthma diagnostic models (7 June 2013)
1. exp asthma/
2. asthma$.mp.
3. exp respiratory hypersensitivity/
4. exp bronchial hyperreactivity/
5. bronchial spasm/
6. bronchospas$.mp.
7. exp Bronchoconstriction/
8. bronchoconstric$.mp.
9. (bronch$ adj3 constrict$).mp.
10. (bronch$ adj5 spas$).mp.
11. (airway$ adj5 (obstruct$ or inflammation$)).mp.
12. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$
or insufficiency)).mp.
13. or/1-12
14. exp “Costs and Cost Analysis”/
15. Economics/
16. exp Economics, Hospital/
17. exp Economics, Medical/
18. Economics, Nursing/
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19. exp models, economic/
20. Economics, Pharmaceutical/
21. exp “Fees and Charges”/
22. exp Budgets/
23. budget$.tw.
24. ec.fs.
25. cost$.ti.
26. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
27. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
28. (price$ or pricing$).tw.
29. (financial or finance or finances or financed).tw.
30. (fee or fees).tw.
31. (value adj2 (money or monetary)).tw.
32. quality-adjusted life years/
33. (qaly or qalys).af.
34. (quality adjusted life year or quality adjusted life years).af.
35. or/14-34
36. exp “Sensitivity and Specificity”/
37. sensitivity.tw.
38. specificity.tw.
39. ((pre-test or pretest) adj probability).tw.
40. post-test probability.tw.
41. predictive value$.tw.
42. likelihood ratio$.tw.
43. diagnostic$.ti,ab.
44. or/36-43
45. 13 and 35 and 44
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